

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal621con

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 DEC 01 ChemPort single article sales feature unavailable
NEWS 3 JUN 01 CAS REGISTRY Source of Registration (SR) searching
enhanced on STN
NEWS 4 JUN 26 NUTRACEUT and PHARMAML no longer updated
NEWS 5 JUN 29 IMSCOPROFILE now reloaded monthly
NEWS 6 JUN 29 EPFULL adds Simultaneous Left and Right Truncation
(SLART) to AB, MCLM, and TI fields
NEWS 7 JUL 09 PATDPAFULL adds Simultaneous Left and Right
Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS 8 JUL 14 USGENE enhances coverage of patent sequence location
(PSL) data
NEWS 9 JUL 27 CA/CAPplus enhanced with new citing references
NEWS 10 JUL 16 GBFULL adds patent backfile data to 1855
NEWS 11 JUL 21 USGENE adds bibliographic and sequence information
NEWS 12 JUL 28 EPFULL adds first-page images and applicant-cited
references
NEWS 13 JUL 28 INPADOCDB and INPAFAMDB add Russian legal status data
NEWS 14 AUG 10 Time limit for inactive STN sessions doubles to 40
minutes
NEWS 15 AUG 17 CAS REGISTRY, the Global Standard for Chemical
Research, Approaches 50 Millionth Registration
Milestone
NEWS 16 AUG 18 COMPENDEX indexing changed for the Corporate Source
(CS) field
NEWS 17 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 18 AUG 24 CA/CAPplus enhanced with legal status information for
U.S. patents

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial

gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:06:16 ON 24 AUG 2009

=> FILE REG

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.44

0.44

FILE 'REGISTRY' ENTERED AT 08:07:24 ON 24 AUG 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 AUG 2009 HIGHEST RN 1175001-45-2

DICTIONARY FILE UPDATES: 23 AUG 2009 HIGHEST RN 1175001-45-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\GS909.str



chain nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

1-2 2-3 2-9 3-4 3-7 4-5 4-8 5-6 5-10

exact/norm bonds :

1-2 2-3 3-4 3-7 5-6

10/574,993

08/24/2009

STN: SEARCH

exact bonds :

2-9 4-5 4-8 5-10

Match level :


1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:Atom 7:CLASS 8:CLASS 9:CLASS
10:CLASS

L1 STRUCTURE UPLOADED

=> D L1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> S L1 FULL

FULL SEARCH INITIATED 08:07:56 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 88444 TO ITERATE

100.0% PROCESSED 88444 ITERATIONS

1200 ANSWERS

SEARCH TIME: 00.00.02

L2 1200 SEA SSS FUL L1

=> FILE CAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

185.88

186.32

FILE 'CAPLUS' ENTERED AT 08:08:12 ON 24 AUG 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Aug 2009 VOL 151 ISS 9
FILE LAST UPDATED: 23 Aug 2009 (20090823/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAPLUS family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> S L2

L3 106 L2

=> S L3 AND CANCER

419437 CANCER

L4 14 L3 AND CANCER

=> D L3 IBIB ABS HITSTR 1-106

L3 ANSWER 1 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:825033 CAPLUS

DOCUMENT NUMBER: 151:145654

TITLE: Protein kinase genes showing altered levels of expression in breast cancer tissue and their diagnostic use

INVENTOR(S): Bertucci, Francois; Birnbaum, Daniel; Finetti, Pascal

PATENT ASSIGNEE(S): IPSOGEN, Fr.; INSERM-Institut National de la Sante et de la Recherche Medicale; Institut Paoli-Calmettes

SOURCE: PCT Int. Appl., 97pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2009083780	A1	20090709	WO 2008-IB3622	20081224

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2007-9395P

P 20071228

AB The present invention relates to a method for analyzing cancer.e.g., breast cancer comprising detection of differential expression of at least one of the 16 genes encoding serine/threonine kinases listed in Table 1, or of said 16 genes, and to a polynucleotide library comprising at least one said 16 genes. A method of diagnosing breast cancer by anal. of the levels of expression of members of a group of 16 protein kinase genes is described. Levels of expression of the genes can also be used in prognosis and in monitoring the effectiveness of therapies. The levels of expression of these genes were analyzed in 227 samples of breast cancer tissue as part of a larger anal. of gene expression in breast cancer. Validation of the use of these genes in diagnosis and in prognosis is demonstrated.


IT 592542-59-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(selection for cancer therapy; protein kinase genes showing altered levels of expression in breast cancer tissue and their diagnostic use)

RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:739342 CAPLUS

DOCUMENT NUMBER: 151:70265

TITLE: Gene expression markers to determine if a subject will respond to a bcr-abl inhibitor

INVENTOR(S): McWeeney, Shannon K.; Deininger, Michael W. N.

PATENT ASSIGNEE(S): Oregon Health & Science University, USA
SOURCE: PCT Int. Appl., 127pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009076229	A2	20090618	WO 2008-US85724	20081205
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2007-5703P P 20071207

AB Methods of determining if a subject will respond to treatment of BCR-ABL-dependent cancer with BCR-ABL inhibitor by gene expression profiling in CD34-pos. cells is described. A panel of informative genes for use in the test is described. Altered expression of a number of these genes as compared to the control indicates that the subject of interest will respond to treatment with the BCR-ABL inhibitor.


IT 592543-24-3

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cancer therapy with; gene expression markers to determine if subject will respond to bcr-abl inhibitor)

RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L3 ANSWER 3 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:587922 CAPLUS

DOCUMENT NUMBER: 150:533852

TITLE: Inhibition of Polo kinase by Matrimony protein maintains G2 arrest in the meiotic cell cycle

INVENTOR(S): Xiang, Youbin; Jaspersen, Sue; Florens, Laurence; Smith, Sarah Kendall; Hawley, R. Scott

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 41pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090123934	A1	20090514	US 2008-288322	20081017
PRIORITY APPLN. INFO.:			US 2007-999447P	P 20071018

AB Matrimony (Mtrm) protein acts as a neg. regulator of Polo kinase (Polo) during the later stages of G2 arrest. Indeed, both the repression of Polo expression until stage 11 and the inactivation of newly synthesized Polo by Mtrm until stage 13 play critical roles in maintaining and properly terminating G2 arrest. This data suggest a model in which the eventual activation of Cdc25 by an excess of Polo at stage 13 triggers nuclear envelope breakdown and entry into prometaphase. In view of the foregoing, methods for modulating oocyte maturation are provided. More particularly, methods are provided for in vitro maturation of an oocyte. Further provided are methods for identifying functional orthologs of a Drosophila Matrimony polypeptide, as well as inhibitors thereof.

IT 592542-59-1, ON-01910


RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhibition of Polo kinase by Matrimony protein maintains G2 arrest in the meiotic cell cycle)

RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 4 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:325750 CAPLUS

DOCUMENT NUMBER: 150:511500
TITLE: A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53
AUTHOR(S): Sur, Surojit; Pagliarini, Raymond; Bunz, Fred; Rago, Carlo; Diaz, Luis A., Jr.; Kinzler, Kenneth W.; Vogelstein, Bert; Papadopoulos, Nickolas
CORPORATE SOURCE: The Howard Hughes Medical Institute and The Ludwig Center for Cancer Genetics and Therapeutics, The Johns Hopkins Kimmel Cancer Center, Baltimore, MD, 21231, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2009), 106(10), 3964-3969
CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Through targeted homologous recombination, we developed a panel of matched colorectal cancer cell lines that differ only with respect to their endogenous TP53 status. We then used these lines to define the genes whose expression was altered after DNA damage induced by ionizing radiation. Transcriptome analyses revealed a consistent upregulation of polo-like kinase 1 (PLK1) as well as other genes controlling the G2/M transition in the cells whose TP53 genes were inactivated compared with those with WT TP53 genes. This led to the hypothesis that the viability of stressed cells without WT TP53 depended on PLK1. This hypothesis was validated by demonstrating that stressed cancer cells without WT TP53 alleles were highly sensitive to PLK1 inhibitors, both in vivo and in vitro.

IT 592542-59-1, ON 01910


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(panel of isogenic human cancer cells suggests therapeutic approach for cancers with inactivated p53)

RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:291726 CAPLUS
DOCUMENT NUMBER: 150:327889
TITLE: Novel methods and antibodies for treating cancer
INVENTOR(S): Van De Winkel, Jan; Parren, Paul; Bleeker, Willem
Karel; Edvardsen, Klaus; Lammerts Van Bueren, Jeroen;
Valerius, Thomas; Dechant, Michael; Weisner, Wencke;
Berger, Sven
PATENT ASSIGNEE(S): Genmab A/S, Den.
SOURCE: PCT Int. Appl., 133pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2009030239	A1	20090312	WO 2008-DK50220	20080905
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: DK 2007-1278 A 20070906
DK 2008-912 A 20080630

AB The authors disclose a method for inducing complement-mediated cell killing in the treatment of a tumor. The method comprises the combined administration of a first and a second antibody wherein the first antibody binds a tumor-specific epitope of EGF receptors, the second antibody binds wild-type EGF receptor, and the first and second antibodies are non-cross-blocking.


IT 592543-24-3, ON 012380

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in anti-EGFR antibody combination therapy for cancer)

RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:237899 CAPLUS

DOCUMENT NUMBER: 150:252611

TITLE: Methods and compositions of a hedgehog signaling antagonist and a BCR-ABL inhibitor for treating cancers

INVENTOR(S): Dierks, Christine; Warmuth, Markus

PATENT ASSIGNEE(S): Irm LLC, Bermuda

SOURCE: PCT Int. Appl., 49pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009026075	A1	20090226	WO 2008-US73049	20080813
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2007-956295P P 20070816

AB This invention provides a combination of antagonists of the hedgehog signaling pathway with a BCR-ABL inhibitor. The combination of the present invention may be used for treating cancers known to be associated with protein tyrosine kinases such as, for example, Src, BCR-ABL and c-kit. Thus, the combination of ABL inhibitor (AMN-107, 50 mg/kg qd) and Smo inhibitor (cyclopamine, 25 mg/kg bid) in mice with chronic myeloid leukemia (CML)-like disease reduced the amount of colony forming units and

enhanced time to relapse, indicating that the combination of AMN-107 and cyclopamine may be beneficial in the treatment of CML.


IT 592543-24-3, ON 012380

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of hedgehog signaling antagonist and BCR-ABL inhibitor for treating cancers)

RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:153884 CAPLUS

DOCUMENT NUMBER: 150:413477

TITLE: Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells

AUTHOR(S): Prasad, A.; Park, I.-W.; Allen, H.; Zhang, X.; Reddy, M. V. R.; Boominathan, R.; Reddy, E. P.; Groopman, J. E.

CORPORATE SOURCE: Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA

SOURCE: Oncogene (2009), 28(12), 1518-1528

CODEN: ONCNES; ISSN: 0950-9232

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Mantle cell lymphoma (MCL) is characterized by the uncontrolled overexpression of cyclin D1. Styryl sulfonyl compds. have shown potent antitumor activity against MCL by inducing cell-cycle arrest and apoptosis. However, the exact mol. mechanism by which these compds. function is yet to be elucidated. Here, we show that the prototypical styryl sulfonyl compound ON 01910.Na decreased cyclin D1 and c-Myc protein levels in MCL cells, whereas mRNA levels of cyclin D1 were minimally affected. Notably, ON 01910.Na suppressed eukaryotic translation initiation factor 4E (eIF4E)-mediated cyclin D1 mRNA translation, decreased levels of phosphorylated Akt, mammalian target of Rapamycin

(mTOR) and eIF4E-binding protein (eIF4E-BP), lowered the cap site binding activity of eIF4E and directly inhibited activity of phosphatidylinositol-3 kinase (PI-3K). Anal. of apoptotic signaling pathways revealed that ON 01910.Na induced the release of cytochrome c from mitochondria, altered expression of Bcl-2 family of proteins and stimulated activation of caspases. Taken together, styryl sulfonyls can cause a rapid decrease of cyclin D1 by blocking cyclin D1 mRNA translation through inhibition of the PI-3K/Akt/mTOR/eIF4E-BP signaling pathway and triggering a cytochrome c-dependent apoptotic pathway in MCL cells.


IT 592542-60-4, ON 01910 sodium salt

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(styryl sulfonyl compds. inhibit translation of cyclin D1 in mantle cell lymphoma cells)

RN 592542-60-4 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, sodium salt (1:1) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:37222 CAPLUS

DOCUMENT NUMBER: 151:198009

TITLE: Synthesis and Suzuki reaction of (E)-chlorovinyl sulfides and sulfones

AUTHOR(S): Abele, E.; Visnevskaya, J.

CORPORATE SOURCE: Latv. Inst. of Org. Synthesis, Latvia

SOURCE: Latvijas Kimijas Zurnals (2008), (3), 263-267

CODEN: LKZUE8; ISSN: 0868-8249

PUBLISHER: Latvijas Kimijas Biedriba

DOCUMENT TYPE: Journal

LANGUAGE: English

AB (E)-RSCH:CHCl [R = Ph, CH₂Ph] were prepared from RSH and Cl₂CHCH₂Cl and oxidized to RSO₂CH:CHCl. Both the sulfides and sulfones were subjected to Suzuki coupling reaction to give arylvinyl sulfides and sulfones.


IT 32093-01-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis and Suzuki reaction of (E)-chlorovinyl sulfides and sulfones)

RN 32093-01-9 CAPLUS

CN Benzene, [[[1E)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1440234 CAPLUS

DOCUMENT NUMBER: 150:121557

TITLE: Michael adducts of vinyl sulfones; source for thiadiazoles, oxadiazoles and triazoles

AUTHOR(S): Padmavathi, Venkatapuram; Reddy, Guda Dinneswara; Reddy, Gali Sudhakar

CORPORATE SOURCE: Department of Chemistry, Sri Venkateswara University, Tirupati, 517502, India

SOURCE: Journal of Heterocyclic Chemistry (2008), 45(6), 1633-1639

CODEN: JHTCAD; ISSN: 0022-152X

PUBLISHER: HeteroCorporation

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 150:121557

AB Michael addition of H₂C(CO₂Me)₂ to 4-arenesulfonyl- or 4-arylmethanesulfonyl-3-arylbutyrate and subsequent hydrazinolysis, dithiocarbamoylation, and cyclization led to thiadiazoles, oxadiazoles, and triazoles.


IT 90616-42-5 90616-48-1 92549-14-9
911833-17-5 911833-20-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of thiadiazoles, oxadiazoles and triazoles by Michael addition of malonate to vinyl sulfones)


RN 90616-42-5 CAPLUS

CN Benzene, 1-chloro-4-[2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)




RN 90616-48-1 CAPLUS

CN Benzene, 1-methyl-4-[2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)




RN 92549-14-9 CAPLUS

CN Benzene, [[(2-phenylethenyl)sulfonyl]methyl]- (CA INDEX NAME)




RN 911833-17-5 CAPLUS

CN Benzene, 1-chloro-4-[[[(2-phenylethenyl)sulfonyl]methyl]- (CA INDEX NAME)



RN 911833-20-0 CAPLUS

CN Benzene, 1-chloro-4-[[[2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1412920 CAPLUS

DOCUMENT NUMBER: 150:136262

TITLE: Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay

AUTHOR(S): Jimeno, A.; Chan, A.; Cusatis, G.; Zhang, X.; Wheelhouse, J.; Solomon, A.; Chan, F.; Zhao, M.;

Cosenza, S. C.; Ramana Reddy, M. V.; Rudek, M. A.; Kulesza, P.; Donehower, R. C.; Reddy, E. P.; Hidalgo, M.
CORPORATE SOURCE: Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
SOURCE: Oncogene (2009), 28(4), 610-618
CODEN: ONCNES; ISSN: 0950-9232
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English


AB The purpose of this study was to evaluate the activity of ON 01910.Na, a mitotic inhibitor, in in vitro and in vivo models of pancreatic cancer and to discover biomarkers predictive of efficacy. Successive in vitro and in vivo models were used; these included cell line-derived and patient-derived tumors from our PancXenoBank, a live collection of freshly generated pancreatic cancer xenografts. ON 01910.Na showed equivalent activity to gemcitabine against pancreatic cancer cell lines in vitro. The activity of the agent correlated with suppression of phospho-CDC25C and cyclin B1. These markers were optimized for a fine-needle aspirate ex vivo rapid assay. Cyclin B1 mRNA evaluation yielded the most optimal combination of accuracy and reproducibility. Next, nine patient-derived tumors from the PancXenoBank were profiled using the assay developed in cell lines and treated with ON 01910.Na for 28 days. Two cases were cataloged as potential responders and seven as resistant. There was a correlation between the ex vivo assay and sensitivity to the tested agent, as the two cases prospectively identified as sensitive met prespecified criteria for response. Of the seven tumors of predictive resistant, only one was sensitive to ON 01910.Na. In addition, there was a good correlation between cyclin B1 downregulation ex vivo and changes in cyclin B1 protein post-treatment. The novel mitotic inhibitor, ON 01910.Na, showed activity in preclin. model of pancreatic cancer. A rapid assay was rationally developed that not only identified cases sensitive to ON 01910.Na, but also anticipated the pharmacodynamic events occurring after in vivo exposure.

IT 592542-60-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclin. development of an ex vivo predictive assay)

RN 592542-60-4 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, sodium salt (1:1) (CA INDEX NAME)

Double bond geometry as shown.




● Na

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 11 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:1383635 CAPLUS
 DOCUMENT NUMBER: 149:512468
 TITLE: The Ramberg-Baecklund rearrangement
 AUTHOR(S): Paquette, Leo A.
 CORPORATE SOURCE: The Ohio State University, Columbus, OH, USA
 SOURCE: Organic Reactions (Hoboken, NJ, United States) (1977),
 25, No pp. given
 CODEN: ORHNBA
 URL: <http://www3.interscience.wiley.com/cgi-bin/mrwhome/107610747/HOME>
 PUBLISHER: John Wiley & Sons, Inc.
 DOCUMENT TYPE: Journal; General Review; (online computer file)
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 149:512468
 AB A review of the article The Ramberg-Baecklund rearrangement.
 IT 32093-01-9P 32291-81-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (The Ramberg-Baecklund Rearrangement)
 RN 32093-01-9 CAPLUS
 CN Benzene, [[[1E]-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 32291-81-9 CAPLUS
 CN Benzene, [[[1Z]-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 12 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:1368234 CAPLUS
 DOCUMENT NUMBER: 149:550457
 TITLE: Protein sequences of Plk1 kinase substrate Myt1 and CENPB and methods for modulation of Plk1 kinase activity
 INVENTOR(S): Loganzo, Frank, Jr.; Krishnamurthy, Girija; Ding, Weidong Warren; Tan, Xingzhi Cindy; Patel, Jagruti Hasmukh
 PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
 SOURCE: U.S. Pat. Appl. Publ., 64pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080279874	A1	20081113	US 2008-115750	20080506
PRIORITY APPLN. INFO.:			US 2007-916433P	P 20070507
			US 2007-974618P	P 20070924

AB The invention describes compns. and methods for activating a Plk1 protein as well as phospho-specific anti-Myt1 antibodies that can be used to detect phosphorylation of Myt1. The protein sequences of human Myt1 kinase and CENPB have been presented. Activated Plk1 protein, phospho-specific anti-Myt1 antibodies, and/or Plk1 substrates can be used in screening assays to identify compds. that modulate the ability of Plk1 to phosphorylate and/or bind to a Plk1 substrate. The invention relates to a method of detecting the kinase activity of Plk1 protein. The method includes the steps of : contacting a Plk1 protein with a Plk1 substrate to permit phosphorylation of the Plk1 substrate, wherein the Plk1 substrate is a CENPB protein. The invention further provides a method for generating a compound that inhibits the interaction between a Plk1 protein and a CENPB protein. The method includes the steps of : providing a three-dimensional structure of a mol. or a mol. complex containing a Plk1 protein or a CENPB-binding fragment and designing a compound containing a region


that inhibits the interaction between a Plk1 protein and CEPB.

IT 592542-59-1, On01910
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anti-Plk1 agent; protein sequences of Plk1 kinase substrate Myt1 and CENPB and methods for modulation of Plk1 kinase activity)

RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 13 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:1071184 CAPLUS
 DOCUMENT NUMBER: 149:315788
 TITLE: Formulations of radioprotective
 α,β -unsaturated aryl sulfones
 INVENTOR(S): Maniar, Manoj; Bell, Stanley C.
 PATENT ASSIGNEE(S): Onconova Therapeutics, Inc., USA
 SOURCE: PCT Int. Appl., 66pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008105808	A2	20080904	WO 2007-US16879	20070727
WO 2008105808	A3	20081113		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
CA 2659222	A1	20080904	CA 2007-2659222	20070727
EP 2046343	A2	20090415	EP 2007-873711	20070727
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
IN 2009CN01029	A	20090529	IN 2009-CN1029	20090224
KR 2009040354	A	20090423	KR 2009-704064	20090226
PRIORITY APPLN. INFO.:			US 2006-833842P	P 20060728
			WO 2007-US16879	W 20070727

OTHER SOURCE(S): MARPAT 149:315788

AB A pharmaceutical composition, for example, an aqueous solution and a suspension is provided, comprising an effective amount of at least one radioprotective

α,β -unsatd. aryl sulfone, wherein the composition has a pH within the range of about 8 to about 9, for administration prior to or after exposure to ionizing radiation for reducing toxic effects of the radiation in a subject. The composition further comprises a buffer and a wetting agent. Thus, radioprotective effect of i.p. injection of 200 μ g of (E)-4-carboxystyryl-4-chlorobenzylsulfone dissolved in DMSO was demonstrated in mice exposed to γ -radiation.


IT 334969-03-8

RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(aqueous solution and suspension formulations of radioprotective α,β -unsatd. aryl sulfones)

RN 334969-03-8 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 922139-31-9P, ON 01210.Na


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(aqueous solution and suspension formulations of radioprotective α,β -unsatd. aryl sulfones)

RN 922139-31-9 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-, sodium salt (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● Na

IT 118672-28-9 158606-44-1 300699-33-6

300699-42-7 334969-29-8,

(E)-2,4,6-Trimethoxystyryl-4-methoxybenzyl sulfone 334969-61-8

334970-03-5, (E)-3-Furanethenyl-2,4-dichlorobenzyl sulfone

457624-55-4 457624-56-5 457624-57-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)


(aqueous solution and suspension formulations of radioprotective

α,β -unsatd. aryl sulfones)

RN 118672-28-9 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 158606-44-1 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-33-6 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-4-
(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-42-7 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 334969-29-8 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-61-8 CAPLUS

CN Pyridine, 4-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-03-5 CAPLUS

CN Furan, 3-[(1E)-2-[[2,4-dichlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-55-4 CAPLUS

CN Benzene, 1-methoxy-2-[(1E)-2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 457624-56-5 CAPLUS

CN Benzene, 1,2,3,4,5-pentafluoro-6-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-57-6 CAPLUS

CN Phenol, 4-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 14 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:881304 CAPLUS

DOCUMENT NUMBER: 149:207951

TITLE: Formulations for parenteral administration of
(E)-2,6-dialkoxystyryl 4-substituted benzylsulfones

INVENTOR(S): Bell, Stanley C.; Maniar, Manoj
 PATENT ASSIGNEE(S): Onconova Therapeutics, Inc., USA
 SOURCE: PCT Int. Appl., 94pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008088803	A2	20080724	WO 2008-US523	20080116
WO 2008088803	A3	20081016		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2007-880376P P 20070116
 OTHER SOURCE(S): MARPAT 149:207951


AB Formulations are provided for parenteral administration of amino substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones and the sodium and potassium salts thereof for the prevention and/or treatment of conditions mediated by abnormal cell proliferation. Composition for parenteral administration are provided which comprise an effective amount of the compound and about 50% a water-soluble polymer selected from the group consisting of polyethylene glycol, polyoxyethylene-polyoxypropylene copolymers, polyglycerol, poly(vinyl alc.), polyvinylpyrrolidone, polyvinylpyridine N-oxide, copolymer of vinylpyridine N-oxide and vinylpyridine. Thus, (E)-2,4,6-trimethoxystyryl-3'-amino-4'-methoxybenzylsulfone (ON0-1500) was prepared and converted to {N-[2-methoxy-5-methylene(2',4',6'-trimethoxystyrylsulfonyl)phenyl]amino}acetic acid sodium salt (ON 01910 sodium salt). A stabilization effect was observed by lowering the dielec. constant of the formulation vehicle. A shelf stable formulation was developed based on PEG-400.

IT 592542-60-4P, ON01910 sodium salt
 RL: PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (formulations for parenteral administration of dialkoxystyrylbenzylsulfones)

RN 592542-60-4 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, sodium salt (1:1) (CA INDEX NAME)


Double bond geometry as shown.



● Na


IT 592542-50-2P, ON 01500
 RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (formulations for parenteral administration of dialkoxystyrylbenzylsulfones)
 RN 592542-50-2 CAPLUS
 CN Benzenamine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 592542-61-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (formulations for parenteral administration of dialkoxystyrylbenzylsulfones)
 RN 592542-61-5 CAPLUS
 CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.



IT 592542-52-4P


RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)

(formulations for parenteral administration of
dialkoxystyrylbenzylsulfones)

RN 592542-52-4 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[[4-methoxy-3-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




IT	592542-53-5	592542-55-7	592542-56-8
	592542-59-1	592542-62-6	592542-63-7
	592542-64-8	592542-65-9	592542-66-0
	592542-67-1	592542-68-2	592542-69-3
	592542-70-6	592542-72-8	592542-74-0
	592542-76-2	592542-77-3	592542-78-4
	592542-81-9	592542-82-0	592542-83-1
	592542-84-2	592542-85-3	592542-86-4
	592542-87-5	592542-88-6	592542-89-7
	592542-90-0	592542-91-1	592542-92-2
	592542-93-3	592542-95-5	592542-97-7
	592542-99-9	592543-01-6	592543-03-8
	592543-05-0	592543-06-1	592543-08-3
	592543-09-4	592543-10-7	592543-11-8
	592543-12-9	592543-13-0	592543-14-1
	592543-15-2	592543-17-4	592543-18-5
	592543-20-9	592543-22-1	592543-23-2
	592543-24-3	874198-32-0	874198-33-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(formulations for parenteral administration of
dialkoxystyrylbenzylsulfones)

RN 592542-53-5 CAPLUS

CN Acetic acid, 2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]sulfonyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-55-7 CAPLUS

CN Propanoic acid, 3-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-3-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-56-8 CAPLUS

CN Guanidine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-62-6 CAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-3,5-dinitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-63-7 CAPLUS

CN Benzamide, 3,5-diamino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-64-8 CAPLUS

CN Acetamide, 2-chloro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-65-9 CAPLUS

CN 1-Piperazineacetamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-4-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-66-0 CAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-67-1 CAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-4-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-68-2 CAPLUS

CN Benzamide, 4-amino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-69-3 CAPLUS

CN Benzenamine, 2-methoxy-N-[(4-nitrophenyl)methylene]-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 592542-70-6 CAPLUS

CN Hexanamide, 2,6-diamino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 592542-72-8 CAPLUS


CN Propanamide, 2-amino-3-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 592542-74-0 CAPLUS
CN Propanamide, 2-amino-3-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 592542-76-2 CAPLUS
CN Urea, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-77-3 CAPLUS

CN Benzenamine, 2-methoxy-N-methyl-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-78-4 CAPLUS

CN Acetamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-81-9 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-82-0 CAPLUS

CN Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-83-1 CAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-84-2 CAPLUS

CN Acetamide, 2-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-85-3 CAPLUS

CN Acetamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-86-4 CAPLUS

CN Pyridinium, 1-[2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxoethyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-87-5 CAPLUS

CN Propanamide, 2-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-88-6 CAPLUS

CN Propanamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-89-7 CAPLUS

CN Ethanaminium, N,N,N-triethyl-2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-90-0 CAPLUS

CN Ethanaminium, N,N,N-tris(2-hydroxyethyl)-2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-91-1 CAPLUS

CN Propanamide, 2-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-92-2 CAPLUS

CN Propanamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-93-3 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-95-5 CAPLUS

CN Methanesulfonamide, 1,1,1-trifluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-97-7 CAPLUS

CN Butanoic acid, 4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-4-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-99-9 CAPLUS

CN Butanoyl chloride, 4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-4-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-01-6 CAPLUS

CN Butanedioic acid, 1-[2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxoethyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-03-8 CAPLUS

CN	Pentanoic acid, 5-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-5-oxo-	(CA INDEX NAME)
----	---	-----------------


Double bond geometry as shown.



RN 592543-05-0 CAPLUS

CN Acetamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2-(phosphonoxy)-, sodium salt (1:2) (CA INDEX NAME)

Double bond geometry as shown.




● 2 Na

RN 592543-06-1 CAPLUS

CN Butanoic acid, 4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-08-3 CAPLUS

CN β -Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-09-4 CAPLUS

CN Carbamic acid, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-10-7 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-11-8 CAPLUS

CN Butanoic acid, 4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-4-oxo-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-12-9 CAPLUS

CN Propanoic acid, 3-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-3-oxo-, ethyl ester
(CA INDEX NAME)


Double bond geometry as shown.



RN 592543-13-0 CAPLUS

CN Propanamide, 2,2,3,3,3-pentafluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-14-1 CAPLUS

CN Propanoic acid, 2,2-difluoro-3-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-3-oxo-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-15-2 CAPLUS

CN Butanoic acid, 2,2,3,3-tetrafluoro-4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-4-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-17-4 CAPLUS

CN Propanoic acid, 2,2-difluoro-3-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-3-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-18-5 CAPLUS

CN Acetamide, 2-(dimethylamino)-2,2-difluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-20-9 CAPLUS

CN Phosphoric acid, diethyl 2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxoethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-22-1 CAPLUS

CN Acetamide, 2-amino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-23-2 CAPLUS

CN D-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 874198-32-0 CAPLUS

CN Benzenesulfonamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2,4-dinitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 874198-33-1 CAPLUS

CN Benzenesulfonamide, 2,4-diamino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 15 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:352827 CAPLUS

DOCUMENT NUMBER: 148:379331


TITLE: Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions

INVENTOR(S): Fegley, Glenn; Bell, Stanley C.; Costenza, Steven;

PATENT ASSIGNEE(S): Duke, Jodie; Reddy, E. Premkumar; Reddy, M. V. Ramana
SOURCE: Onconova Therapeutics, Inc., USA
PCT Int. Appl., 106pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008033475	A2	20080320	WO 2007-US19943	20070914
WO 2008033475	A3	20080814		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
CA 2663375	A1	20080320	CA 2007-2663375	20070914
PRIORITY APPLN. INFO.:			US 2006-844639P	P 20060915
			WO 2007-US19943	W 20070914

GI



AB Activated cytotoxic compds. are described for attachment to targeting mols. for the treatment of a mammalian disease condition which comprise, an activator, a spacer linker, a linker (e.g., self-immolative), and a cytotoxic drug selected from the group consisting of amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones, amino- and hydroxy-substituted styrylsulfonanilides, and substituted phenoxy- and phenylthio-styrylsulfone derivs. Activated cytotoxic compound attached to a targeting mol. are described wherein the targeting mol. is selected from the group consisting essentially of an antibody, a receptor, a ligand, a cytokine, a hormone, and a signal transduction mol. The invention is further directed to a method of treatment of disease conditions. Example compound I was prepared by a bromination of 4-methyl-2-nitroanisole; the resulting 4-methoxy-3-nitrobenzyl bromide underwent substitution with thioglycolic acid to give 4-methoxy-3-nitrobenzylthioacetic acid, which underwent oxidation to give the corresponding sulfone, which underwent reduction

to give compound I. The example compds. were activated for attachment to targeting mols. to create drug delivery entries (examples given). All the invention compds. were evaluated for their anticancer activity (some data given).

IT 592542-50-2P 865783-95-5P 1013422-07-5P
 1013422-09-7P 1013422-14-4P 1013422-17-7P
 1013422-21-3P 1013422-24-6P 1013422-41-7P
 1013422-45-1P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of activated cytotoxic compds. for attachment to targeting mols. for the treatment of mammalian disease conditions)

RN 592542-50-2 CAPLUS

CN Benzenamine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865783-95-5 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1013422-07-5 CAPLUS

CN Carbonic acid, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl 4-nitrophenyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 1013422-09-7 CAPLUS


CN Pentanoic acid, 5-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]carbonyl]amino]ethyl]amino]-5-oxo-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 1013422-14-4 CAPLUS

CN Pentanoic acid, 5-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]carbonyl]methylamino]ethyl]methylamino]-5-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 1013422-17-7 CAPLUS

CN Pentanoic acid, 5-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]carbonyl]methylamino]ethyl]amino]-5-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 1013422-21-3 CAPLUS

CN Pentanoic acid, 5-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]carbonyl]amino]ethyl]methylamino]-5-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 1013422-24-6 CAPLUS

CN Pentanoic acid, 5-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]carbonyl]amino]ethyl]amino]-5-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 1013422-41-7 CAPLUS

CN Carbamic acid, N-[4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-4-oxobutyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 1013422-45-1 CAPLUS

CN Pentanoic acid, 5-[[4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-4-oxobutyl]amino]-5-oxo- (CA INDEX NAME)

Double bond geometry as shown.



IT 1013422-09-7DP, reaction products with Herceptin

1013422-12-2P	1013422-28-0P	1013422-31-5P
1013422-34-8P	1013422-38-2P	1013422-48-4P
1013422-51-9P	1013422-54-2P	1013422-57-5P
1013422-60-0P	1013422-62-2P	1013422-64-4P
1013422-67-7P	1013422-70-2P	1013422-73-5P
1013422-76-8P	1013422-79-1P	1013422-82-6P
1013422-85-9P	1013422-88-2P	1013422-93-9P
1013422-96-2P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of activated cytotoxic compds. for attachment to targeting mols. for the treatment of mammalian disease conditions)

RN 1013422-09-7 CAPLUS


CN Pentanoic acid, 5-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]carbonyl]amino]ethyl]amino]-5-oxo-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 1013422-12-2 CAPLUS

CN Carbamic acid, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, 4-nitrophenyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 1013422-28-0 CAPLUS


CN Pentanoic acid, 5-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]carbonyl]methylamino]ethyl]methylamino]-5-oxo-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 1013422-31-5 CAPLUS


CN Pentanoic acid, 5-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]carbonyl]amino]ethyl]methylamino]-5-oxo-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 1013422-34-8 CAPLUS


CN Pentanoic acid, 5-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]carbonyl]methylamino]ethyl]amino]-5-oxo-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 1013422-38-2 CAPLUS


CN Pentanoic acid, 5-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]carbonyl]amino]ethyl]amino]-5-oxo-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 1013422-48-4 CAPLUS


CN Pentanoic acid, 5-[[4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-4-oxobutyl]amino]-5-oxo-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 1013422-51-9 CAPLUS


CN Benzenepropanoic acid, 4-[[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]carbonyl]amino]ethyl]amino]carbonyl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 1013422-54-2 CAPLUS


CN Benzenepropanoic acid, 4-[[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]carbonyl]methylamino]ethyl]methylamino]carbonyl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 1013422-57-5 CAPLUS


CN Benzenepropanoic acid, 4-[[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]carbonyl]amino]ethyl]methylamino]carbonyl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 1013422-60-0 CAPLUS


CN Benzenepropanoic acid, 4-[[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]carbonyl]methylamino]ethyl]amino]carbonyl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 1013422-62-2 CAPLUS


CN Benzoic acid, 4-[3-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]carbonyl]amino]ethyl]amino]-3-oxopropyl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 1013422-64-4 CAPLUS


CN Benzoic acid, 4-[3-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]carbonyl]methylamino]ethyl]methylamino]-3-oxopropyl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 1013422-67-7 CAPLUS


CN Benzoic acid, 4-[3-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]carbonyl]amino]ethyl]methylamino]-3-oxopropyl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 1013422-70-2 CAPLUS


CN Benzoic acid, 4-[3-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]carbonyl]methylamino]ethyl]amino]-3-oxopropyl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 1013422-73-5 CAPLUS


CN Pentanoic acid, 5-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]carbonyl]oxy]ethyl]amino]-5-oxo-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 1013422-76-8 CAPLUS


CN Pentanoic acid, 5-[[4-[[[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]carbonyl]oxy]methyl]phenyl]amino]-5-oxo-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 1013422-79-1 CAPLUS


CN Pentanoic acid, 5-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]carbonyl]methylamino]ethyl]amino]-5-oxo-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RN 1013422-82-6 CAPLUS

CN Pentanoic acid, 5-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]carbonyl]oxy]ethyl]amino]-5-oxo-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A






RN 1013422-85-9 CAPLUS

CN Benzoic acid, 2-[2-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]carbonyl]amino]ethyl]amino]-2-oxoethyl]-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 1013422-88-2 CAPLUS


CN Pentanoic acid, 5-[[4-[[[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]carbonyl]oxy]methyl]phenyl]amino]-5-oxo-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 1013422-93-9 CAPLUS


CN Pentanoic acid, 5-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]carbonyl]amino]ethyl]meth
ylamino]-5-oxo-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 1013422-96-2 CAPLUS


CN Pentanoic acid, 5-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]carbonyl]methylamino]ethyl]methylamino]-5-oxo-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



IT 1013423-49-8P

RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of activated cytotoxic compds. for attachment to targeting mols. for the treatment of mammalian disease conditions)


RN 1013423-49-8 CAPLUS

CN Butanamide, 4-amino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 1013423-48-7
 CMF C23 H30 N2 O7 S

Double bond geometry as shown.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



IT 592542-52-4P 1013423-20-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of activated cytotoxic compds. for attachment to targeting
 mols. for the treatment of mammalian disease conditions)
 RN 592542-52-4 CAPLUS
 CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[(4-methoxy-3-
 nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1013423-20-5 CAPLUS

CN Pentanoic acid, 5-[[2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]carbonyl]amino]ethyl]amino]-5-oxo- (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 16 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:286043 CAPLUS

DOCUMENT NUMBER: 148:323096

TITLE: Composition and methods using methoxyphenylaminoacetic acid derivatives for the treatment of myelodysplastic syndrome and acute myeloid leukemia

INVENTOR(S): Reddy, E. Premkumar; Reddy, M. V. Ramana; Holland, James F.; Silverman, Lewis R.; Zinzar, Svetlana

PATENT ASSIGNEE(S): Temple University, USA; Mount Sinai School of Medicine of New York University

SOURCE: PCT Int. Appl., 42pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008027049	A1	20080306	WO 2006-US34093	20060830
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
CA 2661983	A1	20080306	CA 2006-2661983	20060830
PRIORITY APPLN. INFO.:			WO 2006-US34093	W 20060830
OTHER SOURCE(S):	MARPAT	148:323096		

GI



AB Methods and compns. are provided for treating myelodysplastic syndrome and acute myeloid leukemia, wherein the composition comprises at least one compound I

(R1 = NH₂, NHCH₂CO₂H, NHCH(Me)CO₂H, NHC(Me)₂CO₂H), or a pharmaceutically acceptable salt of such a compound; and a DNA methyltransferase inhibitor, or a pharmaceutically acceptable salt thereof. Compound preparation is included.

IT 592542-50-2P 592542-59-1P 592542-82-0P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(methoxyphenylaminoacetic acid derivs. for treatment of myelodysplastic syndrome and acute myeloid leukemia)

RN 592542-50-2 CAPLUS

CN Benzenamine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-82-0 CAPLUS

CN Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 592542-60-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(methoxyphenylaminoacetic acid derivs. for treatment of myelodysplastic syndrome and acute myeloid leukemia)

RN 592542-60-4 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, sodium salt (1:1) (CA INDEX NAME)


Double bond geometry as shown.



● Na


IT 592542-50-2D, salts 592542-59-1D, salts
 592542-82-0D, salts 1009990-14-0
 1009990-14-0D, salts 1009990-27-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (methoxyphenylaminoacetic acid derivs. for treatment of myelodysplastic
 syndrome and acute myeloid leukemia)
 RN 592542-50-2 CAPLUS
 CN Benzenamine, 2-methoxy-5-[[[(1E)-2-(2,4,6-
 trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 592542-59-1 CAPLUS
 CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-
 trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-82-0 CAPLUS

CN Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1009990-14-0 CAPLUS

CN Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 1009990-14-0 CAPLUS

CN Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 1009990-27-5 CAPLUS


CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, sodium salt (1:1), mixt. with 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one (CA INDEX NAME)

CM 1

CRN 592542-60-4

CMF C21 H25 N O8 S . Na

Double bond geometry as shown.




● Na

CM 2

CRN 320-67-2

CMF C8 H12 N4 O5

Absolute stereochemistry.



IT 911294-96-7P


RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(methoxyphenylaminoacetic acid derivs. for treatment of myelodysplastic syndrome and acute myeloid leukemia)

RN 911294-96-7 CAPLUS

CN Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.



IT 592542-52-4P 592542-61-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(methoxyphenylaminoacetic acid derivs. for treatment of myelodysplastic syndrome and acute myeloid leukemia)

RN 592542-52-4 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[(4-methoxy-3-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-61-5 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:47632 CAPLUS

DOCUMENT NUMBER: 151:33439

TITLE: Product subclass 4: cyclic dialkyl sulfoxides and derivatives

AUTHOR(S): Garcia-Ruano, J. L.; Cid, M. B.; Martin-Castro, A. M.; Aleman, J.

CORPORATE SOURCE: Departamento de Quimica Organica, Facultad de Ciencias, Universidad Autonoma de Madrid, Madrid, 28049, Spain

SOURCE: Science of Synthesis (2007), 39, 757-809
CODEN: SSCYJ9

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review of methods to prepare cyclic dialkyl sulfoxide derivs.

IT 100420-61-9

RL: RCT (Reactant); RACT (Reactant or reagent)


(review preparation of cyclic dialkyl sulfoxide derivs.)

RN 100420-61-9 CAPLUS

CN Benzene, [[[2-(1-cyclohexen-1-yl)ethenyl]sulfinyl]methyl]-, (Z)- (9CI)

(CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 322 THERE ARE 322 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 18 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1441255 CAPLUS

DOCUMENT NUMBER: 148:238835

TITLE: Design, Synthesis, and Biological Evaluation of (E)-Styrylbenzylsulfones as Novel Anticancer Agents

AUTHOR(S): Reddy, M. V. Ramana; Mallireddigari, Muralidhar R.; Cosenza, Stephen C.; Pallela, Venkat R.; Iqbal, Nabisa M.; Robell, Kimberly A.; Kang, Anthony D.; Reddy, E. Premkumar

CORPORATE SOURCE: Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA, 19140-5101, USA

SOURCE: Journal of Medicinal Chemistry (2008), 51(1), 86-100
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 148:238835

AB Cell cycle progression is regulated by cyclins and cyclin-dependent kinases, which are formed at specific stages of the cell cycle and regulate the G1/S and G2/M phase transitions, employing a series of checkpoints governed by phosphorylation of their substrates. Tumor development is associated with the loss of these checkpoint controls and this provides an approach for the development of therapeutic agents that can specifically target tumor cells. Here, the authors describe the synthesis and SAR of a novel group of cytotoxic mols. that selectively induce growth arrest of normal cells in the G1 phase while inducing a mitotic arrest of tumor cells resulting in selective killing of tumor cell populations with little or no effect on normal cell viability. The broad spectrum of antitumor activity in vitro and xenograft models, lack of in vivo toxicity and drug resistance suggest potential for use of these agents in cancer therapy.

IT 300700-00-9P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of [(phenylmethyl)sulfonyl]ethenyl]benzene derivs. and determination of their activity as anticancer agents)

RN 300700-00-9 CAPLUS

CN Benzene, 1-methoxy-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)

Double bond geometry as shown.



IT	300699-94-9P	300699-95-0P	334969-29-8P
	334969-31-2P	334969-37-8P	334969-39-0P
	334969-40-3P	334969-44-7P	334969-46-9P
	334969-47-0P	334969-52-7P	334969-54-9P
	409357-58-0P	409357-60-4P	409357-62-6P
	409357-63-7P	409357-67-1P	409357-71-7P
	409357-73-9P	409357-77-3P	851799-32-1P
	865783-95-5P	865784-01-6P	908343-87-3P
	1005494-38-1P	1005494-39-2P	1005494-40-5P
	1005494-41-6P	1005494-42-7P	1005494-43-8P
	1005494-44-9P	1005494-45-0P	1005494-46-1P
	1005494-47-2P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(preparation of [(phenylmethyl)sulfonyl]ethenyl]benzene derivs. and determination

of their activity as anticancer agents)

RN 300699-94-9 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-95-0 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[[[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-29-8 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[[4-methoxyphenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-31-2 CAPLUS

CN Benzene, 1,2,3-trimethoxy-5-[(1E)-2-[[4-methoxyphenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-37-8 CAPLUS

CN Phenol, 3,5-dimethoxy-4-[(1E)-2-[[4-methoxyphenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-39-0 CAPLUS

CN Benzene, 1,2,4-trimethoxy-5-[(1E)-2-[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-40-3 CAPLUS

CN Benzene, 1,2,3-trimethoxy-4-[(1E)-2-[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-44-7 CAPLUS

CN Benzene, 5-fluoro-1,3-dimethoxy-2-[(1E)-2-[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-46-9 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-1,3,5-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-47-0 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-1,3,5-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-52-7 CAPLUS

CN Benzene, 1,2,3-trimethoxy-4-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-54-9 CAPLUS

CN Benzene, 1,2,3-trimethoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-58-0 CAPLUS

CN Benzene, 1,3-dimethoxy-2-[(1E)-2-[[[4-methoxyphenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-60-4 CAPLUS

CN Benzene, 2,4-dimethoxy-1-[(1E)-2-[[[4-methoxyphenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-62-6 CAPLUS

CN Benzene, 1,3-dimethoxy-5-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-63-7 CAPLUS

CN Benzene, 1,4-dimethoxy-2-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-67-1 CAPLUS

CN Benzene, 1,2-dimethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-71-7 CAPLUS

CN Benzene, 1-[(1E)-2-[[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-73-9 CAPLUS

CN Benzene, 2-[(1E)-2-[[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]-1,3-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-77-3 CAPLUS

CN Benzene, 1-[(1E)-2-[[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]-3,5-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-32-1 CAPLUS

CN Benzoic acid, 4-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 865783-95-5 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-01-6 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]-, 1-(dihydrogen phosphate),
sodium salt (1:2) (CA INDEX NAME)

Double bond geometry as shown.




● 2 Na

RN 908343-87-3 CAPLUS

CN Benzene, 1-methoxy-4-[[[(1E)-2-(4-methoxyphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-38-1 CAPLUS

CN Benzenamine, 4-[(1E)-2-[[[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-39-2 CAPLUS

CN Benzene, 1-methoxy-2-[(1E)-2-[[[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-40-5 CAPLUS

CN Benzene, 2-chloro-4-fluoro-1-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-41-6 CAPLUS

CN Benzene, 4-fluoro-2-methoxy-1-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-42-7 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[[4-(trifluoromethoxy)phenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-43-8 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(3,4,5-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-44-9 CAPLUS

CN Phenol, 4-[(1E)-2-[[[(3-hydroxy-4-methoxyphenyl)methyl]sulfonyl]ethenyl]-3,5-dimethoxy]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-45-0 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[[[(4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-46-1 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-47-2 CAPLUS

CN Phenol, 4-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA
INDEX NAME)

Double bond geometry as shown.



IT 865783-99-9P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl dihydrogen phosphate 865784-00-5P
865784-04-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)


(preparation of [(phenylmethyl)sulfonyl]ethenyl]benzene derivs. and
determination

of their activity as anticancer agents)

RN 865783-99-9 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]-, 1-(dihydrogen phosphate) (CA
INDEX NAME)


Double bond geometry as shown.



RN 865784-00-5 CAPLUS

CN Phosphoric acid, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl bis(phenylmethyl) ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-04-9 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]-, 1-(4-methylbenzenesulfonate) (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1153309 CAPLUS
DOCUMENT NUMBER: 148:298631
TITLE: The Bcr-Abl tyrosine kinase inhibitor imatinib and
promising new agents against Philadelphia
chromosome-positive leukemias
AUTHOR(S): Maekawa, Taira; Ashihara, Eishi; Kimura, Shinya
CORPORATE SOURCE: Department of Transfusion Medicine and Cell Therapy,
Kyoto University Hospital, 54 Kawahara-cho, Shogoin,
Sakyo-ku, 606-8507, Japan
SOURCE: International Journal of Clinical Oncology (2007),
12(5), 327-340
CODEN: IJCOF6; ISSN: 1341-9625
PUBLISHER: Springer Japan
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Chronic myeloid leukemia (CML) was the first human malignant disease to be linked to a single, acquired genetic abnormality. Identification of the Bcr-Abl kinase fusion protein and its pivotal role in the pathogenesis of CML provided new opportunities to develop mol.-targeted therapies. Imatinib mesylate (IM, Gleevec, Novartis Pharmaceuticals, Basel, Switzerland), which specifically inhibits the autophosphorylation of the Abl TK, has improved the treatment of CML. However, resistance is often reported in patients with advanced-stage disease. Several novel TK inhibitors have been developed that override IM resistance mechanisms caused by point mutations within the Abl kinase domain. Inhibitors of Abl TK are divided into two main groups, namely, ATP-competitive and ATP noncompetitive inhibitors. The ATP-competitive inhibitors fall into two subclasses, the Src/Abl inhibitors, and the 2-phenylaminopyrimidine-based compds. Dasatinib (formerly BMS-354825), AP23464, SKI-606, and PD166326 are classified as Src/Abl inhibitors, while nilotinib (AMN107) and INNO-406 (NS-187) belong to the latter subclass of inhibitors. Of these agents, dasatinib and nilotinib underwent clin. trials earlier than the others and favorable results are now accumulating. Clin. studies of the other compds., including SKI-606 and INNO-406, have been performed in rapid succession. Because of their strong affinities for the ATP-binding site compared to IM, most ATP-competitive inhibitors may be effective in IM-resistant patients. However, an ATP-competitive inhibitor that can inhibit the phosphorylation of T315I Bcr-Abl has not yet been developed. Instead, ATP noncompetitive inhibitors, such as ON012380, Aurora kinase inhibitor MK0457 (VX-680), and p38 MAP kinase inhibitor BIRB-796, have been developed to address this problem. This review provides an update on the underlying pathophysiologies of disease progression and IM resistance, and discusses the development of new targeted TK inhibitors for managing CML and the importance of future strategies targeting CML stem cells.

IT 592543-24-3, ON 012380

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(Bcr-Abl tyrosine kinase inhibitors Gleevec, dasatinib, AP23464, SKI-606, PD166326, nilotinib, INNO-406, ON012380, MK0457 and BIRB-796 may be useful in treatment of patient with Philadelphia chromosome-pos. chronic myeloid leukemia)

RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 134 THERE ARE 134 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:996362 CAPLUS

DOCUMENT NUMBER: 147:442786

TITLE: Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma

AUTHOR(S): Li, Jing; Zhao, Ming; Jimeno, Antonio; He, Ping; Reddy, M. V. Ramana; Hidalgo, Manuel; Donehower, Ross C.; Rudek, Michelle A.

CORPORATE SOURCE: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, 21231, USA

SOURCE: Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences (2007), 856(1-2), 198-204

CODEN: JCBAAI; ISSN: 1570-0232

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A reverse-phase high performance liquid chromatog. method with tandem mass spectrometry (LC-MS/MS) was developed and validated for the quantitation of ON 01910.Na, a novel synthetic benzyl styryl sulfone, in human plasma. The assay involved a simple sample preparation with acetonitrile protein precipitation

ON 01910.Na and the internal standard temazepam were separated on a Waters X-Terra

MS C18 column with mobile phase of acetonitrile containing 0.1% formic acid /10 mM ammonium acetate (55:45, volume/volume) using isocratic flow at 0.2 mL/min for 5 min. The analytes were monitored by tandem-mass spectrometry with electrospray pos. ionization. Two calibration curves were generated over the range of 10-2000 ng/mL and 100-20,000 ng/mL. The lower limit of quantitation (LLOQ) was 10 ng/mL for ON 01910.Na in human plasma. The accuracy and within- and between-day precisions were within the acceptance criteria for bioanal. assays. ON 01910.Na was found stable in plasma at

-70° for at least 1 yr. The method was successfully applied to characterize the plasma concentration-time profiles of ON 01910.Na in the cancer

patients in the Phase I study.

IT 592542-59-1, ON 01910 592542-60-4


RL: ANT (Analyte); ANST (Analytical study)

(validation and implementation of liquid chromatog./tandem mass spectrometry assay to quantitate ON 01910.Na as mitotic progression modulator, in human plasma)

RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-60-4 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, sodium salt (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● Na

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 21 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:913575 CAPLUS

DOCUMENT NUMBER: 147:439685

TITLE: Evaluation of novel cell cycle inhibitors in mantle cell lymphoma

AUTHOR(S): Park, I.-W.; Reddy, M. V. R.; Reddy, E. P.; Groopman, J. E.

CORPORATE SOURCE: Department of Medicine, Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

SOURCE: Oncogene (2007), 26(38), 5635-5642

CODEN: ONCNES; ISSN: 0950-9232

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Signature abnormalities in the cell cycle and apoptotic pathway have been identified in mantle cell lymphoma (MCL), affording the opportunity to develop targeted therapies. In this study, we tested a novel class of kinase inhibitors, styryl sulfones, which differ from prior cell cycle inhibitors in that they are not related to purines or pyrimidines. We observed that two closely related compds., ON013100 and ON01370, altered the growth and cell cycle status of MCL lines and potently inhibited the expression of several important mols., including cyclin-dependent kinase 4, p53, mouse double minute 2 (MDM2), and cyclin D as well as increased cyclin B expression. Using both terminal deoxy transferase uridine triphosphate nick end-labeling and poly ADP-ribose polymerase assays, we found that these compds. caused apoptosis in MCL cells. In addition, using mol. analyses, we observed the modulation of caspase-3 activity but not the expression of B-cell lymphoma family mols. Next, we investigated the cytotoxicity of the MCL lines upon treatment with styryl sulfone compds. in combination with other currently used chemotherapeutic agents, such as doxorubicin (DOX) or vincristine (VCR). We found that the combination of DOX plus styryl sulfone or VCR plus styryl sulfone increased cytotoxicity by one log scale, compared with the single styryl sulfone compound. Thus, styryl sulfones alone, or in combination with chemotherapeutic agents, present attractive opportunities for new drug development in MCL.


IT 952304-24-4, ON0 13100 952304-25-5, ON0 1370

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(effect of novel cell cycle inhibitors (ON013100 and ON01370) in mantle cell lymphoma)


RN 952304-24-4 CAPLUS

CN Phenol, 2-methoxy-5-[[[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)



RN 952304-25-5 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 22 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:414462 CAPLUS

DOCUMENT NUMBER: 147:31006

TITLE: Synthesis of a new class of sulfone linked
bisheterocycles

AUTHOR(S): Padmavathi, Venkatapuram; Reddy, Boreddy Chandra
Obula; Mohan, Annaji Venkata Nagendra; Padmaja,
Adivireddy

CORPORATE SOURCE: Department of Chemistry, Sri Venkateswara University,
Tirupati, 517 502, India

SOURCE: Journal of Heterocyclic Chemistry (2007), 44(2),
459-462

CODEN: JHTCAD; ISSN: 0022-152X

PUBLISHER: HeteroCorporation

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:31006

AB Some bis-heterocycles, 2-[(pyrrol-3-ylsulfonyl)methyl]oxazolines and
-thiazolines, were synthesized from (Z-styrylsulfonyl)acetates by
cyclocondensation with ethanolamine or ethanethiolamine using samarium
chloride.

IT 938076-04-1P 938076-06-3P 938076-08-5P

938076-11-0P 938076-13-2P 938076-15-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of [(pyrrolylsulfonyl)methyl]oxazolines and -thiazolines by
condensation of (styrylsulfonyl)acetates with ethanol- or
ethanethiolamine using samarium chloride catalyst)

RN 938076-04-1 CAPLUS

CN Oxazole, 4,5-dihydro-2-[[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 938076-06-3 CAPLUS

CN Oxazole, 4,5-dihydro-2-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 938076-08-5 CAPLUS

CN Oxazole, 2-[[[(1Z)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-4,5-dihydro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 938076-11-0 CAPLUS

CN Thiazole, 4,5-dihydro-2-[[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 938076-13-2 CAPLUS

CN Thiazole, 4,5-dihydro-2-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 938076-15-4 CAPLUS

CN Thiazole, 2-[[[(1Z)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-4,5-dihydro-
(CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:345370 CAPLUS

DOCUMENT NUMBER: 147:39590

TITLE: Development and validation of a sensitive liquid chromatographic method for the analysis of a novel radioprotectant: ON 01210.Na

AUTHOR(S): Fernandes, Parina P.; Maniar, Manoj; Dash, Alekha K.
CORPORATE SOURCE: Department of Pharmacy Sciences, Creighton University Medical Centre, Omaha, NE, 68178, USA

SOURCE: Journal of Pharmaceutical and Biomedical Analysis (2007), 43(5), 1796-1803
CODEN: JPBADA; ISSN: 0731-7085

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB ON 01210.Na is a chlorobenzylsulfone derivative with potential property to mitigate the effects of accidental or intentional exposure to life threatening levels of radiation. A simple and sensitive HPLC method was developed and validated for the assay of ON 01210.Na. The isocratic system used a mobile phase consisting of acetonitrile:0.1% trifluoroacetic acid in water (60:40, volume/volume) at a flow rate of 1 mL/min. The method used a C-18 Gemini column (250 mm + 4.6 mm) with column effluents monitored at 254 nm. Forced degradation of the drug was achieved by autoclaving ON 01210.Na with 0.05N HCl, 0.05N NaOH or 1.5% (volume/volume) hydrogen peroxide. The assay validation parameters evaluated include specificity, linearity, precision, accuracy and sensitivity. The retention time of the drug and the other effluents were well within 7 min. Standard curves were linear over the concentration range of 10-500 µg/mL. The R.S.D. values for the within-day and day-to-day precision ranged from 0.4 to 2.5 and 2.2 to 4.4%, resp. The R.S.D. for accuracy measurement ranged from 0.85 to 1.7%. The critical level, the detection level and the determination

level for this assay were 2.86±0.67, 5.69±0.67 and 15.6±1.8 µg/mL, resp. A simple, sensitive and stability indicating HPLC assay was developed and validated for the anal. of a novel radioprotectant. This method was used to evaluate the aqueous as well as solid-state stability of this drug during autoclaving.

IT 922139-31-9, ON 01210.Na


RL: ANT (Analyte); ANST (Analytical study)

(development and validation of a sensitive liquid chromatog. method for anal. of ON01210.Na)

RN 922139-31-9 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-, sodium salt (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● Na

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 24 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:146818 CAPLUS
DOCUMENT NUMBER: 146:190592
TITLE: Formulation of radioprotective α , β
unsaturated aryl sulfones
INVENTOR(S): Maniar, Manoj; Bell, Stanley C.
PATENT ASSIGNEE(S): Onconova Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007016201	A2	20070208	WO 2006-US29109	20060728
WO 2007016201	A3	20090416		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2006275822	A1	20070208	AU 2006-275822	20060728
CA 2617147	A1	20070208	CA 2006-2617147	20060728
EP 1909775	A2	20080416	EP 2006-788612	20060728
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			

JP 2009502943	T	20090129	JP 2008-524129	20060728
IN 2008KN00381	A	20081212	IN 2008-KN381	20080128
KR 2008046164	A	20080526	KR 2008-704185	20080221
PRIORITY APPLN. INFO.:			US 2005-704236P	P 20050729
			WO 2006-US29109	W 20060728

OTHER SOURCE(S): MARPAT 146:190592


AB A pharmaceutical composition is provided for administration prior to or after exposure to ionizing radiation for reducing toxic effects of the radiation in a subject. An effective amount of the pharmaceutical composition provided comprising an effective amount of at least one radioprotective α , β unsatd. aryl sulfone, and at least one component selected from the group consisting of a) at least one water soluble polymer in an amount between about 0.5% and about 90% w/v, b) at least one chemical modified cyclodextrin in an amount between about 20% and about 60% w/v, and c) N,N-dimethylacetamide in an amount between about 10% and about 50% w/v.

IT 334969-03-8 922139-31-9
RL: ANT (Analyte); PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
(formulation of radioprotectant unsatd. aryl sulfones)

RN 334969-03-8 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 922139-31-9 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-, sodium salt (1:1) (CA INDEX NAME)


Double bond geometry as shown.



● Na


IT 158606-44-1 222639-19-2 300699-33-6
334969-61-8 334970-03-5 457624-55-4
457624-56-5 457624-57-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(formulation of radioprotectant unsatd. aryl sulfones)
RN 158606-44-1 CAPLUS
CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)

Double bond geometry as shown.




RN 222639-19-2 CAPLUS
CN Benzene, 1-fluoro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)

Double bond geometry as shown.




RN 300699-33-6 CAPLUS
CN Benzene, 1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-4-
(trifluoromethyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 334969-61-8 CAPLUS
CN Pyridine, 4-[(1E)-2-[[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 334970-03-5 CAPLUS

CN Furan, 3-[(1E)-2-[(2,4-dichlorophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-55-4 CAPLUS

CN Benzene, 1-methoxy-2-[(1E)-2-[(4-nitrophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-56-5 CAPLUS

CN Benzene, 1,2,3,4,5-pentafluoro-6-[(1E)-2-[(4-methoxyphenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-57-6 CAPLUS

CN Phenol, 4-[(1E)-2-[[4-(4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 25 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:81706 CAPLUS

DOCUMENT NUMBER: 146:219955

TITLE: Targeted anti-mitotic therapies: can we improve on tubulin agents?

AUTHOR(S): Jackson, Jeffrey R.; Patrick, Denis R.; Dar, Mohammed M.; Huang, Pearl S.

CORPORATE SOURCE: Oncology Center of Excellence in Drug Discovery, Departments of Biology and Discovery Medicine, GlaxoSmithKline, Collegeville, PA, USA

SOURCE: Nature Reviews Cancer (2007), 7(2), 107-117

CODEN: NRCAC4; ISSN: 1474-175X

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. The advent of molecularly targeted drug discovery has facilitated the identification of a new generation of anti-mitotic therapies that target proteins with specific functions in mitosis. The exquisite selectivity for mitosis and the distinct ways in which these new agents interfere with mitosis provides the potential to not only overcome certain limitations of current tubulin-targeted anti-mitotic drugs, but to expand the scope of clin. efficacy that those drugs have established. The development of these new anti-mitotic drugs as targeted therapies faces significant challenges; nevertheless, these potential therapies also serve as unique tools to dissect the mol. mechanisms of the mitotic-checkpoint response.


IT 592542-59-1, ON01910

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(targeted anti-mitotic therapies: can we improve on tubulin agents)

RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 53 THERE ARE 53 CAPLUS RECORDS THAT CITE THIS
RECORD (53 CITINGS)
REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 26 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:14449 CAPLUS
DOCUMENT NUMBER: 146:93517
TITLE: Methods of use of non-ATP competitive tyrosine kinase
inhibitors to treat pathogenic infection
INVENTOR(S): Kalman, Daniel; Bornmann, William Gerard
PATENT ASSIGNEE(S): Emory University, USA
SOURCE: PCT Int. Appl., 85pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007002441	A1	20070104	WO 2006-US24539	20060623
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2005-694032P	P 20050624

OTHER SOURCE(S): MARPAT 146:93517

AB Compns. and methods are provided for using non-ATP competitive tyrosine kinase inhibitors to treat pathogenic infection. In particular, methods for using non-ATP competitive inhibitors such as amino-substituted (E)-2,6-dialkoxystyryl 4-substituted- benzylsulfones, particularly ON012380, to treat pathogenic infection are provided. Infections to be treated according to the present invention include, particularly, those caused by microbial pathogens such as bacteria and viruses.

IT 592542-82-0 592542-83-1 592542-83-1D, derivs., metabolites, salts, and enantiomers 592542-85-3 592542-85-3D, derivs., metabolites, salts, and enantiomers 592542-88-6 592542-88-6D, derivs., metabolites, salts, and enantiomers 592542-89-7 592542-89-7D, derivs., metabolites, salts, and enantiomers 592542-90-0 592542-90-0D, derivs., metabolites, salts, and enantiomers 592542-91-1 592542-91-1D, derivs., metabolites, salts, and enantiomers 592542-92-2 592542-92-2D, derivs., metabolites, salts, and enantiomers 592542-93-3 592542-93-3D, derivs., metabolites, salts, and enantiomers 592542-95-5 592542-95-5D, derivs., metabolites, salts, and enantiomers 592543-01-6 592543-01-6D, derivs., metabolites, salts, and enantiomers 592543-05-0 592543-05-0D, derivs., metabolites, salts, and enantiomers 592543-09-4 592543-09-4D, derivs., metabolites, salts, and enantiomers 592543-13-0 592543-13-0D, derivs., metabolites, salts, and enantiomers 592543-14-1 592543-14-1D, derivs., metabolites, salts, and enantiomers 592543-15-2 592543-15-2D, derivs., metabolites, salts, and enantiomers 592543-17-4 592543-17-4D, derivs., metabolites, salts, and enantiomers 592543-18-5 592543-18-5D, derivs., metabolites, salts, and enantiomers 592543-24-3, ON 012380


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(non-ATP competitive tyrosine kinase inhibitors for treatment of pathogenic infection)

RN 592542-82-0 CAPLUS

CN Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-83-1 CAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-83-1 CAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-85-3 CAPLUS

CN Acetamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-85-3 CAPLUS

CN Acetamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-88-6 CAPLUS

CN Propanamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-88-6 CAPLUS

CN Propanamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-89-7 CAPLUS

CN Ethanaminium, N,N,N-triethyl-2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-89-7 CAPLUS

CN Ethanaminium, N,N,N-triethyl-2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-90-0 CAPLUS

CN Ethanaminium, N,N,N-tris(2-hydroxyethyl)-2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-90-0 CAPLUS

CN Ethanaminium, N,N,N-tris(2-hydroxyethyl)-2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-91-1 CAPLUS

CN Propanamide, 2-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-91-1 CAPLUS

CN Propanamide, 2-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-92-2 CAPLUS

CN Propanamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-92-2 CAPLUS

CN Propanamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-93-3 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-93-3 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-95-5 CAPLUS

CN Methanesulfonamide, 1,1,1-trifluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-95-5 CAPLUS

CN Methanesulfonamide, 1,1,1-trifluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-01-6 CAPLUS

CN Butanedioic acid, 1-[2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxoethyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-01-6 CAPLUS

CN Butanedioic acid, 1-[2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxoethyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-05-0 CAPLUS

CN Acetamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2-(phosphonooxy)-, sodium salt (1:2) (CA INDEX NAME)

Double bond geometry as shown.




●2 Na

RN 592543-05-0 CAPLUS

CN Acetamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2-(phosphonoxy)-, sodium salt (1:2) (CA INDEX NAME)

Double bond geometry as shown.




●2 Na

RN 592543-09-4 CAPLUS

CN Carbamic acid, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-09-4 CAPLUS

CN Carbamic acid, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-13-0 CAPLUS

CN Propanamide, 2,2,3,3,3-pentafluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-13-0 CAPLUS

CN Propanamide, 2,2,3,3,3-pentafluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-14-1 CAPLUS

CN Propanoic acid, 2,2-difluoro-3-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-3-oxo-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-14-1 CAPLUS

CN Propanoic acid, 2,2-difluoro-3-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-3-oxo-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-15-2 CAPLUS

CN Butanoic acid, 2,2,3,3-tetrafluoro-4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-4-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-15-2 CAPLUS

CN Butanoic acid, 2,2,3,3-tetrafluoro-4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-4-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-17-4 CAPLUS

CN Propanoic acid, 2,2-difluoro-3-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-3-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-17-4 CAPLUS

CN Propanoic acid, 2,2-difluoro-3-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-3-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-18-5 CAPLUS

CN Acetamide, 2-(dimethylamino)-2,2-difluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-18-5 CAPLUS

CN Acetamide, 2-(dimethylamino)-2,2-difluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1034395 CAPLUS

DOCUMENT NUMBER: 145:397217

TITLE: (Trimethoxystyrylsulfonylmethyl)benzeneamine derivatives and their preparation, pharmaceutical compositions and methods for the treatment of proliferative diseases

INVENTOR(S): Reddy, E., Premkumar; Holland, James F.

PATENT ASSIGNEE(S): Temple University - of the Commonwealth System of Higher Education, USA; Mount Sinai School of Medicine of New York University

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006104668	A2	20061005	WO 2006-US8704	20060310
WO 2006104668	A3	20071206		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			



US 20080161252 A1 20080703 US 2007-885770 20070906

PRIORITY APPLN. INFO.: US 2005-660784P P 20050311

WO 2006-US8704 W 20060310

OTHER SOURCE(S): CASREACT 145:397217; MARPAT 145:397217

GI



AB Methods and compns. are provided for treating proliferative disorders, wherein the composition comprises at least one compound according to Formula I. Comps. of formula I wherein R1 is OH, NH₂, NH-CH₂-CO₂H, NH-CH(CH₃)-CO₂H, and NH-C(CH₃)₂-CO₂H; and their pharmaceutically acceptable salt and at least one chemotherapeutic agent selected from anthracycline and platin and their pharmaceutically acceptable salt thereof, are claimed. Example compound II was prepared by alkylation of (E)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxybenzenamine with Me bromoacetate to give the Me ester of II, which underwent hydrolysis to give compound II. All the invention compds. were evaluated for their antiproliferative activity.


IT 592542-50-2P 592542-59-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of
(trimethoxystyrylsulfonylmethyl)benzenamine derivs. and their use for
treatment of proliferative disorders)

RN 592542-50-2 CAPLUS

CN Benzenamine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 592542-60-4P 592542-82-0P 865783-95-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of (trimethoxystyrylsulfonylmethyl)benzenamine derivs. and their use for treatment of proliferative disorders)

RN 592542-60-4 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, sodium salt (1:1) (CA INDEX NAME)

Double bond geometry as shown.




● Na

RN 592542-82-0 CAPLUS

CN Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865783-95-5 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 592542-52-4P 592542-61-5P 911294-96-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(intermediate; preparation of (trimethoxystyrylsulfonylmethyl)benzenamine
derivs. and their use for treatment of proliferative disorders)

RN 592542-52-4 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[(4-methoxy-3-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-61-5 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 911294-96-7 CAPLUS

CN Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 28 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:884824 CAPLUS

DOCUMENT NUMBER: 145:292708

TITLE: Synthesis of (E)- α,β -unsaturated sulfides, sulfones, sulfoxides and sulfonamides

INVENTOR(S): Reddy, M. V. Ramana; Reddy, E. Premkumar; Bell, Stanley C.

PATENT ASSIGNEE(S): Temple University- Of the Commonwealth System of Higher Education, USA; Onconova Therapeutics Inc.

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006091870	A2	20060831	WO 2006-US6698	20060224
WO 2006091870	A3	20070118		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006216544	A1	20060831	AU 2006-216544	20060224
CA 2599169	A1	20060831	CA 2006-2599169	20060224
EP 1896401	A2	20080312	EP 2006-736103	20060224
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
IN 2007DN06611	A	20070921	IN 2007-DN6611	20070827
US 20090124828	A1	20090514	US 2007-884601	20070924
PRIORITY APPLN. INFO.:			US 2005-656204P	P 20050225

WO 2006-US6698

W 20060224

OTHER SOURCE(S):


CASREACT 145:292708; MARPAT 145:292708

AB α,β -Unsatd. sulfides, sulfones, sulfoxides and sulfonamides
 (E)-Ar1X(R)SOnCH:CHAR2 (Ar1, Ar2 = aryl, heteroaryl; X = N, CH; n = 0, 1, 2; R = H, C1-C8 hydrocarblyl) are prepared by dehydration of β -hydroxy sulfides, sulfones, sulfoxides or sulfonamides.

IT 93468-07-6P 118672-28-9P 118672-29-0P
 216007-67-9P, (E)-1-Methoxy-4-[(styrylsulfinyl)methyl]benzene
 222639-33-0P 300699-95-0P 592542-50-2P
 592542-59-1P 592542-82-0P 851799-51-4P
 852283-21-7P, (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxybenzenamine 852283-22-8P,
 (E)-5-[[2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenol
 852283-27-3P, (E)-2-[[5-[[2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenyl]amino]ethanoic acid 852283-45-5P
 852284-78-7P, (E)-1-[[4-Chlorostyryl)sulfinyl]methyl]-4-methoxybenzene 852284-85-6P,
 1-[(E)-2-(Benzylsulfinyl)ethenyl]-4-chlorobenzene 852284-86-7P
 , (E)-1-[[4-Fluorostyryl)sulfinyl]methyl]-4-chlorobenzene
 852284-87-8P, (E)-1-[[4-Chlorostyryl)sulfinyl]methyl]-4-chlorobenzene 865783-95-5P,
 (E)-5-[[2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenol
 889862-10-6P 908343-87-3P 908343-95-3P
 908343-96-4P 908343-98-6P,
 1-[(E)-2-(Benzylsulfinyl)ethenyl]-4-fluorobenzene 908344-00-3P
 , 1-[(E)-2-(Benzylsulfinyl)ethenyl]-4-iodobenzene 908344-03-6P
 , (E)-1-[[4-Methoxystyryl)sulfinyl]methyl]-4-methoxybenzene
 908344-04-7P, (E)-1-[[4-Bromostyryl)sulfinyl]methyl]-4-chlorobenzene 908344-05-8P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (preparation of (E)- α,β -unsatd. sulfides, sulfones, sulfoxides, and sulfonamides)


RN 93468-07-6 CAPLUS
 CN Benzene, 1-chloro-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 118672-28-9 CAPLUS
 CN Benzene, 1-chloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-29-0 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 216007-67-9 CAPLUS

CN Benzene, 1-methoxy-4-[[[(1E)-2-phenylethenyl]sulfinyl]methyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 222639-33-0 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[4-(4-chlorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-95-0 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 592542-50-2 CAPLUS

CN Benzenamine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-82-0 CAPLUS

CN Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-51-4 CAPLUS

CN Benzenecetic acid, α -[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-21-7 CAPLUS

CN Benzenamine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 852283-22-8 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-

trimethoxyphenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-27-3 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 852283-45-5 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 852284-78-7 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[(4-methoxyphenyl)methyl]sulfinyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-85-6 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[(phenylmethyl)sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-86-7 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-87-8 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 865783-95-5 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 889862-10-6 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 908343-87-3 CAPLUS

CN Benzene, 1-methoxy-4-[[[(1E)-2-(4-methoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 908343-95-3 CAPLUS

CN Benzene, 1-iodo-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 908343-96-4 CAPLUS

CN Benzene, 1-methoxy-4-[[[(1E)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 908343-98-6 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[(phenylmethyl)sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 908344-00-3 CAPLUS

CN Benzene, 1-iodo-4-[(1E)-2-[(phenylmethyl)sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 908344-03-6 CAPLUS

CN Benzene, 1-methoxy-4-[[[(1E)-2-(4-methoxyphenyl)ethenyl]sulfinyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 908344-04-7 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[4-chlorophenyl]methyl]sulfinyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 908344-05-8 CAPLUS

CN Benzeneacetic acid, α -[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]- (CA INDEX NAME)

Double bond geometry as shown.




IT 300699-94-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of (E)- α,β -unsatd. sulfides, sulfones, sulfoxides,
and sulfonamides)

RN 300699-94-9 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)

Double bond geometry as shown.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 29 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:678223 CAPLUS

DOCUMENT NUMBER: 145:137820

TITLE: Treatment of drug-resistant proliferative disorders

INVENTOR(S): Reddy, Ramana M. V.; Reddy, Premkumar E.; Cosenza,
Stephen C.; Baker, Stacey J.PATENT ASSIGNEE(S): Temple University-of the Commonwealth System of Higher
Education, USA

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006074149	A2	20060713	WO 2006-US59	20060104

WO 2006074149 A3 20071115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
AU 2006204103 A1 20060713 AU 2006-204103 20060104
CA 2593523 A1 20060713 CA 2006-2593523 20060104
EP 1841420 A2 20071010 EP 2006-717284 20060104
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU
JP 2008526852 T 20080724 JP 2007-550417 20060104
KR 2007094956 A 20070927 KR 2007-718000 20070803
PRIORITY APPLN. INFO.: US 2005-641378P P 20050105
WO 2006-US59 W 20060104

OTHER SOURCE(S): MARPAT 145:137820


AB The invention discloses a method of treating a protein kinase-dependent proliferative disorder, particularly cancer, in an individual, which disorder is resistant to treatment with an ATP-competitive protein kinase inhibitor, said method comprising administering to the individual in need of such treatment an effective amount of at least one compound according to the formula Ar1XRSONCH=CHAr2 where Ar1 and Ar2 are independently selected from substituted and unsubstituted aryl and substituted and unsubstituted heteroaryl; X = N or CH; n = 1 or 2; and R = H or (C1-C8)hydrocarbyl.

IT 592542-82-0
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)

RN 592542-82-0 CAPLUS

CN Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 592542-59-1 592543-23-2 592543-24-3
851799-47-8 851799-49-0 851799-50-3
851799-51-4 852283-27-3 852283-45-5
897013-49-9


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(treatment of drug-resistant proliferative disorders resistant to
ATP-competitive protein kinase inhibitors)

RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 592543-23-2 CAPLUS

CN D-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 851799-47-8 CAPLUS

CN Benzene, 1-[(1E)-2-[[[4-bromophenyl)methyl]sulfonyl]ethenyl]-2,4-difluoro-
(CA INDEX NAME)

Double bond geometry as shown.




RN 851799-49-0 CAPLUS

CN Benzeneacetic acid, α -[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-, (α R)- (CA
INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 851799-50-3 CAPLUS

CN Benzeneacetic acid, α -[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-, (α S)- (CA
INDEX NAME)

INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 851799-51-4 CAPLUS

CN Benzeneacetic acid, α -[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-27-3 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-45-5 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 897013-49-9 CAPLUS

CN Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, monosodium salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● Na

L3 ANSWER 30 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:617883 CAPLUS

DOCUMENT NUMBER: 145:448456

TITLE: The second generation of BCR-ABL tyrosine kinase inhibitors

AUTHOR(S): Tauchi, Tetsuzo; Ohyashiki, Kazuma

CORPORATE SOURCE: First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan

SOURCE: International Journal of Hematology (2006), 83(4), 294-300

CODEN: IJHEEY; ISSN: 0925-5710

PUBLISHER: Carden Jennings Publishing

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Imatinib was developed as the first molecularly targeted therapy to specifically inhibit the BCR-ABL kinase in Philadelphia chromosome (Ph)-pos. chronic myeloid leukemia (CML). Because of the excellent hematol. and cytogenetic responses, imatinib has moved toward first-line treatment for newly diagnosed CML. However, the emergence of resistance to imatinib remains a major problem in the treatment of Ph-pos. leukemia. Several mechanisms of imatinib resistance have been identified, including BCR-ABL gene amplification that leads to overexpression of the BCR-ABL protein, point mutations in the BCR-ABL kinase domain that interfere with imatinib binding, and point mutations outside of the kinase domain that allosterically inhibit imatinib binding to BCR-ABL. The need for alternative or addnl. treatment for imatinib-resistant BCR-ABL-pos. leukemia has guided the way to the design of a second generation of targeted therapies, which has resulted mainly in the development of novel small-mol. inhibitors such as AMN107, dasatinib, NS-187, and ON012380. The major goal of these efforts is to create new compds. that are more potent than imatinib and/or more effective against imatinib-resistant BCR-ABL clones. In this review, we discuss the next generation of BCR-ABL kinase inhibitors for overcoming imatinib resistance.

IT 592543-24-3, ON 012380


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(BCR-ABL tyrosine kinase inhibitors of second generation like AMN107, dasatinib, NS-187 and ON012380 were more potent than imatinib and effective against imatinib-resistant BCR-ABL clones)

RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 31 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:501328 CAPLUS

DOCUMENT NUMBER: 146:242788

TITLE: Research development of inhibitors against Gleevec (STI-571)-resistant Bcr-Abl protein tyrosine kinase

AUTHOR(S): Wang, Li-sheng; Yu, Hai-xia; Guo, Xin; Xiao, Jun-hai; Li, Song

CORPORATE SOURCE: College of Chemistry and Chemical Engineering, Guangxi University, Guangxi, 530004, Peop. Rep. China

SOURCE: Guangxi Daxue Xuebao, Ziran Kexueban (2006), 31(1), 10-14, 48

CODEN: GDXZEB; ISSN: 1001-7445

PUBLISHER: Guangxi Daxue Xuebao Bianjibu

DOCUMENT TYPE: Journal; General Review

LANGUAGE: Chinese

AB A review. On research development of inhibitors against Gleevec (STI-571)-resistant Bcr-Abl protein tyrosine kinase, four inhibitors BMS354825, AMN107, ON012380 and PD166326 were reviewed.

IT 592543-24-3, ON 012380


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ON 012380; research development of inhibitors against Gleevec-resistant Bcr-Abl protein tyrosine kinase)

RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L3 ANSWER 32 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:391110 CAPLUS

DOCUMENT NUMBER: 145:471042

TITLE: Michael addition of active methylene compounds to α,β -unsaturated sulfones. [Erratum to document cited in CA145:418413]

AUTHOR(S): Padmavathi, V.; Subbaiah, D. R. C. Venkata; Balaiah, A.; Reddy, B. Chandra Obula; Padmaja, A.

CORPORATE SOURCE: Department of Chemistry, Sri Venkateswara University, Tirupati, 517 502, India

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2006), 45B(4), 1092

CODEN: IJSBDB; ISSN: 0376-4699

PUBLISHER: National Institute of Science Communication and Information Resources

DOCUMENT TYPE: Journal

LANGUAGE: English

AB On page 2570, Scheme II is incorrect; the chemical structures in Scheme II are incorrectly depicted and are those from Scheme III. The corrected version of Scheme II is given.


IT 911833-17-5 911833-20-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(Michael addition of active methylene compds. to α,β -unsatd. sulfones (Erratum))


RN 911833-17-5 CAPLUS

CN Benzene, 1-chloro-4-[[(2-phenylethenyl)sulfonyl]methyl]- (CA INDEX NAME)



RN 911833-20-0 CAPLUS

CN Benzene, 1-chloro-4-[[[2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)



L3 ANSWER 33 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:349040 CAPLUS

DOCUMENT NUMBER: 145:45751

TITLE: The epoxy-Ramberg-Baecklund reaction (ERBR): a sulfone-based method for the synthesis of allylic alcohols

AUTHOR(S): Evans, Paul; Johnson, Paul; Taylor, Richard J. K.

CORPORATE SOURCE: Department of Chemistry, University of York, Heslington, York, YO10 5DD, UK

SOURCE: European Journal of Organic Chemistry (2006), (7), 1740-1754

CODEN: EJOCFK; ISSN: 1434-193X

PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:45751

AB The epoxy-Ramberg-Baecklund reaction (ERBR) is outlined, in which α,β -epoxy sulfones are converted into a range of mono-, di- and tri-substituted allylic alcs., on treatment with base. Modification of this method enabled the preparation of enantio-enriched allylic alcs. following the diastereoselective epoxidn. of enantio-enriched vinyl sulfones that were accessed efficiently from the chiral pool. An example allylic alc. compound thus prepared was (-)-(2R,3S,4E)-5-phenyl-4-pentene-1,2,3-triol. The scope, optimization and limitations of the ERBR as a method for the preparation of allylic alcs. are discussed.

IT 32093-01-9P 889862-09-3P 889862-10-6P

889862-11-7P 889862-12-8P 889862-13-9P

889862-14-0P 889862-46-8P 889862-52-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of allylic alcs. via formation of alkenyl sulfone derivs. and sequential epoxy-Ramberg-Baecklund reaction of intermediate (sulfonyl)epoxide derivs.)

RN 32093-01-9 CAPLUS

CN Benzene, [[[(1E)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 889862-09-3 CAPLUS

CN Benzene, 1-nitro-3-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 889862-10-6 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 889862-11-7 CAPLUS

CN Pyridine, 3-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 889862-12-8 CAPLUS

CN Pyridine, 2-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 889862-13-9 CAPLUS

CN Naphthalene, 2-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 889862-14-0 CAPLUS

CN 1,1'-Biphenyl, 4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 889862-46-8 CAPLUS

CN Benzene, [1-[(1E)-2-phenylethenyl]sulfonyl]ethyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 889862-52-6 CAPLUS

CN 1,3-Dioxolane, 2,2-dimethyl-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



IT 889862-15-1P 889862-16-2P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of allylic alcs. via formation of alkenyl sulfone derivs. and

sequential epoxy-Ramberg-Baecklund reaction of intermediate
(sulfonyl)epoxide derivs.)

RN 889862-15-1 CAPLUS

CN Benzene, 1-methoxy-2-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 889862-16-2 CAPLUS

CN Furan, 2-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 34 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:288947 CAPLUS

DOCUMENT NUMBER: 145:39705

TITLE: Targeting polo-like kinase 1 for cancer therapy

AUTHOR(S): Strebhardt, Klaus; Ullrich, Axel

CORPORATE SOURCE: Department of Obstetrics and Gynecology, School of Medicine, J.W. Goethe-University, Frankfurt, 60590, Germany

SOURCE: Nature Reviews Cancer (2006), 6(4), 321-330

CODEN: NRCAC4; ISSN: 1474-175X

PUBLISHER: Nature Publishing Group


DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Human polo-like kinase 1 (PLK1) is essential during mitosis and in the maintenance of genomic stability. PLK1 is overexpressed in human tumors and has prognostic potential in cancer, indicating its involvement in carcinogenesis and its potential as a therapeutic target. The use of different PLK1 inhibitors has increased our knowledge of mitotic regulation and allowed us to assess their ability to suppress tumor growth in vivo. We address the structural features of the kinase domain and the unique polo-box domain of PLK1 that are most suited for drug development and discuss our current understanding of the therapeutic potential of PLK1.

IT 592542-59-1, ON 01910
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(targeting polo-like kinase 1 for cancer therapy)
RN 592542-59-1 CAPLUS
CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 109 THERE ARE 109 CAPLUS RECORDS THAT CITE THIS
RECORD (109 CITINGS)
REFERENCE COUNT: 129 THERE ARE 129 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 35 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:75198 CAPLUS
DOCUMENT NUMBER: 144:177462
TITLE: Parenteral formulations of (E)-2,6-dialkoxystyryl
4-substituted benzylsulfones for treatment of abnormal
cell proliferation
INVENTOR(S): Bell, Staneley C.; Wong, Albert; Maniar, Manoj
PATENT ASSIGNEE(S): Onconova Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006010152	A2	20060126	WO 2005-US25224	20050715
WO 2006010152	A3	20060908		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,				

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

AU 2005265412	A1	20060126	AU 2005-265412	20050715
CA 2574491	A1	20060126	CA 2005-2574491	20050715
EP 1773353	A2	20070418	EP 2005-773490	20050715
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008506777	T	20080306	JP 2007-522592	20050715
IN 2007KN00499	A	20090403	IN 2007-KN499	20070209
US 20090036462	A1	20090205	US 2008-658054	20080806
PRIORITY APPLN. INFO.:			US 2004-589075P	P 20040719
			WO 2005-US25224	W 20050715

OTHER SOURCE(S): MARPAT 144:177462


AB Parenteral formulations are provided comprising (i) amino substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones and the sodium and potassium salts thereof, and (ii) at least about 50% by weight of at least one water-soluble polymer for the prevention and/or treatment of conditions mediated by abnormal cell proliferation. The water-soluble polymer is selected from polyethylene glycol (PEG), polyoxyethylene, polyoxyethylene-polyoxypropylene copolymers, polyglycerol, polyvinyl alc., polyvinylpyrrolidone (PVP), polyvinylpyridine N-oxide, and copolymer of vinylpyridine N-oxide and vinylpyridine. For example, (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulfone Na salt (ON 01910.Na, Novonex) was prepared and formulated into a stable parenteral solution containing Novonex 75 mg/mL and 50% PEG-400 in 0.016 M phosphate buffer, pH 10. Dilution of this product 1:7 with 0.00025 M phosphoric acid, for example, yielded a product that has a pH of about 7.4 and osmolarity of approx. 300 mOsm/kg.

IT 592542-60-4P, ON 01910 sodium salt
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Novonex; parenteral formulations of dialkoxystyryl benzylsulfones containing water-soluble polymer for prevention and/or treatment of abnormal cell proliferation)

RN 592542-60-4 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, sodium salt (1:1) (CA INDEX NAME)


Double bond geometry as shown.



● Na


IT 592542-50-2P, ON 01500 592542-61-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (parenteral formulations of dialkoxystyryl benzylsulfones containing
 water-soluble polymer for prevention and/or treatment of abnormal cell
 proliferation)
 RN 592542-50-2 CAPLUS
 CN Benzenamine, 2-methoxy-5-[[[(1E)-2-(2,4,6-
 trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 592542-61-5 CAPLUS
 CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-
 trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, methyl ester (CA INDEX
 NAME)

Double bond geometry as shown.



IT 592542-52-4P


RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)

(parenteral formulations of dialkoxystyryl benzylsulfones containing
water-soluble polymer for prevention and/or treatment of abnormal cell
proliferation)

RN 592542-52-4 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[[4-methoxy-3-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT	592542-53-5	592542-55-7	592542-56-8
	592542-59-1, ON	01910	592542-62-6
	592542-63-7	592542-64-8	592542-66-0
	592542-67-1	592542-68-2	592542-69-3
	592542-70-6	592542-72-8	592542-74-0
	592542-76-2	592542-77-3	592542-78-4
	592542-81-9	592542-82-0	592542-83-1
	592542-84-2	592542-85-3	592542-86-4
	592542-87-5	592542-88-6	592542-89-7
	592542-90-0	592542-91-1	592542-92-2
	592542-93-3	592542-95-5	592542-97-7
	592542-99-9	592543-01-6	592543-03-8
	592543-05-0	592543-06-1	592543-08-3
	592543-09-4	592543-10-7	592543-11-8
	592543-12-9	592543-13-0	592543-14-1
	592543-15-2	592543-17-4	592543-18-5
	592543-20-9	592543-22-1	592543-23-2
	592543-24-3	874198-32-0	874198-33-1


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(parenteral formulations of dialkoxystyryl benzylsulfones containing

water-soluble polymer for prevention and/or treatment of abnormal cell proliferation)

RN 592542-53-5 CAPLUS

CN Acetic acid, 2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]sulfonyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-55-7 CAPLUS

CN Propanoic acid, 3-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-3-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-56-8 CAPLUS

CN Guanidine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-62-6 CAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-3,5-dinitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-63-7 CAPLUS

CN Benzamide, 3,5-diamino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-64-8 CAPLUS

CN Acetamide, 2-chloro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-66-0 CAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-67-1 CAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-4-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-68-2 CAPLUS

CN Benzamide, 4-amino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-69-3 CAPLUS

CN Benzenamine, 2-methoxy-N-[(4-nitrophenyl)methylene]-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 592542-70-6 CAPLUS

CN Hexanamide, 2,6-diamino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 592542-72-8 CAPLUS

CN Propanamide, 2-amino-3-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 592542-74-0 CAPLUS

CN Propanamide, 2-amino-3-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 592542-76-2 CAPLUS

CN Urea, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-77-3 CAPLUS

CN Benzenamine, 2-methoxy-N-methyl-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-78-4 CAPLUS

CN Acetamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-81-9 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-82-0 CAPLUS

CN Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-83-1 CAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-84-2 CAPLUS

CN Acetamide, 2-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-85-3 CAPLUS

CN Acetamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-86-4 CAPLUS

CN Pyridinium, 1-[2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxoethyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-87-5 CAPLUS

CN Propanamide, 2-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-88-6 CAPLUS

CN Propanamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-89-7 CAPLUS

CN Ethanaminium, N,N,N-triethyl-2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-90-0 CAPLUS

CN Ethanaminium, N,N,N-tris(2-hydroxyethyl)-2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-91-1 CAPLUS

CN Propanamide, 2-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-92-2 CAPLUS

CN Propanamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-93-3 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-95-5 CAPLUS

CN Methanesulfonamide, 1,1,1-trifluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-97-7 CAPLUS

CN Butanoic acid, 4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-4-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-99-9 CAPLUS

CN Butanoyl chloride, 4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-4-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-01-6 CAPLUS

CN Butanedioic acid, 1-[2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxoethyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-03-8 CAPLUS

CN	Pentanoic acid, 5-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-5-oxo-	(CA INDEX NAME)
----	---	-----------------


Double bond geometry as shown.



RN 592543-05-0 CAPLUS

CN Acetamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2-(phosphonooxy)-, sodium salt (1:2) (CA INDEX NAME)

Double bond geometry as shown.




●2 Na

RN 592543-06-1 CAPLUS

CN Butanoic acid, 4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-08-3 CAPLUS

CN β -Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-09-4 CAPLUS

CN Carbamic acid, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-10-7 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-11-8 CAPLUS

CN Butanoic acid, 4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-4-oxo-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-12-9 CAPLUS

Propanoic acid, 3-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-3-oxo-, ethyl ester
(CA INDEX NAME)


Double bond geometry as shown.



RN 592543-13-0 CAPLUS

CN Propanamide, 2,2,3,3,3-pentafluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-14-1 CAPLUS

CN Propanoic acid, 2,2-difluoro-3-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-3-oxo-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-15-2 CAPLUS

CN Butanoic acid, 2,2,3,3-tetrafluoro-4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-4-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-17-4 CAPLUS

CN Propanoic acid, 2,2-difluoro-3-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-3-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-18-5 CAPLUS

CN Acetamide, 2-(dimethylamino)-2,2-difluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-20-9 CAPLUS

CN Phosphoric acid, diethyl 2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxoethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-22-1 CAPLUS

CN Acetamide, 2-amino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-23-2 CAPLUS

CN D-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 874198-32-0 CAPLUS

CN Benzenesulfonamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2,4-dinitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 874198-33-1 CAPLUS

CN Benzenesulfonamide, 2,4-diamino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 36 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1050 CAPLUS


DOCUMENT NUMBER: 145:418413

TITLE: Michael addition of active methylene compounds to α,β -unsaturated sulfones

AUTHOR(S): Padmavathi, V.; Subbaiah, D. R. C. Venkata; Balaiah, A.; Reddy, B. Chandra Obula; Padmaja, A.
CORPORATE SOURCE: Department of Chemistry, Sri Venkateswara University, Tirupati, 517 502, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2005), 44B(12), 2569-2574
CODEN: IJSBDB; ISSN: 0376-4699
PUBLISHER: National Institute of Science Communication and Information Resources
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:418413
AB The Michael addition of di-Me malonate and Et cyanoacetate to α,β -unsatd. sulfones in the presence of Triton-B and K₂CO₃ was studied.
IT 911833-17-5 911833-20-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(Michael addition of active methylene compds. to α,β -unsatd. sulfones)
RN 911833-17-5 CAPLUS
CN Benzene, 1-chloro-4-[[(2-phenylethenyl)sulfonyl]methyl]- (CA INDEX NAME)



RN 911833-20-0 CAPLUS
CN Benzene, 1-chloro-4-[[[2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 37 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:135549 CAPLUS
DOCUMENT NUMBER: 144:81134
TITLE: Phosphorylation site of paired helical filament tau protein and related kinases and methods of screening for modulators useful in the treatment of Alzheimer's disease and related conditions

INVENTOR(S): Ward, Malcolm; Byers, Helen; Anderton, Brian Henry;
 Derkinderen, Pascal; Reynolds, Christopher Hugh;
 Williamson, Ritchie
 PATENT ASSIGNEE(S): Proteome Sciences PLC, UK; King's College London
 SOURCE: PCT Int. Appl., 72 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123048	A2	20051229	WO 2005-GB2475	20050621
WO 2005123048	A3	20060330		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005253776	A1	20051229	AU 2005-253776	20050621
CA 2571614	A1	20051229	CA 2005-2571614	20050621
EP 1794313	A2	20070613	EP 2005-755789	20050621
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008504022	T	20080214	JP 2007-517457	20050621
US 20080103107	A1	20080501	US 2007-630720	20070604
PRIORITY APPLN. INFO.:			US 2004-580901P	P 20040621
			WO 2005-GB2475	W 20050621
AB The present invention provides materials and methods relating to screening for compds. useful in the treatment of Alzheimer's disease and related conditions. In particular, screening methods using tyrosine kinases are provided, as are methods relating to the role of tyrosine kinases as therapeutic targets. In particular, the invention provides several phosphorylation sites of paired helical filament (PHF) tau protein, including Y18, Y29, Y197, Y310 and Y394; and corresponding related tyrosine kinases c-Abl, Syk and Fyn. IT 592543-24-3, ON 012380 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (for drug screening; phosphorylation sites of PHF tau protein and related kinases and methods of screening for modulators useful in treatment of Alzheimer's disease and related conditions) RN 592543-24-3 CAPLUS CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6- trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)				

Absolute stereochemistry.
 Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L3 ANSWER 38 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1049789 CAPLUS

DOCUMENT NUMBER: 143:346909

TITLE: Preparation of substituted phenoxy- and phenylthio-
derivatives for treating proliferative disorders and
as radioprotectants and chemoprotectants

INVENTOR(S): Reddy, E. Premkumar; Reddy, M. V. Ramana; Bell,
Stanley C.

PATENT ASSIGNEE(S): Temple University-of the Commonwealth System of Higher
Education, USA; Onconova Therapeutics Inc.

SOURCE: PCT Int. Appl., 179 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005089269	A2	20050929	WO 2005-US8429	20050315
WO 2005089269	A3	20061214		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005222947	A1	20050929	AU 2005-222947	20050315
CA 2559187	A1	20050929	CA 2005-2559187	20050315
EP 1740530	A2	20070110	EP 2005-736001	20050315
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			

JP 2007529530	T	20071025	JP 2007-503993	20050315
US 20080058290	A1	20080306	US 2006-592604	20060912
MX 2006010624	A	20061208	MX 2006-10624	20060915
IN 2006DN05660	A	20070824	IN 2006-DN5660	20060928
KR 2007015535	A	20070205	KR 2006-720674	20061002
PRIORITY APPLN. INFO.:			US 2004-554008P	P 20040316
			WO 2005-US8429	W 20050315
OTHER SOURCE(S):			CASREACT 143:346909; MARPAT 143:346909	
GI				




- AB Title compds. I [A = S, O; R1 = H, haloalkyl, (un)substituted hetero/aryl, etc.; Q = hetero/aryl; R2, R3 = independently halo, hydrocarbyl, NO2, CN, OH and derivs., P(:O)(OH)2 and derivs., etc.; X = -NRx-Z-, -CH(Rx)Y-; Y = SO, SO2; Z = CO, SO2; Rx = H, alkyl, -CO-alkyl; with provisos; and their geometrical isomers] were prepared as antiproliferative agents including, for example, anticancer agents and as radioprotective and chemoprotective agents. For example, reacting 2-[(3-hydroxy-4-methoxybenzyl)sulfonyl]acetic acid with 2,4,6-Trimethoxybenzaldehyde in the presence of PhCO2H/piperidine/toluene for 2-3 h at reflux gave II in 62.5% yield.. I displayed antiproliferative activity; for II GI50 values = 0.004 μ M, 0.001 μ M, and 0.005 μ M towards Sk-OV-3, RF-48, and CEM tumor cell lines, resp.
- IT 865783-99-9P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl dihydrogen phosphate 865784-00-5P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl dibenzyl phosphate
- RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of substituted phenoxy- and phenylthio- derivs. for treating proliferative disorders and as radioprotectants and chemoprotectants)

RN 865783-99-9 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]-, 1-(dihydrogen phosphate) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-00-5 CAPLUS

CN Phosphoric acid, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]phenyl bis(phenylmethyl) ester (CA INDEX NAME)

Double bond geometry as shown.



IT 852283-22-8P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxyphenol 865783-95-5P,
 (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenol 865784-01-6P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl dihydrogen phosphate disodium salt 865784-02-7P,
 (E)-4-[3-[5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenoxy]propyl]morpholine 865784-03-8P,
 (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl 2-(dimethylamino)acetate 865784-04-9P,
 (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl 4-methylbenzenesulfonate 865784-05-0P,
 (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxybenzenethiol 865784-06-1P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfinyl]methyl]-2-methoxybenzenethiol 865784-10-7P,

(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl dimethyl phosphate 865784-11-8P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl diethyl phosphate 865784-12-9P,
(E)-S-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl-O,O-dihydrogen phosphorothioate 865784-13-0P,
(E)-S-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl-O,O-dimethyl phosphorothioate 865784-14-1P,
(E)-(S)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl-O,O-diethyl phosphorothioate 865784-15-2P,
(E)-(S)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl-O,O-dibenzyl phosphorothioate 865784-16-3P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl dihydrogen phosphate 865784-17-4P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl dimethyl phosphate 865784-18-5P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl diethyl phosphate 865784-19-6P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl dibenzyl phosphate 865784-20-9P,
(E)-(S)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl-O,O-dihydrogen phosphorothioate 865784-21-0P,
(E)-(S)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl-O,O-dimethyl phosphorothioate 865784-22-1P,
(E)-(S)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl-O,O-diethyl phosphorothioate 865784-23-2P,
(E)-(S)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl-O,O-dibenzyl phosphorothioate 865784-40-3P,
(E)-2-[[5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenoxy]carbonyl]ethanoic acid 865784-41-4P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl 3,5-dinitrobenzoate 865784-42-5P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl 3,5-diaminobenzoate 865784-43-6P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl 2-chloroacetate 865784-44-7P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl 2-(4-methylpiperazin-1-yl)acetate 865784-45-8P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl benzoate 865784-46-9P, (E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl 4-nitrobenzoate 865784-47-0P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl 4-aminobenzoate 865784-48-1P,
(E)-(R)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl 2,6-diaminohexanoate 865784-49-2P,
(E)-(R)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl 2-amino-3-hydroxypropanoate 865784-50-5P,
(E)-(S)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl 2-amino-3-hydroxypropanoate 865784-51-6P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl carbamate 865784-52-7P, (E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl 4-(4-methylpiperazin-1-yl)benzoate 865784-53-8P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl 2-hydroxyacetate 865784-54-9P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl 2-(pyridinium-1-yl)acetate 865784-55-0P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl

2-acetoxyacetate 865784-56-1P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl
2-hydroxypropanoate 865784-57-2P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl
2-(triethylammonium)acetate 865784-58-3P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl
2-[tris(2-hydroxyethyl)ammonium]acetate 865784-59-4P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl
2-hydroxy-2-methylpropanoate 865784-60-7P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl
2-acetoxy-2-methylpropanoate 865784-61-8P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl
2,2,2-trifluoroacetate 865784-62-9P,
(E)-3-[[5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-
methoxyphenoxy]carbonyl]propanoic acid 865784-63-0P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl
3-(chlorocarbonyl)propanoate 865784-64-1P
865784-65-2P, (E)-4-[[5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-
2-methoxyphenoxy]carbonyl]butanoic acid 865784-66-3P,
(E)-[[5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-
methoxyphenoxy]carbonyl]methyl dihydrogen phosphate 865784-67-4P
, (E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl methyl
carbonate 865784-68-5P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl
2-acetoxypropanoate 865784-69-6P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl methyl
succinate 865784-70-9P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl ethyl
malonate 865784-71-0P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl
2,2,3,3,3-pentafluoropropanoate 865784-72-1P,
(E)-1-[5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl]
3-methyl 2,2-difluoromalonate 865784-73-2P,
(E)-3-[[5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-
methoxyphenoxy]carbonyl]-2,2,3,3-tetrafluoropropanoic acid
865784-75-4P, (E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-
methoxyphenyl 2-aminoacetate 865784-76-5P,
(E)-2-[[5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-
methoxyphenoxy]carbonyl]-2,2-difluoroethanoic acid 865784-78-7P
, (E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl
2-(dimethylamino)-2,2-difluoroacetate 865784-80-1P,
5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl
2-(dimethylamino)acetate 865784-81-2P,
(E)-2-[[5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-
methoxyphenoxy]carbonyl]ethanoic acid 865784-82-3P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
3,5-dinitrobenzoate 865784-84-5P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
3,5-diaminobenzoate 865784-85-6P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2-chloroacetate 865784-86-7P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2-(4-methylpiperazin-1-yl)acetate 865784-87-8P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl benzoate
865784-88-9P, (E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-
methoxyphenyl 4-nitrobenzoate 865784-89-0P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl

4-aminobenzoate 865784-90-3P,
(E)-(R)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2,6-diaminohexanoate 865784-91-4P,
(E)-(R)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2-amino-3-hydroxypropanoate 865784-92-5P
865784-93-6P, (E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-
methoxyphenyl carbamate 865784-94-7P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2-(dimethylamino)acetate 865784-95-8P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
4-(4-methylpiperazin-1-yl)benzoate 865784-96-9P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2-hydroxyacetate 865784-97-0P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2-(pyridinium-1-yl)acetate 865784-98-1P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2-acetoxyacetate 865784-99-2P 865785-00-8P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2-(triethylammonium)acetate 865785-01-9P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2-[tris(2-hydroxyethyl)ammonium]acetate 865785-02-0P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2-hydroxy-2-methylpropanoate 865785-03-1P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2-acetoxy-2-methylpropanoate 865785-04-2P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2,2,2-trifluoroacetate 865785-05-3P,
(E)-3-[[5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-
methoxyphenoxy]carbonyl]propanoic acid 865785-06-4P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
3-(chlorocarbonyl)propanoate 865785-07-5P
865785-08-6P, (E)-4-[[5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-
2-methoxyphenoxy]carbonyl]butanoic acid 865785-09-7P,
(E)-[[5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-
methoxyphenoxy]carbonyl]methyl dihydrogen phosphate 865785-10-0P
, (E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl methyl
carbonate 865785-11-1P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2-acetoxypropanoate 865785-12-2P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl methyl
succinate 865785-13-3P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl ethyl
malonate 865785-14-4P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2,2,3,3,3-pentafluoropropanoate 865785-15-5P,
(E)-1-[5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl]
3-methyl 2,2-difluoromalonate 865785-16-6P,
(E)-3-[[5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-
methoxyphenoxy]carbonyl]-2,2,3,3-tetrafluoropropanoic acid
865785-17-7P, (E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-
methoxyphenyl 2-aminoacetate 865785-18-8P,
(E)-2-[[5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-
methoxyphenoxy]carbonyl]-2,2-difluoroethanoic acid 865785-19-9P
, (E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2-(dimethylamino)-2,2-difluoroacetate 865785-20-2P,
5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2-(dimethylamino)acetate 865785-98-4P,

(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl
carboxymethanesulfonate 865785-99-5P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl
2,4-dinitrobenzenesulfonate 865786-00-1P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl
2,4-diaminobenzenesulfonate 865786-01-2P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl
trifluoromethanesulfonate 865786-02-3P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-methoxyphenyl
4-methoxybenzenesulfonate 865786-03-4P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
carboxymethanesulfonate 865786-04-5P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2,4-dinitrobenzenesulfonate 865786-05-6P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
2,4-diaminobenzenesulfonate 865786-06-7P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
trifluoromethanesulfonate 865786-07-8P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
4-methoxybenzenesulfonate 865786-08-9P,
(E)-5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-methoxyphenyl
4-methylbenzenesulfonate 865786-21-6P,
(E)-2-[5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-
methoxyphenoxy]ethanoic acid 865786-22-7P,
(E)-2-[5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-
methoxyphenoxy]propanoic acid 865786-23-8P,
(E)-4-[5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-
methoxyphenoxy]butanoic acid 865786-24-9P,
(E)-3-[5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-
methoxyphenoxy]propanoic acid 865786-25-0P,
(E)-2-[5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-
methoxyphenoxy]ethanoic acid 865786-26-1P,
(E)-2-[5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-
methoxyphenoxy]propanoic acid 865786-27-2P,
(E)-4-[5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-
methoxyphenoxy]butanoic acid 865786-28-3P,
(E)-3-[5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-
methoxyphenoxy]propanoic acid 865786-29-4P,
(E)-4-[2-[5-[[(2,4,6-Trimethoxystyryl) sulfonyl]methyl]-2-
methoxyphenoxy]ethyl]morpholine 865786-30-7P,
(E)-4-[2-[5-[[(2,4,6-Trimethoxystyryl) sulfinyl]methyl]-2-
methoxyphenoxy]ethyl]morpholine


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of substituted phenoxy- and phenylthio- derivs.
for treating proliferative disorders and as radioprotectants and
chemoprotectants)

RN 852283-22-8 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865783-95-5 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-01-6 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]-, 1-(dihydrogen phosphate), sodium salt (1:2) (CA INDEX NAME)

Double bond geometry as shown.




● 2 Na

RN 865784-02-7 CAPLUS

CN Morpholine, 4-[3-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]propyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-03-8 CAPLUS

CN Glycine, N,N-dimethyl-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-04-9 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]-, 1-(4-methylbenzenesulfonate) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-05-0 CAPLUS

CN Benzenethiol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-06-1 CAPLUS

CN Benzenethiol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-10-7 CAPLUS

CN Phosphoric acid, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl dimethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-11-8 CAPLUS

CN Phosphoric acid, diethyl 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-12-9 CAPLUS

CN Benzenethiol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]-, dihydrogen phosphate (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 865784-13-0 CAPLUS

CN Phosphorothioic acid, S-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl] O,O-dimethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-14-1 CAPLUS

CN Phosphorothioic acid, O,O-diethyl S-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-15-2 CAPLUS

CN Phosphorothioic acid, S-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl] O,O-bis(phenylmethyl) ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-16-3 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]-, dihydrogen phosphate (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-17-4 CAPLUS

CN Phosphoric acid, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl dimethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-18-5 CAPLUS

CN Phosphoric acid, diethyl 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-19-6 CAPLUS

CN Phosphoric acid, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl bis(phenylmethyl) ester
(CA INDEX NAME)


Double bond geometry as shown.



RN 865784-20-9 CAPLUS

CN Benzenethiol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]-, dihydrogen phosphate (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 865784-21-0 CAPLUS

CN Phosphorothioic acid, S-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] O,O-dimethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-22-1 CAPLUS

CN Phosphorothioic acid, O,O-diethyl S-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-23-2 CAPLUS

CN Phosphorothioic acid, S-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] O,O-bis(phenylmethyl) ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-40-3 CAPLUS

CN Propanedioic acid, 1-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-41-4 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]-, 1-(3,5-dinitrobenzoate) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-42-5 CAPLUS

CN Benzoic acid, 3,5-diamino-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-43-6 CAPLUS

CN Acetic acid, 2-chloro-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-44-7 CAPLUS

CN 1-Piperazineacetic acid, 4-methyl-,
2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-45-8 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfonyl]methyl]-, 1-benzoate (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-46-9 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfonyl]methyl]-, 1-(4-nitrobenzoate) (CA INDEX
NAME)


Double bond geometry as shown.



RN 865784-47-0 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]-, 1-(4-aminobenzoate) (CA INDEX NAME)

Double bond geometry as shown.




RN 865784-48-1 CAPLUS

CN D-Lysine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 865784-49-2 CAPLUS

CN D-Serine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 865784-50-5 CAPLUS

CN L-Serine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 865784-51-6 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]-, 1-carbamate (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-52-7 CAPLUS

CN Benzoic acid, 4-(4-methyl-1-piperazinyl)-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-53-8 CAPLUS

CN Acetic acid, 2-hydroxy-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-54-9 CAPLUS

CN Pyridinium, 1-[2-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]-2-oxoethyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-55-0 CAPLUS

CN Acetic acid, 2-(acetyloxy)-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-56-1 CAPLUS

CN Propanoic acid, 2-hydroxy-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-57-2 CAPLUS

CN Ethanaminium, N,N,N-triethyl-2-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]-2-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-58-3 CAPLUS

CN Ethanaminium, N,N,N-tris(2-hydroxyethyl)-2-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]-2-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-59-4 CAPLUS

CN Propanoic acid, 2-hydroxy-2-methyl-,
2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-60-7 CAPLUS

CN Propanoic acid, 2-(acetyloxy)-2-methyl-,
2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-61-8 CAPLUS

CN Acetic acid, 2,2,2-trifluoro-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-62-9 CAPLUS

CN Butanedioic acid, 1-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-63-0 CAPLUS

CN Butanoic acid, 4-chloro-4-oxo-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-64-1 CAPLUS

CN Hexanedioic acid, 3-oxo-, 1-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-65-2 CAPLUS

CN Pentanedioic acid, 1-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-66-3 CAPLUS

CN Acetic acid, 2-(phosphonooxy)-, 1-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-67-4 CAPLUS

CN Carbonic acid, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-68-5 CAPLUS

CN Propanoic acid, 2-(acetyloxy)-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-69-6 CAPLUS

CN Butanedioic acid, 1-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl] 4-methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-70-9 CAPLUS

CN Propanedioic acid, 1-ethyl 3-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-71-0 CAPLUS

CN Propanoic acid, 2,2,3,3,3-pentafluoro-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-72-1 CAPLUS

CN Propanedioic acid, 2,2-difluoro-, 1-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl] 3-methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-73-2 CAPLUS

CN Butanedioic acid, 2,2,3,3-tetrafluoro-, 4-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-75-4 CAPLUS

CN Glycine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-76-5 CAPLUS

CN Propanedioic acid, 2,2-difluoro-, 1-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-78-7 CAPLUS


CN Acetic acid, (dimethylamino)difluoro-,
2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (9CI) (CA INDEX
NAME)

Double bond geometry as shown.



RN 865784-80-1 CAPLUS


CN Glycine, N,N-dimethyl-, 2-methoxy-5-[[[2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)



RN 865784-81-2 CAPLUS

CN Propanedioic acid, 1-[2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-82-3 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]-, 1-(3,5-dinitrobenzoate) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-84-5 CAPLUS

CN Benzoic acid, 3,5-diamino-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-85-6 CAPLUS

CN Acetic acid, 2-chloro-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-86-7 CAPLUS

CN 1-Piperazineacetic acid, 4-methyl-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-87-8 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]-, 1-benzoate (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-88-9 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]-, 1-(4-nitrobenzoate) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-89-0 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]-, 1-(4-aminobenzoate) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-90-3 CAPLUS

CN D-Lysine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 865784-91-4 CAPLUS

CN D-Serine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 865784-92-5 CAPLUS

CN L-Serine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 865784-93-6 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]-, 1-carbamate (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-94-7 CAPLUS

CN Glycine, N,N-dimethyl-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-95-8 CAPLUS

CN Benzoic acid, 4-(4-methyl-1-piperazinyl)-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-96-9 CAPLUS

CN Acetic acid, 2-hydroxy-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-97-0 CAPLUS

CN Pyridinium, 1-[2-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenoxy]-2-oxoethyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-98-1 CAPLUS

CN Acetic acid, 2-(acetyloxy)-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-99-2 CAPLUS

CN Propanoic acid, 2-hydroxy-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-00-8 CAPLUS

CN Ethanaminium, N,N,N-triethyl-2-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenoxy]-2-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-01-9 CAPLUS

CN Ethanaminium, N,N,N-tris(2-hydroxyethyl)-2-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenoxy]-2-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-02-0 CAPLUS

CN Propanoic acid, 2-hydroxy-2-methyl-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-03-1 CAPLUS

CN Propanoic acid, 2-(acetyloxy)-2-methyl-,
2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-04-2 CAPLUS

CN Acetic acid, 2,2,2-trifluoro-, 2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-05-3 CAPLUS

CN Butanedioic acid, 1-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-06-4 CAPLUS

CN Butanoic acid, 4-chloro-4-oxo-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-07-5 CAPLUS

CN Hexanedioic acid, 3-oxo-, 1-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-08-6 CAPLUS

CN Pentanedioic acid, 1-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-09-7 CAPLUS

CN Acetic acid, 2-(phosphonooxy)-, 1-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-10-0 CAPLUS

CN Carbonic acid, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-11-1 CAPLUS

CN Propanoic acid, 2-(acetyloxy)-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-12-2 CAPLUS

CN Butanedioic acid, 1-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] 4-methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-13-3 CAPLUS

CN Propanedioic acid, 1-ethyl 3-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-14-4 CAPLUS

CN Propanoic acid, 2,2,3,3,3-pentafluoro-,
2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-15-5 CAPLUS

CN Propanedioic acid, 2,2-difluoro-, 1-[2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] 3-methyl ester (CA INDEX
NAME)


Double bond geometry as shown.



RN 865785-16-6 CAPLUS

CN Butanedioic acid, 2,2,3,3-tetrafluoro-,
4-[2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-17-7 CAPLUS

CN Glycine, 2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-18-8 CAPLUS

CN Propanedioic acid, 2,2-difluoro-, 1-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865785-19-9 CAPLUS


CN Acetic acid, (dimethylamino)difluoro-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 865785-20-2 CAPLUS


CN Glycine, N,N-dimethyl-, 2-methoxy-5-[[[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)



RN 865785-98-4 CAPLUS

CN Acetic acid, 2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]sulfonyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 865785-99-5 CAPLUS

CN Benzenesulfonic acid, 2,4-dinitro-,


2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 865786-00-1 CAPLUS
CN Benzenesulfonic acid, 2,4-diamino-,
2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 865786-01-2 CAPLUS
CN Methanesulfonic acid, 1,1,1-trifluoro-,
2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 865786-02-3 CAPLUS
CN Benzenesulfonic acid, 4-methoxy-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-03-4 CAPLUS

CN Acetic acid, 2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenoxy]sulfonyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-04-5 CAPLUS

CN Benzenesulfonic acid, 2,4-dinitro-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-05-6 CAPLUS

CN Benzenesulfonic acid, 2,4-diamino-, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-06-7 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-,
2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-07-8 CAPLUS

CN Benzenesulfonic acid, 4-methoxy-, 2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-08-9 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfinyl]methyl]-, 1-(4-methylbenzenesulfonate)
(CA INDEX NAME)


Double bond geometry as shown.



RN 865786-21-6 CAPLUS

CN Acetic acid, 2-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-22-7 CAPLUS

CN Propanoic acid, 2-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-23-8 CAPLUS

CN Butanoic acid, 4-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-24-9 CAPLUS

CN Propanoic acid, 3-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-25-0 CAPLUS

CN Acetic acid, 2-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenoxy]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-26-1 CAPLUS

CN Propanoic acid, 2-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenoxy]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-27-2 CAPLUS

CN Butanoic acid, 4-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenoxy]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-28-3 CAPLUS

CN Propanoic acid, 3-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenoxy]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-29-4 CAPLUS

CN Morpholine, 4-[2-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenoxy]ethyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865786-30-7 CAPLUS

CN Morpholine, 4-[2-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenoxy]ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 39 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:638614 CAPLUS

DOCUMENT NUMBER: 143:149136

TITLE: Protection of tissues and cells from cytotoxic effects of ionizing radiation by ABL inhibitors

INVENTOR(S): Reddy, E. Premkumar; Reddy, M. V. Ramana; Cosenza, Stephen C.; Gumireddy, Kiranmai

PATENT ASSIGNEE(S): Temple University of the Commonwealth System of Higher Education, USA

SOURCE: PCT Int. Appl., 151 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005065074	A2	20050721	WO 2004-US28654	20040902
WO 2005065074	A3	20060223		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRIORITY APPLN. INFO.:

US 2003-501783P

P 20030909

OTHER SOURCE(S): MARPAT 143:149136

AB Pre-treatment with ABL protein kinase inhibitors protects normal cells from the toxic side effects of ionizing radiation. Administration of one or more radioprotectant to a patient prior to anticancer radiotherapy reduces the cytotoxic side effects of the radiation on normal cells. The radioprotective effect allows for safely increasing the dosage of anticancer radiation. Amelioration of toxicity following inadvertent radiation exposure may also be mitigated.

IT 334969-03-8 334969-21-0 334969-29-8
592542-77-3 592542-83-1 851799-24-1
851799-25-2 851799-26-3 851799-27-4
851799-28-5 851799-29-6 851799-30-9
851799-31-0 851799-32-1 851799-33-2
851799-34-3 851799-35-4 851799-36-5
851799-37-6 851799-38-7 851799-39-8
851799-40-1 851799-41-2 851799-42-3
851799-47-8


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(ABL protein kinase inhibitors as radioprotectants)

RN 334969-03-8 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 334969-21-0 CAPLUS

CN Benzene, 1-[(1E)-2-[[[4-bromophenyl)methyl]sulfonyl]ethenyl]-2,3,4,5,6-
pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-29-8 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-77-3 CAPLUS

CN Benzenamine, 2-methoxy-N-methyl-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-83-1 CAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-24-1 CAPLUS

CN Benzene, 2-chloro-1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-4-fluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-25-2 CAPLUS

CN Benzene, 3-[(1E)-2-[[[(4-bromophenyl)methyl]sulfonyl]ethenyl]-1,2,4,5-tetrafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-26-3 CAPLUS

CN Benzene, 1-[(1E)-2-[[[(4-bromophenyl)methyl]sulfonyl]ethenyl]-2,4,5-trifluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-27-4 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-1,3,5-trifluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-28-5 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-1,3,4-trifluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-29-6 CAPLUS

CN Benzenamine, 5-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-2-fluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-30-9 CAPLUS

CN Benzenamine, 2-fluoro-5-[(1E)-2-[(4-iodophenyl)methylsulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 851799-31-0 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[(3-amino-4-methoxyphenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-32-1 CAPLUS

CN Benzoic acid, 4-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 851799-33-2 CAPLUS

CN Benzonitrile, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-34-3 CAPLUS

CN Phenol, 3-[(1E)-2-[[[4-bromophenyl]methyl]sulfonyl]ethenyl]-2,6-difluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-35-4 CAPLUS

CN Benzenamine, 2-bromo-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-36-5 CAPLUS

CN Benzene, 4-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-1-fluoro-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-37-6 CAPLUS

CN Benzene, 4-[(1E)-2-[[(4-bromophenyl)methyl]sulfonyl]ethenyl]-1-fluoro-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-38-7 CAPLUS

CN Benzene, 4-chloro-1-[[[(1E)-2-(4-fluoro-3-nitrophenyl)ethenyl]sulfonyl]methyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-39-8 CAPLUS

CN Benzenamine, 5-[[[(1E)-2-(2,4-difluorophenyl)ethenyl]sulfonyl]methyl]-2-methoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-40-1 CAPLUS

CN Benzenamine, 2-bromo-5-[[[(1E)-2-(2,4-difluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-41-2 CAPLUS

CN Benzoic acid, 4-[[[(1E)-2-(2,4-difluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-42-3 CAPLUS

CN L-Alanine, N-[2-methoxy-4-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 851799-47-8 CAPLUS

CN Benzene, 1-[(1E)-2-[[[4-bromophenyl)methyl]sulfonyl]ethenyl]-2,4-difluoro- (CA INDEX NAME)

Double bond geometry as shown.




IT	592542-59-1	592542-82-0	592543-23-2
	592543-24-3	851799-48-9	851799-49-0
	851799-50-3	851799-51-4	859504-18-0
	859504-19-1	859504-20-4	859504-21-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ABL protein kinase inhibitors as radioprotectants)

RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-82-0 CAPLUS


CN Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 592543-23-2 CAPLUS


CN D-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 851799-48-9 CAPLUS

CN Benzenamine, 5-[(1E)-2-[[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-2-fluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-49-0 CAPLUS

CN Benzeneacetic acid, α -[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-, (α R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 851799-50-3 CAPLUS

CN Benzeneacetic acid, α -[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-, (α S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 851799-51-4 CAPLUS

CN Benzeneacetic acid, α -[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]- (CA INDEX NAME)


Double bond geometry as shown.



RN 859504-18-0 CAPLUS

CN Benzoic acid, 2-[(1E)-2-[[[4-(3-methoxyphenyl)methyl]sulfonyl]ethenyl]-2-[[[4-(3-methoxyphenyl)methyl]sulfonyl]ethenyl]]-1-phenylethan-1-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 859504-19-1 CAPLUS

CN Benzoic acid, 2-[(1E)-2-[[[4-(4-iodophenyl)methyl]sulfonyl]ethenyl]-2-[[[4-(4-iodophenyl)methyl]sulfonyl]ethenyl]]-1-phenylethan-1-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 859504-20-4 CAPLUS

CN Benzoic acid, 2-[(1E)-2-[[[4-(4-chlorophenyl)methyl]sulfonyl]ethenyl]-2-[[[4-(4-chlorophenyl)methyl]sulfonyl]ethenyl]]-1-phenylethan-1-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 859504-21-5 CAPLUS

CN Benzoic acid, 2-[(1E)-2-[(3-amino-4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L3 ANSWER 40 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:478171 CAPLUS

DOCUMENT NUMBER: 143:398989

TITLE: ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. [Erratum to document cited in CA142:423311]

AUTHOR(S): Gumireddy, Kiranmai; Reddy, M. V. Ramana; Cosenza, Stephen C.; Boominathan, R.; Baker, Stacey J.; Papathi, Nabisa; Jiang, Jiandong; Holland, James; Reddy, E. Premkumar

CORPORATE SOURCE: Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA, 19140, USA

SOURCE: Cancer Cell (2005), 7(5), 497
CODEN: CCAECI; ISSN: 1535-6108

PUBLISHER: Cell Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The name of one of the authors was listed incorrectly. The author incorrectly listed as "R. Boomi Nathan" is actually R. Boominathan.

IT 592542-59-1, ON 01910


RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ON01910 as non-ATP-competitive small mol. inhibitor of Plk1 is potent anticancer agent (Erratum))

RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 41 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:451126 CAPLUS

DOCUMENT NUMBER: 143:1247

TITLE: α,β -Unsaturated sulfoxides for treating proliferative disorders and as radioprotective and chemoprotective agents

INVENTOR(S): Reddy, Premkumar E.; Reddy, Ramana M. V.; Bell, Stanley C.

PATENT ASSIGNEE(S): Temple University-of the Commonwealth System of Higher Education, USA; Onconova Therapeutics Inc.

SOURCE: PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005046599	A2	20050526	WO 2004-US37293	20041108
WO 2005046599	A3	20051006		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004289281	A1	20050526	AU 2004-289281	20041108
CA 2546495	A1	20050526	CA 2004-2546495	20041108
EP 1689706	A2	20060816	EP 2004-816944	20041108
R:	AT, BE, CH, LI, CY, BG, CZ			
JP 2007513877	T	20070531	JP 2006-539731	20041108
NZ 545995	A	20090430	NZ 2004-545995	20041108

IN 2006DN01508	A	20070810	IN 2006-DN1508	20060321
US 20060280746	A1	20061214	US 2006-574993	20060406
KR 2006109871	A	20061023	KR 2006-707327	20060417
PRIORITY APPLN. INFO.:			US 2003-520523P	P 20031114
			WO 2004-US37293	W 20041108

OTHER SOURCE(S): CASREACT 143:1247; MARPAT 143:1247

AB $\alpha\beta$ -Unsatd. sulfoxides Ar1[CH(R1)]nS(O)CH=CHAr2 [Ar1, Ar2 = (un)substituted (hetero)aryl (when Ar1 and Ar2 are both Ph, at least one of Ar1 and Ar2 is substituted); n = 0, 1; R1 = H, C1-8 hydrocarbyl, CN, etc.; conformation of substituents on carbon-carbon double bond is E or Z; conformation of substituents on sulfoxide S atom is R-, S- or any mixture of R- and S-; when R1 other than H, conformation of substituents on carbon atom to which R1 is attached is R-, S- or any mixture of R- and S-] are disclosed which are useful as antiproliferative agents including e.g. anticancer agents and as radioprotective and chemoprotective agents. Processes or preg. compds. of the invention are also disclosed.

IT 334969-29-8


RL: PRPH (Prophetic)

(α,β -Unsaturated sulfoxides for treating proliferative disorders and as radioprotective and chemoprotective agents)

RN 334969-29-8 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 852283-21-7P 852283-22-8P 852283-23-9P

852283-75-1P 852283-91-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(α,β -unsatd. sulfoxides for treatment of proliferative disorders and as radioprotectants and chemoprotectants)

RN 852283-21-7 CAPLUS

CN Benzenamine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-22-8 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-23-9 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[[4-methoxy-3-nitrophenyl]methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-75-1 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[[4-chlorophenyl]methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-91-1 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT	852283-15-9	852283-16-0	852283-17-1
	852283-18-2	852283-19-3	852283-20-6
	852283-24-0	852283-25-1	852283-26-2
	852283-27-3	852283-28-4	852283-29-5
	852283-30-8	852283-31-9	852283-32-0
	852283-33-1	852283-34-2	852283-35-3
	852283-36-4	852283-37-5	852283-38-6
	852283-39-7	852283-40-0	852283-41-1
	852283-42-2	852283-43-3	852283-44-4
	852283-45-5	852283-46-6	852283-47-7
	852283-48-8	852283-49-9	852283-50-2
	852283-51-3	852283-52-4	852283-53-5
	852283-54-6	852283-55-7	852283-56-8
	852283-57-9	852283-58-0	852283-59-1
	852283-60-4	852283-61-5	852283-62-6
	852283-63-7	852283-64-8	852283-65-9
	852283-66-0	852283-67-1	852283-68-2
	852283-69-3	852283-70-6	852283-71-7
	852283-72-8	852283-73-9	852283-74-0
	852283-76-2	852283-77-3	852283-78-4
	852283-79-5	852283-80-8	852283-81-9
	852283-82-0	852283-83-1	852283-84-2
	852283-85-3	852283-86-4	852283-87-5
	852283-88-6	852283-89-7	852283-90-0
	852283-92-2	852283-93-3	852283-94-4
	852283-95-5	852283-96-6	852283-97-7
	852283-98-8	852283-99-9	852284-00-5
	852284-01-6	852284-02-7	852284-03-8
	852284-04-9	852284-05-0	852284-06-1
	852284-07-2	852284-08-3	852284-09-4

852284-10-7	852284-11-8	852284-12-9
852284-13-0	852284-14-1	852284-15-2
852284-16-3	852284-17-4	852284-18-5
852284-19-6	852284-20-9	852284-21-0
852284-22-1	852284-23-2	852284-24-3
852284-25-4	852284-26-5	852284-27-6
852284-28-7	852284-29-8	852284-30-1
852284-31-2	852284-32-3	852284-33-4
852284-34-5	852284-35-6	852284-36-7
852284-37-8	852284-38-9	852284-39-0
852284-40-3	852284-41-4	852284-42-5
852284-43-6	852284-44-7	852284-45-8
852284-46-9	852284-47-0	852284-48-1
852284-49-2	852284-50-5	852284-51-6
852284-52-7	852284-53-8	852284-54-9
852284-55-0	852284-56-1	852284-57-2
852284-58-3	852284-59-4	852284-60-7
852284-61-8	852284-62-9	852284-63-0
852284-64-1	852284-65-2	852284-66-3
852284-67-4	852284-68-5	852284-69-6
852284-70-9	852284-71-0	852284-72-1
852284-73-2	852284-74-3	852284-75-4
852284-76-5	852284-77-6	852284-78-7
852284-79-8	852284-80-1	852284-81-2
852284-82-3	852284-83-4	852284-84-5
852284-85-6	852284-86-7	852284-87-8
852284-88-9	852284-89-0	852284-90-3
852284-91-4	852284-92-5	852284-93-6
852284-94-7	852284-95-8	852284-96-9
852284-97-0	852284-98-1	852284-99-2
852285-00-8	852285-01-9	852285-02-0
852285-03-1	852285-04-2	852285-05-3
852285-06-4	852285-07-5	852285-08-6
852285-09-7	852285-10-0	852285-11-1
852285-12-2	852285-13-3	852285-14-4
852285-15-5	852285-16-6	852285-17-7
852285-18-8	852285-19-9	852285-20-2
852285-21-3	852285-22-4	852285-23-5
852285-24-6	852285-25-7	852285-26-8
852285-27-9	852285-28-0	852285-29-1
852285-30-4	852285-31-5	852285-32-6
852285-33-7	852285-34-8	852285-35-9
852285-36-0	852285-37-1	852285-38-2
852285-39-3	852285-40-6	852285-41-7
852285-42-8	852285-43-9	852285-44-0
852285-45-1	852285-46-2	852285-47-3
852285-48-4	852285-49-5	852285-50-8
852285-51-9	852285-52-0	852285-53-1
852285-54-2	852285-55-3	


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(α,β -unsatd. sulfoxides for treatment of proliferative
disorders and as radioprotectants and chemoprotectants)

RN 852283-15-9 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 852283-16-0 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 852283-17-1 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfinyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 852283-18-2 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(2-nitrophenyl)ethenyl]sulfinyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 852283-19-3 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(3-nitrophenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-20-6 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-24-0 CAPLUS

CN Acetic acid, 2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]sulfonyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-25-1 CAPLUS

CN Propanoic acid, 3-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-3-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-26-2 CAPLUS

CN Guanidine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-27-3 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-28-4 CAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-3,5-dinitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-29-5 CAPLUS

CN Benzamide, 3,5-diamino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-30-8 CAPLUS

CN Acetamide, 2-chloro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-31-9 CAPLUS

CN 1-Piperazineacetamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-4-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-32-0 CAPLUS

CN	Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-	(CA INDEX NAME)
----	--	-----------------


Double bond geometry as shown.



RN 852283-33-1 CAPLUS

CN	Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-4-nitro-	(CA INDEX NAME)
----	--	-----------------


Double bond geometry as shown.



RN 852283-34-2 CAPLUS

CN Benzamide, 4-amino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-35-3 CAPLUS

CN Benzenamine, 2-methoxy-N-[(4-nitrophenyl)methylene]-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]-, [N(Z)]- (CA INDEX NAME)

Double bond geometry as shown.




RN 852283-36-4 CAPLUS

CN Hexanamide, 2,6-diamino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 852283-37-5 CAPLUS

CN Propanamide, 2-amino-3-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 852283-38-6 CAPLUS

CN Propanamide, 2-amino-3-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 852283-39-7 CAPLUS

CN Urea, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-40-0 CAPLUS

CN Benzenamine, 2-methoxy-N-methyl-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-41-1 CAPLUS

CN Acetamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-42-2 CAPLUS

CN Benzenesulfonamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-2,4-dinitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-43-3 CAPLUS

CN Benzenesulfonamide, 2,4-diamino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-44-4 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 852283-45-5 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 852283-46-6 CAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-47-7 CAPLUS

CN Acetamide, 2-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-48-8 CAPLUS

CN 2-Pyridineacetamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-49-9 CAPLUS

CN Acetamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-50-2 CAPLUS

CN Propanamide, 2-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-51-3 CAPLUS

CN Ethanaminium, N,N,N-triethyl-2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-2-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-52-4 CAPLUS

CN Ethanaminium, N,N,N-tris(2-hydroxyethyl)-2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-2-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-53-5 CAPLUS

CN Propanamide, 2-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-54-6 CAPLUS

CN Butanamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-55-7 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-56-8 CAPLUS

CN Methanesulfonamide, 1,1,1-trifluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-57-9 CAPLUS

CN β -Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-58-0 CAPLUS

CN Propanoyl chloride, 3-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-59-1 CAPLUS

CN Butanedioic acid, 1-[2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-2-oxoethyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-60-4 CAPLUS

CN Pentanoic acid, 5-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-5-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-61-5 CAPLUS

CN Acetamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-2-(phosphonoxy)- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-62-6 CAPLUS

CN Butanoic acid, 4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-63-7 CAPLUS

CN Carbamic acid, [2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-64-8 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-65-9 CAPLUS

CN Propanamide, 3-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-66-0 CAPLUS

CN Butanoic acid, 4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-4-oxo-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-67-1 CAPLUS

CN Propanoic acid, 3-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-3-oxo-, ethyl ester
(CA INDEX NAME)


Double bond geometry as shown.



RN 852283-68-2 CAPLUS

CN Propanamide, 2,2,3,3,3-pentafluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-69-3 CAPLUS

CN Propanoic acid, 2,2-difluoro-3-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-3-oxo-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-70-6 CAPLUS

CN Butanoic acid, 2,2,3,3-tetrafluoro-4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-4-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-71-7 CAPLUS

CN Acetamide, 2-amino-N-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-72-8 CAPLUS

CN Propanoic acid, 2,2-difluoro-3-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-3-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-73-9 CAPLUS

CN Acetamide, 2-(dimethylamino)-2,2-difluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-74-0 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[[[(4-fluorophenyl)methyl]sulfinyl]ethenyl]]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-76-2 CAPLUS

CN Ethanone, 1-[5-[(1E)-2-[[[(4-chlorophenyl)methyl]sulfinyl]ethenyl]]-2-fluorophenyl]-2-(dimethylamino)- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-77-3 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-(bromophenyl)methyl]sulfinyl]ethenyl]-2,4-difluoro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852283-78-4 CAPLUS

CN Benzenamine, 5-[(1E)-2-[[4-(chlorophenyl)methyl]sulfinyl]ethenyl]-2-fluoro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852283-79-5 CAPLUS

CN Benzene, 1,2,3,4,5-pentafluoro-6-[(1E)-2-[[4-(fluorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-80-8 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl]methyl]sulfinyl]ethenyl]-2,3,4,5,6-pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-81-9 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-bromophenyl]methyl]sulfinyl]ethenyl]-2,3,4,5,6-pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-82-0 CAPLUS

CN Benzene, 1,2,3,4,5-pentafluoro-6-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-83-1 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]-2,3,4,5,6-pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-84-2 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfinyl]methyl]-2,3,4,5,6-pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-85-3 CAPLUS

CN Benzene, 1-[(1E)-2-[[[3,4-dichlorophenyl]methyl]sulfinyl]ethenyl]-2,3,4,5,6-pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-86-4 CAPLUS

CN Benzene, 1,2,3,4,5-pentafluoro-6-[(1E)-2-[(4-iodophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-87-5 CAPLUS

CN Phenol, 2-[(1E)-2-[(4-fluorophenyl)methyl]sulfinyl]ethenyl]-4,6-dinitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-88-6 CAPLUS

CN Phenol, 2-[(1E)-2-[(4-bromophenyl)methyl]sulfinyl]ethenyl]-4,6-dinitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-89-7 CAPLUS

CN Phenol, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-4,6-dinitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852283-90-0 CAPLUS

CN Phenol, 2-[(1E)-2-[[2,4-dichlorophenyl)methyl]sulfinyl]ethenyl]-4,6-
dinitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-92-2 CAPLUS

CN Benzene, 1,3-dimethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-93-3 CAPLUS

CN Benzene, 1,2,3-trimethoxy-5-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-94-4 CAPLUS

CN Benzene, 5-[(1E)-2-[[4,5-dimethoxy-2-nitrophenyl)methyl]sulfinyl]ethenyl]-1,2,3-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-95-5 CAPLUS

CN Benzene, 2-[(1E)-2-[[4,5-dimethoxy-2-nitrophenyl)methyl]sulfinyl]ethenyl]-1,3,5-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-96-6 CAPLUS

CN Benzene, 1-[(1E)-2-[[4,5-dimethoxy-2-nitrophenyl)methyl]sulfinyl]ethenyl]-2,4-dimethoxy-3-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-97-7 CAPLUS

CN Benzene, 1,2,3-trifluoro-4-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-98-8 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-2,3,4-trifluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-99-9 CAPLUS

CN Phenol, 3,5-dimethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-00-5 CAPLUS

CN Benzene, 1,2,4,5-tetrafluoro-3-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-01-6 CAPLUS

CN Benzene, 1,2,4-trimethoxy-5-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-02-7 CAPLUS

CN Benzene, 1,2,3-trimethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-03-8 CAPLUS

CN Phenol, 2-methoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]-6-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-04-9 CAPLUS

CN Benzene, 1,2-dimethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]-5-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-05-0 CAPLUS

CN Benzene, 1-iodo-2,3-dimethoxy-5-[(1E)-2-[(4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-06-1 CAPLUS

CN Benzene, 5-fluoro-1,3-dimethoxy-2-[(1E)-2-[(4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-07-2 CAPLUS

CN Phenol, 3,5-dimethoxy-2-[(1E)-2-[(4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-08-3 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]-1,3,5-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-09-4 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-1,3,5-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-10-7 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-5-fluoro-1,3-dimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-11-8 CAPLUS

CN Phenol, 4-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-3,5-dimethoxy-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-12-9 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]-1,3,5-
trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-13-0 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]-5-fluoro-1,3-
dimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-14-1 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-15-2 CAPLUS

CN Benzene, 1-[[[(1E)-2-(2,6-dimethoxyphenyl)ethenyl]sulfinyl]methyl]-2,3,4-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-16-3 CAPLUS

CN Benzene, 1,2,3-trimethoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-17-4 CAPLUS

CN Benzene, 5-[[[(1E)-2-(2,6-dimethoxyphenyl)ethenyl]sulfinyl]methyl]-1,2,3-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-18-5 CAPLUS

CN Benzene, 5-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]-1,2,3-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-19-6 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-20-9 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-21-0 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-22-1 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-23-2 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-24-3 CAPLUS

CN Benzene, 1,2-dichloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-25-4 CAPLUS

CN Benzene, 1,2-dichloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-26-5 CAPLUS

CN Benzene, 4-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfinyl]methyl]-1,2-dichloro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-27-6 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[[(4-nitrophenyl)methyl]sulfinyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-28-7 CAPLUS

CN Benzonitrile, 4-[(1E)-2-[[[(4-fluorophenyl)methyl]sulfinyl]ethenyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 852284-29-8 CAPLUS

CN Benzonitrile, 4-[(1E)-2-[(4-chlorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-30-1 CAPLUS

CN Benzonitrile, 4-[(1E)-2-[(4-bromophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-31-2 CAPLUS

CN Benzene, 4-[(1E)-2-[(4-chlorophenyl)methyl]sulfinyl]ethenyl]-1,2-difluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-32-3 CAPLUS

CN Benzene, 2-chloro-4-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-1-fluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-33-4 CAPLUS

CN Benzene, 2-chloro-1-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-4-fluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-34-5 CAPLUS

CN Benzene, 2,4-dichloro-1-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-35-6 CAPLUS

CN Benzene, 1,2-dichloro-4-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-36-7 CAPLUS

CN Benzene, 1,2-dichloro-3-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-37-8 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[4-iodophenyl)methyl]sulfinyl]ethenyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 852284-38-9 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1E)-2-(4-iodophenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-39-0 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-iodophenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-40-3 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-iodophenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-41-4 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-42-5 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[4-iodophenyl)methyl]sulfinyl]ethenyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 852284-43-6 CAPLUS

CN Benzene, 1-iodo-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfinyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 852284-44-7 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-iodophenyl)methyl]sulfinyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-45-8 CAPLUS

CN Benzene, 1-iodo-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-46-9 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(4-iodophenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-47-0 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]-2-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-48-1 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]-3-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-49-2 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfinyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-50-5 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-51-6 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]-3-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-52-7 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]-4-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-53-8 CAPLUS

CN Benzene, 4-fluoro-1-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-54-9 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-55-0 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-3-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-56-1 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfinyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-57-2 CAPLUS

CN Benzene, 1-[(1E)-2-[[[(4-chlorophenyl)methyl]sulfinyl]ethenyl]-2-(trifluoromethyl)-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-58-3 CAPLUS

CN Benzene, 1-[(1E)-2-[[[(4-chlorophenyl)methyl]sulfinyl]ethenyl]-3-(trifluoromethyl)-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-59-4 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-4-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-60-7 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-61-8 CAPLUS

CN Benzene, 4-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-1-fluoro-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-62-9 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(2-nitrophenyl)ethenyl]sulfinyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-63-0 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-[4-fluoro-2-(trifluoromethyl)phenyl]ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-64-1 CAPLUS

CN Benzene, 1-[(1E)-2-[[[(4-bromophenyl)methyl]sulfinyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-65-2 CAPLUS

CN Benzene, 1-[(1E)-2-[[(4-bromophenyl)methyl]sulfinyl]ethenyl]-3-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-66-3 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-67-4 CAPLUS

CN Benzene, 1-[(1E)-2-[[(4-bromophenyl)methyl]sulfinyl]ethenyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-68-5 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]-4-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-69-6 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(2-nitrophenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-70-9 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(3-nitrophenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-71-0 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-72-1 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[[(4-methylphenyl)methyl]sulfinyl]ethenyl]]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-73-2 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[[(4-methylphenyl)methyl]sulfinyl]ethenyl]]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-74-3 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-methylphenyl)methyl]sulfinyl]ethenyl]-2-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-75-4 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-methylphenyl)methyl]sulfinyl]ethenyl]-3-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-76-5 CAPLUS

CN Benzene, 1-methyl-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfinyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-77-6 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-78-7 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-79-8 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-80-1 CAPLUS

CN Benzene, 1-[(1E)-2-[(4-methoxyphenyl)methyl]sulfinyl]ethenyl]-2-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-81-2 CAPLUS

CN Benzene, 1-[(1E)-2-[(4-methoxyphenyl)methyl]sulfinyl]ethenyl]-3-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-82-3 CAPLUS

CN Benzene, 1-methoxy-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfinyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-83-4 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[(4-nitrophenyl)methyl]sulfinylethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-84-5 CAPLUS

CN Benzene, 1-chloro-2-[(1E)-2-[(phenylmethyl)sulfinylethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-85-6 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[(phenylmethyl)sulfinylethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-86-7 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-87-8 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-88-9 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-89-0 CAPLUS

CN Benzene, 2,4-difluoro-1-[(1E)-2-[[[(4-fluorophenyl)methyl]sulfinyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-90-3 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-91-4 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfinyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 852284-92-5 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[[4-fluorophenyl]methyl]sulfinyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852284-93-6 CAPLUS

CN Benzene, [[[(1Z)-2-phenylethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-94-7 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-phenylethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-95-8 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-phenylethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-96-9 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-phenylethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-97-0 CAPLUS

CN Benzene, 1-chloro-4-[(1Z)-2-[(phenylmethyl)sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-98-1 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-99-2 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-chlorophenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-00-8 CAPLUS

CN Benzene, 1-chloro-4-[(1Z)-2-[(4-fluorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-01-9 CAPLUS

CN Benzene, 1-fluoro-4-[(1Z)-2-[(phenylmethyl)sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-02-0 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-03-1 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-04-2 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-05-3 CAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[(phenylmethyl)sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-06-4 CAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-07-5 CAPLUS

CN Benzene, 1-[[[(1Z)-2-(4-bromophenyl)ethenyl]sulfinyl)methyl]-2-chloro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-08-6 CAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-09-7 CAPLUS

CN Benzene, 1-methyl-4-[(1Z)-2-[(phenylmethyl)sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-10-0 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-11-1 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-12-2 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-13-3 CAPLUS

CN Benzene, 1-fluoro-4-[(1Z)-2-[(4-iodophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-14-4 CAPLUS

CN Pyridine, 2-[(1E)-2-[(4-fluorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-15-5 CAPLUS

CN Pyridine, 3-[(1E)-2-[(4-fluorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-16-6 CAPLUS

CN Pyridine, 4-[(1E)-2-[(4-fluorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-17-7 CAPLUS

CN Pyridine, 2-[(1E)-2-[[[(4-chlorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-18-8 CAPLUS

CN Pyridine, 3-[(1E)-2-[[[(4-chlorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-19-9 CAPLUS

CN Pyridine, 4-[(1E)-2-[[[(4-chlorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-20-2 CAPLUS

CN Pyridine, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-21-3 CAPLUS

CN Pyridine, 3-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-22-4 CAPLUS

CN Pyridine, 4-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-23-5 CAPLUS

CN Thiophene, 2-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-24-6 CAPLUS

CN Thiophene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-25-7 CAPLUS

CN Thiophene, 4-bromo-2-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 852285-26-8 CAPLUS

CN Thiophene, 2-bromo-5-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]-

(CA INDEX NAME)


Double bond geometry as shown.



RN 852285-27-9 CAPLUS

CN Thiophene, 2-bromo-5-[(1E)-2-[(4-chlorophenyl)methyl]sulfinyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852285-28-0 CAPLUS

CN Thiophene, 2-bromo-5-[(1E)-2-[(4-bromophenyl)methyl]sulfinyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852285-29-1 CAPLUS

CN Thiophene, 2-[(1E)-2-[(4-fluorophenyl)methyl]sulfinyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-30-4 CAPLUS

CN Thiophene, 2-[(1E)-2-[(4-chlorophenyl)methyl]sulfinyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-31-5 CAPLUS

CN Thiophene, 2-[(1E)-2-[(4-bromophenyl)methyl]sulfinyl]ethenyl]-, 1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-32-6 CAPLUS

CN Thiophene, 3-[(1E)-2-[(4-fluorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-33-7 CAPLUS

CN Thiophene, 3-[(1E)-2-[(4-chlorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-34-8 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-35-9 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-iodophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-36-0 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-methylphenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-37-1 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-38-2 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-(trifluoromethyl)phenyl]methylsulfinyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 852285-39-3 CAPLUS

CN Thiophene, 3-[(1E)-2-[[2,4-dichlorophenyl]methylsulfinyl]ethenyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 852285-40-6 CAPLUS

CN Thiophene, 3-[(1E)-2-[[3,4-dichlorophenyl]methylsulfinyl]ethenyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 852285-41-7 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(3-thienyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-42-8 CAPLUS

CN Thiophene, 3-[(1E)-2-[[[(4-nitrophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-43-9 CAPLUS

CN Thiophene, 3-[(1E)-2-[[[(4-fluorophenyl)methyl]sulfinyl]ethenyl]-, 1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-44-0 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-45-1 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-46-2 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-47-3 CAPLUS

CN Thiophene, 3-[(1E)-2-[[2-(4-dichlorophenyl)methyl]sulfinyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-48-4 CAPLUS

CN Furan, 2-[(1E)-2-[[2-(4-fluorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 852285-49-5 CAPLUS

CN Furan, 2-[(1E)-2-[[2-(4-chlorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 852285-50-8 CAPLUS

CN Furan, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-51-9 CAPLUS

CN Furan, 3-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-52-0 CAPLUS

CN Furan, 3-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 852285-53-1 CAPLUS

CN Furan, 3-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)

NAME)


Double bond geometry as shown.



RN 852285-54-2 CAPLUS

CN Furan, 3-[(1E)-2-[[4-iodophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-55-3 CAPLUS

CN Furan, 3-[(1E)-2-[[4-methylphenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT	852285-56-4	852285-57-5	852285-58-6
	852285-59-7	852285-60-0	852285-61-1
	852285-62-2	852285-63-3	852285-64-4
	852285-65-5	852285-66-6	852285-67-7
	852285-68-8	852285-69-9	852285-70-2
	852285-71-3	852285-72-4	852285-73-5
	852285-74-6	852285-75-7	852285-76-8
	852285-77-9	852285-80-4	


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(α,β -unsatd. sulfoxides for treatment of proliferative

disorders and as radioprotectants and chemoprotectants)

RN 852285-56-4 CAPLUS

CN Furan, 3-[(1E)-2-[[4-methoxyphenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-57-5 CAPLUS

CN Furan, 3-[(1E)-2-[[4-(trifluoromethyl)phenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-58-6 CAPLUS

CN Furan, 3-[(1E)-2-[[2,4-dichlorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-59-7 CAPLUS

CN Furan, 3-[(1E)-2-[[3,4-dichlorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-60-0 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(3-furanyl)ethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-61-1 CAPLUS

CN Furan, 3-[(1E)-2-[[[4-nitrophenyl]methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-62-2 CAPLUS

CN Thiazole, 2-[(1E)-2-[[[4-chlorophenyl]methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-63-3 CAPLUS

CN 1H-Pyrrole, 2-[(1E)-2-[(4-chlorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-64-4 CAPLUS

CN 1H-Pyrrole, 2-[(1E)-2-[(4-bromophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-65-5 CAPLUS

CN Thiophene, 4-[(1E)-2-[(4-chlorophenyl)methyl]sulfinyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-66-6 CAPLUS

CN Thiophene, 4-[(1E)-2-[(4-iodophenyl)methyl]sulfinyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-67-7 CAPLUS

CN Thiophene, 4-[(1E)-2-[[2-(4-dichlorophenyl)methyl]sulfinyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-68-8 CAPLUS

CN Thiophene, 4-[(1E)-2-[[2-(4-methoxyphenyl)methyl]sulfinyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-69-9 CAPLUS

CN Naphthalene, 1-[(1E)-2-[[2-(4-fluorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-70-2 CAPLUS

CN Naphthalene, 2-[(1E)-2-[(4-fluorophenyl)methylsulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-71-3 CAPLUS

CN Naphthalene, 1-[(1E)-2-[(4-chlorophenyl)methylsulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-72-4 CAPLUS

CN Naphthalene, 2-[(1E)-2-[(4-chlorophenyl)methylsulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-73-5 CAPLUS

CN Naphthalene, 1-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-74-6 CAPLUS

CN Naphthalene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-75-7 CAPLUS

CN Anthracene, 9-[(1E)-2-[[4-fluorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-76-8 CAPLUS

CN Anthracene, 9-[(1E)-2-[[4-chlorophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-77-9 CAPLUS

CN Anthracene, 9-[(1E)-2-[[4-bromophenyl)methyl]sulfinyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852285-80-4 CAPLUS

CN Butanoic acid, 4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]amino]-4-oxo- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 42 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:423713 CAPLUS

DOCUMENT NUMBER: 142:459275

TITLE: Protection of tissues and cells from cytotoxic effects
of ionizing radiation by abl inhibitors

INVENTOR(S) : Reddy, E. Premkumar; Reddy, M. V. Ramana; Cosenza, Stephen C.; Gumireddy, Kiranmai

PATENT ASSIGNEE(S): Temple University of the Commonwealth System of Higher Education, USA

SOURCE: PCT Int. Appl., 127 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.		KIND	DATE	APPLICATION NO.		DATE
WO 2005044181		A2	20050519	WO 2004-US28658		20040902
WO 2005044181		A3	20060309			
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					

PRIORITY APPLN. INFO.: US 2003-501748P P 20030909

OTHER SOURCE(S) : MARPAT 142:459275

AB Pre-treatment with benzyl or styryl sulfonyl compds. protects normal cells from the toxic side effects of ionizing radiation. Administration of one or more radioprotective compds. to a patient prior to anticancer radiotherapy reduces the cytotoxic side effects of the radiation on normal

cells. The radioprotective effect of the compds. allows for the safe increase of the dosage of anticancer radiation. Amelioration of toxicity following inadvertent radiation exposure may also be mitigated with administration of one or more of the compds.


IT 334969-03-8 334969-21-0 334969-29-8
592542-77-3 592542-83-1 851799-24-1
851799-25-2 851799-26-3 851799-27-4
851799-28-5 851799-29-6 851799-30-9
851799-31-0 851799-32-1 851799-33-2
851799-34-3 851799-35-4 851799-36-5
851799-37-6 851799-38-7 851799-39-8
851799-40-1 851799-41-2 851799-42-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(benzyl and styryl sulfonyl compds. as radioprotectants)

RN 334969-03-8 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 334969-21-0 CAPLUS

CN Benzene, 1-[(1E)-2-[[(4-bromophenyl)methyl]sulfonyl]ethenyl]-2,3,4,5,6-
pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-29-8 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[[(4-
methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-77-3 CAPLUS

CN Benzenamine, 2-methoxy-N-methyl-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-83-1 CAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-24-1 CAPLUS

CN Benzene, 2-chloro-1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-4-fluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-25-2 CAPLUS

CN Benzene, 3-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-1,2,4,5-tetrafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-26-3 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-2,4,5-trifluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-27-4 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-1,3,5-trifluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-28-5 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-1,3,4-trifluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-29-6 CAPLUS

CN Benzenamine, 5-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-2-fluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-30-9 CAPLUS

CN Benzenamine, 2-fluoro-5-[(1E)-2-[[4-iodophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-31-0 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[(3-amino-4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-32-1 CAPLUS

CN Benzoic acid, 4-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-33-2 CAPLUS

CN Benzonitrile, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-34-3 CAPLUS

CN Phenol, 3-[(1E)-2-[[4-(4-bromophenyl)methyl]sulfonyl]ethenyl]-2,6-difluoro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 851799-35-4 CAPLUS

CN Benzenamine, 2-bromo-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 851799-36-5 CAPLUS

CN Benzene, 4-[(1E)-2-[[4-(4-chlorophenyl)methyl]sulfonyl]ethenyl]-1-fluoro-2-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 851799-37-6 CAPLUS

CN Benzene, 4-[(1E)-2-[[(4-bromophenyl)methyl]sulfonyl]ethenyl]-1-fluoro-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-38-7 CAPLUS

CN Benzene, 4-chloro-1-[[[(1E)-2-(4-fluoro-3-nitrophenyl)ethenyl]sulfonyl]methyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-39-8 CAPLUS

CN Benzenamine, 5-[[[(1E)-2-(2,4-difluorophenyl)ethenyl]sulfonyl]methyl]-2-methoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-40-1 CAPLUS

CN Benzenamine, 2-bromo-5-[[[(1E)-2-(2,4-difluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-41-2 CAPLUS

CN Benzoic acid, 4-[[[(1E)-2-(2,4-difluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 851799-42-3 CAPLUS

CN L-Alanine, N-[2-methoxy-4-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




IT 592542-59-1 592542-82-0 592543-23-2
 592543-24-3 851799-44-5 851799-45-6
 851799-46-7 851799-47-8 851799-48-9
 851799-49-0 851799-50-3 851799-51-4
 851799-52-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (benzyl and styryl sulfonyl compds. as radioprotectants)

RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-82-0 CAPLUS

CN Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-23-2 CAPLUS

CN D-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 851799-44-5 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[[[(4-fluorophenyl)methyl]sulfonyl]ethenyl]]- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-45-6 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[[[(4-iodophenyl)methyl]sulfonyl]ethenyl]]- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-46-7 CAPLUS

CN Ethanone, 1-[5-[(1E)-2-[[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]]-2-fluorophenyl]-2-(dimethylamino)- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-47-8 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-(bromophenyl)methyl]sulfonyl]ethenyl]-2,4-difluoro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 851799-48-9 CAPLUS

CN Benzenamine, 5-[(1E)-2-[[4-(chlorophenyl)methyl]sulfonyl]ethenyl]-2-fluoro-
(CA INDEX NAME)

Double bond geometry as shown.




RN 851799-49-0 CAPLUS

CN Benzeneacetic acid, α -[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-, (α R)- (CA
INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 851799-50-3 CAPLUS

CN Benzeneacetic acid, α -[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-, (α S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 851799-51-4 CAPLUS

CN Benzeneacetic acid, α -[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-52-5 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-fluoro-3-nitrophenyl)ethenyl]sulfonyl]methyl]-2-nitro- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L3 ANSWER 43 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:372966 CAPLUS

DOCUMENT NUMBER: 143:359525

TITLE: A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. [Erratum to document cited in CA142:329255]

AUTHOR(S): Gumireddy, Kiranmai; Baker, Stacey J.; Cosenza, Stephen C.; John, Premila; Kang, Anthony D.; Robell, Kimberly A.; Reddy, M. V. Ramana; Reddy, E. Premkumar

CORPORATE SOURCE: The Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA, 19140, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2005), 102(15), 5635
CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English


AB An incorrect image was originally published as Figure 1b; the correct version of the Figure and its legend are given. This correction does not affect the conclusions of the article.

IT 592543-24-3, ON 012380
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance (Erratum))

RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L3 ANSWER 44 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:294993 CAPLUS

DOCUMENT NUMBER: 142:423311

TITLE: ON01910, a non-ATP-competitive small molecule

inhibitor of Plk1, is a potent anticancer agent
AUTHOR(S): Gumireddy, Kiranmai; Reddy, M. V. Ramana; Cosenza, Stephen C.; Nathan, R. Boomi; Baker, Stacey J.; Papathi, Nabisa; Jiang, Jiandong; Holland, James; Reddy, E. Premkumar

CORPORATE SOURCE: Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA, 19140, USA

SOURCE: Cancer Cell (2005), 7(3), 275-286
CODEN: CCAECI; ISSN: 1535-6108

PUBLISHER: Cell Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Elevated expression of polo-like kinase-1 (Plk1) has been reported in many human tumors, and inhibition of Plk1 activity results in their mitotic arrest and apoptosis. Here we describe the profile of ON01910, a small mol. inhibitor of Plk1 activity, which induces mitotic arrest of tumor cells characterized by spindle abnormalities leading to their apoptosis. This compound was not ATP-competitive, but competed for the substrate binding site of the enzyme. In vivo, this compound did not exhibit

hematotoxicity, liver damage, or neurotoxicity, and was a potent inhibitor of tumor growth in a variety of xenograft nude mouse models. ON01910 showed strong synergy with several chemotherapeutic agents, often inducing complete regression of tumors.

IT 592542-59-1, ON 01910


RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ON01910, a non-ATP-competitive small mol. inhibitor of Plk1, is a potent anticancer agent)

RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 87 THERE ARE 87 CAPLUS RECORDS THAT CITE THIS RECORD (88 CITINGS)
REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 45 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:195887 CAPLUS

DOCUMENT NUMBER: 142:329255

TITLE: A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

AUTHOR(S): Gumireddy, Kiranmai; Baker, Stacey J.; Cosenza, Stephen C.; John, Premila; Kang, Anthony D.; Robell, Kimberly A.; Reddy, M. V. Ramana; Reddy, E. Premkumar

CORPORATE SOURCE: The Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA, 19140, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2005), 102(6), 1992-1997
CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Imatinib, which is an inhibitor of the BCR-ABL tyrosine kinase, has been a remarkable success for the treatment of Philadelphia chromosome-pos. (Ph+) chronic myelogenous leukemias (CMLs). However, a significant proportion of patients chronically treated with imatinib develop resistance because of the acquisition of mutations in the kinase domain of BCR-ABL. Mutations occur at residues directly implicated in imatinib binding or,

more commonly, at residues important for the ability of the kinase to adopt the specific closed (inactive) conformation to which imatinib binds. In our quest to develop new BCR-ABL inhibitors, we chose to target regions outside the ATP-binding site of this enzyme because these compds. offer the potential to be unaffected by mutations that make CML cells resistant to imatinib. Here we describe the activity of one compound, ON012380, that can specifically inhibit BCR-ABL and induce cell death of Ph+ CML cells at a concentration of <10 nM. Kinetic studies demonstrate that this compound is not

ATP-competitive but is substrate-competitive and works synergistically with imatinib in wild-type BCR-ABL inhibition. More importantly, ON012380 was found to induce apoptosis of all of the known imatinib-resistant mutants at concns. of <10 nM concentration in vitro and cause regression of leukemias induced by i.v. injection of 32Dcl3 cells expressing the imatinib-resistant BCR-ABL isoform T315I. Daily i.v. dosing for up to 3 wk with a >100 mg/kg concentration of this agent is well tolerated in rodents, without any hematotoxicity.


IT 592543-24-3, ON 012380

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance)

RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 120 THERE ARE 120 CAPLUS RECORDS THAT CITE THIS RECORD (120 CITINGS)
REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 46 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:474504 CAPLUS

DOCUMENT NUMBER: 141:349988


TITLE: A simple strategy for the synthesis of 3,4-disubstituted pyrroles

AUTHOR(S): Padmavathi, V.; Reddy, B. Jagan Mohan; Sarma, M. Rajagopala; Thriveni, P.

CORPORATE SOURCE: Department of Chemistry, Sri Venkateswara University,


SOURCE: Tirupati, 517502, India
Journal of Chemical Research (2004), (1), 79-80
CODEN: JCROA4
PUBLISHER: Science Reviews
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:349988
AB 3,4-Disubstituted pyrroles are prepared by cyclocondensation of aryl styryl sulfones and benzyl styryl sulfones with tosyl Me isocyanide. Ph vinyl sulfone under similar conditions forms 3-benzenesulfonylpyrrole and/or 2-(2-benzenesulfonylethyl)-4-benzenesulfonylpyrrole.
IT 32093-01-9 93468-06-5 93468-07-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of 3,4-disubstituted pyrroles by cyclocondensation of aryl styryl sulfones with tosyl Me isocyanide)
RN 32093-01-9 CAPLUS
CN Benzene, [[[1E)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 93468-06-5 CAPLUS
CN Benzene, 1-methyl-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 93468-07-6 CAPLUS
CN Benzene, 1-chloro-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD

(6 CITINGS)
REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 47 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:112342 CAPLUS

DOCUMENT NUMBER: 140:321188

TITLE: Efficient Stereoselective Alkenylation through a
Homolytic Domino Reaction Involving a 1,5
Sulfur-to-Carbon Translocation

AUTHOR(S): Korshin, Edward E.; Bilokin, Yaroslav V.; Zheng,
Hailin; Bachi, Mario D.

CORPORATE SOURCE: Department of Organic Chemistry, The Weizmann
Institute of Science, Rehovot, 76100, Israel

SOURCE: Journal of the American Chemical Society (2004),
126(9), 2708-2709

CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:321188

AB An effective method for cis-stereoselective attachment of functionalized
alkenyl appendages to sp³ carbon is reported. This method is based on a
free-radical process, involving a sequence of addition-elimination steps,
resulting in alkenyl group transposition from divalent sulfur to a
prochiral carbon radical. Absolute stereoselectivity is secured since the new
carbon-carbon bond is formed in a ring-closure reaction leading to a
bridged bicyclic carbon-centered radical intermediate. The latter
undergoes β -scission of the C-S bond, leaving the alkenyl side chain
in its predetd. position while releasing a thiyl radical. This thiyl
radical is trapped by tri-n-butylstyryltin, affording a
(styrylsulfanyl)methyl side chain and a tri-n-butyltin radical that
continues the chain. When 2-(alkenylsulfanyl)methyl-4-bromo(or
iodo)pyrrolidines were used as starting materials 2,4-cis-disubstituted
4-alkenyl-2-(styrylsulfanyl)methylpyrrolidines were obtained as products
(70-90% yield). Tri-n-butylstyryltin was used rather than the more common
n-Bu₃SnH as tin radicals sources because the latter led predominantly to
bridged bicyclic 3-thia-6-azabicyclo[3.2.1]octanes (up to 77% yield). An
addnl. advantage of using tri-n-butylstyryltin derives from the discovery
that the resulting styrylsulfide functionality is an excellent synthetic
equivalent to the formyl group. Thus, using a Pummerer-type oxidative
desulfurization, 4-cis-alkenyl-proline aldehydes were obtained.

IT 677737-01-8P 677737-02-9P 677737-03-0P

677737-10-9P 677737-11-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)


(stereoselective alkenylation through a homolytic domino reaction
involving a 1,5 sulfur-to-carbon translocation)

RN 677737-01-8 CAPLUS

CN Pyrrolidine, 1-[(4-methylphenyl)sulfonyl]-4-[(1E)-2-phenylethenyl]-2-[[(R)-
[(1E)-2-phenylethenyl]sulfinyl]methyl]-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


Double bond geometry as shown.



RN 677737-02-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(1E)-3-methoxy-3-oxo-1-propen-1-yl]-2-[[[(1E)-2-phenylethenyl]sulfinyl]methyl]-, 1,1-dimethylethyl ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 677737-03-0 CAPLUS

CN 2-Propenoic acid, 3-[(3R,5S)-1-[(4-methylphenyl)sulfonyl]-5-[(R)-[(1E)-2-phenylethenyl]sulfinyl]methyl]-3-pyrrolidinyl]-, methyl ester, (2E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.




RN 677737-10-9 CAPLUS

CN Pyrrolidine, 1-[(4-methylphenyl)sulfonyl]-4-[(1E)-2-phenylethenyl]-2-[[(S)-[(1E)-2-phenylethenyl]sulfinyl]methyl]-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Double bond geometry as shown.




RN 677737-11-0 CAPLUS

CN 2-Propenoic acid, 3-[(3R,5S)-1-[(4-methylphenyl)sulfonyl]-5-[[(S)-[(1E)-2-phenylethenyl]sulfinyl]methyl]-3-pyrrolidinyl]-, methyl ester, (2E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Double bond geometry as shown.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 48 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN


ACCESSION NUMBER: 2003:981450 CAPLUS

DOCUMENT NUMBER: 140:217590

TITLE: Synthesis and biological evaluation of [4-(2-phenylethenesulfonylmethyl)phenyl]-quinazolin-4-yl-amines as orally active anti-cancer agents

AUTHOR(S): Sharma, Vedula M.; Seshu, K. V. Adi; Sekhar, V. Chandra; Madan, Sachin; Vishnu, B.; Babu, P. Aravind; Krishna, C. Vamsee; Sreenu, J.; Krishna, V. Ravi;

Venkateswarlu, A.; Rajagopal, Sriram; Ajaykumar, R.; Kumar, T. Sravan
 CORPORATE SOURCE: Discovery Chemistry, Discovery Research, Dr. Reddy's Laboratories, Hyderabad, 500 049, India
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(1), 67-71
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 140:217590
 GI



AB A series of N-[4-(2-phenylethenesulfonylmethyl)phenyl]quinazolin-4-yl-amines, e.g., I (R1 = R2 = R3 = R4 = H) was prepared and tested for its in vitro cytotoxic activity against a panel of 12 human cancer cell lines. I [R1 = R3 = R4 = H; R2 = F (II); R1 = R2 = Cl; R3 = R4 = H, OMe; R3 = Br; R4 = H] showed good in vitro activity and were further tested for their in vivo efficacy in the HT-29 human colon adenocarcinoma xenograft model. II exhibited promising activity in this model. Dose-response studies for II against HT-29 human colon adeno carcinoma xenografts at 100, 200, and 400 mg/kg doses were performed.


IT 664979-26-4P 664979-27-5P 664979-28-6P
 664979-29-7P 664979-30-0P 664979-31-1P
 664979-32-2P 664979-33-3P 664979-34-4P
 664979-35-5P 664979-36-6P 664979-37-7P
 664979-38-8P 664979-39-9P 664979-40-2P
 664979-41-3P 664979-42-4P 664979-43-5P
 664979-44-6P 664979-45-7P 664979-46-8P
 664979-47-9P 664979-48-0P 664979-49-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (phenylethenylsulfonylmethyl)phenylamines via substitution of nitrobenzyl bromide with mercaptoacetic acid followed by oxidation, Knoevenagel condensation with arylaldehydes, and reduction in the preparation of anticancer agents)


RN 664979-26-4 CAPLUS

CN Benzene, 1-nitro-4-[[(2-phenylethenyl)sulfonyl]methyl]- (CA INDEX NAME)




RN 664979-27-5 CAPLUS

CN Benzene, 1-fluoro-4-[2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)




RN 664979-28-6 CAPLUS

CN Benzonitrile, 4-[2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)




RN 664979-29-7 CAPLUS

CN Benzene, 1,2-dichloro-4-[2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)




RN 664979-30-0 CAPLUS

CN Benzene, 1-bromo-4-[2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)




RN 664979-31-1 CAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)




RN 664979-32-2 CAPLUS

CN Benzene, 1-chloro-4-[2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)




RN 664979-33-3 CAPLUS

CN Benzene, 2,4-dichloro-1-[2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)




RN 664979-34-4 CAPLUS


CN Benzene, 2,4-difluoro-1-[2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)



RN 664979-35-5 CAPLUS


CN Benzene, 2-chloro-4-fluoro-1-[2-[(4-nitrophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)

RN 664979-36-6 CAPLUS

CN Benzene, 2-fluoro-1-[2-[(4-nitrophenyl)methyl]sulfonyl]ethenyl]-4-
(trifluoromethyl)- (CA INDEX NAME)


RN 664979-37-7 CAPLUS

CN Phenol, 4-[2-[(4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)




RN 664979-38-8 CAPLUS

CN Benzenamine, 4-[[2-(phenylethenyl)sulfonyl]methyl]- (CA INDEX NAME)




RN 664979-39-9 CAPLUS

CN Benzenamine, 4-[[[2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)




RN 664979-40-2 CAPLUS

CN Benzonitrile, 4-[2-[[[4-aminophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)




RN 664979-41-3 CAPLUS

CN Benzenamine, 4-[[[2-(3,4-dichlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)




RN 664979-42-4 CAPLUS

CN Benzenamine, 4-[[[2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)




RN 664979-43-5 CAPLUS

CN Phenol, 4-[2-[[[4-aminophenyl)methyl]sulfonyl]ethenyl]-2,6-bis(1,1-dimethylethyl)- (CA INDEX NAME)




RN 664979-44-6 CAPLUS

CN Benzenamine, 4-[[[2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)




RN 664979-45-7 CAPLUS

CN Benzenamine, 4-[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)




RN 664979-46-8 CAPLUS

CN Benzenamine, 4-[[[2-(2-chloro-4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)




RN 664979-47-9 CAPLUS

CN Benzenamine, 4-[[[2-(2-chloro-4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)




RN 664979-48-0 CAPLUS

CN Benzenamine, 4-[[[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]sulfonyl]methyl]- (CA INDEX NAME)



RN 664979-49-1 CAPLUS

CN Phenol, 4-[2-[[[4-(aminophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)



IT 664979-76-4P 664979-77-5P 664979-78-6P

664979-79-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-[(phenylethenylsulfonylmethyl)phenyl](chloroalkoxy)quinazolinylamines via substitution of acetoxychloroquinazoline with (phenylethenylsulfonylmethyl)phenylamines followed by hydrolysis and substitution with bromochloroalkenes)


RN 664979-76-4 CAPLUS

CN 6-Quinazolinol, 4-[[4-[[[2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-7-methoxy-, 6-acetate (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-77-5 CAPLUS
CN 6-Quinazolinol, 4-[[4-[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-7-methoxy-, 6-acetate
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-78-6 CAPLUS
CN 6-Quinazolinol, 4-[[4-[[[2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-7-methoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN	664979-79-7	CAPLUS	
CN	6-Quinazolinol, 4-[[4-[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-7-methoxy-		(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




IT 664979-83-3P 664979-84-4P 664979-85-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation, anticancer activity, and SAR of
 N-[(phenylethenylsulfonylmethyl)phenyl] (aminoalkoxy)quinazolinylamine
 s via substitution of N-
 [(phenylethenylsulfonylmethyl)phenyl] (chloroalkoxy)quinazolinylamines
 with morpholine)
 RN 664979-83-3 CAPLUS
 CN 4-Quinazolinamine, N-[4-[[[2-(4-
 fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]-7-methoxy-6-[2-(4-
 morpholinyl)ethoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-84-4 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]-7-methoxy-6-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-85-5 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]-7-methoxy-6-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




IT 664979-80-0P 664979-81-1P 664979-82-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation, anticancer activity, and SAR of
 N-[(phenylethenylsulfonylmethyl)phenyl] (aminoalkoxy)quinazolinylamine
 s via substitution of N-
 [(phenylethenylsulfonylmethyl)phenyl] (chloroalkoxy)quinazolinylamines
 with morpholine)
 RN 664979-80-0 CAPLUS
 CN 4-Quinazolinamine, 6-(2-chloroethoxy)-N-[4-[[[2-(4-
 fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]-7-methoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-81-1 CAPLUS
CN 4-Quinazolinamine, 6-(3-chloropropoxy)-N-[4-[[[2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]-7-methoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-82-2 CAPLUS

CN 4-Quinazolinamine, 6-(3-chloropropoxy)-N-[4-[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]-7-methoxy- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT	664979-50-4P	664979-51-5P	664979-52-6P
	664979-53-7P	664979-54-8P	664979-55-9P
	664979-56-0P	664979-57-1P	664979-58-2P
	664979-59-3P	664979-60-6P	664979-61-7P
	664979-62-8P	664979-63-9P	664979-64-0P
	664979-65-1P	664979-66-2P	664979-67-3P
	664979-68-4P	664979-69-5P	664979-70-8P
	664979-71-9P	664979-72-0P	664979-73-1P
	664979-74-2P	664979-75-3P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation, anticancer activity, and structure-activity relationship of N-[(phenylethenylsulfonylmethyl)phenyl]quinazolinylamines via substitution of chloroquinazolines with (phenylethenylsulfonylmethyl)phenylamines)

RN 664979-50-4 CAPLUS

CN 4-Quinazolinamine, N-[4-[[[(2-phenylethenyl)sulfonyl]methyl]phenyl]]- (CA


INDEX NAME)




RN 664979-51-5 CAPLUS

CN 4-Quinazolinamine, N-[4-[[[2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-52-6 CAPLUS
CN Benzonitrile, 4-[2-[[[4-(4-quinazolinylamino)phenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-53-7 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(3,4-

dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-54-8 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(4-bromophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN	664979-55-9	CAPLUS	
CN	Phenol, 2,6-bis(1,1-dimethylethyl)-4-[2-[[[4-(4-quinazolinylamino)phenyl]methyl]sulfonyl]ethenyl]-		(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-56-0 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-57-1 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-58-2 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(2,4-difluorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-59-3 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(2-chloro-4-fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-60-6 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-61-7 CAPLUS
CN Phenol, 4-[2-[[[4-(4-quinazolinylamino)phenyl]methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-62-8 CAPLUS
CN 4-Quinazolinamine, 6-bromo-N-[4-[[[2-(3,4-dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-63-9 CAPLUS
CN 4-Quinazolinamine, 6-bromo-N-[4-[[[2-(4-bromophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-64-0 CAPLUS
CN 4-Quinazolinamine, 6-bromo-N-[4-[[[2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-65-1 CAPLUS
CN Phenol, 4-[2-[[[4-[(6-bromo-4-quinazolinyl)amino]phenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-66-2 CAPLUS
CN 4-Quinazolinamine, 6-bromo-N-[4-[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-67-3 CAPLUS
CN 4-Quinazolinamine, 6-bromo-N-[4-[[[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-68-4 CAPLUS
CN 4-Quinazolinamine, 6-bromo-N-[4-[[[2-(2,4-difluorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-69-5 CAPLUS
CN 4-Quinazolinamine, 7-chloro-N-[4-[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-70-8 CAPLUS
CN 4-Quinazolinamine, 7-chloro-N-[4-[[[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-71-9 CAPLUS
CN 4-Quinazolinamine, 7-chloro-N-[4-[[[2-(2-chloro-4-fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-72-0 CAPLUS
CN 4-Quinazolinamine, 7-chloro-N-[4-[[[2-(2,4-difluorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-73-1 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]-6,7-dimethoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-74-2 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]-6,7-dimethoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-75-3 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(4-bromophenyl)ethenyl]sulfonyl]methyl]phenyl]-6,7-dimethoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 49 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:804505 CAPLUS
DOCUMENT NUMBER: 140:59567
TITLE: New styryl sulfones as anticancer agents
AUTHOR(S): Vedula, Manohar Sharma; Pulipaka, Aravind Babu; Venna, Chandrasekhar; Chintakunta, Vamsee Krishna; Jinnapally, Sreenu; Kattuboina, Venkata Adishesu; Vallakati, Ravi Krishna; Basetti, Vishnu; Akella, Venkateswarlu; Rajgopal, Sriram; Reka, Ajaya Kumar; Teepireddy, Sravan Kumar; Mamnoor, Prem Kumar; Rajagopalan, Ramanujam; Bulusu, Gopalakrishnan; Khandelwal, Akash; Upreti, Vijay V.; Mamidi, Srinivas

CORPORATE SOURCE: Rao
Discovery Research, Discovery Chemistry, Dr. Reddy's
Laboratories, Hyderabad, 500 050, India
SOURCE: European Journal of Medicinal Chemistry (2003), 38(9),
811-824
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:59567
GI



AB Styryl sulfone compds. have been synthesized and evaluated for their anti-proliferative activity. Among the compds. synthesized, I has shown 51% tumor growth inhibition in mice implanted with HT-29 human carcinoma at 400 mg kg⁻¹ orally.

IT 639494-91-0P 639494-94-3P 639494-97-6P
639495-00-4P 639495-03-7P 639495-06-0P
639495-09-3P 639495-12-8P 639495-15-1P
639495-19-5P


RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(stereoselective preparation, CoMSIA-predicted and actual tumor growth inhibition, and structure-activity relationship of styryl sulfones via mesylation of phenylhydroxyethyl sulfones followed by elimination and hydrolysis)

RN 639494-91-0 CAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[(1E)-2-[[[1-(methanesulfonyl)-1H-benzimidazol-2-yl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 639494-94-3 CAPLUS

CN 1H-Benzimidazole, 2-[[[(1E)-2-(4-methoxyphenyl)ethenyl]sulfonyl]methyl]-1-(methylsulfonyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 639494-97-6 CAPLUS

CN 1H-Benzimidazole, 2-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-1-(methylsulfonyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 639495-00-4 CAPLUS

CN 1H-Benzimidazole, 2-[[[(1E)-2-(4-fluoro-3-methylphenyl)ethenyl]sulfonyl]methyl]-1-(methylsulfonyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 639495-03-7 CAPLUS

CN 1H-Benzimidazole, 6-chloro-2-[[[(1E)-2-(4-fluoro-3-methylphenyl)ethenyl]sulfonyl]methyl]-1-(methylsulfonyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 639495-06-0 CAPLUS

CN 1H-Benzimidazole, 6-chloro-2-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-1-(methylsulfonyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 639495-09-3 CAPLUS

CN 1H-Benzimidazole, 2-[[[(1E)-2-(3,4-dichlorophenyl)ethenyl]sulfonyl]methyl]-1-(methylsulfonyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 639495-12-8 CAPLUS

CN 1H-Benzimidazole, 2-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-1-(methylsulfonyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 639495-15-1 CAPLUS

CN 1H-Benzimidazole, 2-[[[(1E)-2-(4-chloro-3-methylphenyl)ethenyl]sulfonyl]methyl]-1-(methylsulfonyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 639495-19-5 CAPLUS

CN 1H-Benzimidazole, 6-chloro-2-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-1-(methylsulfonyl)- (CA INDEX NAME)

Double bond geometry as shown.




IT 639495-26-4P 639495-30-0P 639495-34-4P
 639495-38-8P 639495-42-4P 639495-46-8P
 639495-50-4P 639495-54-8P 639495-57-1P
 639495-60-6P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (stereoselective preparation, CoMSIA-predicted and actual tumor growth inhibition, and structure-activity relationship of styryl sulfones via mesylation of phenylhydroxyethyl sulfones followed by elimination and hydrolysis)

RN 639495-26-4 CAPLUS

CN Phenol, 4-[(1E)-2-[(1H-benzimidazol-2-ylmethyl)sulfonyl]ethenyl]-2,6-bis(1,1-dimethylethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 639495-30-0 CAPLUS

CN 1H-Benzimidazole, 2-[[[(1E)-2-(4-methoxyphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 639495-34-4 CAPLUS

CN 1H-Benzimidazole, 2-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 639495-38-8 CAPLUS

CN 1H-Benzimidazole, 2-[[[(1E)-2-(4-fluoro-3-
methylphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 639495-42-4 CAPLUS

CN 1H-Benzimidazole, 6-chloro-2-[[[(1E)-2-(4-fluoro-3-methylphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 639495-46-8 CAPLUS

CN 1H-Benzimidazole, 6-chloro-2-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 639495-50-4 CAPLUS

CN 1H-Benzimidazole, 2-[[[(1E)-2-(3,4-dichlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 639495-54-8 CAPLUS

CN 1H-Benzimidazole, 2-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 639495-57-1 CAPLUS

CN 1H-Benzimidazole, 2-[[[(1E)-2-(4-chloro-3-methylphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 639495-60-6 CAPLUS

CN 1H-Benzimidazole, 6-chloro-2-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 639495-63-9P


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(stereoselective preparation, CoMSIA-predicted and actual tumor growth inhibition, structure-activity relationship, and pharmacokinetics of styryl sulfones via mesylation of phenylhydroxyethyl sulfones followed by elimination and hydrolysis)

RN 639495-63-9 CAPLUS

CN 1H-Benzimidazole, 6-chloro-2-[[[(1E)-2-(4-chloro-3-methylphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 639495-22-0P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(stereoselective preparation, anticancer activity, and structure-activity relationship of styryl sulfones via mesylation of phenylhydroxyethyl sulfones followed by elimination and hydrolysis)

RN 639495-22-0 CAPLUS

CN 1H-Benzimidazole, 6-chloro-2-[[[(1E)-2-(4-chloro-3-methylphenyl)ethenyl]sulfonyl]methyl]-1-(methylsulfonyl)- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
 REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 50 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:696704 CAPLUS

DOCUMENT NUMBER: 139:230469

TITLE: Preparation of amino-substituted (E)-2,6-dialkoxytyrlyl 4-substituted benzyl sulfones for treating proliferative disorders

INVENTOR(S): Reddy, Premkumar E.; Reddy, Ramana M. V.; Bell, Stanley C.

PATENT ASSIGNEE(S): Temple University-of the Commonwealth System of Higher Education, USA; Onconova Therapeutics, Inc.

SOURCE: PCT Int. Appl., 189 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072062	A2	20030904	WO 2003-US6357	20030228
WO 2003072062	A3	20031204		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2477232	A1	20030904	CA 2003-2477232	20030228
AU 2003213660	A1	20030909	AU 2003-213660	20030228
EP 1487428	A2	20041222	EP 2003-711347	20030228

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005531503	T	20051020	JP 2003-570809	20030228
NZ 535232	A	20070531	NZ 2003-535232	20030228
US 20050130942	A1	20050616	US 2004-506005	20040827
MX 2004008356	A	20050912	MX 2004-8356	20040827
IN 2004DN02651	A	20050401	IN 2004-DN2651	20040909
PRIORITY APPLN. INFO.:			US 2002-360697P	P 20020228
			WO 2003-US6357	W 20030228

OTHER SOURCE(S): MARPAT 139:230469
 GI




AB Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzyl sulfones (shown as I; variables defined below; e.g. (E)-2,4,6-trimethoxystyryl 3-(carboxymethylamino)-4-methoxybenzyl sulfone), useful as antiproliferative agents, including, for example, anticancer agents, are provided. The authors believe that I affect the mitogen activated protein kinase (MAPK) signal transduction pathway, thereby affecting tumor cell growth and viability. This cell growth inhibition is associated with regulation of the extracellular-signal-regulated kinase (ERK) and c-Jun NH2-terminated kinase (JNK) types of MAPK; I may block the phosphorylating capacity of ERK-2. Tumor cells treated with I are believed to accumulate in the G2/M phase of the cell cycle; as the cells exit the G2/M phase, they appear to undergo apoptosis. Compds. I can readily be covalently bonded to antibodies, preferably tumor-specific monoclonal antibodies (Mab) via a suitable bifunctional linker (-L-) to yield a conjugate I-L-Ab. The effect (IC50 < 10 μ M) of .apprx.50 examples of I on prostate carcinoma cell line DU-145, breast adenocarcinoma cell line BT-20, colorectal carcinoma cell line DLD-1 and non-small cell lung carcinoma cell line H157 are tabulated. Fifty-one example preps. of I are included. For I: X = N(R2)(MyR1), N:CR1R5; X1 = N(R2)(MyR1), N:CR1R5, NO2 (X1 is optionally protected with ≥ 1 chemical protecting groups); g is 0 or 1; each M is a bivalent connecting group = -(C1-C6)alkylene-, -(CH2)a-V-(CH2)b-, -(CH2)d-W-(CH2)e- and -Z-; each y = 0 and 1; each V = arylene, heteroarylene, -C(O)-, -C(S)-, -S(O)-, -SO2-, -C(O)O-; -C(O)(C1-C6)perfluoroalkylene-, -C(O)NR4-, -C(S)-NR4- and -SO2NR4-; each W = -NR4-, -O- and -S-; a = 0-3; b = 0-3; d = 1-3; e = 0-3. -Z- = -C(O)RaR4N(R4)- wherein the absolute stereochem. of -Z- is D or L or a mixture of D and L; Ra = -H, -(C1-C6) alkyl, -(CH2)3-NH-C(NH2)(:NH), etc.; R1 = -H, (un)substituted aryl, (un)substituted heterocyclic, -CO2R5, etc.; R2 = -H, -(C1-C6)alkyl, and aryl(C1-C3)alkyl; R3 = -(C1-C6)alkyl; R4 = -H, and-(C1-C6)alkyl; R5 = -H, -(C1-C6)alkyl and -(C1-C6)acyl; R6 = -H, -(C1-C6)alkyl, -CO2R5, -C(O)R7, -OC(O)(CH2)2CO2R5, -SR4, guanidino, -NR42, -NR43+, -N+(CH2CH2OR5)3, (un)substituted Ph, (un)substituted

heterocyclic and halogen; R7 = -Ra, halogen, -NR42, and heterocycles containing two N atoms. Q = -H, -(C1-C6)alkoxy, halogen, -(C1-C6)alkyl and -NR42; wherein the substituents for the substituted aryl and substituted heterocyclic groups comprising or included within = halogen, (C1-C6)alkyl, -NO2, -CN, -CO2R5, -C(O)O(C1-C3)alkyl, -OR5, -(C2-C6)-OH, phosphonato, -NR42, -NHC(O)(C1-C6)alkyl, sulfamyl, -OC(O)(C1-C3)alkyl, -O(C2-C6)-N-[(C1-C6)alkyl]2 and -CF3; addnl. details including provisos are given in the claims.


IT 592542-50-2P, (E)-2,4,6-Trimethoxystyryl 3-Amino-4-Methoxybenzyl Sulfone 592542-52-4P, (E)-2,4,6-Trimethoxystyryl 4-Methoxy-3-Nitrobenzyl sulfone 592542-62-6P, (E)-2,4,6-Trimethoxystyryl 3-(3,5-dinitrobenzamido)-4-methoxybenzyl sulfone 592542-64-8P, (E)-2,4,6-Trimethoxystyryl 3-(2-chloroacetamido)-4-methoxybenzyl sulfone 592542-67-1P, (E)-2,4,6-Trimethoxystyryl 3-(4-nitrobenzamido)-4-methoxybenzyl sulfone 592542-79-5P, (E)-2,4,6-Trimethoxystyryl 3-(2,4-dinitrobenzenesulfamyl)-4-methoxybenzyl sulfone 592542-84-2P, (E)-2,4,6-Trimethoxystyryl 3-(hydroxyacetamido)-4-methoxybenzyl sulfone 592542-85-3P, (E)-2,4,6-Trimethoxystyryl 3-(acetoxyacetamido)-4-methoxybenzyl sulfone 592542-88-6P, (E)-2,4,6-Trimethoxystyryl 3-(2-acetoxypropionamido)-4-methoxybenzyl sulfone 592543-14-1P, (E)-2,4,6-Trimethoxystyryl 3-[(2,2-difluoro-3-methoxy-3-oxopropanoyl)amino]-4-methoxybenzyl sulfone
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzyl sulfones for treating proliferative disorders)
 RN 592542-50-2 CAPLUS
 CN Benzenamine, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 592542-52-4 CAPLUS
 CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[[4-methoxy-3-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-62-6 CAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-3,5-dinitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-64-8 CAPLUS

CN Acetamide, 2-chloro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-67-1 CAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-4-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-79-5 CAPLUS

CN Benzenesulfonamide, N-(2,4-dinitrophenyl)-2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-84-2 CAPLUS

CN Acetamide, 2-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-85-3 CAPLUS

CN Acetamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-88-6 CAPLUS

CN Propanamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-14-1 CAPLUS

CN Propanoic acid, 2,2-difluoro-3-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-3-oxo-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.



IT 592542-53-5P, (E)-2,4,6-Trimethoxystyryl
3-(carboxymethylsulfonylamino)-4-methoxybenzyl sulfone
592542-55-7P, (E)-2,4,6-Trimethoxystyryl
3-(carboxyacetamido)-4-methoxybenzyl sulfone 592542-56-8P,
(E)-2,4,6-Trimethoxystyryl 3-(guanidino)-4-methoxybenzyl sulfone
592542-59-1P, (E)-2,4,6-Trimethoxystyryl
3-[(carboxymethyl)amino]-4-methoxybenzyl sulfone 592542-60-4P,
(E)-2,4,6-Trimethoxystyryl 3-[(carboxymethyl)amino]-4-methoxybenzyl
sulfone sodium salt 592542-63-7P, (E)-2,4,6-Trimethoxystyryl
3-(3,5-diaminobenzamido)-4-methoxybenzyl sulfone 592542-65-9P,
(E)-2,4,6-Trimethoxystyryl 3-[(4-methylpiperazin-1-yl)acetamido]-4-
methoxybenzyl sulfone 592542-66-0P, (E)-2,4,6-Trimethoxystyryl
3-(benzamido)-4-methoxybenzyl sulfone 592542-68-2P,
(E)-2,4,6-Trimethoxystyryl 3-(4-aminobenzamido)-4-methoxybenzyl sulfone
592542-69-3P, (E)-2,4,6-Trimethoxystyryl
3-[(4-nitrophenyl)methyleneamino]-4-methoxybenzyl sulfone
592542-70-6P, (E)-2,4,6-Trimethoxystyryl
3-[(2S)-2,6-diaminohexanoyl]amino]-4-methoxybenzyl sulfone
592542-72-8P, (E)-2,4,6-Trimethoxystyryl
3-[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-methoxybenzyl sulfone
592542-74-0P, (E)-2,4,6-Trimethoxystyryl
3-[(2R)-2-amino-3-hydroxypropanoyl]amino]-4-methoxybenzyl sulfone
592542-76-2P, (E)-2,4,6-Trimethoxystyryl
3-(ureido)-4-methoxybenzyl sulfone 592542-77-3P,
(E)-2,4,6-Trimethoxystyryl 3-(methylamino)-4-methoxybenzyl sulfone
592542-78-4P, (E)-2,4,6-Trimethoxystyryl
3-(acetamido)-4-methoxybenzyl sulfone 592542-80-8P,
(E)-2,4,6-Trimethoxystyryl 3-(2,4-diaminobenzenesulfamyl)-4-methoxybenzyl
sulfone 592542-81-9P, (E)-2,4,6-Trimethoxystyryl
3-(dimethylaminoacetamido)-4-methoxybenzyl sulfone 592542-82-0P
, (E)-2,4,6-Trimethoxystyryl 3-[(1-carboxyethyl)amino]-4-methoxybenzyl
sulfone 592542-83-1P, (E)-2,4,6-Trimethoxystyryl
3-[4-(4-methylpiperazin-1-yl)benzamido]-4-methoxybenzyl sulfone
592542-86-4P, (E)-2,4,6-Trimethoxystyryl
3-(pyridinium-1-yl)acetamido-4-methoxybenzyl sulfone
592542-87-5P, (E)-2,4,6-Trimethoxystyryl
3-(2-hydroxypropionamido)-4-methoxybenzyl sulfone 592542-89-7P
, (E)-2,4,6-Trimethoxystyryl 3-(triethylammonioacetamido)-4-methoxybenzyl
sulfone 592542-90-0P, (E)-2,4,6-Trimethoxystyryl
3-[[tris(2-hydroxyethyl)ammonio]acetamido]-4-methoxybenzyl sulfone
592542-91-1P, (E)-2,4,6-Trimethoxystyryl


3-(2-methyl-2-hydroxypropionamido)-4-methoxybenzyl sulfone
592542-92-2P, (E)-2,4,6-Trimethoxystyryl
3-(2-methyl-2-acetoxypropionamido)-4-methoxybenzyl sulfone
592542-93-3P, (E)-2,4,6-Trimethoxystyryl
3-(trifluoroacetamido)-4-methoxybenzyl sulfone 592542-95-5P
592542-97-7P, (E)-2,4,6-Trimethoxystyryl
3-[(4-hydroxy-4-oxobutanoyl)amino]-4-methoxybenzyl sulfone
592542-99-9P, (E)-2,4,6-Trimethoxystyryl
3-[(4-chloro-4-oxobutanoyl)amino]-4-methoxybenzyl sulfone
592543-01-6P, (E)-2,4,6-Trimethoxystyryl
3-[2-[(3-carboxypropanoyl)oxy]acetamido]-4-methoxybenzyl sulfone
592543-03-8P, (E)-2,4,6-Trimethoxystyryl
3-[(5-hydroxy-5-oxopentanoyl)amino]-4-methoxybenzyl sulfone
592543-05-0P, (E)-2,4,6-Trimethoxystyryl
3-(phosphonoxyacetamido)-4-methoxybenzyl sulfone disodium salt
592543-06-1P, (E)-2,4,6-Trimethoxystyryl
3-[(3-carboxypropyl)amino]-4-methoxybenzyl sulfone 592543-08-3P
, (E)-2,4,6-Trimethoxystyryl 3-[(2-carboxyethyl)amino]-4-methoxybenzyl
sulfone 592543-09-4P, (E)-2,4,6-Trimethoxystyryl
3-(methoxycarbonylamino)-4-methoxybenzyl sulfone 592543-10-7P,
(E)-2,4,6-Trimethoxystyryl 3-[(4-methoxybenzenesulfonyl)amino]-4-
methoxybenzyl sulfone 592543-11-8P, (E)-2,4,6-Trimethoxystyryl
3-[(4-methoxy-4-oxobutanoyl)amino]-4-methoxybenzyl sulfone
592543-12-9P, (E)-2,4,6-Trimethoxystyryl
3-[(3-ethoxy-3-oxopropanoyl)amino]-4-methoxybenzyl sulfone
592543-13-0P, (E)-2,4,6-Trimethoxystyryl
3-(pentafluoropropionamido)-4-methoxybenzyl sulfone 592543-15-2P
, (E)-2,4,6-Trimethoxystyryl 3-[(2,2,3,3-tetrafluoro-4-hydroxy-4-
oxobutanoyl)amino]-4-methoxybenzyl sulfone 592543-16-3P,
(E)-2,4,6-Trimethoxystyryl 3-(aminoacetamido)-4-methoxybenzyl sulfone
hydrochloride 592543-17-4P, (E)-2,4,6-Trimethoxystyryl
3-[(2,2-difluoro-3-hydroxy-3-oxopropanoyl)amino]-4-methoxybenzyl sulfone
592543-18-5P, (E)-2,4,6-Trimethoxystyryl
3-(2-dimethylamino-2,2-difluoroacetamido)-4-methoxybenzyl sulfone
592543-20-9P, (E)-2,4,6-Trimethoxystyryl
3-(diethylphosphonoxyacetamido)-4-methoxybenzyl sulfone
592543-21-0P, (E)-2,4,6-Trimethoxystyryl
3-[(4-ethoxy-2,2,3,3-tetrafluoro-4-oxobutanoyl)amino]-4-methoxybenzyl
sulfone 592543-22-1P, (E)-2,4,6-Trimethoxystyryl
3-(aminoacetamido)-4-methoxybenzyl sulfone 592543-23-2P,
(E)-2,4,6-Trimethoxystyryl 3-[(R)-1-carboxyethyl)amino]-4-methoxybenzyl
sulfone 592543-24-3P, (E)-2,4,6-Trimethoxystyryl
3-[(S)-1-carboxyethyl)amino]-4-methoxybenzyl sulfone
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of amino-substituted (E)-2,6-dialkoxystyryl
4-substituted benzyl sulfones for treating proliferative disorders)

RN 592542-53-5 CAPLUS

CN Acetic acid, 2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]sulfonyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 592542-55-7 CAPLUS

CN Propanoic acid, 3-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-3-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-56-8 CAPLUS

CN Guanidine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-60-4 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, sodium salt (1:1) (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-63-7 CAPLUS

CN Benzamide, 3,5-diamino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-65-9 CAPLUS

CN 1-Piperazineacetamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-4-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-66-0 CAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-68-2 CAPLUS

CN Benzamide, 4-amino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-69-3 CAPLUS

CN Benzenamine, 2-methoxy-N-[(4-nitrophenyl)methylene]-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 592542-70-6 CAPLUS

CN Hexanamide, 2,6-diamino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 592542-72-8 CAPLUS

CN Propanamide, 2-amino-3-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 592542-74-0 CAPLUS

CN Propanamide, 2-amino-3-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 592542-76-2 CAPLUS

CN Urea, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-77-3 CAPLUS

CN Benzenamine, 2-methoxy-N-methyl-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-78-4 CAPLUS

CN Acetamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-80-8 CAPLUS

CN Benzenesulfonamide, N-(2,4-diaminophenyl)-2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-81-9 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-82-0 CAPLUS

CN Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-83-1 CAPLUS

CN Benzamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-86-4 CAPLUS

CN Pyridinium, 1-[2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxoethyl]]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-87-5 CAPLUS

CN Propanamide, 2-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-89-7 CAPLUS

CN Ethanaminium, N,N,N-triethyl-2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-90-0 CAPLUS

CN Ethanaminium, N,N,N-tris(2-hydroxyethyl)-2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-91-1 CAPLUS

CN Propanamide, 2-hydroxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-92-2 CAPLUS

CN Propanamide, 2-(acetyloxy)-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-93-3 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-95-5 CAPLUS

CN Methanesulfonamide, 1,1,1-trifluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-97-7 CAPLUS

CN Butanoic acid, 4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-4-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-99-9 CAPLUS

CN Butanoyl chloride, 4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-4-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-01-6 CAPLUS

CN Butanedioic acid, 1-[2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxoethyl] ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-03-8 CAPLUS

CN	Pentanoic acid, 5-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-5-oxo-	(CA INDEX NAME)
----	---	-----------------


Double bond geometry as shown.



RN 592543-05-0 CAPLUS

CN Acetamide, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-2-(phosphonooxy)-, sodium salt (1:2) (CA INDEX NAME)

Double bond geometry as shown.




●2 Na

RN 592543-06-1 CAPLUS

CN Butanoic acid, 4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-08-3 CAPLUS

CN β -Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-09-4 CAPLUS

CN Carbamic acid, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-10-7 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-11-8 CAPLUS

CN Butanoic acid, 4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-4-oxo-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-12-9 CAPLUS

CN Propanoic acid, 3-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-3-oxo-, ethyl ester
(CA INDEX NAME)


Double bond geometry as shown.



RN 592543-13-0 CAPLUS

CN Propanamide, 2,2,3,3,3-pentafluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-15-2 CAPLUS

CN Butanoic acid, 2,2,3,3-tetrafluoro-4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-4-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-16-3 CAPLUS

CN Acetamide, 2-amino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 592543-17-4 CAPLUS

CN Propanoic acid, 2,2-difluoro-3-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-3-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-18-5 CAPLUS

CN Acetamide, 2-(dimethylamino)-2,2-difluoro-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-20-9 CAPLUS

CN Phosphoric acid, diethyl 2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxoethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-21-0 CAPLUS

CN Butanoic acid, 2,2,3,3-tetrafluoro-4-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-4-oxo-, ethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-22-1 CAPLUS

CN Acetamide, 2-amino-N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 592543-23-2 CAPLUS

CN D-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




IT 592542-61-5, (E)-2,4,6-Trimethoxystyryl
3-(carbomethoxymethylamino)-4-methoxybenzyl sulfone
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amino-substituted (E)-2,6-dialkoxystyryl 4-substituted
benzyl sulfones for treating proliferative disorders)

RN 592542-61-5 CAPLUS


CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.




IT 592542-54-6P, (E)-2,4,6-Trimethoxystyryl
 3-(methoxycarbonylmethanesulfonylamino)-4-methoxybenzyl sulfone
 592542-57-9P, (E)-2,4,6-Trimethoxystyryl
 3-[N',N'-bis(tert-butoxycarbonyl)guanidino]-4-methoxybenzyl sulfone
 592542-71-7P, (E)-2,4,6-Trimethoxystyryl
 3-[[(2S)-2,6-bis(Fmoc-amino)hexanoyl]amino]-4-methoxybenzyl sulfone
 592542-73-9P, (E)-2,4,6-Trimethoxystyryl
 3-[[(2S)-2-(Fmoc-amino)-3-hydroxypropanoyl]amino]-4-methoxybenzyl sulfone
 592542-75-1P, (E)-2,4,6-Trimethoxystyryl
 3-[[(2R)-2-(Fmoc-amino)-3-hydroxypropanoyl]amino]-4-methoxybenzyl sulfone
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of amino-substituted (E)-2,6-dialkoxystyryl 4-substituted
 benzyl sulfones for treating proliferative disorders)
 RN 592542-54-6 CAPLUS
 CN Acetic acid, 2-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-
 trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]sulfonyl]-, methyl
 ester (CA INDEX NAME)

Double bond geometry as shown.



RN 592542-57-9 CAPLUS
 CN Imidodicarbonic acid, N-[imino[[2-methoxy-5-[[[(1E)-2-(2,4,6-
 trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]methyl]-,
 C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-71-7 CAPLUS

CN Carbamic acid, [(1S)-1-[[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]carbonyl]-1,5-pentanedyl]bis-, bis(9H-fluoren-9-ylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 592542-73-9 CAPLUS

CN Carbamic acid, [(1S)-1-(hydroxymethyl)-2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 592542-75-1 CAPLUS

CN Carbamic acid, [(1R)-1-(hydroxymethyl)-2-[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 51 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:613306 CAPLUS

DOCUMENT NUMBER: 140:111018

TITLE: Stereospecific Grignard reactions of cholesteryl 1-alkenesulfinate esters: Application of the Andersen protocol to the preparation of non-racemic α,β -unsaturated sulfoxides

AUTHOR(S): Strickler, Rick R.; Motto, John M.; Humber, Craig C.;
Schwan, Adrian L.
CORPORATE SOURCE: Guelph-Waterloo Centre for Graduate Work in Chemistry
and Biochemistry, Department of Chemistry and
Biochemistry, University of Guelph, Guelph, ON, N1G
2W1, Can.
SOURCE: Canadian Journal of Chemistry (2003), 81(6), 423-430
CODEN: CJCHAG; ISSN: 0008-4042
PUBLISHER: National Research Council of Canada
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:111018
GI



AB Enantiomerically enriched α,β -unsatd. sulfinate esters of
(-)-cholesterol undergo stereospecific substitutions at sulfur when
treated with Grignard reagents. Sulfoxides, e.g., I, with enantiomeric
excesses of 85-99.5% were obtained when enantiopure sulfonates were used.
The substitution reactions proceed with inversion of sulfur configuration.
Enantiomerically pure cholesteryl (E)-2-carbomethoxyethenesulfinate is not
a suitable reactant under the Grignard reaction conditions. It is
suggested that the ester group induces unwanted reactions significantly
lowering both the yield and sulfur stereogenicity.


IT 646516-55-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(asym. synthesis of α,β -unsatd. sulfoxides via nucleophilic
substitution of chiral cholesteryl alkenesulfonates with Grignard
reagents)

RN 646516-55-4 CAPLUS

CN Benzene, [[(S)-[(1E)-2-phenylethenyl]sulfinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 52 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:449847 CAPLUS
 DOCUMENT NUMBER: 139:17566
 TITLE: Z-styryl sulfone anticancer agents, and preparation thereof
 INVENTOR(S): Reddy, E. Premkumar; Reddy, M. V. Ramana
 PATENT ASSIGNEE(S): Temple University, USA
 SOURCE: U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 282,855.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6576675	B1	20030610	US 2001-937805	20010928
US 6201154	B1	20010313	US 1999-282855	19990331
WO 2000057872	A1	20001005	WO 2000-US8350	20000330

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-282855 A2 19990331
 WO 2000-US8350 W 20000330

OTHER SOURCE(S): MARPAT 139:17566
 GI



AB (Z)-styryl benzylsulfones I (R1 = H, Cl, NO2; R2 = H, lower alkyl, lower alkoxy, Cl, Br, I, F; R3, R4 = H, lower alkyl, NO2, Cl, Br, I, F; provided that at least one of R1 or R2 is H) are useful as anticancer agents. The corresponding (Z)-styryl benzylsulfides are useful as intermediates in the preparation of the biol. active (Z)-styryl benzyl sulfones.

IT 32291-81-9P 136272-42-9P 158606-43-0P
 158606-44-1P 158606-45-2P 298197-01-0P
 298197-03-2P 298197-05-4P 298197-09-8P
 298197-11-2P 298197-13-4P 298197-14-5P
 298197-15-6P 298197-16-7P 298197-17-8P

298197-18-9P 298197-19-0P 298197-20-3P

298197-21-4P 298197-22-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Z-styryl sulfone anticancer agents, and preparation)

RN 32291-81-9 CAPLUS

CN Benzene, [[[1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-42-9 CAPLUS

CN Benzene, 1-chloro-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 158606-43-0 CAPLUS

CN Benzene, 1-methyl-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 158606-44-1 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 158606-45-2 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-

(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-01-0 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-03-2 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-05-4 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-09-8 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-11-2 CAPLUS

CN Benzene, 1-chloro-4-[(1Z)-2-[(4-fluorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-13-4 CAPLUS

CN Benzene, 1-fluoro-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 298197-14-5 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-15-6 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-16-7 CAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-17-8 CAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-18-9 CAPLUS

CN Benzene, 1-[[[(1Z)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-2-chloro- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-19-0 CAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-20-3 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-21-4 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-22-5 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)

Double bond geometry as shown.




IT 298197-23-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(Z-styryl sulfone anticancer agents, and preparation)

RN 298197-23-6 CAPLUS

CN Benzene, 1-fluoro-4-[(1Z)-2-[[[4-iodophenyl]methyl]sulfonyl]ethenyl]- (CA
INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
 REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 53 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:434551 CAPLUS

DOCUMENT NUMBER: 139:22117

TITLE: Preparation of
 N-[2-(3-quinolylmethanesulfonyl)-1-tetrahydrofuran-2-ylethyl]-N-hydroxyformamide for the treatment of diseases mediated by soluble CD23

INVENTOR(S): Best, Desmond John; Bruton, Gordon; Orlek, Barry Sidney

PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045938	A1	20030605	WO 2002-EP13264	20021125
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002365511	A1	20030610	AU 2002-365511	20021125
EP 1448552	A1	20040825	EP 2002-790436	20021125
EP 1448552	B1	20060726		
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005513036	T	20050512	JP 2003-547388	20021125
AT 334124	T	20060815	AT 2002-790436	20021125
ES 2268133	T3	20070316	ES 2002-790436	20021125
US 20050085505	A1	20050421	US 2004-496193	20041115
US 7045626	B2	20060516		

PRIORITY APPLN. INFO.: GB 2001-28378 A 20011127
 WO 2002-EP13264 W 20021125

AB N-[2-(3-quinolylmethanesulfonyl)-1-tetrahydrofuran-2-ylethyl]-N-

hydroxyformamide and (S)-N-[2-(3-quinolylmethanesulfonyl)-1-(R)-tetrahydrofuran-2-ylethyl]-N-hydroxyformamide-N-[2-(3-Quinolylmethanesulfonyl)-1-(R)-tetrahydrofuran-2-yl]ethylhydroxylamine are claimed. Thus, (E)-2-(3-quinolylmethanesulfonyl)-1-(R)-tetrahydrofuran-2-ylethene (preparation given) in THF was treated with aqueous NH₂OH in water and allowed to stir at rt for 15 min. to give N-[2-(3-quinolylmethanesulfonyl)-1-(R)-tetrahydrofuran-2-yl]ethylhydroxylamine. The latter was treated with HCO₂H and Ac₂O and kept overnight at rt.; the reaction mixture was evaporated, redissolved in MeOH and treated with K₂CO₃ followed by stirring at rt for 30 min. to give (S)-N-[2-(3-quinolylmethanesulfonyl)-1-(R)-tetrahydrofuran-2-ylethyl]-N-hydroxyformamide. The latter in a RPMI 8866 cell membrane CD23 cleavage activity assay showed an IC₅₀ = 0.06 μ M.

IT 537684-29-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of quinolylmethanesulfonyltetrahydrofuranylethylhydroxyformamide for the treatment of diseases mediated by soluble CD23)

RN 537684-29-0 CAPLUS

CN Quinoline, 3-[[[(1E)-2-[(2R)-tetrahydro-2-furanyl]ethenyl]sulfonyl]methyl]-(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 54 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:695716 CAPLUS

DOCUMENT NUMBER: 137:212986

TITLE: Method for protecting cells and tissues from ionizing radiation toxicity with α , β unsaturated aryl sulfones

INVENTOR(S): Reddy, Premkumar E.; Reddy, Ramana M. V.; Cosenza, Stephen C.; Helson, Lawrence

PATENT ASSIGNEE(S): Temple University of the Commonwealth System of Higher Education, USA; Onconova Therapeutics, Inc.

SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2002069892	A2	20020912	WO 2002-US6107	20020228

WO 2002069892 A3 20021107
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2439288 A1 20020912 CA 2002-2439288 20020228
 AU 2002305942 A1 20020919 AU 2002-305942 20020228
 AU 2002305942 B2 20061026
 US 20030060505 A1 20030327 US 2002-85745 20020228
 US 6667346 B2 20031223
 EP 1370253 A2 20031217 EP 2002-733811 20020228
 EP 1370253 B1 20080903
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004525908 T 20040826 JP 2002-569071 20020228
 JP 4302986 B2 20090729
 AT 406881 T 20080915 AT 2002-733811 20020228
 KR 850331 B1 20080804 KR 2003-711357 20030828
 PRIORITY APPLN. INFO.: US 2001-271990P P 20010228
 WO 2002-US6107 W 20020228

OTHER SOURCE(S): MARPAT 137:212986

AB Pre-treatment with α , β unsatd. aryl sulfones protects normal cells from the toxic side effects of ionizing radiation. Administration of a radioprotective α , β unsatd. aryl sulfone compound to a patient prior to anticancer radiotherapy reduces the cytotoxic side effects of the radiation on normal cells. The radioprotective effect of the α , β unsatd. aryl sulfone allows the clinician to safely increase the dosage of anticancer radiation. In some instances, amelioration of toxicity following inadvertent radiation exposure may be mitigated with administration of α , β unsatd. arylsulfone. Examples are provided showing that aryl sulfones such as E-4-fluorostyryl-4-chlorobenzylsulfone and E-4-carboxystyryl-4-chlorobenzylsulfone are radioprotective for normal cells (such as fibroblasts) but do not interfere with tumor cell (such as prostate carcinoma) killing by ionizing radiation. In another example, aryl sulfones are used to protect normal hematopoietic progenitor cells during bone marrow purging with ionizing radiation before transplantation in subjects with myelogenous leukemia.

IT 118672-28-9P 158606-44-1P 300699-33-6P
 300699-42-7P 334969-03-8P 334969-29-8P
 334969-61-8P 334970-03-5P 457624-55-4P
 457624-56-5P 457624-57-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of unsatd. aryl sulfones as radioprotectants)

RN 118672-28-9 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 158606-44-1 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-33-6 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-4-
(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-42-7 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA
INDEX NAME)

Double bond geometry as shown.




RN 334969-03-8 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]]- (CA

INDEX NAME)


Double bond geometry as shown.



RN 334969-29-8 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-61-8 CAPLUS

CN Pyridine, 4-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-03-5 CAPLUS

CN Furan, 3-[(1E)-2-[[2,4-dichlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-55-4 CAPLUS

CN Benzene, 1-methoxy-2-[(1E)-2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 457624-56-5 CAPLUS

CN Benzene, 1,2,3,4,5-pentafluoro-6-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-57-6 CAPLUS

CN Phenol, 4-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT	32291-81-9P	93468-07-6P	118672-24-5P
	118672-26-7P	118672-29-0P	118672-30-3P
	118672-33-6P	118672-34-7P	136272-35-0P
	136272-42-9P	158606-43-0P	158606-45-2P
	222639-19-2P	222639-21-6P	222639-24-9P
	222639-26-1P	222639-29-4P	222639-31-8P
	222639-33-0P	298197-01-0P	298197-03-2P
	298197-05-4P	298197-11-2P	298197-13-4P
	298197-14-5P	298197-15-6P	298197-16-7P
	298197-17-8P	298197-18-9P	298197-19-0P
	298197-20-3P	298197-21-4P	298197-22-5P
	300699-34-7P	300699-35-8P	300699-36-9P
	300699-37-0P	300699-39-2P	300699-40-5P
	300699-41-6P	300699-43-8P	300699-44-9P
	300699-45-0P	300699-46-1P	300699-47-2P
	300699-48-3P	300699-49-4P	300699-50-7P
	300699-62-1P	300699-63-2P	300699-64-3P
	300699-67-6P	300699-68-7P	300699-70-1P
	300699-71-2P	300699-72-3P	300699-73-4P
	300699-74-5P	300699-75-6P	300699-76-7P
	300699-77-8P	300699-78-9P	300699-79-0P
	300699-80-3P	300699-81-4P	300699-82-5P
	300699-83-6P	300699-85-8P	300699-86-9P
	300699-87-0P	300699-88-1P	300699-89-2P
	300699-90-5P	300699-91-6P	300699-92-7P
	300699-93-8P	300699-94-9P	300699-95-0P
	300699-96-1P	300699-98-3P	300699-99-4P
	300700-00-9P	334969-04-9P	334969-19-6P
	334969-20-9P	334969-21-0P	334969-22-1P
	334969-23-2P	334969-24-3P	334969-25-4P
	334969-26-5P	334969-27-6P	334969-28-7P
	334969-30-1P	334969-31-2P	334969-32-3P
	334969-33-4P	334969-34-5P	334969-35-6P
	334969-36-7P	334969-37-8P	334969-38-9P
	334969-39-0P	334969-40-3P	334969-41-4P
	334969-42-5P	334969-43-6P	334969-44-7P
	334969-45-8P	334969-46-9P	334969-47-0P
	334969-48-1P	334969-49-2P	334969-50-5P
	334969-51-6P	334969-52-7P	334969-53-8P
	334969-54-9P	334969-55-0P	334970-14-8P
	334970-16-0P	334970-18-2P	334970-20-6P
	334970-21-7P	334970-22-8P	366807-70-7P
	366807-72-9P	366807-74-1P	366807-77-4P
	457623-80-2P	457623-81-3P	457623-82-4P
	457623-83-5P	457623-84-6P	457623-85-7P
	457623-86-8P	457623-87-9P	457623-88-0P

457623-89-1P	457623-90-4P	457623-91-5P
457623-92-6P	457623-93-7P	457623-94-8P
457623-95-9P	457623-96-0P	457623-97-1P
457623-98-2P	457623-99-3P	457624-00-9P
457624-01-0P	457624-02-1P	457624-03-2P
457624-04-3P	457624-05-4P	457624-06-5P
457624-07-6P	457624-08-7P	457624-09-8P
457624-10-1P	457624-11-2P	457624-12-3P
457624-13-4P	457624-14-5P	457624-15-6P
457624-16-7P	457624-17-8P	457624-18-9P
457624-19-0P	457624-20-3P	457624-21-4P
457624-22-5P	457624-23-6P	457624-24-7P
457624-25-8P	457624-26-9P	457624-27-0P
457624-28-1P	457624-29-2P	457624-30-5P
457624-32-7P	457624-34-9P	457624-35-0P
457624-37-2P	457624-39-4P	457624-41-8P
457624-42-9P	457624-43-0P	457624-44-1P
457624-46-3P	457624-47-4P	457624-48-5P
457624-50-9P	457624-51-0P	457624-53-2P
457624-54-3P		


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of unsatd. aryl sulfones as radioprotectants)

RN 32291-81-9 CAPLUS

CN Benzene, [[[1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 93468-07-6 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-24-5 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[(4-methylphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-26-7 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[(4-methylphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-29-0 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-30-3 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-33-6 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-34-7 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 136272-35-0 CAPLUS

CN Benzene, 1-chloro-2-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 136272-42-9 CAPLUS

CN Benzene, 1-chloro-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 158606-43-0 CAPLUS

CN Benzene, 1-methyl-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 158606-45-2 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 222639-19-2 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 222639-21-6 CAPLUS

CN Benzene, 2,4-difluoro-1-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-24-9 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl)methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-26-1 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl)methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 222639-29-4 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-31-8 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-33-0 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[[4-chlorophenyl]methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-01-0 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 298197-03-2 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-05-4 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-11-2 CAPLUS

CN Benzene, 1-chloro-4-[(1Z)-2-[(4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-13-4 CAPLUS

CN Benzene, 1-fluoro-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-14-5 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-15-6 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-16-7 CAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 298197-17-8 CAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-18-9 CAPLUS

CN Benzene, 1-[[[(1Z)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-2-chloro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-19-0 CAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[(4-fluorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-20-3 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-21-4 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-22-5 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-34-7 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-35-8 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-36-9 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 300699-37-0 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-

(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-39-2 CAPLUS

CN Benzene, 1,2-dichloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-40-5 CAPLUS

CN Benzene, 1,2-dichloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-41-6 CAPLUS

CN Benzene, 4-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-1,2-dichloro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-43-8 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-44-9 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-45-0 CAPLUS

CN Benzene, 4-[(1E)-2-[[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-1,2-difluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-46-1 CAPLUS

CN Benzene, 2-chloro-4-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-1-fluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-47-2 CAPLUS

CN Benzene, 2-chloro-1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-4-fluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-48-3 CAPLUS

CN Benzene, 2,4-dichloro-1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-49-4 CAPLUS

CN Benzene, 1,2-dichloro-4-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-50-7 CAPLUS

CN Benzene, 1,2-dichloro-3-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-62-1 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-2-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-63-2 CAPLUS

CN Benzene, 1-[(1E)-2-[[(4-fluorophenyl)methyl]sulfonyl]ethenyl]-3-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-64-3 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-67-6 CAPLUS

CN Benzene, 1-[(1E)-2-[[(4-fluorophenyl)methyl]sulfonyl]ethenyl]-2-
(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-68-7 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-3-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-70-1 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-4-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-71-2 CAPLUS

CN Benzene, 4-fluoro-1-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-72-3 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-2-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-73-4 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-3-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-74-5 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-2-
(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-75-6 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-3-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-76-7 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-4-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-77-8 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-78-9 CAPLUS

CN Benzene, 4-[(1E)-2-[[4-chlorophenyl)methylsulfonyl]ethenyl]-1-fluoro-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-79-0 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(2-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-80-3 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-[4-fluoro-2-(trifluoromethyl)phenyl]ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-81-4 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-82-5 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-3-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-83-6 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-85-8 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-86-9 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-3-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-87-0 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-4-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-88-1 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(2-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-89-2 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(3-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-90-5 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-91-6 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-methylphenyl)methyl]sulfonyl]ethenyl]-2-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-92-7 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-methylphenyl)methyl]sulfonyl]ethenyl]-3-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-93-8 CAPLUS

CN Benzene, 1-methyl-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-94-9 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-95-0 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-96-1 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-98-3 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-2-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-99-4 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-3-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300700-00-9 CAPLUS

CN Benzene, 1-methoxy-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-04-9 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-19-6 CAPLUS

CN Benzene, pentafluoro[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-20-9 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-2,3,4,5,6-pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-21-0 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-2,3,4,5,6-pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-22-1 CAPLUS

CN Benzene, 1-[(1E)-2-[[3,4-dichlorophenyl)methyl]sulfonyl]ethenyl]-2,3,4,5,6-pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-23-2 CAPLUS

CN Benzene, pentafluoro[[[(1E)-2-(pentafluorophenyl)ethenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-24-3 CAPLUS

CN Benzene, pentafluoro[(1E)-2-[[4-(iodophenyl)methyl]sulfonyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-25-4 CAPLUS

CN Phenol, 2-[(1E)-2-[[4-(fluorophenyl)methyl]sulfonyl]ethenyl]-4,6-dinitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-26-5 CAPLUS

CN Phenol, 2-[(1E)-2-[[4-(bromophenyl)methyl]sulfonyl]ethenyl]-4,6-dinitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-27-6 CAPLUS

CN Phenol, 2-[(1E)-2-[(4-chlorophenyl)methylsulfonyl]ethenyl]-4,6-dinitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-28-7 CAPLUS

CN Phenol, 2-[(1E)-2-[(2,4-dichlorophenyl)methylsulfonyl]ethenyl]-4,6-
dinitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-30-1 CAPLUS

CN Benzene, 1,3-dimethoxy-4-[(1E)-2-[(4-methoxyphenyl)methylsulfonyl]ethenyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-31-2 CAPLUS

CN Benzene, 1,2,3-trimethoxy-5-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-32-3 CAPLUS

CN Benzene, 5-[(1E)-2-[[4,5-dimethoxy-2-nitrophenyl)methyl]sulfonyl]ethenyl]-1,2,3-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-33-4 CAPLUS

CN Benzene, 2-[(1E)-2-[[4,5-dimethoxy-2-nitrophenyl)methyl]sulfonyl]ethenyl]-1,3,5-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-34-5 CAPLUS

CN Benzene, 1-[(1E)-2-[[4,5-dimethoxy-2-nitrophenyl)methyl]sulfonyl]ethenyl]-2,4-dimethoxy-3-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-35-6 CAPLUS

CN Benzene, 1,2,3-trifluoro-4-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-36-7 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-2,3,4-trifluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-37-8 CAPLUS

CN Phenol, 3,5-dimethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-38-9 CAPLUS

CN Benzene, 1,2,4,5-tetrafluoro-3-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-39-0 CAPLUS

CN Benzene, 1,2,4-trimethoxy-5-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-40-3 CAPLUS

CN Benzene, 1,2,3-trimethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-41-4 CAPLUS

CN Phenol, 2-methoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-6-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-42-5 CAPLUS

CN Benzene, 1,2-dimethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-5-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-43-6 CAPLUS

CN Benzene, 1-iodo-2,3-dimethoxy-5-[(1E)-2-[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-44-7 CAPLUS

CN Benzene, 5-fluoro-1,3-dimethoxy-2-[(1E)-2-[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-45-8 CAPLUS

CN Phenol, 3,5-dimethoxy-2-[(1E)-2-[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-46-9 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-1,3,5-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-47-0 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-1,3,5-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-48-1 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-5-fluoro-1,3-dimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-49-2 CAPLUS

CN Phenol, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-3,5-dimethoxy-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-50-5 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-1,3,5-
trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-51-6 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-5-fluoro-1,3-
dimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-52-7 CAPLUS

CN Benzene, 1,2,3-trimethoxy-4-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-53-8 CAPLUS

CN Benzene, 1-[[[(1E)-2-(2,6-dimethoxyphenyl)ethenyl]sulfonyl]methyl]-2,3,4-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-54-9 CAPLUS

CN Benzene, 1,2,3-trimethoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-55-0 CAPLUS

CN Benzene, 5-[[[(1E)-2-(2,6-dimethoxyphenyl)ethenyl]sulfonyl]methyl]-1,2,3-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-14-8 CAPLUS

CN Naphthalene, 1-[(1E)-2-[[[4-fluorophenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-16-0 CAPLUS

CN Naphthalene, 1-[(1E)-2-[[[4-chlorophenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-18-2 CAPLUS

CN Naphthalene, 1-[(1E)-2-[(4-bromophenyl)methylsulfonyl]ethenyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 334970-20-6 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 334970-21-7 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 334970-22-8 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 366807-70-7 CAPLUS

CN Benzene, 1,2,3,4,5-pentafluoro-6-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 366807-72-9 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-2,3,4,5,6-pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 366807-74-1 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-2,3,4,5,6-pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 366807-77-4 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-2,3,4-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 457623-80-2 CAPLUS

CN Pyridine, 2-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457623-81-3 CAPLUS

CN Pyridine, 3-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457623-82-4 CAPLUS

CN Pyridine, 4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457623-83-5 CAPLUS

CN Pyridine, 2-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457623-84-6 CAPLUS

CN Pyridine, 3-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457623-85-7 CAPLUS

CN Pyridine, 4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457623-86-8 CAPLUS

CN Pyridine, 2-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457623-87-9 CAPLUS

CN Pyridine, 3-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457623-88-0 CAPLUS

CN Pyridine, 4-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457623-89-1 CAPLUS

CN Thiophene, 2-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457623-90-4 CAPLUS

CN Thiophene, 2-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457623-91-5 CAPLUS

CN Thiophene, 2-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457623-92-6 CAPLUS

CN Thiophene, 4-bromo-2-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457623-93-7 CAPLUS

CN Thiophene, 4-bromo-2-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457623-94-8 CAPLUS

CN Thiophene, 4-bromo-2-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 457623-95-9 CAPLUS

CN Thiophene, 2-bromo-5-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 457623-96-0 CAPLUS

CN Thiophene, 2-bromo-5-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 457623-97-1 CAPLUS

CN Thiophene, 2-bromo-5-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 457623-98-2 CAPLUS

CN Thiophene, 2-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 457623-99-3 CAPLUS

CN Thiophene, 2-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-00-9 CAPLUS

CN Thiophene, 2-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-01-0 CAPLUS

CN Thiophene, 3-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-02-1 CAPLUS

CN Thiophene, 3-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-03-2 CAPLUS

CN Thiophene, 3-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-04-3 CAPLUS

CN Thiophene, 3-[[[(1E)-2-(4-iodophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-05-4 CAPLUS

CN Thiophene, 3-[[[(1E)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-06-5 CAPLUS

CN Thiophene, 3-[[[(1E)-2-(4-methoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-07-6 CAPLUS

CN Thiophene, 3-[[[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-08-7 CAPLUS

CN Thiophene, 3-[[[(1E)-2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-09-8 CAPLUS

CN Thiophene, 3-[[[(1E)-2-(3,4-dichlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-10-1 CAPLUS

CN Benzonitrile, 4-[(1E)-2-[(3-thienylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-11-2 CAPLUS

CN Thiophene, 3-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-12-3 CAPLUS

CN Thiophene, 3-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-, 1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-13-4 CAPLUS

CN Thiophene, 3-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-, 1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-14-5 CAPLUS

CN Thiophene, 3-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-15-6 CAPLUS

CN Thiophene, 3-[[[(1E)-2-(4-methoxyphenyl)ethenyl]sulfonyl]methyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-16-7 CAPLUS

CN Thiophene, 3-[[[(1E)-2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-17-8 CAPLUS

CN Furan, 2-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-18-9 CAPLUS

CN Furan, 2-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-19-0 CAPLUS

CN Furan, 2-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-20-3 CAPLUS

CN Furan, 3-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-21-4 CAPLUS

CN Furan, 3-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-22-5 CAPLUS

CN Furan, 3-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-23-6 CAPLUS

CN Furan, 3-[[[(1E)-2-(4-iodophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-24-7 CAPLUS

CN Furan, 3-[[[(1E)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-25-8 CAPLUS

CN Furan, 3-[[[(1E)-2-(4-methoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-26-9 CAPLUS

CN Furan, 3-[[[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-27-0 CAPLUS

CN Furan, 3-[[[(1E)-2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-28-1 CAPLUS

CN Furan, 3-[[[(1E)-2-(3,4-dichlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-29-2 CAPLUS

CN Benzonitrile, 4-[(1E)-2-[(3-furanylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-30-5 CAPLUS

CN Furan, 3-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-32-7 CAPLUS

CN Thiazole, 2-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-34-9 CAPLUS


CN 1H-Pyrrole, 2-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 457624-35-0 CAPLUS
CN 1H-Pyrrole, 2-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 457624-37-2 CAPLUS
CN Thiophene, 4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-2-nitro- (CA INDEX NAME)

Double bond geometry as shown.




RN 457624-39-4 CAPLUS
CN Thiophene, 4-[[[(1E)-2-(4-iodophenyl)ethenyl]sulfonyl]methyl]-2-nitro- (CA INDEX NAME)

Double bond geometry as shown.



RN 457624-41-8 CAPLUS
CN Thiophene, 4-[[[(1E)-2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-42-9 CAPLUS

CN Thiophene, 4-[[[(1E)-2-(4-methoxyphenyl)ethenyl]sulfonyl]methyl]-2-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 457624-43-0 CAPLUS

CN Naphthalene, 2-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 457624-44-1 CAPLUS

CN Naphthalene, 2-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 457624-46-3 CAPLUS

CN Naphthalene, 2-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-47-4 CAPLUS

CN Naphthalene, 1-[(1E)-2-[(2-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-48-5 CAPLUS

CN Naphthalene, 1-[(1E)-2-[(3-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 457624-50-9 CAPLUS

CN Naphthalene, 1-[(1E)-2-[(4-nitrophenyl)methylsulfonyl]ethenyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 457624-51-0 CAPLUS

CN Anthracene, 9-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 457624-53-2 CAPLUS

CN Anthracene, 9-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 457624-54-3 CAPLUS

CN Anthracene, 9-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 55 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:675817 CAPLUS

DOCUMENT NUMBER: 137:216758

TITLE: Antitumor (Z)-styryl benzyl sulfones

INVENTOR(S): Reddy, E. Premkumar; Reddy, M. V. Ramana

PATENT ASSIGNEE(S): Temple University, USA

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002067913	A1	20020906	WO 2002-US5817	20020226
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2439256 A1 20020906 CA 2002-2439256 20020226
 AU 2002247222 A1 20020912 AU 2002-247222 20020226
 EP 1379228 A1 20040114 EP 2002-714999 20020226
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004521126 T 20040715 JP 2002-567281 20020226
 US 20040133030 A1 20040708 US 2003-469056 20030821
 US 6833480 B2 20041221
 PRIORITY APPLN. INFO.: US 2001-271762P P 20010227
 WO 2002-US5817 W 20020226
 OTHER SOURCE(S): MARPAT 137:216758
 GI



AB The title compds. [I; R1, R2 = halo, alkyl, alkoxy, etc.; R3, R4 = H, halo, alkyl, etc.], useful as cell antiproliferative agents, including, for example, anticancer agents (no biol. data), were claimed. General procedure for preparation of compds. I such as I [R1, R2 = 2,4-F2; R3 = 4-Cl; R4 = H], were given.

IT 454714-91-1P 454714-92-2P 454714-94-4P
 454714-96-6P 454714-98-8P 454715-00-5P
 454715-02-7P 454715-04-9P 454715-06-1P
 454715-07-2P 454715-08-3P 454715-09-4P
 454715-10-7P 454715-12-9P 454715-14-1P
 454715-16-3P 454715-18-5P 454715-20-9P
 454715-22-1P 454715-24-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antitumor (Z)-styryl benzyl sulfones)

RN 454714-91-1 CAPLUS

CN Benzene, 1-[(1Z)-2-[[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-2,4-difluoro-
 (CA INDEX NAME)


Double bond geometry as shown.



RN 454714-92-2 CAPLUS

CN Benzene, 1-[(1Z)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-2,3-dichloro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 454714-94-4 CAPLUS

CN Benzene, 2,4-dichloro-1-[(1Z)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 454714-96-6 CAPLUS

CN Benzene, 1-[(1Z)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-2,4-dimethyl-
(CA INDEX NAME)

Double bond geometry as shown.




RN 454714-98-8 CAPLUS

CN Benzene, 1-[(1Z)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-2,3-dimethyl-

(CA INDEX NAME)


Double bond geometry as shown.



RN 454715-00-5 CAPLUS

CN Benzene, 1-[(1Z)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-2,4-dimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 454715-02-7 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1Z)-2-(2,4-difluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 454715-04-9 CAPLUS

CN Benzene, 1,2-dichloro-3-[(1Z)-2-[(2-chloro-4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 454715-06-1 CAPLUS

CN Benzene, 2-chloro-1-[[[(1Z)-2-(2,4-dichlorophenyl)ethenyl]sulfonylmethyl]-4-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 454715-07-2 CAPLUS

CN Benzene, 1-[[[(1Z)-2-(2,4-dimethylphenyl)ethenyl]sulfonylmethyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 454715-08-3 CAPLUS

CN Benzene, 1-[(1Z)-2-[[2-chloro-4-methoxyphenyl)methyl]sulfonyl]ethenyl]-2,3-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 454715-09-4 CAPLUS

CN Benzene, 1-[[[(1Z)-2-(2,4-dimethoxyphenyl)ethenyl]sulfonylmethyl]-2,4-dimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 454715-10-7 CAPLUS

CN Phenol, 4-[(1Z)-2-[(2,4-dichlorophenyl)methyl]sulfonyl]ethenyl]-2-methoxy-, 1-acetate (CA INDEX NAME)


Double bond geometry as shown.



RN 454715-12-9 CAPLUS

CN Phenol, 4-[(1Z)-2-[(2-chloro-4-methoxyphenyl)methyl]sulfonyl]ethenyl]-2-methoxy-, 1-acetate (CA INDEX NAME)


Double bond geometry as shown.



RN 454715-14-1 CAPLUS

CN Phenol, 2-methoxy-4-[(1Z)-2-[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 454715-16-3 CAPLUS

CN Phenol, 2-methoxy-4-[(1Z)-2-[[(4-methylphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 454715-18-5 CAPLUS

CN Phenol, 4-[(1Z)-2-[[(2-chloro-4-fluorophenyl)methyl]sulfonyl]ethenyl]-2-methoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 454715-20-9 CAPLUS

CN 1,2-Benzenediol, 4-[(1Z)-2-[[(2-chloro-4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 454715-22-1 CAPLUS

CN Benzenamine, 2-[[[(1Z)-2-(2,4-difluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 454715-24-3 CAPLUS

CN Phosphonic acid, [4-[(1Z)-2-[[2-chloro-4-methoxyphenyl)methyl]sulfonyl]ethenyl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 56 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:275959 CAPLUS

DOCUMENT NUMBER: 136:309755

TITLE: Preparation of (E)-styryl benzyl sulfones for treating proliferative disorders

INVENTOR(S): Reddy, E. Premkumar; Reddy, M. V. Ramana

PATENT ASSIGNEE(S): Temple University - of the Commonwealth System of Higher Education, USA

SOURCE: PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028828	A1	20020411	WO 2001-US31337	20011005
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2424884	A1	20020411	CA 2001-2424884	20011005
AU 2001096677	A	20020415	AU 2001-96677	20011005
EP 1328511	A1	20030723	EP 2001-977567	20011005
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004510761 T 20040408 JP 2002-532414 20011005
 IN 2003DN00606 A 20070316 IN 2003-DN606 20030421
 US 20050101528 A1 20050512 US 2003-398545 20030828
 US 7053123 B2 20060530
 PRIORITY APPLN. INFO.: US 2000-238222P P 20001005
 WO 2001-US31337 W 20011005
 OTHER SOURCE(S): MARPAT 136:309755
 GI



AB The title compds. [I or II; R1 = halo, alkoxy, NO2, etc.; R2, R3 = halo, alkoxy, alkyl, etc.; provided: R1 may not be halogen when R2 and R3 are both halogen; R2 may not be 2-halogen when R3 is 4-halogen; R4 = alkoxy, phosphonato, NH2, etc.; R5 = H, alkoxy, NH2, etc.; R6 = NO2, H, phosphonato, etc.; R7 = halo, alkoxy, alkyl, etc.; provided R5 and R6 may not be hydrogen in the same compound], useful as antiproliferative agents, including, for example, anticancer agents, were prepared. Thus, reacting 4-chlorobenzylsulfonylacetic acid with 3-hydroxy-4-nitrobenzaldehyde in the presence of PhCH2NH2 in glacial AcOH afforded 58% (E)-I [R1 = Cl; R2 = 3-OH; R3 = 4-NO2]. Biol. data for two of 39 exemplified compds. I were given.

IT	300699-78-9P	409357-35-3P	409357-37-5P
	409357-40-0P	409357-42-2P	409357-44-4P
	409357-46-6P	409357-48-8P	409357-50-2P
	409357-52-4P	409357-54-6P	409357-56-8P
	409357-58-0P	409357-60-4P	409357-62-6P
	409357-63-7P	409357-65-9P	409357-67-1P

409357-69-3P	409357-71-7P	409357-73-9P
409357-75-1P	409357-77-3P	409357-79-5P
409357-81-9P	409357-83-1P	409357-85-3P
409357-87-5P	409357-89-7P	409357-90-0P
409357-91-1P	409357-92-2P	409357-93-3P
409357-95-5P	409357-97-7P	409357-98-8P
409357-99-9P	409358-01-6P	409358-02-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (E)-styryl benzyl sulfones for treating proliferative disorders)

RN 300699-78-9 CAPLUS

CN Benzene, 4-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-1-fluoro-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-35-3 CAPLUS

CN Phenol, 5-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-37-5 CAPLUS

CN Benzenamine, 4-chloro-2-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-40-0 CAPLUS

CN Benzene, 2-[(1E)-2-[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-1,3-dimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-42-2 CAPLUS

CN Benzenamine, 2-[(1E)-2-[(4-bromophenyl)methyl]sulfonyl]ethenyl]-4-chloro- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-44-4 CAPLUS

CN Benzene, 2-[(1E)-2-[(4-bromophenyl)methyl]sulfonyl]ethenyl]-1,3-dimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-46-6 CAPLUS

CN Phenol, 5-[(1E)-2-[[(4-bromophenyl)methyl]sulfonyl]ethenyl]-2-fluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-48-8 CAPLUS

CN Benzene, 4-[(1E)-2-[[(4-bromophenyl)methyl]sulfonyl]ethenyl]-1-fluoro-2-methoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-50-2 CAPLUS

CN Benzenamine, 4-chloro-2-[(1E)-2-[[(4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-52-4 CAPLUS

CN Phenol, 2-ethoxy-6-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 409357-54-6 CAPLUS

CN Phenol, 2-ethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 409357-56-8 CAPLUS

CN Benzene, 1-ethoxy-2-methoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 409357-58-0 CAPLUS

CN Benzene, 1,3-dimethoxy-2-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-60-4 CAPLUS

CN Benzene, 2,4-dimethoxy-1-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-62-6 CAPLUS

CN Benzene, 1,3-dimethoxy-5-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-63-7 CAPLUS

CN Benzene, 1,4-dimethoxy-2-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-65-9 CAPLUS

CN Benzene, 1,2-dimethoxy-3-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-67-1 CAPLUS

CN Benzene, 1,2-dimethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-69-3 CAPLUS

CN Benzene, 1-methoxy-3-[(1E)-2-[(4-methoxyphenyl)methylsulfonyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-71-7 CAPLUS

CN Benzene, 1-[(1E)-2-[(4-methoxyphenyl)methylsulfonyl]ethenyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-73-9 CAPLUS

CN Benzene, 2-[(1E)-2-[(4-methoxyphenyl)methylsulfonyl]ethenyl]-1,3-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-75-1 CAPLUS

CN Benzene, 1-[(1E)-2-[[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]-2,3-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-77-3 CAPLUS

CN Benzene, 1-[(1E)-2-[[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]-3,5-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-79-5 CAPLUS

CN Benzene, 2,4-diethoxy-1-[(1E)-2-[[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-81-9 CAPLUS

CN Benzene, 1,4-diethoxy-2-[(1E)-2-[[4-methoxyphenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-83-1 CAPLUS

CN Benzene, 1-fluoro-2-methoxy-4-[(1E)-2-[[4-methoxyphenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-85-3 CAPLUS

CN Benzenamine, 4-chloro-2-[(1E)-2-[[4-methoxyphenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-87-5 CAPLUS

CN Benzenamine, 4-chloro-2-[(1E)-2-[[4-nitrophenyl]methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 409357-89-7 CAPLUS

CN Benzene, 1,3-dimethoxy-2-[(1E)-2-[[4-nitrophenyl]methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 409357-90-0 CAPLUS

CN Benzene, 2-[[[(1E)-2-(4-iodophenyl)ethenyl]sulfonyl]methyl]-1-methoxy-4-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 409357-91-1 CAPLUS

CN Benzene, 2-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-1-methoxy-4-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-92-2 CAPLUS

CN Benzene, 2-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-1-methoxy-4-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-93-3 CAPLUS

CN Benzene, 2-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-1-methoxy-4-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-95-5 CAPLUS

CN Benzene, 1-methoxy-4-nitro-2-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-97-7 CAPLUS

CN Benzene, 1,3-dimethoxy-2-[[[(1E)-2-(2-methoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-98-8 CAPLUS

CN Benzene, 2-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-1,3-dimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-99-9 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 409358-01-6 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(3-nitrophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 409358-02-7 CAPLUS

CN Benzene, 1,3-dimethoxy-2-[(1E)-2-[(2-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 57 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:143297 CAPLUS

DOCUMENT NUMBER: 136:183608

TITLE: Preparation of styryl aryl sulfones as anticancer agents

INVENTOR(S): Reddy, E. Premkumar; Reddy, M. V. Ramana

PATENT ASSIGNEE(S): Temple University, USA

SOURCE: U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of U.S.
Ser. No. 509,227.

CODEN: USXXCO


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020022666	A1	20020221	US 2001-919061	20010731
US 6548553	B2	20030415		
WO 9918068	A1	19990415	WO 1998-US20580	19981001
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6359013	B1	20020319	US 2000-509227	20000324
US 20030114538	A1	20030619	US 2002-255218	20020926
PRIORITY APPLN. INFO.:			US 1997-60933P	P 19971003
			WO 1998-US20580	W 19981001
			US 2000-509227	A2 20000324
			US 2001-919061	A3 20010731
OTHER SOURCE(S):		MARPAT 136:183608		
GI				



AB Title compds. (I; Q = (CH₂)_n; n = 0, 1; R₁ = H, Cl, F, Br; R₂ = H, Cl, F, Br, Me, MeO; R₃ = H, Cl, F; R₂ may not = Me or MeO when R₁ and R₃ both = H and n = 0, 1; and R₁, R₂ and R₃ may not all = H when n = 1), were prepared Thus, 4-bromobenzylsulfonylacetic acid reacted with 4-fluorobenzaldehyde to give 82% (E)-4-fluorostyryl 4-bromobenzyl sulfone. The latter inhibited growth of H157 non-small cell lung cancer cells with IC₅₀ <1.0 μM.

IT 93468-07-6P 118672-28-9P 118672-29-0P
 136272-35-0P 222639-19-2P 222639-21-6P
 222639-24-9P 222639-26-1P 222639-29-4P
 222639-31-8P 222639-33-0P 300699-47-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of styryl aryl sulfones as anticancer agents)

RN 93468-07-6 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-28-9 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-29-0 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 136272-35-0 CAPLUS

CN Benzene, 1-chloro-2-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 222639-19-2 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-21-6 CAPLUS

CN Benzene, 2,4-difluoro-1-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-24-9 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-26-1 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 222639-29-4 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-31-8 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-33-0 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[[4-chlorophenyl]methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-47-2 CAPLUS

CN Benzene, 2-chloro-1-[(1E)-2-[[[4-chlorophenyl]methyl]sulfonyl]ethenyl]-4-fluoro-
(CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L3 ANSWER 58 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:780690 CAPLUS

DOCUMENT NUMBER: 135:303783

TITLE: Preparation of α,β -unsaturated sulfones for treating proliferative disorders

INVENTOR(S): Reddy, E. Premkumar; Reddy, M. V. Ramana

PATENT ASSIGNEE(S): Temple University - of the Commonwealth System of Higher Education, USA

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001078733	A1	20011025	WO 2001-US12133	20010413
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020028818	A1	20020307	US 2001-833834	20010412
US 6541475	B2	20030401		
CA 2405172	A1	20011025	CA 2001-2405172	20010413
EP 1292308	A1	20030319	EP 2001-925013	20010413
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 522715	A	20030926	NZ 2001-522715	20010413
JP 2003530439	T	20031014	JP 2001-576033	20010413
AU 2001251614	B2	20050505	AU 2001-251614	20010413
IL 152211	A	20080807	IL 2001-152211	20010413
KR 828449	B1	20080513	KR 2002-713800	20021014
IN 2002DN01089	A	20070406	IN 2002-DN1089	20021105
IN 2002DN01090	A	20080926	IN 2002-DN1090	20021105
US 20030130339	A1	20030710	US 2002-301332	20021121
US 6599932	B2	20030729		

PRIORITY APPLN. INFO.:





US 2000-197368P

P 20000414

US 2001-833834
WO 2001-US12133

A1 20010412
W 20010413

OTHER SOURCE(S): MARPAT 135:303783
GI




AB Sulfones (E)-Q1CH2S(O)2CH:CHQ2 (I; e.g. (E)-2-pyridineethenyl 4-fluorobenzyl sulfone) and pharmaceutically acceptable salts thereof are useful as antiproliferative agents, including, for example, anticancer agents. In I, Q1 = (a) Ph radical R1R2R3R4R5C6 (R1, R2, R3, R4 and R5 independently = H, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, amino, C1-C6 trifluoroalkoxy and trifluoromethyl); (b) 1-naphthyl, 2-naphthyl and 9-anthryl; and (c) I wherein n1 = 1 or 2, Y1 and Y2 independently = H, halogen, and nitro, and X1 = O, N, S and S(O)2. Q2 = (d) Ph radical R1R2R3R4R5C6; (e) 1-naphthyl, 2-naphthyl and 9-anthryl; (f) an aromatic radical II wherein n1 = 1 or 2, Y3 and Y4 independently = H, halogen, and nitro, and X2, X3 and X4 independently = C, O, N, S and S(O)2 provided that not all of X2, X3 and X4 may be C; and (g) 1-piperazinyl; provided that at least one of Q1 or Q2 is other than a Ph radical according to R1R2R3R4R5C6. Sulfones III or pharmaceutically acceptable salts thereof are also useful as antiproliferative agents, including, for example, anticancer agents, wherein X is S or O; Ya and Yb independently = H, halogen, and nitro; and R1-R5 are defined as above. Various processes for preparing I and III are claimed, for example, Knoevenagel condensation of Q1CH2S(O)2CH2CO2H with Q2CHO. Q1CH2S(O)2CH2CO2H can be prepared by reacting Na glycolate with Q1CH2Cl to form Q1CH2SCH2CO2H that is then oxidized, or by reacting HSCH2CO2R (R = C1-C6 alkyl) with Q1CH2Cl to form Q1CH2SCH2CO2H and hydrolyzing this compound. In another example, IV can be reacted with R1R2R3R4R5C6C.tplbond.CH followed by oxidation to give III. Seventy-six example preps. are given. The effect of I on normal fibroblasts and on tumor cells of prostate, colon, lung and breast origin was examined; semiquant. results are tabulated for many of the example compds., e.g. (E)-3-furanethenyl 4-chlorobenzyl sulfone displayed >80% growth inhibition for all cell lines.

IT 334969-56-1P, (E)-2-Pyridineethenyl 4-fluorobenzyl sulfone
334969-57-2P, (E)-3-Pyridineethenyl 4-fluorobenzyl sulfone

334969-58-3P, (E)-4-Pyridineethenyl 4-fluorobenzyl sulfone
334969-59-4P, (E)-2-Pyridineethenyl 4-chlorobenzyl sulfone
334969-60-7P, (E)-3-Pyridineethenyl 4-chlorobenzyl sulfone
334969-61-8P, (E)-4-Pyridineethenyl 4-chlorobenzyl sulfone
334969-62-9P, (E)-2-Pyridineethenyl 4-bromobenzyl sulfone
334969-63-0P, (E)-3-Pyridineethenyl 4-bromobenzyl sulfone
334969-64-1P, (E)-4-Pyridineethenyl 4-bromobenzyl sulfone
334969-65-2P, (E)-2-Thiopheneethenyl 4-fluorobenzyl sulfone
334969-66-3P, (E)-2-Thiopheneethenyl 4-chlorobenzyl sulfone
334969-67-4P, (E)-2-Thiopheneethenyl 4-bromobenzyl sulfone
334969-68-5P, (E)-4-Bromo-2-thiopheneethenyl 4-fluorobenzyl sulfone
334969-69-6P, (E)-4-Bromo-2-thiopheneethenyl 4-chlorobenzyl sulfone
334969-70-9P, (E)-4-Bromo-2-thiopheneethenyl 4-bromobenzyl sulfone
334969-71-0P, (E)-5-Bromo-2-thiopheneethenyl 4-fluorobenzyl sulfone
334969-72-1P, (E)-5-Bromo-2-thiopheneethenyl 4-chlorobenzyl sulfone
334969-73-2P, (E)-5-Bromo-2-thiopheneethenyl 4-bromobenzyl sulfone
334969-74-3P, (E)-1,1-Dioxo-2-Thiopheneethenyl 4-fluorobenzyl sulfone
334969-75-4P, (E)-1,1-Dioxo-2-Thiopheneethenyl 4-chlorobenzyl sulfone
334969-76-5P, (E)-1,1-Dioxo-2-Thiopheneethenyl 4-bromobenzyl sulfone
334969-77-6P, (E)-3-Thiopheneethenyl 4-fluorobenzyl sulfone
334969-78-7P, (E)-3-Thiopheneethenyl 4-chlorobenzyl sulfone
334969-79-8P, (E)-3-Thiopheneethenyl 4-bromobenzyl sulfone
334969-80-1P, (E)-3-Thiopheneethenyl 4-iodobenzyl sulfone
334969-81-2P, (E)-3-Thiopheneethenyl-4-methylbenzylsulfone
334969-82-3P, (E)-3-Thiopheneethenyl 4-methoxybenzyl sulfone
334969-84-5P, (E)-3-Thiopheneethenyl 2,4-dichlorobenzyl sulfone
334969-85-6P, (E)-3-Thiopheneethenyl 3,4-dichlorobenzyl sulfone
334969-86-7P, (E)-3-Thiopheneethenyl 4-cyanobenzyl sulfone
334969-87-8P, (E)-3-Thiopheneethenyl 4-nitrobenzyl sulfone
334969-88-9P, (E)-1,1-Dioxo-3-Thiopheneethenyl 4-fluorobenzyl sulfone
334969-89-0P, (E)-1,1-Dioxo-3-Thiopheneethenyl 4-chlorobenzyl sulfone
334969-90-3P, (E)-1,1-Dioxo-3-Thiopheneethenyl 4-bromobenzyl sulfone
334969-91-4P, (E)-1,1-Dioxo-3-Thiopheneethenyl 4-methoxybenzyl sulfone
334969-92-5P, (E)-1,1-Dioxo-3-Thiopheneethenyl 2,4-dichlorobenzyl sulfone
334969-93-6P, (E)-2-Furanethenyl 4-fluorobenzyl sulfone
334969-94-7P, (E)-2-Furanethenyl 4-chlorobenzyl sulfone
334969-95-8P, (E)-2-Furanethenyl 4-bromobenzyl sulfone
334969-96-9P, (E)-3-Furanethenyl 4-fluorobenzyl sulfone
334969-97-0P, (E)-3-Furanethenyl 4-chlorobenzyl sulfone
334969-98-1P, (E)-3-Furanethenyl 4-bromobenzyl sulfone
334969-99-2P, (E)-3-Furanethenyl 4-iodobenzyl sulfone
334970-00-2P, (E)-3-Furanethenyl-4-methylbenzylsulfone
334970-01-3P, (E)-3-Furanethenyl 4-methoxybenzyl sulfone
334970-02-4P, (E)-3-Furanethenyl-4-trifluoromethylbenzylsulfone
334970-03-5P, (E)-3-Furanethenyl 2,4-dichlorobenzyl sulfone
334970-04-6P, (E)-3-Furanethenyl 3,4-dichlorobenzyl sulfone
334970-05-7P, (E)-3-Furanethenyl 4-cyanobenzyl sulfone
334970-06-8P, (E)-3-Furanethenyl 4-nitrobenzyl sulfone
334970-08-0P, (E)-2-Pyrroleethenyl 4-chlorobenzyl sulfone
334970-09-1P, (E)-2-Pyrroleethenyl 4-bromobenzyl sulfone
334970-10-4P, (E)-2-Nitro-4-thiopheneethenyl 4-chlorobenzyl sulfone
334970-11-5P, (E)-2-Nitro-4-thiopheneethenyl 4-iodobenzyl sulfone


334970-12-6P, (E)-2-Nitro-4-thiopheneethenyl 2,4-dichlorobenzyl sulfone 334970-13-7P, (E)-2-Nitro-4-thiopheneethenyl 4-methoxybenzyl sulfone 334970-14-8P, (E)-1-Naphthaleneethenyl 4-fluorobenzyl sulfone 334970-15-9P, (E)-2-Naphthaleneethenyl 4-fluorobenzyl sulfone 334970-16-0P, (E)-1-Naphthaleneethenyl 4-chlorobenzyl sulfone 334970-17-1P, (E)-2-Naphthaleneethenyl 4-chlorobenzyl sulfone 334970-18-2P, (E)-1-Naphthaleneethenyl 4-bromobenzyl sulfone 334970-19-3P, (E)-2-Naphthaleneethenyl 4-bromobenzyl sulfone 334970-20-6P, (E)-4-Fluorostyryl 1-naphthylmethyl sulfone 334970-21-7P, (E)-4-Chlorostyryl 1-naphthylmethyl sulfone 334970-22-8P, (E)-4-Bromostyryl 1-naphthylmethyl sulfone 334970-23-9P, (E)-2-Nitrostyryl 1-naphthylmethyl sulfone 334970-24-0P, (E)-3-Nitrostyryl 1-naphthylmethyl sulfone 334970-25-1P, (E)-4-Nitrostyryl 1-naphthylmethyl sulfone 367266-53-3P, (E)-3-Thiopheneethenyl 4-trifluoromethoxybenzyl sulfone 367266-56-6P 367266-57-7P 367266-58-8P 367266-59-9P, (E)-9-Anthraceneethenyl 4-fluorobenzyl sulfone 367266-60-2P, (E)-9-Anthraceneethenyl 4-chlorobenzyl sulfone 367266-61-3P, (E)-9-Anthraceneethenyl 4-bromobenzyl sulfone
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of α,β -unsatd. sulfones for treating proliferative disorders)
 RN 334969-56-1 CAPLUS
 CN Pyridine, 2-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 334969-57-2 CAPLUS
 CN Pyridine, 3-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-58-3 CAPLUS

CN Pyridine, 4-[(1E)-2-[[[(4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-59-4 CAPLUS

CN Pyridine, 2-[(1E)-2-[[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-60-7 CAPLUS

CN Pyridine, 3-[(1E)-2-[[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-61-8 CAPLUS

CN Pyridine, 4-[(1E)-2-[[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-62-9 CAPLUS

CN Pyridine, 2-[(1E)-2-[(4-bromophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-63-0 CAPLUS

CN Pyridine, 3-[(1E)-2-[(4-bromophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-64-1 CAPLUS

CN Pyridine, 4-[(1E)-2-[(4-bromophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-65-2 CAPLUS

CN Thiophene, 2-[(1E)-2-[(4-fluorophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-66-3 CAPLUS

CN Thiophene, 2-[(1E)-2-[(4-chlorophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-67-4 CAPLUS

CN Thiophene, 2-[(1E)-2-[(4-bromophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-68-5 CAPLUS

CN Thiophene, 4-bromo-2-[(1E)-2-[(4-fluorophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-69-6 CAPLUS

CN Thiophene, 4-bromo-2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-70-9 CAPLUS

CN Thiophene, 4-bromo-2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-71-0 CAPLUS

CN Thiophene, 2-bromo-5-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-72-1 CAPLUS

CN Thiophene, 2-bromo-5-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-73-2 CAPLUS

CN Thiophene, 2-bromo-5-[(1E)-2-[[(4-bromophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-74-3 CAPLUS

CN Thiophene, 2-[(1E)-2-[[(4-fluorophenyl)methyl]sulfonyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-75-4 CAPLUS

CN Thiophene, 2-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-76-5 CAPLUS

CN Thiophene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-77-6 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 334969-78-7 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 334969-79-8 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 334969-80-1 CAPLUS

CN Thiophene, 3-[(1E)-2-[(4-iodophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-81-2 CAPLUS

CN Thiophene, 3-[(1E)-2-[(4-methylphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-82-3 CAPLUS

CN Thiophene, 3-[(1E)-2-[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-84-5 CAPLUS

CN Thiophene, 3-[(1E)-2-[[2,4-dichlorophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-85-6 CAPLUS

CN Thiophene, 3-[(1E)-2-[[3,4-dichlorophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-86-7 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(3-thienyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-87-8 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-88-9 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-, 1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-89-0 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-, 1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-90-3 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-91-4 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-92-5 CAPLUS

CN Thiophene, 3-[(1E)-2-[[2,4-dichlorophenyl)methyl]sulfonyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-93-6 CAPLUS

CN Furan, 2-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-94-7 CAPLUS

CN Furan, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-95-8 CAPLUS

CN Furan, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 334969-96-9 CAPLUS

CN Furan, 3-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

NAME)


Double bond geometry as shown.



RN 334969-97-0 CAPLUS

CN Furan, 3-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 334969-98-1 CAPLUS

CN Furan, 3-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 334969-99-2 CAPLUS

CN Furan, 3-[(1E)-2-[[4-iodophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 334970-00-2 CAPLUS

CN Furan, 3-[(1E)-2-[[4-methylphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-01-3 CAPLUS

CN Furan, 3-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-02-4 CAPLUS

CN Furan, 3-[(1E)-2-[[4-(trifluoromethyl)phenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-03-5 CAPLUS

CN Furan, 3-[(1E)-2-[(2,4-dichlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-04-6 CAPLUS

CN Furan, 3-[(1E)-2-[(3,4-dichlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-05-7 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(3-furanyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-06-8 CAPLUS

CN Furan, 3-[(1E)-2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-08-0 CAPLUS

CN 1H-Pyrrole, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-09-1 CAPLUS

CN 1H-Pyrrole, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 334970-10-4 CAPLUS

CN Thiophene, 4-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-2-nitro-

(CA INDEX NAME)


Double bond geometry as shown.



RN 334970-11-5 CAPLUS

CN Thiophene, 4-[(1E)-2-[[[4-iodophenyl)methyl]sulfonyl]ethenyl]-2-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334970-12-6 CAPLUS

CN Thiophene, 4-[(1E)-2-[[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-2-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334970-13-7 CAPLUS

CN Thiophene, 4-[(1E)-2-[[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-2-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334970-14-8 CAPLUS

CN Naphthalene, 1-[(1E)-2-[[4-fluorophenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-15-9 CAPLUS

CN Naphthalene, 2-[(1E)-2-[[4-fluorophenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-16-0 CAPLUS

CN Naphthalene, 1-[(1E)-2-[[4-chlorophenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-17-1 CAPLUS

CN Naphthalene, 2-[(1E)-2-[(4-chlorophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-18-2 CAPLUS

CN Naphthalene, 1-[(1E)-2-[(4-bromophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-19-3 CAPLUS

CN Naphthalene, 2-[(1E)-2-[(4-bromophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-20-6 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-21-7 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-22-8 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-23-9 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(2-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-24-0 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(3-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-25-1 CAPLUS


CN Naphthalene, 1-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 367266-53-3 CAPLUS
CN Thiophene, 3-[(1E)-2-[[4-(trifluoromethoxy)phenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 367266-56-6 CAPLUS
CN Piperazine, 1-[(1E)-2-[[4-(trifluoromethoxy)phenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 367266-57-7 CAPLUS
CN Piperazine, 1-[(1E)-2-[[4-(trifluoromethoxy)phenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 367266-58-8 CAPLUS

CN Piperazine, 1-[(1E)-2-[[(4-bromophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 367266-59-9 CAPLUS

CN Anthracene, 9-[(1E)-2-[[(4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 367266-60-2 CAPLUS

CN Anthracene, 9-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 367266-61-3 CAPLUS

CN Anthracene, 9-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]- (CA
INDEX NAME)

Double bond geometry as shown.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 59 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:780671 CAPLUS

DOCUMENT NUMBER: 135:303672

TITLE: Preparation of substituted styryl benzyl sulfones for
treating proliferative disorders

INVENTOR(S): Reddy, E. Premkumar; Reddy, M. V. Ramana

PATENT ASSIGNEE(S): Temple University, USA

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001078712	A1	20011025	WO 2001-US12134	20010413
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,				

HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
 RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN,
 YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 20020115643 A1 20020822 US 2001-833287 20010412
 US 6486210 B2 20021126
 CA 2406212 A1 20011025 CA 2001-2406212 20010413
 AU 2001051615 A 20011030 AU 2001-51615 20010413
 EP 1305015 A1 20030502 EP 2001-925014 20010413
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2003530433 T 20031014 JP 2001-576013 20010413
 NZ 522551 A 20040326 NZ 2001-522551 20010413
 AU 2001251615 B2 20050811 AU 2001-251615 20010413
 US 20030036536 A1 20030220 US 2002-207429 20020729
 US 6642410 B2 20031104
 KR 768415 B1 20071018 KR 2002-713708 20021011
 IN 2002DN01077 A 20050128 IN 2002-DN1077 20021030
 IN 2002DN01079 A 20050128 IN 2002-DN1079 20021030
 IN 2008DN01505 A 20080620 IN 2008-DN1505 20080221
 PRIORITY APPLN. INFO.: US 2000-197849P P 20000414
 US 2000-234707P P 20000922
 US 2001-271640P P 20010227
 US 2001-833287 A3 20010412
 WO 2001-US12134 W 20010413
 IN 2002-DN1077 A3 20021030
 OTHER SOURCE(S): MARPAT 135:303672
 GI



AB Styryl benzyl sulfones (I; e.g. (E)-2,3,4,5,6-Pentafluorostyryl 4-fluorobenzyl sulfone), or a pharmaceutically acceptable salt thereof, are useful as antiproliferative agents, including, for example, anticancer agents. In said formula, (a) (i) at least three of R1, R2, R3, R4 and R5 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxyl, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R1, R2, R3, R4 and R5 are independently selected from the group consisting of H, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro,

cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R6, R7, R8, R9, and R10 are independently selected from the group consisting of H, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl. Or (b) (i) at least three of R6, R7, R8, R9, and R10 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R6, R7, R8, R9, and R10 are independently selected from the group consisting of H, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R1, R2, R3, R4 and R5 are independently selected from the group consisting of H, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl. Various processes for preparing I are claimed. For example, condensing R1R2R3R4R5C6CH2S(O)2CH2CO2H with R6R7R8R9R10C6CHO gives a compound with E configuration; R1R2R3R4R5C6CH2S(O)2CH2CO2H can be prepared by reacting Na glycolate with R1R2R3R4R5C6CH2Cl to form a benzylthioacetic acid that is then oxidized. The benzylthioacetic acid can also be prepared by reacting HSCH2CO2R (R = C1-C6 alkyl) with R1R2R3R4R5C6CH2Cl to form R1R2R3R4R5C6CH2SCH2CO2R and hydrolyzing this compound to obtain said benzylthioacetic acid. In another example, R1R2R3R4R5C6CH2SNa can be reacted with R6R7R8R9R10C6C.tplbond.CH followed by oxidation to give a product with Z configuration. Fifty-three example preps. are given. The effect of the (E)-styryl benzyl sulfones on normal fibroblasts and on tumor cells of prostate, colon, lung and breast origin was examined; each compound tested showed activity, inducing cell death against all tumor cell lines, in $\geq 5-10\%$ of the treated cells.

IT 1098535-73-9 1098535-76-2


RL: PRPH (Prophetic)

(Preparation of substituted styryl benzyl sulfones for treating proliferative disorders)

RN 1098535-73-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RN 1098535-76-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




IT 334969-19-6P, (E)-2,3,4,5,6-Pentafluorostyryl 4-fluorobenzyl sulfone 334969-20-9P, (E)-2,3,4,5,6-Pentafluorostyryl 4-chlorobenzyl sulfone 334969-21-0P, (E)-2,3,4,5,6-Pentafluorostyryl 4-bromobenzyl sulfone 334969-22-1P, (E)-2,3,4,5,6-Pentafluorostyryl 3,4-dichlorobenzyl sulfone 334969-23-2P, (E)-2,3,4,5,6-Pentafluorostyryl 2,3,4,5,6-pentafluorobenzyl sulfone 334969-24-3P, (E)-2,3,4,5,6-Pentafluorostyryl 4-iodobenzyl sulfone 334969-25-4P, (E)-2-Hydroxy-3,5-dinitrostyryl 4-fluorobenzyl sulfone 334969-26-5P, (E)-2-Hydroxy-3,5-dinitrostyryl 4-bromobenzyl sulfone 334969-27-6P, (E)-2-Hydroxy-3,5-dinitrostyryl 4-chlorobenzyl sulfone 334969-28-7P, (E)-2-Hydroxy-3,5-dinitrostyryl 2,4-dichlorobenzyl sulfone 334969-29-8P, (E)-2,4,6-Trimethoxystyryl 4-methoxybenzyl sulfone 334969-30-1P, (E)-3-Methyl-2,4-dimethoxystyryl 4-methoxybenzyl sulfone 334969-31-2P, (E)-3,4,5-Trimethoxystyryl 4-methoxybenzyl sulfone 334969-32-3P, (E)-3,4,5-Trimethoxystyryl 2-nitro-4,5-dimethoxybenzyl sulfone 334969-33-4P, (E)-2,4,6-Trimethoxystyryl 2-nitro-4,5-dimethoxybenzyl sulfone 334969-34-5P, (E)-3-Methyl-2,4-dimethoxystyryl 2-nitro-4,5-dimethoxybenzyl sulfone 334969-35-6P, (E)-2,3,4-Trifluorostyryl 4-fluorobenzyl sulfone 334969-36-7P, (E)-2,3,4-Trifluorostyryl 4-chlorobenzyl sulfone 334969-37-8P, (E)-2,6-Dimethoxy-4-hydroxystyryl 4-methoxybenzyl sulfone 334969-38-9P, (E)-2,3,5,6-Tetrafluorostyryl 4-methoxybenzyl sulfone 334969-39-0P, (E)-2,4,5-Trimethoxystyryl 4-methoxybenzyl sulfone 334969-40-3P, (E)-2,3,4-Trimethoxystyryl 4-methoxybenzyl sulfone 334969-41-4P, (E)-3-Nitro-4-hydroxy-5-methoxystyryl 4-methoxybenzyl sulfone 334969-42-5P, (E)-3,4-Dimethoxy-6-nitrostyryl 4-methoxybenzyl sulfone 334969-43-6P, (E)-3,4-Dimethoxy-5-iodostyryl 4-methoxybenzyl sulfone 334969-44-7P, (E)-2,6-Dimethoxy-4-fluorostyryl 4-methoxybenzyl sulfone 334969-45-8P, (E)-2-Hydroxy-4,6-dimethoxystyryl 4-methoxybenzyl sulfone 334969-46-9P, (E)-2,4,6-Trimethylstyryl 4-methoxybenzyl sulfone 334969-47-0P, (E)-2,4,6-Trimethoxystyryl 4-chlorobenzyl sulfone 334969-48-1P, (E)-2,6-Dimethoxy-4-fluorostyryl 4-chlorobenzyl sulfone 334969-49-2P, (E)-2-Hydroxy-4,6-dimethoxystyryl 4-chlorobenzyl sulfone 334969-50-5P, (E)-2,4,6-Trimethoxystyryl 4-bromobenzyl sulfone 334969-51-6P, (E)-2,6-Dimethoxy-4-fluorostyryl 4-bromobenzyl sulfone 334969-52-7P, (E)-2,4,6-Trimethoxystyryl 2,3,4-trimethoxybenzyl sulfone 334969-53-8P, (E)-2,6-Dimethoxystyryl 2,3,4-trimethoxybenzyl sulfone

334969-54-9P, (E)-2,4,6-Trimethoxystyryl 3,4,5-trimethoxybenzyl sulfone 334969-55-0P, (E)-2,6-Dimethoxystyryl 3,4,5-trimethoxybenzyl sulfone 366807-70-7P
366807-72-9P 366807-74-1P 366807-77-4P
366807-78-5P 366807-81-0P 366807-83-2P
366807-85-4P 366807-90-1P 366807-93-4P
366807-97-8P, (Z)-3-Methoxy-4-acetoxystyryl 2,4,5-trimethoxybenzyl sulfone 366808-02-8P, (Z)-3,4-Dihydroxystyryl 2,4,6-trimethoxybenzyl sulfone 366808-08-4P
366808-12-0P, (Z)-2-Hydroxystyryl 2,4,6-trimethoxybenzyl sulfone 366808-16-4P, (Z)-2-Phosphonostyryl 2,3,4-trimethoxybenzyl sulfone 366808-22-2P, (Z)-4-Phosphonostyryl 2,4,6-trimethoxybenzyl sulfone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted styryl benzyl sulfones for treating proliferative disorders)

RN 334969-19-6 CAPLUS

CN Benzene, pentafluoro[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-20-9 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-2,3,4,5,6-pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-21-0 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-2,3,4,5,6-pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-22-1 CAPLUS

CN Benzene, 1-[(1E)-2-[[3,4-dichlorophenyl)methyl]sulfonyl]ethenyl]-2,3,4,5,6-pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-23-2 CAPLUS

CN Benzene, pentafluoro[[[(1E)-2-(pentafluorophenyl)ethenyl]sulfonyl]methyl]-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-24-3 CAPLUS

CN Benzene, pentafluoro[(1E)-2-[[4-iodophenyl)methyl]sulfonyl]ethenyl]-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-25-4 CAPLUS

CN Phenol, 2-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-4,6-dinitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-26-5 CAPLUS

CN Phenol, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-4,6-dinitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-27-6 CAPLUS

CN Phenol, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-4,6-dinitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-28-7 CAPLUS

CN Phenol, 2-[(1E)-2-[(2,4-dichlorophenyl)methylsulfonyl]ethenyl]-4,6-dinitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-29-8 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[(4-methoxyphenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-30-1 CAPLUS

CN Benzene, 1,3-dimethoxy-4-[(1E)-2-[(4-methoxyphenyl)methylsulfonyl]ethenyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-31-2 CAPLUS

CN Benzene, 1,2,3-trimethoxy-5-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-32-3 CAPLUS

CN Benzene, 5-[(1E)-2-[[4,5-dimethoxy-2-nitrophenyl)methyl]sulfonyl]ethenyl]-1,2,3-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-33-4 CAPLUS

CN Benzene, 2-[(1E)-2-[[4,5-dimethoxy-2-nitrophenyl)methyl]sulfonyl]ethenyl]-1,3,5-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-34-5 CAPLUS

CN Benzene, 1-[(1E)-2-[[4,5-dimethoxy-2-nitrophenyl)methyl]sulfonyl]ethenyl]-2,4-dimethoxy-3-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-35-6 CAPLUS

CN Benzene, 1,2,3-trifluoro-4-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-36-7 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-2,3,4-trifluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-37-8 CAPLUS

CN Phenol, 3,5-dimethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-38-9 CAPLUS

CN Benzene, 1,2,4,5-tetrafluoro-3-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-39-0 CAPLUS

CN Benzene, 1,2,4-trimethoxy-5-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-40-3 CAPLUS

CN Benzene, 1,2,3-trimethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-41-4 CAPLUS

CN Phenol, 2-methoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-6-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-42-5 CAPLUS

CN Benzene, 1,2-dimethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-5-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-43-6 CAPLUS

CN Benzene, 1-iodo-2,3-dimethoxy-5-[(1E)-2-[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-44-7 CAPLUS

CN Benzene, 5-fluoro-1,3-dimethoxy-2-[(1E)-2-[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-45-8 CAPLUS

CN Phenol, 3,5-dimethoxy-2-[(1E)-2-[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-46-9 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-1,3,5-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-47-0 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-1,3,5-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-48-1 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-5-fluoro-1,3-dimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-49-2 CAPLUS

CN Phenol, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-3,5-dimethoxy-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-50-5 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-1,3,5-
trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-51-6 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-5-fluoro-1,3-
dimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-52-7 CAPLUS

CN Benzene, 1,2,3-trimethoxy-4-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-53-8 CAPLUS

CN Benzene, 1-[[[(1E)-2-(2,6-dimethoxyphenyl)ethenyl]sulfonyl]methyl]-2,3,4-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-54-9 CAPLUS

CN Benzene, 1,2,3-trimethoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-55-0 CAPLUS

CN Benzene, 5-[[[(1E)-2-(2,6-dimethoxyphenyl)ethenyl]sulfonyl]methyl]-1,2,3-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 366807-70-7 CAPLUS

CN Benzene, 1,2,3,4,5-pentafluoro-6-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 366807-72-9 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-2,3,4,5,6-pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 366807-74-1 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-2,3,4,5,6-pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 366807-77-4 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-2,3,4-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 366807-78-5 CAPLUS

CN Benzene, 1,3,5-trifluoro-2-[(1Z)-2-[[[(4-methylphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 366807-81-0 CAPLUS

CN Benzene, 1-[(1Z)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-2,3,4,5,6-pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 366807-83-2 CAPLUS

CN Benzene, pentafluoro[(1Z)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 366807-85-4 CAPLUS

CN Benzene, pentafluoro[(1Z)-2-[[2,3,4-trimethoxyphenyl)methyl]sulfonyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 366807-90-1 CAPLUS

CN Benzene, pentafluoro[(1Z)-2-[[3,4,5-trimethoxyphenyl)methyl]sulfonyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 366807-93-4 CAPLUS

CN Benzene, pentafluoro[(1Z)-2-[[2,4,6-trimethoxyphenyl)methyl]sulfonyl]ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 366807-97-8 CAPLUS

CN Phenol, 2-methoxy-4-[(1Z)-2-[[2,4,5-trimethoxyphenyl)methyl]sulfonyl]ethenyl]-, 1-acetate (CA INDEX NAME)


Double bond geometry as shown.



RN 366808-02-8 CAPLUS

CN 1,2-Benzenediol, 4-[(1Z)-2-[[2,4,6-trimethoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 366808-08-4 CAPLUS

CN Benzene, 1,3,5-trifluoro-2-[(1Z)-2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 366808-12-0 CAPLUS

CN Phenol, 2-[(1Z)-2-[[2,4,6-trimethoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 366808-16-4 CAPLUS

CN Phosphonic acid, [2-[(1Z)-2-[[2,3,4-trimethoxyphenyl]methyl]sulfonyl]ethenyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 366808-22-2 CAPLUS

CN Phosphonic acid, [4-[(1Z)-2-[[2,4,6-trimethoxyphenyl]methyl]sulfonyl]ethenyl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 60 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:440082 CAPLUS

DOCUMENT NUMBER: 135:180576

TITLE: β -Sulfinyl α,β -Unsaturated Carbonyl

Compounds from Enantiomerically Pure Sulfenic Acids
Aversa, Maria C.; Barattucci, Anna; Bonaccorsi, Paola;
Giannetto, Placido; Policicchio, Manuela

CORPORATE SOURCE: Dipartimento di Chimica Organica e biologica,
Universita degli Studi di Messina, Messina, 98166,
Italy

SOURCE: Journal of Organic Chemistry (2001), 66(14), 4845-4851
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:180576


AB The addition of enantiopure sulfenic acids to oxoalkynes constitutes a new and efficient methodol. for the synthesis of β -sulfinyl α,β -unsatd. carbonyl compds. RSOH [R = 10-isoborneyl, 2-borneyl] were generated by thermolysis of suitable precursors and trapped in situ by oxoalkynes, affording (RS,E)- and (SS,E)-3-alkylsulfinyl-1-phenyl-2-propen-1-ones, 4-alkylsulfinyl-3-buten-2-ones, and 3-[(1S)-isoborneol-10-sulfinyl]-2-propenoates in good yields and in enantiomerically pure form after simple column chromatog. (RS,E)-3-[(1S)-isoborneol-10-sulfinyl]-1-phenyl-2-propen-1-one (I) was involved as a heterodiene in inverse-electron-demanding Diels-Alder reactions with readily available electron-rich dienophiles, corroborating in each case the sulfinyl auxiliary capability in controlling the stereochem. outcome of these cycloadns. Furthermore, the addition of methylmagnesium iodide to the carbonyl moiety of I demonstrated that the chiral sulfur atom exerts a remote stereocontrol in this reaction if assisted by the hydroxy group being part of the isoborneol substituent.

IT 355807-23-7P 355807-24-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of β -sulfinyl α,β -unsatd. carbonyl compds. from enantiomerically pure sulfenic acids)

RN 355807-23-7 CAPLUS

CN Bicyclo[2.2.1]heptan-2-ol, 7,7-dimethyl-1-[[(R)-[(1E)-2-(2-phenyl-1,3-dithian-2-yl)ethenyl]sulfinyl]methyl]-, (1S,2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 355807-24-8 CAPLUS

CN Bicyclo[2.2.1]heptan-2-ol, 7,7-dimethyl-1-[[(S)-[(1E)-2-(2-phenyl-1,3-dithian-2-yl)ethenyl]sulfinyl]methyl]-, (1S,2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)
 REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 61 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2001:334964 CAPLUS
 DOCUMENT NUMBER: 135:122252
 TITLE: Simple and stereoselective synthetic route to (E)-1-alkenyl sulfoxides via terminal alkynes
 AUTHOR(S): Zhong, Ping; Guo, Meng-Ping; Huang, Xian
 CORPORATE SOURCE: Department of Chemistry, Yichun Normal Institute, Yichun, 336000, Peop. Rep. China
 SOURCE: Journal of Chemical Research, Synopses (2000), (12), 588-589
 CODEN: JRPSDC; ISSN: 0308-2342
 PUBLISHER: Science Reviews Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:122252
 AB Terminal alkynes react with Cp₂Zr(H)Cl (Cp = η⁵-C₅H₅) to give organozirconium(IV) complexes, which are trapped with sulfinyl chlorides to afford (E)-1-alkenyl sulfoxides.
 IT 160426-22-2P
 RL: SPN (Synthetic preparation); PREP (Preparation) (stereoselective preparation of (E)-1-alkenyl sulfoxides via terminal alkynes)
 RN 160426-22-2 CAPLUS
 CN Benzene, [[[1E)-2-phenylethenyl]sulfinyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 62 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:283778 CAPLUS
 DOCUMENT NUMBER: 134:305291
 TITLE: Method for protecting normal cells from cytotoxicity
 of chemotherapeutic agents by pretreatment with
 α,β -unsaturated aryl sulfones
 INVENTOR(S): Cosenza, Stephen A.; Reddy, M. V. Ramana; Reddy, E.
 Premkumar
 PATENT ASSIGNEE(S): Temple University, USA
 SOURCE: PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001026645	A1	20010419	WO 2000-US28250	20001011
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2387539	A1	20010419	CA 2000-2387539	20001011
AU 2001011989	A	20010423	AU 2001-11989	20001011
AU 780844	B2	20050421		
EP 1223923	A1	20020724	EP 2000-973486	20001011
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003511412	T	20030325	JP 2001-529435	20001011
US 6767926	B1	20040727	US 2000-689281	20001011
US 20030149109	A1	20030807	US 2002-305694	20021127
US 6656973	B2	20031202		
US 20040214903	A1	20041028	US 2004-851829	20040521
IN 2005DN03668	A	20070824	IN 2005-DN3668	20050818
PRIORITY APPLN. INFO.:			US 1999-159123P	P 19991012
			US 2000-689281	A1 20001011
			WO 2000-US28250	W 20001011
			IN 2002-DN441	A3 20020429

OTHER SOURCE(S): MARPAT 134:305291

AB Pre-treatment with α,β unsatd. aryl sulfones protects normal cells from the cytotoxic side effects of two classes of anticancer chemotherapeutics. Administration of a cytoprotective sulfone compound to a patient prior to anticancer chemotherapy with a mitotic phase cell cycle inhibitor or topoisomerase inhibitor reduces or eliminates the cytotoxic side effects of the anticancer agent on normal cells. The cytoprotective effect of the α,β unsatd. aryl sulfone allows the clinician to safely increasing the dosage of the anticancer chemotherapeutic. Pretreatment of normal human fibroblasts with

(E)-4-fluorostyryl-4-chlorobenzyl sulfone conferred protection from the toxic effects of paclitaxel.

IT 118672-29-0P 300699-36-9P 300699-47-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological


study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antitumor and cytoprotective effects of; protecting normal cells from cytotoxicity of chemotherapeutic agents by pretreatment with α,β -unsatd. aryl sulfones)

RN 118672-29-0 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-36-9 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-47-2 CAPLUS

CN Benzene, 2-chloro-1-[(1E)-2-[[4-(4-chlorophenyl)methyl]sulfonyl]ethenyl]-4-fluoro-
(CA INDEX NAME)

Double bond geometry as shown.



IT 334969-03-8


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antitumor and cytoprotective effects of; protecting normal cells from cytotoxicity of chemotherapeutic agents by pretreatment with α,β -unsatd. aryl sulfones)

RN 334969-03-8 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 118672-28-9P


RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(protecting normal cells from cytotoxicity of chemotherapeutic agents by pretreatment with α,β -unsatd. aryl sulfones)

RN 118672-28-9 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 32291-81-9P	93468-07-6P	118672-24-5P
118672-26-7P	118672-30-3P	118672-33-6P
118672-34-7P	136272-35-0P	158606-43-0P
158606-45-2P	222639-19-2P	222639-21-6P
222639-24-9P	222639-26-1P	222639-31-8P
298197-01-0P	298197-03-2P	298197-05-4P
298197-09-8P	298197-11-2P	298197-14-5P
298197-15-6P	298197-16-7P	298197-17-8P
298197-18-9P	298197-19-0P	298197-20-3P
298197-21-4P	298197-22-5P	300699-33-6P
300699-34-7P	300699-35-8P	300699-37-0P
300699-39-2P	300699-40-5P	300699-41-6P
300699-42-7P	300699-43-8P	300699-44-9P
300699-45-0P	300699-46-1P	300699-50-7P
300699-62-1P	300699-63-2P	300699-64-3P

300699-67-6P	300699-68-7P	300699-71-2P
300699-72-3P	300699-73-4P	300699-74-5P
300699-75-6P	300699-77-8P	300699-78-9P
300699-79-0P	300699-80-3P	300699-81-4P
300699-82-5P	300699-83-6P	300699-85-8P
300699-88-1P	300699-89-2P	300699-90-5P
300699-91-6P	300699-92-7P	300699-93-8P
300699-94-9P	300699-95-0P	300699-96-1P
300699-98-3P	300699-99-4P	300700-00-9P
334969-04-9P	334969-19-6P	334969-20-9P
334969-21-0P	334969-22-1P	334969-23-2P
334969-24-3P	334969-25-4P	334969-26-5P
334969-27-6P	334969-28-7P	334969-29-8P
334969-30-1P	334969-31-2P	334969-32-3P
334969-33-4P	334969-34-5P	334969-35-6P
334969-36-7P	334969-37-8P	334969-38-9P
334969-39-0P	334969-40-3P	334969-41-4P
334969-42-5P	334969-43-6P	334969-44-7P
334969-45-8P	334969-46-9P	334969-47-0P
334969-48-1P	334969-49-2P	334969-50-5P
334969-51-6P	334969-52-7P	334969-53-8P
334969-54-9P	334969-55-0P	334969-56-1P
334969-57-2P	334969-58-3P	334969-59-4P
334969-60-7P	334969-61-8P	334969-62-9P
334969-63-0P	334969-64-1P	334969-65-2P
334969-66-3P	334969-67-4P	334969-68-5P
334969-69-6P	334969-70-9P	334969-71-0P
334969-72-1P	334969-73-2P	334969-74-3P
334969-75-4P	334969-76-5P	334969-77-6P
334969-78-7P	334969-79-8P	334969-80-1P
334969-81-2P	334969-82-3P	334969-83-4P
334969-84-5P	334969-85-6P	334969-86-7P
334969-87-8P	334969-88-9P	334969-89-0P
334969-90-3P	334969-91-4P	334969-92-5P
334969-93-6P	334969-94-7P	334969-95-8P
334969-96-9P	334969-97-0P	334969-98-1P
334969-99-2P	334970-00-2P	334970-01-3P
334970-02-4P	334970-03-5P	334970-04-6P
334970-05-7P	334970-06-8P	334970-07-9P
334970-08-0P	334970-09-1P	334970-10-4P
334970-11-5P	334970-12-6P	334970-13-7P
334970-14-8P	334970-15-9P	334970-16-0P
334970-17-1P	334970-18-2P	334970-19-3P
334970-20-6P	334970-21-7P	334970-22-8P
334970-23-9P	334970-24-0P	334970-25-1P
334970-26-2P	334970-27-3P	334970-28-4P


RL: SPN (Synthetic preparation); PREP (Preparation)

(protecting normal cells from cytotoxicity of chemotherapeutic agents
by pretreatment with α,β -unsatd. aryl sulfones)

RN 32291-81-9 CAPLUS

CN Benzene, [[[1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 93468-07-6 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-24-5 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[4-methylphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-26-7 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[4-methylphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-30-3 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-33-6 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-34-7 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 136272-35-0 CAPLUS

CN Benzene, 1-chloro-2-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 158606-43-0 CAPLUS

CN Benzene, 1-methyl-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 158606-45-2 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 222639-19-2 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 222639-21-6 CAPLUS

CN Benzene, 2,4-difluoro-1-[(1E)-2-[[[(4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 222639-24-9 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-26-1 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 222639-31-8 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-01-0 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-03-2 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-05-4 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-09-8 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-11-2 CAPLUS

CN Benzene, 1-chloro-4-[(1Z)-2-[(4-fluorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-14-5 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-15-6 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-16-7 CAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 298197-17-8 CAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-18-9 CAPLUS

CN Benzene, 1-[[[(1Z)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-2-chloro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-19-0 CAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[(4-fluorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-20-3 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-21-4 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-22-5 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-33-6 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-4-(trifluoromethyl)-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-34-7 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-4-(trifluoromethyl)-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-35-8 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-37-0 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-39-2 CAPLUS

CN Benzene, 1,2-dichloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-40-5 CAPLUS

CN Benzene, 1,2-dichloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-41-6 CAPLUS

CN Benzene, 4-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-1,2-dichloro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-42-7 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 300699-43-8 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-44-9 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-45-0 CAPLUS

CN Benzene, 4-[(1E)-2-[[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-1,2-difluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-46-1 CAPLUS

CN Benzene, 2-chloro-4-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-1-fluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-50-7 CAPLUS

CN Benzene, 1,2-dichloro-3-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-62-1 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-63-2 CAPLUS

CN Benzene, 1-[(1E)-2-[[(4-fluorophenyl)methyl]sulfonyl]ethenyl]-3-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-64-3 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-67-6 CAPLUS

CN Benzene, 1-[(1E)-2-[[(4-fluorophenyl)methyl]sulfonyl]ethenyl]-2-
(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-68-7 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-3-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-71-2 CAPLUS

CN Benzene, 4-fluoro-1-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-72-3 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-73-4 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-3-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-74-5 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-2-
(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-75-6 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-3-
(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-77-8 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-78-9 CAPLUS

CN Benzene, 4-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-1-fluoro-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-79-0 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(2-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-80-3 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-[4-fluoro-2-(trifluoromethyl)phenyl]ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-81-4 CAPLUS

CN Benzene, 1-[(1E)-2-[[[4-bromophenyl]methyl]sulfonyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-82-5 CAPLUS

CN Benzene, 1-[(1E)-2-[[[4-bromophenyl]methyl]sulfonyl]ethenyl]-3-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-83-6 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-85-8 CAPLUS

CN Benzene, 1-[(1E)-2-[[[4-bromophenyl)methyl]sulfonyl]ethenyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-88-1 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(2-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-89-2 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(3-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-90-5 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-91-6 CAPLUS

CN Benzene, 1-[(1E)-2-[[[(4-methylphenyl)methyl]sulfonyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-92-7 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-methylphenyl)methyl]sulfonyl]ethenyl]-3-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-93-8 CAPLUS

CN Benzene, 1-methyl-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-94-9 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-95-0 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-96-1 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-98-3 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-2-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-99-4 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-3-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300700-00-9 CAPLUS

CN Benzene, 1-methoxy-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-04-9 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 334969-19-6 CAPLUS

CN Benzene, pentafluoro[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-20-9 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-2,3,4,5,6-
pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-21-0 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-2,3,4,5,6-
pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-22-1 CAPLUS

CN Benzene, 1-[(1E)-2-[[(3,4-dichlorophenyl)methyl]sulfonyl]ethenyl]-
2,3,4,5,6-pentafluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-23-2 CAPLUS

CN Benzene, pentafluoro[[[(1E)-2-(pentafluorophenyl)ethenyl]sulfonyl]methyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-24-3 CAPLUS

CN Benzene, pentafluoro[(1E)-2-[[(4-iodophenyl)methyl]sulfonyl]ethenyl]-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-25-4 CAPLUS

CN Phenol, 2-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-4,6-dinitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-26-5 CAPLUS

CN Phenol, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-4,6-dinitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-27-6 CAPLUS

CN Phenol, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-4,6-dinitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-28-7 CAPLUS

CN Phenol, 2-[(1E)-2-[(2,4-dichlorophenyl)methylsulfonyl]ethenyl]-4,6-dinitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-29-8 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[(4-methoxyphenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-30-1 CAPLUS

CN Benzene, 1,3-dimethoxy-4-[(1E)-2-[(4-methoxyphenyl)methylsulfonyl]ethenyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-31-2 CAPLUS

CN Benzene, 1,2,3-trimethoxy-5-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-32-3 CAPLUS

CN Benzene, 5-[(1E)-2-[[4,5-dimethoxy-2-nitrophenyl)methyl]sulfonyl]ethenyl]-1,2,3-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-33-4 CAPLUS

CN Benzene, 2-[(1E)-2-[[4,5-dimethoxy-2-nitrophenyl)methyl]sulfonyl]ethenyl]-1,3,5-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-34-5 CAPLUS

CN Benzene, 1-[(1E)-2-[[4,5-dimethoxy-2-nitrophenyl)methyl]sulfonyl]ethenyl]-2,4-dimethoxy-3-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-35-6 CAPLUS

CN Benzene, 1,2,3-trifluoro-4-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-36-7 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-2,3,4-trifluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-37-8 CAPLUS

CN Phenol, 3,5-dimethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-38-9 CAPLUS

CN Benzene, 1,2,4,5-tetrafluoro-3-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-39-0 CAPLUS

CN Benzene, 1,2,4-trimethoxy-5-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-40-3 CAPLUS

CN Benzene, 1,2,3-trimethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-41-4 CAPLUS

CN Phenol, 2-methoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-6-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-42-5 CAPLUS

CN Benzene, 1,2-dimethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-5-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-43-6 CAPLUS

CN Benzene, 1-iodo-2,3-dimethoxy-5-[(1E)-2-[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-44-7 CAPLUS

CN Benzene, 5-fluoro-1,3-dimethoxy-2-[(1E)-2-[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-45-8 CAPLUS

CN Phenol, 3,5-dimethoxy-2-[(1E)-2-[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-46-9 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-1,3,5-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-47-0 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-1,3,5-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-48-1 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-5-fluoro-1,3-dimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-49-2 CAPLUS

CN Phenol, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-3,5-dimethoxy-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-50-5 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-1,3,5-
trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-51-6 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-5-fluoro-1,3-
dimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-52-7 CAPLUS

CN Benzene, 1,2,3-trimethoxy-4-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-53-8 CAPLUS

CN Benzene, 1-[[[(1E)-2-(2,6-dimethoxyphenyl)ethenyl]sulfonyl]methyl]-2,3,4-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-54-9 CAPLUS

CN Benzene, 1,2,3-trimethoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-55-0 CAPLUS

CN Benzene, 5-[[[(1E)-2-(2,6-dimethoxyphenyl)ethenyl]sulfonyl]methyl]-1,2,3-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-56-1 CAPLUS

CN Pyridine, 2-[(1E)-2-[[[(4-fluorophenyl)methyl]sulfonyl]ethenyl]]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-57-2 CAPLUS

CN Pyridine, 3-[(1E)-2-[[[(4-fluorophenyl)methyl]sulfonyl]ethenyl]]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-58-3 CAPLUS

CN Pyridine, 4-[(1E)-2-[(4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-59-4 CAPLUS

CN Pyridine, 2-[(1E)-2-[(4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-60-7 CAPLUS

CN Pyridine, 3-[(1E)-2-[(4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-61-8 CAPLUS

CN Pyridine, 4-[(1E)-2-[(4-chlorophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-62-9 CAPLUS

CN Pyridine, 2-[(1E)-2-[(4-bromophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-63-0 CAPLUS

CN Pyridine, 3-[(1E)-2-[(4-bromophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-64-1 CAPLUS

CN Pyridine, 4-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-65-2 CAPLUS

CN Thiophene, 2-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-66-3 CAPLUS

CN Thiophene, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 334969-67-4 CAPLUS

CN Thiophene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

NAME)


Double bond geometry as shown.



RN 334969-68-5 CAPLUS

CN Thiophene, 4-bromo-2-[(1E)-2-[[4-fluorophenyl)methylsulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-69-6 CAPLUS

CN Thiophene, 4-bromo-2-[(1E)-2-[[4-chlorophenyl)methylsulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-70-9 CAPLUS

CN Thiophene, 4-bromo-2-[(1E)-2-[[4-bromophenyl)methylsulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-71-0 CAPLUS

CN Thiophene, 2-bromo-5-[(1E)-2-[(4-fluorophenyl)methylsulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-72-1 CAPLUS

CN Thiophene, 2-bromo-5-[(1E)-2-[(4-chlorophenyl)methylsulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-73-2 CAPLUS

CN Thiophene, 2-bromo-5-[(1E)-2-[(4-bromophenyl)methylsulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334969-74-3 CAPLUS

CN Thiophene, 2-[(1E)-2-[(4-fluorophenyl)methylsulfonyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-75-4 CAPLUS

CN Thiophene, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-76-5 CAPLUS

CN Thiophene, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-77-6 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 334969-78-7 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 334969-79-8 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-80-1 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-iodophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-81-2 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-methylphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-82-3 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-83-4 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-(trifluoromethyl)phenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-84-5 CAPLUS

CN Thiophene, 3-[(1E)-2-[[2,4-dichlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-85-6 CAPLUS

CN Thiophene, 3-[(1E)-2-[[(3,4-dichlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-86-7 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(3-thienyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-87-8 CAPLUS

CN Thiophene, 3-[(1E)-2-[[(4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-88-9 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-89-0 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-90-3 CAPLUS

CN Thiophene, 3-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-91-4 CAPLUS

CN Thiophene, 3-[(1E)-2-[[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-92-5 CAPLUS

CN Thiophene, 3-[(1E)-2-[[(2,4-dichlorophenyl)methyl]sulfonyl]ethenyl]-,
1,1-dioxide (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-93-6 CAPLUS

CN	Furan, 2-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]- (NAME)	(CA INDEX)
----	---	------------


Double bond geometry as shown.



RN 334969-94-7 CAPLUS

CN Furan, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-95-8 CAPLUS

CN Furan, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-96-9 CAPLUS

CN Furan, 3-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-97-0 CAPLUS

CN Furan, 3-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-98-1 CAPLUS

CN Furan, 3-[(1E)-2-[[[4-bromophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-99-2 CAPLUS

CN Furan, 3-[(1E)-2-[[[4-iodophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-00-2 CAPLUS

CN Furan, 3-[(1E)-2-[[[4-methylphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-01-3 CAPLUS

CN Furan, 3-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-02-4 CAPLUS

CN Furan, 3-[(1E)-2-[[4-(trifluoromethyl)phenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-03-5 CAPLUS

CN Furan, 3-[(1E)-2-[[2,4-dichlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-04-6 CAPLUS

CN Furan, 3-[(1E)-2-[(3,4-dichlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-05-7 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(3-furanyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-06-8 CAPLUS

CN Furan, 3-[(1E)-2-[(4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-07-9 CAPLUS

CN Thiazole, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-08-0 CAPLUS

CN 1H-Pyrrole, 2-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-09-1 CAPLUS

CN 1H-Pyrrole, 2-[(1E)-2-[[4-bromophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-10-4 CAPLUS

CN Thiophene, 4-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-11-5 CAPLUS

CN Thiophene, 4-[(1E)-2-[[4-iodophenyl)methyl]sulfonyl]ethenyl]-2-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334970-12-6 CAPLUS

CN Thiophene, 4-[(1E)-2-[[2,4-dichlorophenyl)methyl]sulfonyl]ethenyl]-2-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334970-13-7 CAPLUS

CN Thiophene, 4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-2-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 334970-14-8 CAPLUS

CN Naphthalene, 1-[(1E)-2-[[4-fluorophenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-15-9 CAPLUS

CN Naphthalene, 2-[(1E)-2-[[4-fluorophenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-16-0 CAPLUS

CN Naphthalene, 1-[(1E)-2-[[4-chlorophenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-17-1 CAPLUS

CN Naphthalene, 2-[(1E)-2-[(4-chlorophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-18-2 CAPLUS

CN Naphthalene, 1-[(1E)-2-[(4-bromophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-19-3 CAPLUS

CN Naphthalene, 2-[(1E)-2-[(4-bromophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-20-6 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-21-7 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-22-8 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-23-9 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(2-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-24-0 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(3-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-25-1 CAPLUS

CN Naphthalene, 1-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-26-2 CAPLUS

CN Anthracene, 9-[(1E)-2-[(4-fluorophenyl)methyl]sulfonyl]ethenyl]-1,2,3,4-tetrahydro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-27-3 CAPLUS

CN Anthracene, 9-[(1E)-2-[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-1,2,3,4-tetrahydro- (CA INDEX NAME)


Double bond geometry as shown.



RN 334970-28-4 CAPLUS

CN Anthracene, 9-[(1E)-2-[(4-bromophenyl)methyl]sulfonyl]ethenyl]-1,2,3,4-tetrahydro- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 63 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:725456 CAPLUS

DOCUMENT NUMBER: 133:296275

TITLE: Preparation of (E)-styryl sulfone anticancer agents

INVENTOR(S): Reddy, E. Premkumar; Reddy, M. V. Ramana

PATENT ASSIGNEE(S): Temple University - of the Commonwealth System of Higher Education, USA

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059495	A1	20001012	WO 2000-US8565	20000331
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2366750	A1	20001012	CA 2000-2366750	20000331
EP 1173160	A1	20020123	EP 2000-921553	20000331
EP 1173160	B1	20050622		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002541102	T	20021203	JP 2000-609059	20000331
AU 774738	B2	20040708	AU 2000-41853	20000331
AT 298234	T	20050715	AT 2000-921553	20000331
US 6762207	B1	20040713	US 2001-937684	20010928
IN 2001DN00898	A	20070309	IN 2001-DN898	20011003
US 20030216535	A1	20031120	US 2003-462919	20030616
US 6787667	B2	20040907		
US 20040229959	A1	20041118	US 2004-848454	20040518

US 7056953
PRIORITY APPLN. INFO.:

B2 20060606

US 1999-127683P P 19990402
US 1999-143975P P 19990715
WO 2000-US8565 W 20000331
US 2001-937684 A3 20010928

OTHER SOURCE(S): MARPAT 133:296275
GI



I

AB The title compds. [I; R1-R4 = H, F, Cl, etc. (with the proviso that R1-R3 not all are H when R4 = 2-Cl or 4-Cl; when R1 and R3 = H and R2 = 4-Br or 4-Cl, then R4 may not be 4-Cl, 4-F or 4-Br; when R1 and R3 = H and R2 = 4-F, then R4 may not be 4-F or 4-Br; when R1 = H, and R4 = 2-F, the R2 and R3 may not be 4-F; and when R1 = H and R3 = 4-H, 4-Cl, 4-Br, 4-Me or 4-MeO, and R4 = 2-H, 2-Cl, or 2-F, then R2 may not be 4-H, 4-Cl, 4-F, or 4-Br)], useful as anticancer agents, were prepared General procedures for synthesis of compds. I was given. E.g., the prepared compound (E)-I [R1 = 4-Cl; R2 = H; R3 = 2-Cl; R4 = 4-F] showed high activity (above 80%) against breast tumor cell line MCF-7 and prostate tumor cell line DU-145. The compds. I may be utilized as as monomers in the synthesis of polymers having pendant aryl and benzylsulfone groups (no data).

IT 118672-24-5P 118672-26-7P 118672-30-3P
118672-33-6P 118672-34-7P 300699-33-6P
300699-34-7P 300699-35-8P 300699-36-9P
300699-37-0P 300699-39-2P 300699-40-5P
300699-41-6P 300699-42-7P 300699-43-8P
300699-44-9P 300699-45-0P 300699-46-1P
300699-47-2P 300699-48-3P 300699-49-4P
300699-50-7P 300699-51-8P 300699-53-0P
300699-54-1P 300699-55-2P 300699-56-3P
300699-57-4P 300699-58-5P 300699-59-6P
300699-60-9P 300699-61-0P 300699-62-1P
300699-63-2P 300699-64-3P 300699-67-6P
300699-68-7P 300699-70-1P 300699-71-2P
300699-72-3P 300699-73-4P 300699-74-5P
300699-75-6P 300699-76-7P 300699-77-8P
300699-78-9P 300699-79-0P 300699-80-3P
300699-81-4P 300699-82-5P 300699-83-6P
300699-85-8P 300699-86-9P 300699-87-0P
300699-88-1P 300699-89-2P 300699-90-5P
300699-91-6P 300699-92-7P 300699-93-8P
300699-94-9P 300699-95-0P 300699-96-1P
300699-98-3P 300699-99-4P 300700-00-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (E)-styryl sulfone anticancer agents)

RN 118672-24-5 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[(4-methylphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-26-7 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[(4-methylphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-30-3 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-33-6 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[(4-nitrophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-34-7 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[(4-nitrophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-33-6 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-4-
(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-34-7 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-4-
(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-35-8 CAPLUS

CN Benzene, 1-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-36-9 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-37-0 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-39-2 CAPLUS

CN Benzene, 1,2-dichloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-40-5 CAPLUS

CN Benzene, 1,2-dichloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-41-6 CAPLUS

CN Benzene, 4-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-1,2-dichloro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-42-7 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 300699-43-8 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-44-9 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-45-0 CAPLUS

CN Benzene, 4-[(1E)-2-[[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-1,2-difluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-46-1 CAPLUS

CN Benzene, 2-chloro-4-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-1-fluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-47-2 CAPLUS

CN Benzene, 2-chloro-1-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-4-fluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-48-3 CAPLUS

CN Benzene, 2,4-dichloro-1-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-49-4 CAPLUS

CN Benzene, 1,2-dichloro-4-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-50-7 CAPLUS

CN Benzene, 1,2-dichloro-3-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-51-8 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[(4-iodophenyl)methyl]sulfonyl]ethenyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 300699-53-0 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1E)-2-(4-iodophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-54-1 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-iodophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-55-2 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-iodophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-56-3 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[(4-iodophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-57-4 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[(4-iodophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-58-5 CAPLUS

CN Benzene, 1-[(1E)-2-[(4-iodophenyl)methyl]sulfonyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-59-6 CAPLUS

CN Benzene, 1-iodo-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-60-9 CAPLUS

CN Benzene, 1-iodo-4-[(1E)-2-[[[4-methoxyphenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-61-0 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(4-iodophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-62-1 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-2-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-63-2 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-3-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-64-3 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-67-6 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-68-7 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-3-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-70-1 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-4-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-71-2 CAPLUS

CN Benzene, 4-fluoro-1-[(1E)-2-[[4-(fluorophenyl)methyl]sulfonyl]ethenyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-72-3 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-(chlorophenyl)methyl]sulfonyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-73-4 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-(chlorophenyl)methyl]sulfonyl]ethenyl]-3-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-74-5 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-75-6 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-3-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-76-7 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-4-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-77-8 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-78-9 CAPLUS

CN Benzene, 4-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-1-fluoro-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-79-0 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-(2-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-80-3 CAPLUS

CN Benzene, 2,4-dichloro-1-[[[(1E)-2-[4-fluoro-2-(trifluoromethyl)phenyl]ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-81-4 CAPLUS

CN Benzene, 1-[(1E)-2-[[[4-bromophenyl]methyl]sulfonyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-82-5 CAPLUS

CN Benzene, 1-[(1E)-2-[[[4-bromophenyl]methyl]sulfonyl]ethenyl]-3-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-83-6 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-85-8 CAPLUS

CN Benzene, 1-[(1E)-2-[[[4-bromophenyl)methyl]sulfonyl]ethenyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-86-9 CAPLUS

CN Benzene, 1-[(1E)-2-[[[4-bromophenyl)methyl]sulfonyl]ethenyl]-3-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-87-0 CAPLUS

CN Benzene, 1-[(1E)-2-[(4-bromophenyl)methylsulfonyl]ethenyl]-4-(trifluoromethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-88-1 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(2-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-89-2 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(3-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-90-5 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-91-6 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-methylphenyl]methyl]sulfonyl]ethenyl]-2-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-92-7 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-methylphenyl]methyl]sulfonyl]ethenyl]-3-nitro- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-93-8 CAPLUS

CN Benzene, 1-methyl-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-94-9 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[[4-methoxyphenyl]methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-95-0 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[[[4-methoxyphenyl]methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-96-1 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-98-3 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-2-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-99-4 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-3-nitro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300700-00-9 CAPLUS

CN Benzene, 1-methoxy-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 64 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:725455 CAPLUS

DOCUMENT NUMBER: 133:296274

TITLE: Preparation of styryl sulfone anticancer agents

INVENTOR(S): Reddy, Premkumar E.; Reddy, Ramana M. V.

PATENT ASSIGNEE(S): Temple University- of the Commonwealth System of
Higher Education, USA

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059494	A1	20001012	WO 1999-US7406	19990402
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

AU 9933813	A	20001023	AU 1999-33813	19990402
JP 2002541101	T	20021203	JP 2000-609058	19990402
PRIORITY APPLN. INFO.:			WO 1999-US7406	A 19990402
OTHER SOURCE(S):	MARPAT 133:296274			
GI				



AB The title compds. [I (wherein n = 0-1; R1 = H, Cl, F, Br; R2 = H, Cl, F, Br, Me, OMe; R3 = H, Cl, F; provided, R2 may not be Me or OMe when R1 and R3 are both H and n = 0-1; R1-R3 may not all be H when n = 1), II (R1 = H, Cl, F, Br), III (R1 = F, Br; R2 = 2-ClC6H4; 4-ClC6H4, 4-FC6H4, 2-O2NC6H4)] which selectively inhibit proliferation of tumor cells, and induce apoptosis of tumor cells, while sparing normal cells, were prepared. The general procedures for synthesis of compds. I-III were given. E.g., the compound (E)-I [R1-R3 = F; n = 1] was found to substantially inhibit and induce the death of LnCaP (androgen-dependent prostate cell line), BT-20 (estrogen-unresponsive breast tumor cell line) and MCF-7 (estrogen-responsive breast tumor cell line) at 2.5 μ M and 5.0 μ M.


IT 93468-07-6P 118672-28-9P 118672-29-0P
 136272-35-0P 222639-19-2P 222639-21-6P
 222639-24-9P 222639-26-1P 222639-29-4P
 222639-31-8P 222639-33-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of styryl sulfone anticancer agents)

RN 93468-07-6 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-28-9 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-29-0 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 136272-35-0 CAPLUS

CN Benzene, 1-chloro-2-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 222639-19-2 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-21-6 CAPLUS

CN Benzene, 2,4-difluoro-1-[(1E)-2-[[4-(4-fluorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-24-9 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-26-1 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-29-4 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[(4-fluorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-31-8 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-33-0 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 65 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:706976 CAPLUS

DOCUMENT NUMBER: 133:266597

TITLE: Preparation of Z-styryl sulfone anticancer agents

INVENTOR(S): Reddy, E. Premkumar; Reddy, M. V. Ramana

PATENT ASSIGNEE(S): Temple University, USA

SOURCE: PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000057872	A1	20001005	WO 2000-US8350	20000330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6201154	B1	20010313	US 1999-282855	19990331
CA 2368653	A1	20001005	CA 2000-2368653	20000330
EP 1180024	A1	20020220	EP 2000-919829	20000330
EP 1180024	B1	20040204		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002540152	T	20021126	JP 2000-607623	20000330
AT 258790	T	20040215	AT 2000-919829	20000330
AU 771133	B2	20040311	AU 2000-40450	20000330
US 6414034	B1	20020702	US 2000-722450	20001122
US 6576675	B1	20030610	US 2001-937805	20010928
IN 2001DN00899	A	20070112	IN 2001-DN899	20011003
PRIORITY APPLN. INFO.:			US 1999-282855	A 19990331
			WO 2000-US8350	W 20000330

OTHER SOURCE(S): MARPAT 133:266597

GI



AB The title compds. [I; R1 = H, Cl, NO2; R2 = H, alkyl, alkoxy, etc.; R3, R4 = H, alkyl, NO2, etc.; provided that at least one of R1 or R2 = H], useful as anticancer agents, were prepared. Thus, reacting 4-chlorophenylacetylene with 4-fluorobenzylmercaptan in the presence of Na followed by oxidation of the resulting Z-4-chlorostyryl 4-fluorobenzylsulfide afforded Z-I [R1 = H; R2 = Cl; R3 = H; R4 = F] which showed kill rates of over 75% at 2.5 mM against breast, prostate, ovarian, lung, renal and glioma cell lines.


IT 32291-81-9P 136272-42-9P 158606-43-0P
 158606-44-1P 158606-45-2P 298197-01-0P
 298197-03-2P 298197-05-4P 298197-09-8P
 298197-11-2P 298197-13-4P 298197-14-5P
 298197-15-6P 298197-16-7P 298197-17-8P
 298197-18-9P 298197-19-0P 298197-20-3P
 298197-21-4P 298197-22-5P 298197-23-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of Z-styryl sulfone anticancer agents)

RN 32291-81-9 CAPLUS

CN Benzene, [[[1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-42-9 CAPLUS

CN Benzene, 1-chloro-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 158606-43-0 CAPLUS

CN Benzene, 1-methyl-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 158606-44-1 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 158606-45-2 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-01-0 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 298197-03-2 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 298197-05-4 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-09-8 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-11-2 CAPLUS

CN Benzene, 1-chloro-4-[(1Z)-2-[[[(4-fluorophenyl)methyl]sulfonyl]ethenyl]]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-13-4 CAPLUS

CN Benzene, 1-fluoro-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-14-5 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-15-6 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-16-7 CAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 298197-17-8 CAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-18-9 CAPLUS

CN Benzene, 1-[[[(1Z)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-2-chloro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-19-0 CAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[[(4-fluorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-20-3 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-21-4 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-22-5 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-23-6 CAPLUS

CN Benzene, 1-fluoro-4-[(1Z)-2-[[4-iodophenyl]methyl]sulfonyl]ethenyl]- (CA
INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 66 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:414144 CAPLUS

DOCUMENT NUMBER: 133:192741

TITLE: The reaction of thiirane S-oxides with methyllithium
lithium bromide complex. A surprising preference for
deprotonation over desulfurization

AUTHOR(S): Schwan, Adrian L.; Lear, Yvonne

CORPORATE SOURCE: Guelph-Waterloo Centre for Graduate Work in Chemistry
and Biochemistry, Department of Chemistry and
Biochemistry, University of Guelph, Guelph, ON, N1G
2W1, Can.

SOURCE: Sulfur Letters (2000), 23(3), 111-119

CODEN: SULED2; ISSN: 0278-6117

PUBLISHER: Harwood Academic Publishers

DOCUMENT TYPE: Journal


LANGUAGE: English

AB Selected organolithium reagents demonstrate a surprising preference for
deprotonation of thiirane S-oxides over other modes of attack including

desulfurization. The MeLi·LiBr complex in particular was shown to generate (E)-1-alkenesulfenate anions in 50-75% yield via an initial deprotonation reaction of alkyl substituted thiirane S-oxides. These results are comparable to the established deprotonation reaction using disilazide bases, but lead to cleaner reaction mixts.

IT 160426-22-2P, [[(E)-(2-Phenylethenyl)sulfinyl]methyl]benzene
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of [(alkenylsulfinyl)methyl]benzene derivs. by deprotonation of thiirane oxides with methyl lithium-lithium bromide complex)
 RN 160426-22-2 CAPLUS
 CN Benzene, [[[(1E)-2-phenylethenyl]sulfinyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
 REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 67 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1999:244629 CAPLUS
 DOCUMENT NUMBER: 130:281870
 TITLE: Preparation of styryl sulfone anticancer agents
 INVENTOR(S): Reddy, Premkumar E.; Reddy, Ramana M. V.
 PATENT ASSIGNEE(S): Temple University - of the Commonwealth System of Higher Education, USA
 SOURCE: PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9918068	A1	19990415	WO 1998-US20580	19981001
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2305790	A1	19990415	CA 1998-2305790	19981001
CA 2305790	C	20080923		
AU 9895954	A	19990427	AU 1998-95954	19981001
AU 741042	B2	20011122		
EP 1027330	A1	20000816	EP 1998-949680	19981001
EP 1027330	B1	20041208		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

BR 9814059	A	20000926	BR 1998-14059	19981001
JP 2001519326	T	20011023	JP 2000-514880	19981001
JP 4294217	B2	20090708		
NZ 503479	A	20020828	NZ 1998-503479	19981001
RU 2201919	C2	20030410	RU 2000-111513	19981001
CN 1163480	C	20040825	CN 1998-809819	19981001
AT 284386	T	20041215	AT 1998-949680	19981001
IL 135438	A	20051218	IL 1998-135438	19981001
CZ 299718	B6	20081029	CZ 2000-1174	19981001
IN 1999MA00360	A	20050304	IN 1999-MA360	19990330
US 6359013	B1	20020319	US 2000-509227	20000324
HK 1031373	A1	20050708	HK 2001-100906	20010208
US 20020022666	A1	20020221	US 2001-919061	20010731
US 6548553	B2	20030415		
US 20030114538	A1	20030619	US 2002-255218	20020926
PRIORITY APPLN. INFO.:			US 1997-60933P	P 19971003
			WO 1998-US20580	W 19981001
			US 2000-509227	A2 20000324
			US 2001-919061	A3 20010731
OTHER SOURCE(S):	MARPAT 130:281870			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I (wherein R1 = H, Cl, F, Br; R2 = H, Cl, F, Br, Me, MeO; R3 = H, Cl, F; provided that R2 may not be Me or MeO when R1 and R3 are both H and n is 0 or 1; and R1-R3 may not all be H when n = 1), II (wherein R1 = H, Cl, F, Br), III (wherein R1 = F, Br; R2 = 2-ClC6H4, 4-ClC6H4, 4-FC6H4, 4-NO2C6H4)] which selectively inhibit proliferation of breast and prostate tumor cells, and induce apoptosis of such tumor cells, while sparing normal cells, were prepared Thus, reaction of phenylsulfonylacetic acid with benzaldehyde afforded 68-72% (E)-I [R1-R3 = H; n = 0] which showed 89% viable LnCaP and MCF-7 cells at 5.0 μ M.


IT 93468-07-6P 118672-28-9P 118672-29-0P
136272-35-0P 222639-19-2P 222639-21-6P
222639-24-9P 222639-26-1P 222639-29-4P
222639-31-8P 222639-33-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of styryl sulfone anticancer agents)

RN 93468-07-6 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-28-9 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-29-0 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 136272-35-0 CAPLUS

CN Benzene, 1-chloro-2-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 222639-19-2 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-21-6 CAPLUS

CN Benzene, 2,4-difluoro-1-[(1E)-2-[[4-(4-fluorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-24-9 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-26-1 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-29-4 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[(4-fluorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-31-8 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 222639-33-0 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 68 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:651752 CAPLUS

DOCUMENT NUMBER: 130:13631

TITLE: 1-Alkenesulfinyl Chlorides: Synthesis, Characterization, and Some Substitution Reactions

AUTHOR(S): Schwan, Adrian L.; Strickler, Rick R.; Lear, Yvonne; Kalin, Mark L.; Rietveld, Tanya E.; Xiang, Ting-Jian; Brillon, Denis

CORPORATE SOURCE: Guelph-Waterloo Centre for Graduate Work in Chemistry and Biochemistry Department of Chemistry and Biochemistry, University of Guelph, Guelph, ON, N1G 2W1, Can.

SOURCE: Journal of Organic Chemistry (1998), 63(22), 7825-7832
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 130:13631

AB A number of 1-alkenyl sulfoxides bearing either a diphenylmethyl (DPM) or a p-methoxybenzyl (PMB) group have been prepared and exposed to the chlorine surrogate SO₂Cl₂. Through an oxidative fragmentation reactions, a new family of sulfur acid derivs., 1-alkenesulfinyl chlorides, is generated. They can be characterized by IR spectroscopy before chemical capture with an alc. Ethenesulfinyl chloride and 1-propenesulfinyl chloride, obtained from their corresponding DPM precursor, can be distilled at reduced pressure to afford ca. 90% pure material. NMR chemical shift comparison of various 1-alkenesulfinyl-containing compds. is made. 1-Alkenesulfinylmethyl phenyl(alkyl) ketones can be prepared directly from 1-alkenesulfinyl chlorides although decomposition and/or isomerization is sometimes extensive during purification

IT 216007-66-8P 216007-67-9P 216007-71-5P
216007-73-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reactions of alkenesulfinyl chlorides)

RN 216007-66-8 CAPLUS

CN Benzene, 1,1'-[[(1E)-2-phenylethenyl]sulfinyl]methylene]bis- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 216007-67-9 CAPLUS

CN Benzene, 1-methoxy-4-[[[(1E)-2-phenylethenyl]sulfinyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 216007-71-5 CAPLUS

CN Benzene, 1,1'-[[[(1Z)-2-phenylethenyl]sulfinyl]methylene]bis- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 216007-73-7 CAPLUS

CN Benzene, 1-methoxy-4-[[[(1Z)-2-phenylethenyl]sulfinyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 69 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:717923 CAPLUS

DOCUMENT NUMBER: 128:3692


ORIGINAL REFERENCE NO.: 128:799a,802a

TITLE: Fused imidazopyridine derivatives as antihyperlipidemic agents

INVENTOR(S): Takatani, Muneo; Shibouta, Yumiko; Sugiyama, Yasuo; Kawamoto, Tetsuji

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 457 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9740051	A1	19971030	WO 1997-JP1395	19970423
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2251625	A1	19971030	CA 1997-2251625	19970423
AU 9724048	A	19971112	AU 1997-24048	19970423
JP 10226689	A	19980825	JP 1997-105625	19970423
ZA 9703493	A	19981023	ZA 1997-3493	19970423
EP 915888	A1	19990519	EP 1997-919649	19970423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1223659	A	19990721	CN 1997-193938	19970423
US 6235731	B1	20010522	US 1998-155889	19981008
PRIORITY APPLN. INFO.:				JP 1996-102303 A 19960424
				JP 1996-330801 A 19961211
				WO 1997-JP1395 W 19970423
OTHER SOURCE(S): MARPAT 128:3692				
GI				



AB Novel compds. I [wherein ring Q is optionally substituted; one of R0, R1, and R2 = -Y0-Z0, and the others = H, halo, (un)substituted OH, (un)substituted hydrocarbonyl, or acyl; Y0 = bond, (un)substituted bivalent hydrocarbon group; Z0 = basic group which may be bonded via O, N, CO, CS, SO2N(R3) (where R3 = H or (un)substituted hydrocarbonyl), or S(O)n (where n = 0, 1, or 2); dotted line = optional pi bond] and salts thereof are disclosed. The compds. have excellent LDL receptor up-regulating, blood lipid-lowering, blood sugar-lowering, and diabetic

complication-ameliorating activities. Examples include 178 synthetic examples, 79 reference examples, and biol. data for approx. 20 selected compds. For instance, Et 5-thia-1,8b-diazaacenaphthylene-4-carboxylate underwent a sequence of DIBAL reduction to an alc. (87%), oxidation to an aldehyde and Wittig-based homologation to an acrylic acid derivative (84%), amidation with 1-Boc-piperidin-4-ylmethylamine and deprotection (92%), N-alkylation with Ph(CH₂)₃Br (55%), and salification with methanolic HCl, to give the title compound II.2HCl. In hamsters, II.2HCl reduced non-HDL cholesterol to 62.3% of control, and triglycerides to 67.0% of control.


IT 198896-82-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of fused imidazopyridine derivs. as antihyperlipidemic agents)

RN 198896-82-1 CAPLUS

CN 5-Thia-1,8b-diazaacenaphthylene, 4-[2-[(4-piperidinylmethyl)sulfonyl]ethenyl]-, dihydrochloride, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● 2 HCl


IT 198892-49-8P 198894-77-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused imidazopyridine derivs. as antihyperlipidemic agents)

RN 198892-49-8 CAPLUS

CN 5-Thia-1,8b-diazaacenaphthylene, 4-[2-[[[1-(3-phenylpropyl)-4-piperidinylmethyl]sulfonyl]ethenyl]-, dihydrochloride, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




●2 HCl

RN 198894-77-8 CAPLUS

CN 5-Thia-1,8b-diazaacenaphthylene, 4-[2-[[[1-(3-phenylpropyl)-4-piperidinyl]methyl]sulfonyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (26 CITINGS)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 70 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:711553 CAPLUS

DOCUMENT NUMBER: 128:48012

ORIGINAL REFERENCE NO.: 128:9427a,9430a

TITLE: Some reactions of the (chloromethyl)-trans-β-styrylsulfone carbanion

AUTHOR(S): Makosza, Mieczyslaw; Krylova, Irina

CORPORATE SOURCE: Institute Organic Chemistry, Polish Academy Science, Warsaw, 01224, Pol.

SOURCE: Liebigs Annalen/Recueil (1997), (11), 2337-2340
 CODEN: LIARFV

PUBLISHER: Wiley-VCH

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 128:48012

AB (E)-PhCH:CHSO₂C-HCl reacts with PhCHO and CH₂:CHCN under phase-transfer catalysis conditions to give 2-phenyl-3-(trans-β-

styrylsulfonyl)oxirane and [1-chloro-3-cyano-1-(cyanoethyl)propyl](trans- β -styryl)sulfone, resp., and with nitroarenes to form the products of vicarious nucleophilic substitution of hydrogen.

IT 199864-27-2P 199864-29-4P 199864-31-8P

199864-33-0P 199864-35-2P 199864-37-4P


RL: SPN (Synthetic preparation); PREP (Preparation)

(reactions of (chloromethyl)styrylsulfone carbanion)

RN 199864-27-2 CAPLUS

CN Benzene, 4-chloro-1-nitro-2-[[[(1E)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 199864-29-4 CAPLUS

CN Benzene, 1-chloro-2,4-dinitro-5-[[[(1E)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 199864-31-8 CAPLUS

CN Benzene, 2,4-dinitro-1-[[[(1E)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 199864-33-0 CAPLUS

CN Thiophene, 2-nitro-3-[[[(1E)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 199864-35-2 CAPLUS

CN Pyridine, 6-methoxy-3-nitro-2-[[[(1E)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 199864-37-4 CAPLUS

CN Naphthalene, 1-nitro-2-[[[(1E)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

L3 ANSWER 71 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN


ACCESSION NUMBER: 1997:304567 CAPLUS

DOCUMENT NUMBER: 127:33922

ORIGINAL REFERENCE NO.: 127:6543a

TITLE: The epoxy-Ramberg-Baecklund reaction: a new route to allylic alcohols

AUTHOR(S): Evans, Paul; Taylor, Richard J.
CORPORATE SOURCE: Dep. Chem., Univ. York, Heslington/York, YO1 5DD, UK
SOURCE: Tetrahedron Letters (1997), 38(17), 3055-3058
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 127:33922
GI




AB A new variant of the Ramberg-Baecklund reaction is described, the epoxy-Ramberg-Baecklund reaction (ERBR), in which α,β -epoxy sulfones, on treatment with base, are converted into a range of mono-, di- and tri-substituted allylic alcs. The scope and limitations of the ERBR are discussed. For example, the epoxy-Ramberg-Baecklund reaction of trans-2-phenyl-3-[(phenylmethyl)sulfonyl]oxirane (I) with LiHMDS gave a mixture of (E)- α -(2-phenylethenyl)benzenemethanol (II) and (Z)- α -(2-phenylethenyl)benzenemethanol [82:18 (E)/(Z) ratio] in 68% overall yield.

IT 32093-01-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of allylic alcs. via epoxy-Ramberg-Baecklund reaction)

RN 32093-01-9 CAPLUS

CN Benzene, [[[(1E)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.




OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)


REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 72 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:213412 CAPLUS
DOCUMENT NUMBER: 124:342597
ORIGINAL REFERENCE NO.: 124:63631a,63634a
TITLE: Oxidative fragmentations of selected 1-alkenyl sulfoxides. Chemical and spectroscopic evidence for 1-alkenesulfinyl chlorides
AUTHOR(S): Schwan, Adrian L.; Kalin, Mark L.; Vajda, Kristin E.;

CORPORATE SOURCE: Xiang, Ting-Jian; Brillon, Denis
Guelph-Waterloo Cent. Grad. Work Chem., Univ. Guelph,
Guelph, ON, N1G 2W1, Can.
SOURCE: Tetrahedron Letters (1996), 37(14), 2345-8
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 124:342597
AB A collection of 1-alkenyl sulfoxides possessing diphenylmethyl,
p-methoxybenzyl or 2-(trimethylsilyl)ethyl groups, e.g.,
RCH₂CCl:C(CH₂R)S(O)(CH₂)₂SiMe₃ (R = Me, OAc), can be converted to
1-alkenesulfinyl chlorides using SO₂Cl₂. The 1-alkenesulfinyl chlorides
were spectroscopically characterized by IR and were chemical captured as
their cyclohexyl or 3-phenylpropyl 1-alkenesulfinate esters.
IT 176907-88-3 176907-94-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(substitution of alkenyl sulfoxides via sulfinyl chlorides)
RN 176907-88-3 CAPLUS
CN Benzene, 1,1'-[[(2-phenylethenyl)sulfinyl]methylene]bis- (9CI) (CA INDEX
NAME)



RN 176907-94-1 CAPLUS
CN Benzene, 1-methoxy-4-[[(2-phenylethenyl)sulfinyl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)

L3 ANSWER 73 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:673414 CAPLUS
DOCUMENT NUMBER: 123:313471
ORIGINAL REFERENCE NO.: 123:56183a, 56186a
TITLE: Synthesis of some
1,2-bis(styrylsulfonylmethyl)benzenes
AUTHOR(S): Reddy, D. Bhaskar; Subba Reddy, N.; Reddy, S.
CORPORATE SOURCE: Dep. Chem., S. V. Univ., Tirupati, 517 502, India
SOURCE: Journal of the Indian Chemical Society (1995), 72(2),
133-5
CODEN: JICSAH; ISSN: 0019-4522
PUBLISHER: Indian Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

OTHER SOURCE(S): CASREACT 123:313471

AB The title compds., i.e., 1,2-bis[[2-phenylethenyl)sulfonyl)methyl]benzenes [i.e., 1,2-bis(styrylsulfonylmethyl)benzenes] were prepared starting from 1,2-dimethylbenzene via 2,2'-[1,2-phenylenebis(methylenethio)]bis[acetic acid] as intermediate.


IT 169891-29-6P 169891-30-9P 169891-31-0P
169891-32-1P 169891-33-2P 169891-34-3P
169891-35-4P 169891-36-5P 169891-37-6P
169891-38-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 1,2-bis[[2-phenylethenyl)sulfonyl)methyl]benzenes)

RN 169891-29-6 CAPLUS

CN Benzene, 1,2-bis[[2-phenylethenyl)sulfonyl)methyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169891-30-9 CAPLUS

CN Benzene, 1,2-bis[[[2-(4-methylphenyl)ethenyl]sulfonyl)methyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169891-31-0 CAPLUS

CN Benzene, 1,2-bis[[[2-(2-chlorophenyl)ethenyl]sulfonyl)methyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169891-32-1 CAPLUS

CN Benzene, 1,2-bis[[[2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-, (E,E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169891-33-2 CAPLUS

CN Benzene, 1,2-bis[[[2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-, (E,E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169891-34-3 CAPLUS

CN Benzene, 1,2-bis[[[2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-, (E,E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169891-35-4 CAPLUS

CN Benzene, 1,2-bis[[[2-(2-nitrophenyl)ethenyl]sulfonyl]methyl]-, (E,E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169891-36-5 CAPLUS

CN Benzene, 1,2-bis[[[2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-, (E,E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169891-37-6 CAPLUS

CN Benzene, 1,2-bis[[[2-(4-ethoxy-3-methoxyphenyl)ethenyl]sulfonyl]methyl]-,
(E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169891-38-7 CAPLUS

CN Benzene, 1,2-bis[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]-, (E,E)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 74 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:504330 CAPLUS

DOCUMENT NUMBER: 123:83260

ORIGINAL REFERENCE NO.: 123:14901a,14904a

TITLE: 1,3-Dipolar cycloaddition of diazo compounds to
1-alkenylboronic esters

AUTHOR(S): Jazouli, Mohammed; Carboni, Bertrand; Carrie, Robert

CORPORATE SOURCE: GRPS, Univ. Rennes I, Rennes, 35042, Fr.

SOURCE: Heteroatom Chemistry (1994), 5(5/6), 513-18

CODEN: HETCE8; ISSN: 1042-7163


PUBLISHER: Wiley

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 123:83260

GI




AB Diazo compds. $R_1R_2CN_2$ ($R_1 = H, Ph, CO_2Me$; $R_2 = H, Ph, Me, Et, Me_2CH, Me_3C$) were added to the parent vinylboronic ester derived from pinacol. The reactivity of some substituted 1-alkenylboronic esters is also briefly examined. The nonisolated primary adducts spontaneously rearrange via a 1,3-boron migration and lead to 1-borylated-2-pyrazolines. The structure of one of these compds., I ($R_1 = R_2 = Ph$), has been established by X-ray diffraction anal.

IT 164928-14-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(dipolar cycloaddn. of diazo compds. to alkenylboronic esters)

RN 164928-14-7 CAPLUS

CN 1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-[2-
[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

L3 ANSWER 75 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:283696 CAPLUS

DOCUMENT NUMBER: 122:80624

ORIGINAL REFERENCE NO.: 122:15311a,15314a

TITLE: Theoretical and Experimental Analyses of the
Deprotonation of Thiirane S-Oxides: The
Stereoselective Formation of trans-Alkyl- and
gem-Silylthiiranesulfenate Anions

AUTHOR(S): Refvik, Mitchell D.; Froese, Robert D. J.; Goddard,
John D.; Pham, Hung H.; Pippert, Mark F.; Schwan,
Adrian L.

CORPORATE SOURCE: Guelph-Waterloo Centre for Graduate Work in Chemistry,
University of Guelph, Guelph, ON, N1G 2W1, Can.

SOURCE: Journal of the American Chemical Society (1995),
117(1), 184-92

CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Exptl. and theor. studies of the regioselective deprotonation of thiirane S-oxides are reported. Exptl. under the reaction conditions of LiHMDS/THF/-78° with anti-alkylthiirane S-oxides or anti-silylthiirane S-oxides as starting materials, the products of ring opening are (E)-2-alkylethenesulfenate and 1-silylethenesulfenate anions, resp. Expts. involving deuterium labeling clearly indicate that a regioselective deprotonation reaction was followed by a stereoselective ring opening. Ab initio methods at both the Hartree-Fock and Moeller-Plesset perturbation theory levels with the 6-31+G(d) basis set were used to exam. both lithiated methyl- and silylthiirane S-oxides. Of the possible anti-substituted species, the coordination of the lithium anti to the Me and gem to the silyl is predicted to be the most stable. These stable intermediates with the lithium syn to the sulfoxide could open to yield the exptl. observed products.

IT 152459-47-7P 160426-22-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 152459-47-7 CAPLUS

CN Benzene, [[(2-cyclohexylethenyl)sulfinyl]methyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 160426-22-2 CAPLUS

CN Benzene, [[[1E]-2-phenylethenyl]sulfinyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)

L3 ANSWER 76 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:259329 CAPLUS

DOCUMENT NUMBER: 122:132682

ORIGINAL REFERENCE NO.: 122:24739a, 24742a

TITLE: Stereospecific synthesis of some new Z- and E-cyclopropyl benzyl sulfones and E,Z- and E,E-bis(cyclopropyl)sulfones by PTC method

AUTHOR(S): Reddy, D. Bhaskar; Reddy, P. V. Ramana; Padmavathi, V.
CORPORATE SOURCE: Dept. Chemistry, Sri Venkateswara Univ., Tirupati, 517 502, India

SOURCE: Phosphorus, Sulfur and Silicon and the Related
Elements (1994), 90(1-4), 1-10
CODEN: PSSLEC; ISSN: 1042-6507
PUBLISHER: Gordon & Breach
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 122:132682
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds., Z- and E-(2-aryl-3-arylsulfonylcyclopropyl)benzyl
sulfones I (R1 = H, 4-Me, 4-Cl, R2 = H, 4-Cl, 4-Br, 4-F, R3 = H, 4-Me,
4-Cl) and E,Z- and E,E-bis(2-aryl-3-arylsulfonylcyclopropyl)sulfones II
(R1 = H, 4-Me, R2 = H, 4-OEt, 4-Cl, 4-CHMe2, 2,4-Cl2, 2,6-Cl2, 2-Cl, R3 =
H, 4-Cl, 4-Me) have been prepared by the reaction of aryl thiocarbenes with
Z- and E-styryl benzyl sulfones III and E,Z- and
E,E-bis(2-aryl-3-arylsulfonylcyclopropyl) sulfones IV under phase transfer
conditions. The geometry of the substrates was found to be retained in
the product formation as is evidenced by the PMR spectra, thus, confirming
the stereospecificity of the reaction. The compds. were tested for
bactericidal and fungicidal activity. Their toxicity was evaluated on
Periplaneta americana (cockroach).

IT 32291-81-9 118672-26-7 118672-27-8
118672-28-9 130828-65-8 130828-69-2
136272-42-9 136272-43-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(stereospecific preparation and antimicrobial and insecticidal activity of
cyclopropyl sulfones)


RN 32291-81-9 CAPLUS
CN Benzene, [[[1Z]-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 118672-26-7 CAPLUS
CN Benzene, 1-bromo-4-[(1E)-2-[(4-methylphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-27-8 CAPLUS

CN Benzene, 1-chloro-4-[[[2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-, (E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-28-9 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 130828-65-8 CAPLUS

CN Benzene, 1-methyl-4-[[[2-(phenylethenyl)sulfonyl]methyl]-, (E)- (9CI) (CA
INDEX NAME)


Double bond geometry as shown.



RN 130828-69-2 CAPLUS

CN Benzene, 1-methyl-4-[[[2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-, (E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-42-9 CAPLUS

CN Benzene, 1-chloro-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-43-0 CAPLUS

CN Benzene, 1-methyl-4-[[2-[(phenylethenyl)sulfonyl]methyl]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L3 ANSWER 77 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:234327 CAPLUS
Correction of: 1994:655346

DOCUMENT NUMBER: 122:160195
Correction of: 121:255346

ORIGINAL REFERENCE NO.: 122:29517a, 29520a

TITLE: Phase transfer catalysis - a facile method for cyclopropanation of some isomeric styryl benzyl sulfones and bis(styryl)sulfones

AUTHOR(S): Reddy, D. Bhaskar; Reddy, P. V. Ramana; Seenaiiah, B.
CORPORATE SOURCE: Dep. Chem., Sri Venkateswara Univ., Tirupati, 517 502, India


SOURCE: ACH - Models in Chemistry (1994), 131(1), 83-92
CODEN: ACMCEI; ISSN: 1217-8969

PUBLISHER: Akademiai Kiado


DOCUMENT TYPE: Journal

LANGUAGE: English


GI



I



II



III

AB Cyclopropanation of (Z)- and (E)-styryl benzyl sulfones I (R1, R2 = H, halo, alkyl, etc.) was carried out with phenacyldimethylsulfonium bromides in the presence of a phase transfer catalyst, PhCH2N+Et3.Cl-, to give benzoylcyclopropanes II (same R1, R2; R3 = H, Me, halo, etc.). Cyclopropanation of (E,Z)- and (E,E)-bis(styryl)sulfones III (same R1, R2) was also carried out with phenacyldimethylsulfonium bromides in the presence of a phase transfer catalyst. In the absence of a phase-transfer catalyst the reaction did not proceed. The direct addition of dimethylsulfoxonium phenacylides to I gave the same products II.

IT 32093-01-9 32291-81-9 93468-06-5
 93468-07-6 118672-25-6 118672-28-9
 118672-29-0 130828-65-8 136272-35-0
 136272-37-2 136272-40-7 136272-41-8
 136272-42-9 136272-43-0 136272-44-1
 136272-45-2 158606-43-0 158606-44-1
 158606-45-2 158606-46-3


RL: RCT (Reactant); RACT (Reactant or reagent)

(phase-transfer catalyzed cyclopropanation of styryl sulfones)

RN 32093-01-9 CAPLUS

CN Benzene, [[[1E]-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 32291-81-9 CAPLUS

CN Benzene, [[[1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 93468-06-5 CAPLUS

CN Benzene, 1-methyl-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 93468-07-6 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-25-6 CAPLUS

CN Benzene, 1-chloro-4-[2-[[4-methylphenyl)methyl]sulfonyl]ethenyl]-, (E)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-28-9 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-29-0 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 130828-65-8 CAPLUS

CN Benzene, 1-methyl-4-[[[(2-phenylethenyl)sulfonyl]methyl]-, (E)- (9CI) (CA
INDEX NAME)


Double bond geometry as shown.



RN 136272-35-0 CAPLUS

CN Benzene, 1-chloro-2-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-37-2 CAPLUS

CN Benzene, 1-chloro-2-[2-[[[4-methylphenyl)methyl]sulfonyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-40-7 CAPLUS

CN Benzene, 1-chloro-4-[[[2-(4-ethoxyphenyl)ethenyl]sulfonyl]methyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-41-8 CAPLUS

CN Benzene, 1-chloro-2-[2-[(phenylmethyl)sulfonyl]ethenyl]-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-42-9 CAPLUS

CN Benzene, 1-chloro-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-43-0 CAPLUS

CN Benzene, 1-methyl-4-[[2-(2-phenylethenyl)sulfonyl]methyl]-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-44-1 CAPLUS

CN Benzene, 1-chloro-2-[2-[[4-(4-methylphenyl)methyl]sulfonyl]ethenyl]-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-45-2 CAPLUS

CN Benzene, 1-chloro-4-[2-[[4-(4-methylphenyl)methyl]sulfonyl]ethenyl]-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 158606-43-0 CAPLUS

CN Benzene, 1-methyl-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 158606-44-1 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 158606-45-2 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 158606-46-3 CAPLUS

CN Benzene, 1-chloro-4-[[[2-(4-ethoxyphenyl)ethenyl]sulfonyl]methyl]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L3 ANSWER 78 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:655346 CAPLUS

DOCUMENT NUMBER: 121:255346

ORIGINAL REFERENCE NO.: 121:46607a, 46610a

TITLE: Phase transfer catalysis - a facile method for
cyclopropanation of some isomeric styryl benzyl
sulfones and bis(styryl)sulfones

AUTHOR(S): Reddy, D. Bhaskar; Reddy, P. V. Ramana; Seenaiiah, B.
CORPORATE SOURCE: Dep. Chem., Sri Venkateswara Univ., Tirupati, 517 502,
India




SOURCE: Acta Chimica Hungarica (1994), 131(1), 83-92

CODEN: ACHUDC; ISSN: 0231-3146

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Cyclopropanation of (Z)- and (E)-styryl benzyl sulfones I (R1, R2 = H, halo, alkyl, etc.) was carried out with phenacyldimethylsulfonium bromides in the presence of a phase transfer catalyst, benzyltriethylammonium chloride to give products II (same R1, R2; R3 = H, Me, halo, etc.). Cyclopropanation of (E,Z)- and (E,E)-bis(styryl)sulfones III (Same R1, R2) was also carried out with phenacyldimethylsulfonium bromides in the presence of a phase transfer catalyst. In the absence of a phase-transfer catalyst the reaction did not proceed. The direct addition of dimethylsulfoxonium phenacylides to I gave the same products III.


IT 32093-01-9 32291-81-9 93468-06-5
 93468-07-6 118672-25-6 118672-28-9
 118672-29-0 130828-65-8 136272-35-0
 136272-37-2 136272-40-7 136272-41-8
 136272-42-9 136272-43-0 136272-44-1
 136272-45-2 158606-43-0 158606-44-1
 158606-45-2 158606-46-3

RL: RCT (Reactant); RACT (Reactant or reagent)
 (cyclopropanation with phenacyldimethylsulfonium bromide)

RN 32093-01-9 CAPLUS

CN Benzene, [[[1E)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 32291-81-9 CAPLUS

CN Benzene, [[[1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 93468-06-5 CAPLUS

CN Benzene, 1-methyl-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 93468-07-6 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)

NAME)


Double bond geometry as shown.



RN 118672-25-6 CAPLUS

CN Benzene, 1-chloro-4-[2-[[(4-methylphenyl)methyl]sulfonyl]ethenyl]-, (E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-28-9 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-29-0 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 130828-65-8 CAPLUS

CN Benzene, 1-methyl-4-[[2-(4-chlorophenyl)sulfonyl]methyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-35-0 CAPLUS

CN Benzene, 1-chloro-2-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-37-2 CAPLUS

CN Benzene, 1-chloro-2-[2-[[2-(4-methylphenyl)methyl]sulfonyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 136272-40-7 CAPLUS

CN Benzene, 1-chloro-4-[[[2-(4-ethoxyphenyl)ethenyl]sulfonyl]methyl]-, (E)-

(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-41-8 CAPLUS

CN Benzene, 1-chloro-2-[2-[(phenylmethyl)sulfonyl]ethenyl]-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-42-9 CAPLUS

CN Benzene, 1-chloro-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-43-0 CAPLUS

CN Benzene, 1-methyl-4-[[2-[(2-phenylethenyl)sulfonyl]methyl]-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-44-1 CAPLUS

CN Benzene, 1-chloro-2-[2-[[4-methylphenyl)methyl]sulfonyl]ethenyl]-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-45-2 CAPLUS

CN Benzene, 1-chloro-4-[2-[[4-methylphenyl)methyl]sulfonyl]ethenyl]-, (Z)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 158606-43-0 CAPLUS

CN Benzene, 1-methyl-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 158606-44-1 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 158606-45-2 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 158606-46-3 CAPLUS

CN Benzene, 1-chloro-4-[[[2-(4-ethoxyphenyl)ethenyl]sulfonyl]methyl]-, (Z)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L3 ANSWER 79 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:76865 CAPLUS

DOCUMENT NUMBER: 120:76865

ORIGINAL REFERENCE NO.: 120:13821a,13824a

TITLE: The selective generation of trans-substituted lithium and sodium ethenesulfenate anions

AUTHOR(S): Schwan, Adrian L.; Pippert, Mark F.; Pham, Hung H.; Roche, Michael R.

CORPORATE SOURCE: Guelph-Waterloo Cent. Grad. Work Chem., Univ. Guelph, Guelph, ON, N1G 2W1, Can.

SOURCE: Journal of the Chemical Society, Chemical Communications (1993), (17), 1312-14
CODEN: JCCCAT; ISSN: 0022-4936

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 120:76865

AB The reaction of anti-alkylthiirane S-oxides with hindered amide bases affords trans-substituted ethenesulfenate anions via a deprotonation-ring opening sequence. Thus, treatment of methylthiirane S-oxide with LDA and then p-MeC₆H₄CH₂Br in THF afforded 58% (E)-MeCH:CHS(O)CH₂C₆H₄Me-p and 12% CH₂:CMeS(O)CH₂C₆H₄Me-p.


IT 152459-47-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 152459-47-7 CAPLUS


CN Benzene, [[(2-cyclohexylethenyl)sulfinyl]methyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)

L3 ANSWER 80 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1991:558544 CAPLUS
 DOCUMENT NUMBER: 115:158544
 ORIGINAL REFERENCE NO.: 115:27131a,27134a
 TITLE: Synthesis and cyclopropanation of (E)- and (Z)-styryl
 benzyl sulfones
 AUTHOR(S): Reddy, D. Bhaskar; Reddy, P. V. Ramana; Padmavathi,
 V.; Reddy, M. V. Ramana
 CORPORATE SOURCE: Dep. Chem., S. V. Univ., Tirupati, 517502, India
 SOURCE: Sulfur Letters (1991), 13(2), 83-90
 CODEN: SULED2; ISSN: 0278-6117
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 115:158544
 GI




AB (E)-Styryl sulfones, e.g., I (R = H, Me, Cl; R1 = 4-C6H4Me, 2-, 4-C6H4Cl, Ph, 1-C10H7) were prepared by the condensation of 4-RC6H4CH2SO2CH2CO2H with R1CHO in the presence of a catalytic amount of PhCH2NH2. (Z)-Styryl sulfones II (R = H, Me; R2 = 2-, 4-Cl) were prepared by the addition of 4-RC6H4CH2SH to R2C6H4C.tplbond.CH in presence of NaOMe. Cyclopropanation of I with dimethylsulfoxonium methylide gave trans-cyclopropanes III (R, R1 as above).

IT 93468-06-5P 93468-07-6P 130828-65-8P
 130828-69-2P 136272-35-0P 136272-36-1P
 136272-37-2P 136272-38-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and cyclopropanation of)

RN 93468-06-5 CAPLUS

CN Benzene, 1-methyl-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 93468-07-6 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 130828-65-8 CAPLUS

CN Benzene, 1-methyl-4-[[2-(2-phenylethenyl)sulfonyl]methyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 130828-69-2 CAPLUS

CN Benzene, 1-methyl-4-[[[2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-35-0 CAPLUS

CN Benzene, 1-chloro-2-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-36-1 CAPLUS

CN Naphthalene, 1-[2-[(phenylmethyl)sulfonyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-37-2 CAPLUS

CN Benzene, 1-chloro-2-[2-[[4-methylphenyl)methyl]sulfonyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-38-3 CAPLUS


CN Naphthalene, 1-[2-[[4-methylphenyl)methyl]sulfonyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 32291-81-9P 136272-39-4P 136272-40-7P
 136272-41-8P 136272-42-9P 136272-43-0P
 136272-44-1P 136272-45-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 32291-81-9 CAPLUS
 CN Benzene, [[[1Z]-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 136272-39-4 CAPLUS
 CN Benzene, 1-chloro-4-[[[2-[4-(1-methylethyl)phenyl]ethenyl]sulfonyl]methyl]-
 , (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 136272-40-7 CAPLUS
 CN Benzene, 1-chloro-4-[[[2-(4-ethoxyphenyl)ethenyl]sulfonyl]methyl]-, (E)-
 (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-41-8 CAPLUS

CN Benzene, 1-chloro-2-[2-[(phenylmethyl)sulfonyl]ethenyl]-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-42-9 CAPLUS

CN Benzene, 1-chloro-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-43-0 CAPLUS

CN Benzene, 1-methyl-4-[[2-(phenylethenyl)sulfonyl]methyl]-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-44-1 CAPLUS

CN Benzene, 1-chloro-2-[2-[[4-methylphenyl)methyl]sulfonyl]ethenyl]-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-45-2 CAPLUS

CN Benzene, 1-chloro-4-[2-[[4-methylphenyl)methyl]sulfonyl]ethenyl]-, (Z)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)

L3 ANSWER 81 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1991:514078 CAPLUS

DOCUMENT NUMBER: 115:114078

ORIGINAL REFERENCE NO.: 115:19553a,19556a

TITLE: Synthesis of some novel α,β -ethylenic
sulfones

AUTHOR(S): Reddy, M. V. Ramana; Vijayalakshmi, S.; Reddy, D.
Bhaskar; Reddy, P. V. Ramana

CORPORATE SOURCE: Pondicherry Eng. Coll., Pondicherry, India


SOURCE: Phosphorus, Sulfur and Silicon and the Related
Elements (1991), 60(3-4), 209-14
CODEN: PSSLEC; ISSN: 1042-6507

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 115:114078

GI



AB Novel unsatd. sulfones E-I (R = NH₂, OMe, OEt, R₁ = H, Me, Br, Cl) and
p-PhCH₂NHCOC₆H₄CH₂:SO₂CH:CHC₆H₄R₁-p (R₁ = H, Br, Cl, F, NO₂, OEt) have
been prepared by the Knoevenagel condensation of alkoxy/carbamoyl
benzylsulfonylacetic acids II and p-HO₂CC₆H₄CH₂SO₂CH₂CO₂H with

p-R1C6H4CHO. The (E) geometry of these compds. has been assigned based by IR and 1H NMR spectral data.


IT 135653-98-4P 135653-99-5P 135654-00-1P
135654-01-2P 135654-02-3P 135654-03-4P
135654-04-5P 135654-05-6P 135654-06-7P
135654-07-8P 135654-08-9P 135654-09-0P
135654-10-3P 135654-11-4P 135654-12-5P
135654-13-6P 135654-14-7P 135654-15-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 135653-98-4 CAPLUS

CN Benzoic acid, 3-[[2-(2-phenylethenyl)sulfonyl]methyl]-, methyl ester, (E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 135653-99-5 CAPLUS

CN Benzoic acid, 3-[[2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-, methyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 135654-00-1 CAPLUS

CN Benzoic acid, 3-[[2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-, methyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 135654-01-2 CAPLUS

CN Benzoic acid, 3-[[[2-(phenylethenyl)sulfonyl]methyl]-, ethyl ester, (E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 135654-02-3 CAPLUS

CN Benzoic acid, 3-[[[2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-, ethyl
ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 135654-03-4 CAPLUS

CN Benzoic acid, 3-[[[2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-, ethyl
ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 135654-04-5 CAPLUS

CN Benzamide, 3-[[[2-(phenylethenyl)sulfonyl]methyl]-, (E)- (9CI) (CA INDEX
NAME)


Double bond geometry as shown.



RN 135654-05-6 CAPLUS

CN Benzamide, 3-[[[2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-, (E)- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 135654-06-7 CAPLUS

CN Benzamide, 3-[[[2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-, (E)- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 135654-07-8 CAPLUS

CN Benzoic acid, 4-[[[2-(phenylethenyl)sulfonyl]methyl]-, methyl ester, (E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 135654-08-9 CAPLUS

CN Benzoic acid, 4-[[[2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-, methyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 135654-09-0 CAPLUS

CN Benzoic acid, 4-[[[2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-, methyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 135654-10-3 CAPLUS

CN Benzamide, 4-[[[2-(phenylethenyl)sulfonyl]methyl]-N-(phenylmethyl)-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 135654-11-4 CAPLUS

CN Benzamide, 4-[[[2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-N-(phenylmethyl)-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 135654-12-5 CAPLUS

CN Benzamide, 4-[[[2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-N-(phenylmethyl)-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 135654-13-6 CAPLUS

CN Benzamide, 4-[[[2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-N-(phenylmethyl)-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 135654-14-7 CAPLUS

CN Benzamide, 4-[[[2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-N-(phenylmethyl)-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 135654-15-8 CAPLUS

CN Benzamide, 4-[[[2-(4-ethoxyphenyl)ethenyl]sulfonyl]methyl]-N-(phenylmethyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

L3 ANSWER 82 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1991:5934 CAPLUS

DOCUMENT NUMBER: 114:5934

ORIGINAL REFERENCE NO.: 114:1171a,1174a

TITLE: A new route for the synthesis of styryl benzyl
sulfones, precursors of
1-(benzylsulfonyl)-2-arylcyclopropanesAUTHOR(S): Reddy, M. V. Ramana; Reddy, D. Bhaskar; Reddy, P. V.
Ramana; Vijayalaskhmi, S.

CORPORATE SOURCE: Wistar Inst. Anat. Biol., Philadelphia, PA, USA

SOURCE: Phosphorus, Sulfur and Silicon and the Related
Elements (1990), 53(1-4), 285-90
CODEN: PSSLEC; ISSN: 1042-6507

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 114:5934

AB A novel method for the synthesis of (E)-styryl benzyl sulfones from (E)-sodium styrylsulfinates and benzyl chlorides has been described. The cyclopropanation of these compds. with dimethylsulfonium methylide gave (E)-1-(benzylsulfonyl)-2-arylcyclopropanes in good yields. The corresponding Z isomers have been obtained by the cycloaddn. of benzylthiocarbenes to styrenes under phase-transfer catalysis. Their geometry has been assigned from IR and ¹H NMR spectral data.


IT 32093-01-9P 93468-06-5P 118672-27-8P
130828-65-8P 130828-66-9P 130828-67-0P
130828-68-1P 130828-69-2P 130828-70-5P
130828-71-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and cyclopropanation of)
RN 32093-01-9 CAPLUS
CN Benzene, [[[1E)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 93468-06-5 CAPLUS
CN Benzene, 1-methyl-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 118672-27-8 CAPLUS
CN Benzene, 1-chloro-4-[[[2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 130828-65-8 CAPLUS
CN Benzene, 1-methyl-4-[[[2-phenylethenyl]sulfonyl]methyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 130828-66-9 CAPLUS

CN Benzene, 1-chloro-2-[[(2-phenylethenyl)sulfonyl]methyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 130828-67-0 CAPLUS

CN Benzene, 1-chloro-4-[[(2-phenylethenyl)sulfonyl]methyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 130828-68-1 CAPLUS

CN Naphthalene, 1-[[(2-phenylethenyl)sulfonyl]methyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 130828-69-2 CAPLUS

CN Benzene, 1-methyl-4-[[[2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 130828-70-5 CAPLUS

CN Benzene, 1-chloro-2-[[[2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-, (E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 130828-71-6 CAPLUS

CN Naphthalene, 1-[[[2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-, (E)- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

L3 ANSWER 83 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1990:631146 CAPLUS


DOCUMENT NUMBER: 113:231146

ORIGINAL REFERENCE NO.: 113:38997a,39000a

TITLE: Synthesis and properties of substituted
 α' -lithiated $\alpha(Z),\gamma$ -dienyl
sulfoxides. Part II. Stereochemical studies on
products obtained by cyclization of α' -lithiated
 $\alpha(Z),\gamma$ -dienyl sulfide, sulfoxide, and
sulfone


AUTHOR(S): Reglier, M.; Julia, S. A.

CORPORATE SOURCE: Fac. Sci. Saint-Jerome, Univ. Aix-Marseille III,
Marseille, 13397, Fr.
SOURCE: Bulletin de la Societe Chimique de France (1990),
(March-April), 236-44
CODEN: BSCFAS; ISSN: 0037-8968
DOCUMENT TYPE: Journal
LANGUAGE: French
OTHER SOURCE(S): CASREACT 113:231146
GI




AB The lithio derivative of sulfide I was prepared and gave after protonation the two compds. trans-II (45%) and cis-III (15%). In the same way, the corresponding sulfoxide and sulfone were converted stereospecifically into the anti,cis (68%) and cis (61%) compds., resp. For each of the three lithio derivs., the possible transition states were examined
IT 100420-61-9P 130629-39-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and sequential lithiation and cyclization of)
RN 100420-61-9 CAPLUS
CN Benzene, [[[2-(1-cyclohexen-1-yl)ethenyl]sulfinyl]methyl]-, (Z)- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 130629-39-9 CAPLUS
CN Benzene, [[[2-(1-cyclohexen-1-yl)ethenyl]sulfonyl]methyl]-, (Z)- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



IT 100420-70-0P 130629-43-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 100420-70-0 CAPLUS
CN Benzene, [[[2-(1-cyclohexen-1-yl)ethenyl]sulfinyl]methyl]-, (E)- (9CI)

(CA INDEX NAME)


Double bond geometry as shown.



RN 130629-43-5 CAPLUS

CN Benzene, [[[2-(1-cyclohexen-1-yl)ethenyl]sulfonyl]methyl]-, (E)- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 84 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1990:441028 CAPLUS

DOCUMENT NUMBER: 113:41028

ORIGINAL REFERENCE NO.: 113:6983a,6986a

TITLE: Conjugate addition of amines to (Rs)-10-isobornyl vinyl sulfoxides

AUTHOR(S): Pyne, Stephen G.; Bloem, Peter; Griffith, Renate

CORPORATE SOURCE: Dept. Chem., Univ. Wollongong, Wollongong, 2500, Australia

SOURCE: Tetrahedron (1989), 45(22), 7013-22


CODEN: TETRAB; ISSN: 0040-4020

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 113:41028

GI




AB Chiral (E)- and (Z)-(Rs)-10-isobornyl vinyl sulfoxides were prepared the (Z) isomers undergo highly diastereoselective conjugate addition with PhCH₂NH₂ whereas the (E) isomers show poor product diastereoselection. Thus, sulfoxide I (R = Ph, CH₂OSiMe₂CMe₃), when treated with PhCH₂NH₂, gave amines II, preferentially.

IT 127891-51-4P 127994-60-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and conjugate addition to, by benzylamine)

RN 127891-51-4 CAPLUS

CN Bicyclo[2.2.1]heptan-2-ol, 7,7-dimethyl-1-[[(2-phenylethenyl)sulfinyl]methyl]-, [1S-[1 α [S*(E)],2 β ,4 β]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 127994-60-9 CAPLUS

CN Bicyclo[2.2.1]heptan-2-ol, 7,7-dimethyl-1-[[(2-phenylethenyl)sulfinyl]methyl]-, [1S-[1 α [S*(Z)],2 β ,4 β]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)

L3 ANSWER 85 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1989:573260 CAPLUS
DOCUMENT NUMBER: 111:173260
ORIGINAL REFERENCE NO.: 111:28851a,28854a


TITLE: Synthesis and carbon-13 NMR spectral study of
bis(benzyl- and arylsulfonylethenyl)benzenes
AUTHOR(S): Reddy, M. V. Ramana; Balasubramanyam, S.; Reddy, D.
Bhaskar; Reddy, S.; Seenaiiah, B.
CORPORATE SOURCE: Dep. Chem., Pondicherry Eng. Coll., Pondicherry, 605
104, India
SOURCE: Sulfur Letters (1988), 8(4), 237-44
CODEN: SULED2; ISSN: 0278-6117
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 111:173260
AB Benzyl- and arylsulfonylacetic acids have been condensed with
benzenedicarboxaldehydes to give a new class of unsatd. sulfones, 1,2-,
1,3-, and 1,4-bis(benzyl- and arylsulfonylethenyl)benzenes. Their
configurations were assigned on the basis of IR and proton and ¹³C NMR
spectral data.
IT 123147-25-1P 123147-26-2P 123147-27-3P
123147-28-4P 123147-31-9P 123147-32-0P
123147-33-1P 123147-34-2P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and spectra of)
RN 123147-25-1 CAPLUS
CN Benzene, 1,2-bis[2-[[(4-methylphenyl)methyl]sulfonyl]ethenyl]-, (E,E)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 123147-26-2 CAPLUS
CN Benzene, 1,3-bis[2-[(phenylmethyl)sulfonyl]ethenyl]-, (E,E)- (9CI) (CA
INDEX NAME)


Double bond geometry as shown.



RN 123147-27-3 CAPLUS

CN Benzene, 1,3-bis[2-[[4-methylphenyl)methylsulfonyl]ethenyl]-, (E,E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 123147-28-4 CAPLUS

CN Benzene, 1,3-bis[2-[[4-chlorophenyl)methylsulfonyl]ethenyl]-, (E,E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 123147-31-9 CAPLUS

CN Benzene, 1,4-bis[2-[(phenylmethyl)sulfonyl]ethenyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 123147-32-0 CAPLUS

CN Benzene, 1,4-bis[2-[[(4-methylphenyl)methylsulfonyl]ethenyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 123147-33-1 CAPLUS

CN Benzene, 1,4-bis[2-[[(4-chlorophenyl)methylsulfonyl]ethenyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 123147-34-2 CAPLUS

CN Benzene, 1,4-bis[2-[(4-nitrophenyl)methyl]sulfonyl]ethenyl]-, (E,E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 86 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1989:533711 CAPLUS

DOCUMENT NUMBER: 111:133711

ORIGINAL REFERENCE NO.: 111:22371a,22374a

TITLE: Synthesis of 1,3-xylylenebis(sulfonylstyrenes)

AUTHOR(S): Reddy, M. V. Ramana; Vijayalakshmi, S.; Reddy, D. Bhaskar; Reddy, N. Subba

CORPORATE SOURCE: Dep. Chem., Pondicherry Eng. Coll., Pillaichavadi, 605 104, India

SOURCE: Acta Chimica Hungarica (1988), 125(6), 793-6

CODEN: ACHUDC; ISSN: 0231-3146

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 111:133711

AB Eleven 1,3-C₆H₄(CH₂SO₂CH:CHR)₂ [I; R = (un)substituted Ph] have been prepared by condensing 1,3-Xylylenedisulfonylacetic acid with aromatic aldehydes. I had the (E,E) configuration.

IT 122590-98-1P 122590-99-2P 122591-00-8P

122591-01-9P 122591-02-0P 122591-03-1P

122591-04-2P 122591-05-3P 122591-06-4P

122591-07-5P 122591-08-6P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 122590-98-1 CAPLUS

CN Benzene, 1,3-bis[[2-(phenylethenyl)sulfonyl]methyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 122590-99-2 CAPLUS

CN Benzene, 1,3-bis[[[2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 122591-00-8 CAPLUS

CN Benzene, 1,3-bis[[[2-(2-chlorophenyl)ethenyl]sulfonyl]methyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 122591-01-9 CAPLUS

CN Benzene, 1,3-bis[[[2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 122591-02-0 CAPLUS

CN Benzene, 1,3-bis[[[2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-, (E,E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 122591-03-1 CAPLUS

CN Benzene, 1,3-bis[[[2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-, (E,E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 122591-04-2 CAPLUS

CN Benzene, 1,3-bis[[[2-(4-methoxyphenyl)ethenyl]sulfonyl]methyl]-, (E,E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 122591-05-3 CAPLUS

CN Benzene, 1,3-bis[[[2-[4-(1-methylethyl)phenyl]ethenyl]sulfonyl]methyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 122591-06-4 CAPLUS

CN Benzene, 1,3-bis[[[2-(2-nitrophenyl)ethenyl]sulfonyl]methyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 122591-07-5 CAPLUS

CN Benzene, 1,3-bis[[[2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 122591-08-6 CAPLUS

CN Benzene, 1,3-bis[[2-(2,4-dichlorophenyl)ethenyl]sulfonylmethyl]-, (E,E)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 87 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1989:74956 CAPLUS

DOCUMENT NUMBER: 110:74956

ORIGINAL REFERENCE NO.: 110:12369a,12372a

TITLE: Preparation of styryl benzyl sulfones and
1,2-bis(styrylsulfonylmethyl)-4,5-dimethylbenzenes

AUTHOR(S): Reddy, D. Bhaskar; Reddy, N. S.; Reddy, S.; Reddy, M.
V. R.; Balasubramanyam, S.

CORPORATE SOURCE: Dep. Chem., Sri Venkateswara Univ., Tirupati, 517 502,
India

SOURCE: Organic Preparations and Procedures International
(1988), 20(3), 205-12


CODEN: OPPIAK; ISSN: 0030-4948

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 110:74956

GI



AB The Knoevenagel reaction of $\text{R}^1\text{CH}_2\text{SO}_2\text{CH}_2\text{CO}_2\text{H}$ ($\text{R}^1 = \text{Ph}$, tolyl, ClC_6H_4 , $\text{O}_2\text{NC}_6\text{H}_4$) with R^2CHO ($\text{R}^2 = \text{Ph}$, $\text{O}_2\text{NC}_6\text{H}_4$, anthryl, halophenyl, tolyl, anisyl) in HOAc containing PhCH_2NH_2 gave trans-styryl sulfones I.


IT 32093-01-9P 118672-22-3P 118672-23-4P
 118672-24-5P 118672-25-6P 118672-26-7P
 118672-27-8P 118672-28-9P 118672-29-0P
 118672-30-3P 118672-31-4P 118672-32-5P
 118672-33-6P 118672-34-7P 118672-35-8P
 118672-36-9P 118672-37-0P 118672-38-1P
 118672-39-2P 118672-40-5P 118672-41-6P
 118672-42-7P 118672-43-8P 118672-44-9P
 118672-45-0P 118693-27-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 32093-01-9 CAPLUS

CN Benzene, [[[1E)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-22-3 CAPLUS

CN Benzene, 1-nitro-2-[2-[(phenylmethyl)sulfonyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-23-4 CAPLUS

CN Anthracene, 9-[2-[(phenylmethyl)sulfonyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-24-5 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[(4-methylphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-25-6 CAPLUS

CN Benzene, 1-chloro-4-[2-[[(4-methylphenyl)methyl]sulfonyl]ethenyl]-, (E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-26-7 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[(4-methylphenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-27-8 CAPLUS

CN Benzene, 1-chloro-4-[[[2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-, (E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-28-9 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-29-0 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-30-3 CAPLUS

CN Benzene, 1-chloro-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-31-4 CAPLUS

CN Benzene, 1-methyl-4-[2-[[[(4-nitrophenyl)methyl]sulfonyl]ethenyl]-, (E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-32-5 CAPLUS

CN Benzene, 1-methoxy-4-[2-[[[(4-nitrophenyl)methyl]sulfonyl]ethenyl]-, (E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-33-6 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[4-nitrophenyl]methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-34-7 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[[4-nitrophenyl]methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 118672-35-8 CAPLUS

CN Benzene, 1-nitro-4-[[[2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-, (E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-36-9 CAPLUS

CN Benzene, 1,2-dimethyl-4,5-bis[[2-phenylethenyl)sulfonyl)methyl]-, (E,E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-37-0 CAPLUS

CN Benzene, 1,2-dimethyl-4,5-bis[[2-(4-methylphenyl)ethenyl)sulfonyl)methyl]-
, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-38-1 CAPLUS

CN Benzene, 1,2-bis[[2-(4-fluorophenyl)ethenyl)sulfonyl)methyl]-4,5-dimethyl-
, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-39-2 CAPLUS

CN Benzene, 1,2-bis[[[2-(2-chlorophenyl)ethenyl]sulfonyl]methyl]-4,5-dimethyl-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-40-5 CAPLUS

CN Benzene, 1,2-bis[[[2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-4,5-dimethyl-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-41-6 CAPLUS

CN Benzene, 1,2-dimethyl-4,5-bis[[[2-(2-nitrophenyl)ethenyl]sulfonyl]methyl]-
, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-42-7 CAPLUS

CN Benzene, 1,2-dimethyl-4,5-bis[[[2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-
, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-43-8 CAPLUS

CN Benzene, 1,2-bis[[[2-(3,4-dimethoxyphenyl)ethenyl]sulfonyl]methyl]-4,5-dimethyl-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-44-9 CAPLUS

CN Benzene, 1,2-bis[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]-4,5-dimethyl-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118672-45-0 CAPLUS

CN Benzene, 1,2-bis[[[2-(4-ethoxy-3-methoxyphenyl)ethenyl]sulfonyl]methyl]-4,5-dimethyl-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 118693-27-9 CAPLUS

CN Benzene, 1,2-bis[[[2-(4-methoxyphenyl)ethenyl]sulfonyl]methyl]-4,5-dimethyl-, (E,E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)

L3 ANSWER 88 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1988:74910 CAPLUS

DOCUMENT NUMBER: 108:74910

ORIGINAL REFERENCE NO.: 108:12375a,12378a

TITLE: Synthesis of 1,4-xylylene-bis(sulfonylstyrenes)

AUTHOR(S): Reddy, D. Bhaskar; Reddy, M. V. R.; Reddy, N. Subba; Reddy, S.

CORPORATE SOURCE: Dep. Chem., Sri Venkateswara Univ., Tirupati, 517 502, India

SOURCE: Sulfur Letters (1986), 5(3), 63-9

CODEN: SULED2; ISSN: 0278-6117

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 108:74910

AB 1,4-(HO₂CCH₂SO₂CH₂)₂C₆H₄, prepared in 2 steps from 1,4-(ClCH₂)₂C₆H₄, condenses with 11 RCHO (e.g., R = Ph, p-FC₆H₄, o-ClC₆H₄, o-NO₂C₆H₄, 3,4-Cl₂C₆H₃) to give 72-89% (E,E)-1,4-(RCH:CHSO₂CH₂)₂C₆H₄.

IT 112752-23-5P 112752-24-6P 112752-25-7P

112752-26-8P 112752-27-9P 112752-28-0P

112752-29-1P 112752-30-4P 112752-31-5P

112752-32-6P 112766-20-8P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 112752-23-5 CAPLUS

CN Benzene, 1,4-bis[[(2-phenylethenyl)sulfonyl]methyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 112752-24-6 CAPLUS

CN Benzene, 1,4-bis[[[2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-, (E,E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 112752-25-7 CAPLUS

CN Benzene, 1,4-bis[[[2-(2-chlorophenyl)ethenyl]sulfonyl]methyl]-, (E,E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 112752-26-8 CAPLUS

CN Benzene, 1,4-bis[[[2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-, (E,E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 112752-27-9 CAPLUS

CN Benzene, 1,4-bis[[[2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-, (E,E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 112752-28-0 CAPLUS

CN Benzene, 1,4-bis[[[2-(4-methoxyphenyl)ethenyl]sulfonyl]methyl]-, (E,E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 112752-29-1 CAPLUS

CN Benzene, 1,4-bis[[[2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-, (E,E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 112752-30-4 CAPLUS

CN Benzene, 1,4-bis[[[2-(3,4-dichlorophenyl)ethenyl]sulfonyl]methyl]-, (E,E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 112752-31-5 CAPLUS

CN Benzene, 1,4-bis[[[2-(3,4-dimethoxyphenyl)ethenyl]sulfonyl]methyl]-,
(E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 112752-32-6 CAPLUS

CN Benzene, 1,4-bis[[[2-(4-ethoxy-3-methoxyphenyl)ethenyl]sulfonyl]methyl]-,
(E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 112766-20-8 CAPLUS

CN Benzene, 1,4-bis[[[2-(2-nitrophenyl)ethenyl]sulfonyl]methyl]-, (E,E)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 89 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1986:88389 CAPLUS

DOCUMENT NUMBER: 104:88389

ORIGINAL REFERENCE NO.: 104:14019a,14022a

TITLE: Stereospecific cyclizations of substituted
 α' -lithiated $\alpha(Z),\gamma$ -butadienyl
sulfoxides

AUTHOR(S): Reglier, Marius; Julia, Sylvestre A.

CORPORATE SOURCE: Lab. Chim., Ec. Norm. Super., Paris, 75231, Fr.

SOURCE: Tetrahedron Letters (1985), 26(22), 2655-8


CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 104:88389

GI




AB The title compds. I [R = Ph, Me₂C:CH, R₁ = H, R₂ = Me; R = Ph, R₁R₂ = (CH₂)₄] were prepared and converted stereospecifically to the lithiated cyclic sulfoxides I through a concerted disrotatory electrocyclization.

IT 100420-61-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and lithiation-stereoselective cyclization of)

RN 100420-61-9 CAPLUS

CN Benzene, [[[2-(1-cyclohexen-1-yl)ethenyl]sulfinyl]methyl]-, (Z)- (9CI)
 (CA INDEX NAME)

Double bond geometry as shown.




IT 100420-70-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 100420-70-0 CAPLUS

CN Benzene, [[[2-(1-cyclohexen-1-yl)ethenyl]sulfinyl]methyl]-, (E)- (9CI)
 (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)

L3 ANSWER 90 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1985:5286 CAPLUS


DOCUMENT NUMBER: 102:5286

ORIGINAL REFERENCE NO.: 102:971a,974a

TITLE: Desulfonylation of arylmethanesulfonyl chlorides catalyzed by


AUTHOR(S): dichlorotris(triphenylphosphine)ruthenium(II)
Kamigata, Nobumasa; Suzuki, Norihiro; Kobayashi,
Michio
CORPORATE SOURCE: Fac. Sci., Tokyo Metrop. Univ., Setagaya, 158, Japan
SOURCE: Phosphorus and Sulfur and the Related Elements (1984),
20(2), 139-44
CODEN: PREEDF; ISSN: 0308-664X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The title reaction gave chloromethylarenes in high yields. No addition of
the sulfonyl chloride to olefin was observed when the reaction was carried
out in the presence of an equimolar amount of an olefin such as styrene.
However, the rate of disappearance of the sulfonyl chloride was
accelerated by addition of an olefin. The desulfonylation is assumed to
proceed by a redox transfer promoted homolytic mechanism in the
coordination sphere of the catalyst. In the presence of a large excess of
styrenes, arylmethanesulfonyl chlorides added to the olefins to give 1:1
adducts competitively with the desulfonylation yielding
chloromethylarenes.
IT 32093-01-9P 93468-06-5P 93468-07-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 32093-01-9 CAPLUS
CN Benzene, [[[1E)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 93468-06-5 CAPLUS
CN Benzene, 1-methyl-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX
NAME)

Double bond geometry as shown.



RN 93468-07-6 CAPLUS
CN Benzene, 1-chloro-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX
NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L3 ANSWER 91 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1984:423063 CAPLUS

DOCUMENT NUMBER: 101:23063

ORIGINAL REFERENCE NO.: 101:3645a,3648a

TITLE: Synthesis of α,β -unsaturated sulfones

AUTHOR(S): Reddy, M. V. R.; Reddy, S.

CORPORATE SOURCE: Chem. Lab., K.S.R.M. Coll. Eng., Cuddapah, 516 001, India

SOURCE: Acta Chimica Hungarica (1984), 115(3), 269-71

CODEN: ACHUDC; ISSN: 0231-3146

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 101:23063

AB Eleven benzyl styryl sulfones, $\text{PhCH}_2\text{SO}_2\text{CH:CHR}$ (R = substituted Ph), were prepared in 62.5-89.2% yield by condensation of RCHO with $\text{PhCH}_2\text{SO}_2\text{CH}_2\text{CO}_2\text{H}$, prepared by benzylation of $\text{HSCH}_2\text{CO}_2\text{H}$ followed by oxidation with H_2O_2 .

IT 90616-41-4P 90616-42-5P 90616-43-6P

90616-44-7P 90616-45-8P 90616-46-9P

90616-47-0P 90616-48-1P 90616-49-2P


90616-50-5P 90616-51-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation, IR, and NMR spectra of)


RN 90616-41-4 CAPLUS

CN Benzene, 1-chloro-2-[2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)




RN 90616-42-5 CAPLUS

CN Benzene, 1-chloro-4-[2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)




RN 90616-43-6 CAPLUS

CN Benzene, 2,4-dichloro-1-[2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)




RN 90616-44-7 CAPLUS

CN Benzene, 1-methoxy-4-[2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)




RN 90616-45-8 CAPLUS

CN Benzene, 1,2-dimethoxy-3-[2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)




RN 90616-46-9 CAPLUS

CN Benzene, 1,2-dimethoxy-4-[2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)




RN 90616-47-0 CAPLUS

CN Benzene, 1-ethoxy-4-[2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)




RN 90616-48-1 CAPLUS

CN Benzene, 1-methyl-4-[2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)




RN 90616-49-2 CAPLUS

CN Benzene, 1-nitro-3-[2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)




RN 90616-50-5 CAPLUS

CN Benzene, 1-nitro-4-[2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)



RN 90616-51-6 CAPLUS

CN Benzene, 1-fluoro-4-[2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

L3 ANSWER 92 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1984:67936 CAPLUS

DOCUMENT NUMBER: 100:67936

ORIGINAL REFERENCE NO.: 100:10341a,10344a

TITLE: Sodium bromite: a new selective reagent for the oxidation of sulfides and alcohols

AUTHOR(S): Kageyama, Toshifumi; Ueno, Yoshio; Okawara, Makoto

CORPORATE SOURCE: Fac. Eng., Kanto Gakuin Univ., Yokohama, 236, Japan

SOURCE: Synthesis (1983), (10), 815-16

CODEN: SYNTBF; ISSN: 0039-7881

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 100:67936

AB Oxidation of 8 RSR1 (R = Ph, Bu, p-tolyl, styryl, 2-hydroxycyclohexanol, R1 = Ph, Bu, PhCH2, p-tolyl, allyl, morpholino) with NaBrO2 in aqueous dioxane gave 78-97% RS(O)R1. Similarly RCH(OH)R1 [R = Me, R1 = (CH2)4Me, HOCH2CH2; RR1 = (CH2)n, n = 4-6] gave 82-100% RCOR1.


IT 88584-31-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, by oxidation of the sulfide by sodium bromite)

RN 88584-31-0 CAPLUS


CN Benzene, [[(2-phenylethenyl)sulfinyl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)


L3 ANSWER 93 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1983:125701 CAPLUS
DOCUMENT NUMBER: 98:125701
ORIGINAL REFERENCE NO.: 98:19139a,19142a
TITLE: Synthesis of the thienamycin nucleus: a synthesis of
(±)-diethyl
3-benzylthio-7-oxo-1-azabicyclo[3.2.0]hept-3-ene-2,2-
bis(carboxylate)
AUTHOR(S): Shiozaki, Masao; Ishida, Noboru; Hiraoka, Tetsuo
CORPORATE SOURCE: Chem. Res. Lab., Sankyo Co., Ltd., Tokyo, 140, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1982), 30(10),
3624-31
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB The title compound (I) was prepared from H₂NCH(CO₂Et)₂ and BrCH₂CO₂Et in 15 steps.
IT 84691-96-3P 84691-97-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deoxygenation of)
RN 84691-96-3 CAPLUS
CN 1-Azetidineacetic acid, 2-oxo-4-[(1E)-2-[(R)-(phenylmethyl)sulfinyl]ethenyl]-, ethyl ester, (4R)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 84691-97-4 CAPLUS
CN 1-Azetidineacetic acid, 2-oxo-4-[(1E)-2-[(R)-(phenylmethyl)sulfinyl]ethenyl]-, ethyl ester, (4S)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



L3 ANSWER 94 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1978:529116 CAPLUS
 DOCUMENT NUMBER: 89:129116
 ORIGINAL REFERENCE NO.: 89:19969a,19972a
 TITLE: 11-Desoxy-15-thiaprostaglandins
 INVENTOR(S): Plattner, Jacob J.
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: U.S., 12 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4092349	A	19780530	US 1976-740381	19761110
US 4129728	A	19781212	US 1978-868503	19780111
US 4148804	A	19790410	US 1978-919849	19780628
US 4169849	A	19791002	US 1978-955492	19781027
PRIORITY APPLN. INFO.:			US 1976-740381	A3 19761110
			US 1978-868503	A3 19780111
OTHER SOURCE(S):		MARPAT 89:129116		
GI				




AB 11-Deoxy-15-deoxy-15-thiaprostaglandins of the E and F zero and 1 series were prepared Thus, I was treated with $\text{PhCH}_2\text{S(O)CH}_2\text{P(O)(OEt)}_2$, the product hydrogenated to saturate the side chain, reduced to the lactol with $(\text{Me}_2\text{CHCH}_2)_2\text{AlH}$, and condensed with, e.g., $\text{HO}_2\text{C(CH}_2)_3\text{PH}_3\text{Br}$ to give II, which was converted into several other derivs., e.g., III.

IT 67647-35-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenation of)

RN 67647-35-2 CAPLUS

CN 2H-Cyclopenta[b]furan-2-one, hexahydro-4-[2-[(phenylmethyl)sulfinyl]ethenyl]-, [3aR-(3a α , 4 α , 6 α)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L3 ANSWER 95 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1978:59266 CAPLUS

DOCUMENT NUMBER: 88:59266

ORIGINAL REFERENCE NO.: 88:9323a, 9326a

TITLE: Structure-activity study of S-1358 and its derivatives. Part II. Structure modifications of S-n-butyl S'-p-tert-butylbenzyl N-3-pyridyldithiocarbonimide (S-1358, Denmert) and fungicidal activities

AUTHOR(S): Tanaka, Shizuya; Kato, Toshiro; Yamamoto, Shigeo; Yoshioka, Hirotsuke

CORPORATE SOURCE: Pestic. Div., Sumitomo Chem. Co., Ltd., Takarazuka, Japan

SOURCE: Agricultural and Biological Chemistry (1977), 41(10), 1953-9
CODEN: ABCHA6; ISSN: 0002-1369


DOCUMENT TYPE: Journal

LANGUAGE: English

AB Structural modifications of S-n-Bu S'-p-tert-butylbenzyl N-3-pyridyldithiocarbonimide [51308-54-4], potent fungicide to powdery mildew, and inhibitor of ergosterol biosynthesis in *Monilinia fructigena* were studied utilizing 24 compds. having other substituents than the 3-pyridyl and on 24 compds. having a variety of different structures connecting the 3-pyridyl and the p-tert-butylphenyl group from that of the dithiocarbonimide against the aforementioned biol. activities. In the former group the 3-pyridyl group was essential for the activities and the substitution at the 2- or 6-position resulted, on available data, in inactive compds. Several other β -N-heterocyclic analogs were also


active. In the latter group, a number of modified compds. from the dithiocarbainimdate structure were shown to be active. Preparative data is given.

IT 65413-22-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and fungicidal activities of)
 RN 65413-22-1 CAPLUS
 CN Pyridine, 3-[2-[[[4-(1,1-dimethylethyl)phenyl]methyl]sulfonyl]ethenyl]-
 (CA INDEX NAME)




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)

L3 ANSWER 96 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1976:559581 CAPLUS
 DOCUMENT NUMBER: 85:159581
 ORIGINAL REFERENCE NO.: 85:25537a,25540a
 TITLE: Styrylsulfonylation of conjugated nitroalkenes
 AUTHOR(S): Aleksiev, D.
 CORPORATE SOURCE: Higher Inst. Chem.-Technol. A. Zlatarov, Sofia, Bulg.
 SOURCE: Vestsi Akademii Navuk BSSR, Seryya Khimichnykh Navuk
 (1976), (4), 123
 CODEN: VBSKAK; ISSN: 0002-3590
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 AB PhCH:CHSO2CH(R)CH2NO2 (R = Ph, p-tolyl, p-MeOC6H4, m-O2NC6H4) were prepared in 60-80% yield by reaction of PhCH:CHSO2H with RCH:CHNO2.
 IT 61150-79-6P 61150-80-9P 61150-81-0P
 61150-82-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 61150-79-6 CAPLUS
 CN Benzene, [2-nitro-1-[(2-phenylethenyl)sulfonyl]ethyl]- (CA INDEX NAME)




RN 61150-80-9 CAPLUS
 CN Benzene, 1-methyl-4-[2-nitro-1-[(2-phenylethenyl)sulfonyl]ethyl]- (CA INDEX NAME)




RN 61150-81-0 CAPLUS

CN Benzene, 1-methoxy-4-[2-nitro-1-[(2-phenylethenyl)sulfonyl]ethyl]- (CA INDEX NAME)



RN 61150-82-1 CAPLUS

CN Benzene, 1-nitro-3-[2-nitro-1-[(2-phenylethenyl)sulfonyl]ethyl]- (CA INDEX NAME)



L3 ANSWER 97 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1976:420755 CAPLUS

DOCUMENT NUMBER: 85:20755

ORIGINAL REFERENCE NO.: 85:3381a,3384a

TITLE: Styrylsulfonylation of heteroconjugated alkenes

AUTHOR(S): Aleksiev, D.

CORPORATE SOURCE: Higher Inst. Chem.-Technol., Sofia, Bulg.

SOURCE: Zhurnal Organicheskoi Khimii (1976), 12(4), 906-7

CODEN: ZORKAE; ISSN: 0514-7492


DOCUMENT TYPE: Journal

LANGUAGE: Russian


OTHER SOURCE(S): CASREACT 85:20755

AB Reactions of PhCH:CHSO2H with RCR1:CHY (R, R1, Y given; H, H, CN; H, p-O2NC6H4, O2N; Me, Me, Ac; Me, Ph, Ac; H, Ph, Ac) gave 52-92% PhCH:CHSO2CRR1CH2Y.


IT 59548-27-5P 59548-29-7P 59548-30-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 59548-27-5 CAPLUS
CN Benzene, 1-nitro-4-[2-nitro-1-[(2-phenylethenyl)sulfonyl]ethyl]- (CA
INDEX NAME)



RN 59548-29-7 CAPLUS
CN 2-Butanone, 4-phenyl-4-[(2-phenylethenyl)sulfonyl]- (CA INDEX NAME)



RN 59548-30-0 CAPLUS
CN 1-Propanone, 1,3-diphenyl-3-[(2-phenylethenyl)sulfonyl]- (CA INDEX NAME)



L3 ANSWER 98 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1976:405316 CAPLUS
DOCUMENT NUMBER: 85:5316
ORIGINAL REFERENCE NO.: 85:851a,854a
TITLE: Nucleophilic addition of styrenesulfinic acid to
 α -haloacrylonitriles and
 β -halogen- β -nitroalkenes
AUTHOR(S): Aleksiev, D.
CORPORATE SOURCE: Higher Inst. Chem.-Technol., Sofia, Bulg.
SOURCE: Zhurnal Organicheskoi Khimii (1976), 12(4), 907-8
CODEN: ZORKAE; ISSN: 0514-7492
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 85:5316
AB Reaction of PhCH:CHSO₂H with α -chloro(or bromo)acrylonitriles or
with a series of β -bromo- β -nitroalkenes gave 62% yield of


sulfones PhCH:CHSO₂CHRCHXY (R = Ph, X = Br, Y = NO₂) or 27-76% yield of sulfones PhCH:CHSO₂CR:CHY (R, Y given; H, CN; p-O₂NC₆H₄, NO₂; m-O₂NC₆H₄, NO₂), resp.

IT 59409-35-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 59409-35-7 CAPLUS

CN Benzene, [2-[(2-bromo-2-nitro-1-phenylethyl)sulfonyl]ethenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 99 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1971:463306 CAPLUS

DOCUMENT NUMBER: 75:63306

ORIGINAL REFERENCE NO.: 75:10031a,10034a

TITLE: Products of the reaction of benzylsulfonylacetic acid with benzaldehyde and salicylaldehyde

AUTHOR(S): Larsson, E.

CORPORATE SOURCE: Chem. Inst., Univ. Lund, Lund, Swed.

SOURCE: Tetrahedron (1971), 27(12), 2553-6

CODEN: TETRAB; ISSN: 0040-4020

DOCUMENT TYPE: Journal

LANGUAGE: German

AB Me benzyl sulfone, m. 128°, and benzyl ω-styryl sulfone (I), m. 145°, were obtained in several ways from benzylsulfonylacetic acid and BzH. The Et ester of benzylsulfonylacetic acid (II) and BzH gave the Et ester of α-benzylsulfonylcinnamic acid. 3-Benzylsulfonylcoumarin, m. 175°, was obtained from II and salicylaldehyde. I has trans-configuration.


IT 32093-01-9P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and spectra of)

RN 32093-01-9 CAPLUS

CN Benzene, [[[1E]-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L3 ANSWER 100 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1971:405393 CAPLUS

DOCUMENT NUMBER: 75:5393

ORIGINAL REFERENCE NO.: 75:895a,898a
TITLE: Preparation and absorption spectra of some cis- and trans- $\alpha\beta$ -unsaturated sulfides and sulfones
AUTHOR(S): Baliah, V.; Rathinasamy, T. K.
CORPORATE SOURCE: Dep. Chem., Annamalai Univ., Annamalainagar, India
SOURCE: Indian Journal of Chemistry (1971), 9(3), 220-5
CODEN: IJOCAP; ISSN: 0019-5103
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Aryl trans-styryl sulfides were prepared by the reaction of trans- β -bromostyrene with RSNa (R = aryl). Oxidation of the sulfides gave the corresponding sulfones. These aryl trans-styryl sulfones were also obtained by the condensation of arylsulfonylacetic acids with benzaldehyde. Addition of thiophenols to arylacetylenes gave the cis, trans, or a mixture of both the $\alpha\beta$ -unsatd. sulfides depending upon the exptl. conditions. In alkaline medium only the cis-sulfides were formed. In an inert solvent or in the absence of a solvent a mixture of the 2 isomers were formed. In alkaline medium the addition proceeded by an ionic mechanism,

in

neutral medium it occurred by both a free radical and an ionic mechanism. The IR and UV spectra of the unsatd. sulfides and sulfones was discussed.


IT 32291-81-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 32291-81-9 CAPLUS

CN Benzene, [[[1Z]-2-phenylethenyl]sulfonylmethyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

L3 ANSWER 101 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1971:63788 CAPLUS

DOCUMENT NUMBER: 74:63788

ORIGINAL REFERENCE NO.: 74:10299a,10302a

TITLE: Cyclic sulfones. X. Kinetic evidence for the aromatic character of anions derived from benzo- and dibenzothiopyran S,S-dioxide systems

AUTHOR(S): Pagani, Giorgio; Bradamante Pagani, Silvia; Maiorana, Stefano; Mangia, A.

CORPORATE SOURCE: Inst. Chim. Ind., Univ. Milano, Milan, Italy

SOURCE: Journal of the Chemical Society [Section] B: Physical Organic (1971), (1), 74-8
CODEN: JCSPAC; ISSN: 0045-6470

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Kinetic acidities of benzo- and dibenzothiopyran S,S-dioxides of some Me derivs., and of the corresponding open-chain analogs were determined in [2H₅]pyridine-heavy water. The 2 pairs of isomers show similar kinetic acidities and their D-exchange rates exceed those of the open-chain analogs by a factor of 10³-10⁵. Other stabilizing features being common

in the two series, the greater stability of the cyclic anions must be associated with their cyclic unsatd. nature. To account for the magnitude of the effect, it is suggested that the conjugative stabilization developing in the anions is aromatic in character.

IT 32093-01-9


RL: PRP (Properties)

(hydrogen exchange with deuterium in, kinetics of)

RN 32093-01-9 CAPLUS

CN Benzene, [[[1E)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 102 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1968:451906 CAPLUS

DOCUMENT NUMBER: 69:51906

ORIGINAL REFERENCE NO.: 69:9682h,9683a

TITLE: Unsaturated heterocyclic systems. XL. Evaluation of spiro[9,10-ethanoanthracene-11,2'-thietane] S,S-dioxides and 2 α -dialkylaminoalkyl-3-dialkylaminothietane 1,1-dioxides as precursors of 2-methylenethiete 1,1-dioxide derivatives

AUTHOR(S): Paquette, Leo A.; Rosen, Melvin; Stucki, Heinz

CORPORATE SOURCE: Ohio State Univ., Columbus, OH, USA

SOURCE: Journal of Organic Chemistry (1968), 33(8), 3020-7
CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 69:51906

GI For diagram(s), see printed CA Issue.


AB Three synthetic approaches to the highly strained 2-methylenethiete 1,1-dioxide (I) ring system were evaluated. The retro-Diels-Alder route wherein the 9,10-ethanoanthracene moiety was employed as a blocking group for the exocyclic double bond met with failure when it was recognized that the temperatures required to liberate anthracene were well above those at which the desired tetravalent sulfur heterocycles decomposed. The Hofmann degradation approach suffered from the fact that 2 α -dialkylaminoalkyl-3-dialkylaminoethietane 1,1-dioxides displayed a propensity for ring cleavage when treated with MeI. Two intermediate methiodides could, however, be isolated. When subjected in turn to the conditions of Hofmann elimination, these methiodides were especially prone to demethylation. Alternatively, N-oxide degradation of 2 α -dialkylaminothietane 1,1-dioxides, although not an entirely general procedure, gave rise to 2 methylenethiete dioxides. Pertinent mechanistic implications of the above reactions and the phys. and spectral properties of the title sulfones were presented in some detail. 28 references.

IT 16790-87-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 16790-87-7 CAPLUS

CN Piperidine, 1-[2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)



L3 ANSWER 103 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1963:428075 CAPLUS

DOCUMENT NUMBER: 59:28075

ORIGINAL REFERENCE NO.: 59:5004b-c

TITLE: Transfer reactions involving boron. III. Hydroboration studies with enethiol ethers

AUTHOR(S): Pasto, D. J.; Miesel, J. L.

CORPORATE SOURCE: Univ. of Notre Dame, Notre Dame, IN

SOURCE: J. Am. Soc. Soc. (1963), 85(14), 2118-24

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable


AB cf. CA 58, 12444a. A new rearrangement reaction of unstable substituted organoboranes is reported. Hydroboration of enethiol ethers gives both possible substituted organoboranes in which H and C undergo an intermol. transfer from B to C with the sulfur residue migrating from C to B. The reactions are proposed to proceed via fourcentered transition states.

IT 88584-31-0 92549-14-9

(Derived from data in the 7th Collective Formula Index (1962-1966))


RN 88584-31-0 CAPLUS

CN Benzene, [[(2-phenylethenyl)sulfinyl]methyl]- (CA INDEX NAME)



RN 92549-14-9 CAPLUS

CN Benzene, [[(2-phenylethenyl)sulfonyl]methyl]- (CA INDEX NAME)



IT 32093-01-9P, Sulfone, benzyl styryl, trans-

32291-81-9P, Sulfone, benzyl styryl, cis- 852284-93-6P

, Sulfoxide, benzyl styryl, cis-


RL: PREP (Preparation)

(preparation of)

RN 32093-01-9 CAPLUS

CN Benzene, [[[(1E)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 32291-81-9 CAPLUS

CN Benzene, [[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-93-6 CAPLUS

CN Benzene, [[[(1Z)-2-phenylethenyl]sulfinyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L3 ANSWER 104 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1963:428074 CAPLUS

DOCUMENT NUMBER: 59:28074

ORIGINAL REFERENCE NO.: 59:5003g-h, 5004a-b

TITLE: Intermolecular transfer of the 2,4,6-trinitrophenyl group bound to amino radicals

AUTHOR(S): Tanaka, Masaru; Tsuzukida, Yasuharu; Satake, Kazuo

CORPORATE SOURCE: Tokyo Metropolitan Univ.

SOURCE: Nippon Kagaku Zasshi (1962), (83), 895-901

CODEN: NPKZAZ; ISSN: 0369-5387

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable


AB Transferability of the picryl (TNP) group in picramide (I) and its derivs. was studied especially with amino acids. Analyses of the starting material and the product were carried out by electronic absorption spectra or by paper chromatography followed by densitometry. TNP-amino acids (20 mol.) were treated with 20 ml. 15N NH₃; TNP-proline (II) was the most reactive. TNP-glycine and TNP-glycylpeptide also react rapidly but no I was detected. Other TNP-amino acids give almost quant. I, but the reaction velocity depends on the steric effect of the α -substituent. TNP-peptides react similarly. TNP group at the α -position of lysine

is more rapidly transferred than that at ϵ -position. When there is a primary CH, CO₂H, or p-C₆H₄OH group β to the TNP-Ngroup, the reaction is slow, but the products are normal. Effect of concentration of NH₃


on

the transfer was studied with TNP-glutamic acid (III). If the concentration is »IN, the reaction rate is not much affected, although more concentrated solution gives faster reaction. The reaction rate also depends on pH, the critical pH being 11.7. The reaction is complete within several min. at 100° and is faster when EtOH is present. Reaction between alkylamines and III produces only alkylpicramide (IV) and glutamic acid. Reaction between I and Me₂NH (V) gives no N,N-dimethylpicramide (VI). IV and NH₃ give I easily but V gives unidentified material. VI and NH₃ react smoothly but reaction between I and alkylamine is slow, especially when the alkyl chain is long. II and V do not react but proline and VI react to produce a little II. Thus it is concluded that, as TNP-donor, the ability is I «IV « VI and that, as acceptor, the ability is NH₃ » primary amine » secondary amine.

IT 88584-31-0 92549-14-9
(Derived from data in the 7th Collective Formula Index (1962-1966))
RN 88584-31-0 CAPLUS
CN Benzene, [[[2-phenylethenyl)sulfinyl]methyl]- (CA INDEX NAME)




RN 92549-14-9 CAPLUS
CN Benzene, [[[2-phenylethenyl)sulfonyl]methyl]- (CA INDEX NAME)




IT 32093-01-9P, Sulfone, benzyl styryl, trans-
32291-81-9P, Sulfone, benzyl styryl, cis- 852284-93-6P
, Sulfoxide, benzyl styryl, cis-
RL: PREP (Preparation)
(preparation of)
RN 32093-01-9 CAPLUS
CN Benzene, [[[(1E)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 32291-81-9 CAPLUS
CN Benzene, [[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852284-93-6 CAPLUS

CN Benzene, [[[(1Z)-2-phenylethenyl]sulfinyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 105 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1961:93498 CAPLUS

DOCUMENT NUMBER: 55:93498

ORIGINAL REFERENCE NO.: 55:17635a-g

TITLE: Synthesis of amino sulfides and amino sulfones

AUTHOR(S): Tsung, Ju-Shih; Chi, Ju-Yun

CORPORATE SOURCE: Acad. Sinica, Shanghai

SOURCE: Huaxue Xuebao (1960), 26, 31-8

CODEN: HHHPA4; ISSN: 0567-7351


DOCUMENT TYPE: Journal

LANGUAGE: Unavailable


AB β -Amino sulfides (having the ring-cleaved structure of phenothiazine and the nucleus of promethazine and chlorpromazine) and their oxidation products, β -amino sulfones, were prepared for pharmacol. exam. PhCH₂SCH₂CH₂NMe₂ was prepared (46% yield, b_{0.1} 93°; MeI salt m. 155-7°) by heating 18.7 g. PhCH₂SCH₂CH₂Cl (I), 40.5 g. 33% alc. solution of Me₂NH, and 10 ml. EtOH in a sealed tube at 100° 4 hrs. Other PhCH₂SCH₂CH₂R' were obtained by refluxing I, R'H, and alc. and isolated as RX quaternary salts (R', RX, % yield, m.p. given): Et₂N, MeI, -, 87-9° (C₆H₆-EtOH); piperidino, HCl, 78, 163-5° (AcOEt-EtOH); piperidino, MeI, -, 102-4° (EtOH); morpholino, HCl, 75, 195-7° (decomposition) (EtOH); morpholino, MeI, -, 157-8° (decomposition). Adding 91.2 g. 30% H₂O₂ gradually to 37.2 g. I in 186 ml. AcOH at 60° and keeping at room temperature 3 days gave PhCH₂SO₂CH₂CH₂Cl (II), 97% yield, m. 96-7°. Similarly, PhSO₂CH₂CH₂Br (III) was obtained from PhSCH₂CH₂Br in 73% yield, m. 75.5-7.0°. Oxidation of PhCH₂SCH₂CH₂NH₂ with H₂O₂ in AcOH at room temperature 2 days and isolation of the product with HCl-Et₂O gave 29% PhCH₂SO₂CH₂CH₂NH₂·HCl, m. 236-8°. Other PhCH₂SO₂CH₂R' (IV) were prepared by addition of R'H to II in alc. solution and isolated as IV·RX (R', RX, % yield, m.p. given): NMe₂, HCl, 95, 184-6°; NMe₂, MeI, -, 206-8° (H₂O-EtOH) (free base m. 68-9°); NEt₂, MeI, -, 147-8°; N(CH₂CH₂OH)₂, HCl, 48, 102-3° (EtOH-AcOH); NBu₂, HCl, quant., 116-17° (AcOEt); piperidino, HCl, 92, 200-2° (EtOH) (decomposition); piperidino, MeI, -, 190-1° (alc.-H₂O) (free base m. 72-3°); morpholino, HCl, 92, 217-19° (90% EtOH); morpholino, MeI, -, 202-3° (free base m. 74-5°). Likewise, 5 g. III shaken with morpholine in alc. solution 3

hrs. and isolated with HCl-Et₂O gave 87% phenyl β-morpholinoethyl sulfone HCl salt, m. 226-8° (H₂O-EtOH). Oxidation of 31 g. Ph₂CHSCH₂CO₂H with H₂O₂ in AcOH at room temperature 3 days yielded 83% Ph₂CHSO₂CH₂CO₂H, m. 141-2° (C₆H₆), which (17.4 g.) underwent a Mannich reaction with 4.6 g. AcONH₄, 6.4 g. PhCHO in 12 ml. AcOH at refluxing temperature (15 min.) to give 18% Et₂O-insol. Ph₂CHSO₂CH:CHPh, m. 179.5-80.5° (EtOH), H₂O-insol. Ph₂CHSO₂Me, m. 128°, and 15% H₂O-soluble Ph₂CHSO₂CH₂CHPhNH₂.HCl, m. 226-7° [the free base m. 136-7° (petr. ether-AcOEt)]. PhCH₂Cl (253 g.) and 152 g. thiourea in 1 l. EtOH refluxed 16 hrs. and an addnl. 2 hrs. with aqueous NaOH (120 g. in 1.2 l.) gave 79% PhCH₂SH, b₂₀ 91°, which (44.7 g.) was converted to 89% PhCH₂SCH₂CO₂H, m. 59-60° (H₂O), by refluxing 2.5 hrs. with 34 g. ClCH₂CO₂H in aqueous NaOH and to 97% PhCH₂SO₂CH₂CO₂H (V), m. 137-8° (C₆H₆-Me₂CO), if followed by oxidation with H₂O₂ in the usual way. Similar Mannich reaction of V was carried out as above to give 26% PhCH₂SO₂CH:CHPh, m. 143-4°, and 15% PhCH₂SO₂CH₂CHPhNH₂.HCl, m. 207-9° (free base m. 97-8°). Adding 8.5 g. piperidine and 8.5 g. 36% HCHO (in order) to 20 g. cold Ph₂CHSH and keeping 3 hrs. at 80° gave 81% Ph₂CHSCH₂NC₅H₁₀.HCl, m. 195-7°; MeI salt m. 178-9° (decomposition). Similarly, 81% diphenylmethyl morpholinomethyl sulfide was prepared as HCl salt (decomposed at 195°).

IT 92549-14-9P, Sulfone, benzyl styryl 102477-98-5P,
Sulfone, diphenylmethyl styryl
RL: PREP (Preparation)
(preparation of)
RN 92549-14-9 CAPLUS
CN Benzene, [[(2-phenylethenyl)sulfonyl]methyl]- (CA INDEX NAME)



RN 102477-98-5 CAPLUS
CN Sulfone, diphenylmethyl styryl (6CI) (CA INDEX NAME)



L3 ANSWER 106 OF 106 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1956:40367 CAPLUS
DOCUMENT NUMBER: 50:40367
ORIGINAL REFERENCE NO.: 50:7786c-f
TITLE: Synthesis of β-amino sulfones and α,β-unsatd. sulfones
AUTHOR(S): Balasubramanian, M.; Baliah, V.; Rangarajan, T.
CORPORATE SOURCE: Annamalai Univ., Annamalainagar, India
SOURCE: J. Chem. Soc. (1955) 3296-8

DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 OTHER SOURCE(S): CASREACT 50:40367


AB cf. C.A. 49, 8167d. Condensation of alkylsulfonylacetic acids with aldehydes and NH₃ gave the following β -amino sulfones, RSO₂CH₂CHR'NH₂ (R, R', m.p. of free base, and m.p. of hydrochloride given): Me, Ph, -, -; Me, 3,4-(CH₂O₃)C₆H₃ (I), 146-7°, 248-50° (decomposition); Me, o-ClC₆H₄ (II), 77-9°, 195-7°; Me, m-O₂NC₆H₄ (III), -, 202-3°; Et, Ph, -, -; Et, I, -, 206-8° (decomposition); Et, II, 72-3°, 209-10°; Et, o-O₂NC₆H₄, -, 220-2° (decomposition); Et, III, 101-2°, 146-8°; Et, o-HOC₆H₄, -, 211-13° (decomposition); Pr, II, 44-5°, 208-10°; Pr, III, -, 144-6°; Bu, I, -, 164-6°; Bu, II, -, 192-4°; Bu, III, -, 182-4°; PhCH₂ (IV), Ph, 88-9°, 223-4°; IV, I, -, -; IV, II, 100-2°, 226-8°; IV, p-ClC₆H₄, -, 228-30°; IV, III, -, 277-9° (decomposition); IV, o-HOC₆H₄, 153-4°, 225-7° (decomposition). The following unsatd. sulfones RSO₂CH:CHR' were also prepared (R, R', and m.p. given): Me, I, 129-30°; Me, II, 82-3°; Me, III, 130-2°; Et, Ph, 66-7°; Et, I, 80-1°; Et, o-O₂NC₆H₄, 89-90°; Et, III, 124-5°; Pr, II, 76-7°; IV, Ph, 144-5°; IV, I, 150-1°; IV, II, 111-12°; IV, p-ClC₆H₄, 163-5°; IV, III, 184-6°. The condensation of alkylsulfonylacetic acids with o-HOC₆H₄CHO yielded the following 3-alkylsulfonylcoumarins (alkyl group and m.p. given): Me, 184-5°; Et, 163-4°; Pr, 140-1°; Bu, 122-3°; IV, 161-2°. A mixture of MeSO₂CH₂CO₂H, PhCHO, and PhCH₂NH₂ in HOAc refluxed for 10 min. and cooled yielded 2-benzylamino-2-phenethyl Me sulfone hydrochloride, m. 179-81°. Benzyl 2-benzylamino-2-phenylethyl sulfone, m. 108-9°; hydrochloride, m. 187-9° was similarly prepared

IT 93468-07-6P 889862-09-3P 1086240-13-2P
 RL: SPN (Synthetic preparation); PRP (Properties); PREP (Preparation)
 (Synthesis of β -amino sulfones and α,β -unsatd. sulfones)

RN 93468-07-6 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 889862-09-3 CAPLUS

CN Benzene, 1-nitro-3-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1086240-13-2 CAPLUS

CN 1,3-Benzodioxole, 5-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



IT 90616-41-4P, Sulfone, benzyl o-chlorostyryl
 90616-49-2P, Sulfone, benzyl m-nitrostyryl 92549-14-9P
 , Sulfone, benzyl styryl 858467-54-6P, Styrene,
 β-(benzylsulfonyl)-3,4-methylenedioxy-
 RL: PREP (Preparation)
 (preparation of)


RN 90616-41-4 CAPLUS

CN Benzene, 1-chloro-2-[2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)




RN 90616-49-2 CAPLUS

CN Benzene, 1-nitro-3-[2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)




RN 92549-14-9 CAPLUS

CN Benzene, [[(2-phenylethenyl)sulfonyl]methyl]- (CA INDEX NAME)



RN 858467-54-6 CAPLUS

CN 1,3-Benzodioxole, 5-[2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

=> D L4 ININ ABS HITSTR 1-14

'ININ' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
CLASS ----- IPC, NCL, ECLA, FTERM
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, CLASS

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
 SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
 HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
 containing hit terms
 HITRN ----- HIT RN and its text modification
 HITSTR ----- HIT RN, its text modification, its CA index name, and
 its structure diagram
 HITSEQ ----- HIT RN, its text modification, its CA index name, its
 structure diagram, plus NTE and SEQ fields
 FHITSTR ----- First HIT RN, its text modification, its CA index name, and
 its structure diagram
 FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
 structure diagram, plus NTE and SEQ fields
 KWIC ----- Hit term plus 20 words on either side
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
 ENTER DISPLAY FORMAT (BIB):END

=> D L4 IBIB ABS HITSTR 1-14

L4 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2009:825033 CAPLUS
 DOCUMENT NUMBER: 151:145654
 TITLE: Protein kinase genes showing altered levels of
 expression in breast cancer tissue and their
 diagnostic use
 INVENTOR(S): Bertucci, Francois; Birnbaum, Daniel; Finetti, Pascal
 PATENT ASSIGNEE(S): IPSOGEN, Fr.; INSERM-Institut National de la Sante et
 de la Recherche Medicale; Institut Paoli-Calmettes
 SOURCE: PCT Int. Appl., 97pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2009083780	A1	20090709	WO 2008-IB3622	20081224
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,				
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,				
FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,				
KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,				
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,				

PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-9395P P 20071228

AB The present invention relates to a method for analyzing cancer
.e.g., breast cancer comprising detection of differential
expression of at least one of the 16 genes encoding serine/threonine
kinases listed in Table 1, or of said 16 genes, and to a polynucleotide
library comprising at least one said 16 genes. A method of diagnosing
breast cancer by anal. of the levels of expression of members of
a group of 16 protein kinase genes is described. Levels of expression of
the genes can also be used in prognosis and in monitoring the
effectiveness of therapies. The levels of expression of these genes were
analyzed in 227 samples of breast cancer tissue as part of a
larger anal. of gene expression in breast cancer. Validation of
the use of these genes in diagnosis and in prognosis is demonstrated.


IT 592542-59-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(selection for cancer therapy; protein kinase genes showing
altered levels of expression in breast cancer tissue and
their diagnostic use)

RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:739342 CAPLUS

DOCUMENT NUMBER: 151:70265

TITLE: Gene expression markers to determine if a subject will
respond to a bcr-abl inhibitor

INVENTOR(S): McWeeney, Shannon K.; Deininger, Michael W. N.

PATENT ASSIGNEE(S): Oregon Health & Science University, USA

SOURCE: PCT Int. Appl., 127pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009076229	A2	20090618	WO 2008-US85724	20081205
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2007-5703P P 20071207

AB Methods of determining if a subject will respond to treatment of BCR-ABL-dependent cancer with BCR-ABL inhibitor by gene expression profiling in CD34-pos. cells is described. A panel of informative genes for use in the test is described. Altered expression of a number of these genes as compared to the control indicates that the subject of interest will respond to treatment with the BCR-ABL inhibitor.


IT 592543-24-3

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cancer therapy with; gene expression markers to determine if subject will respond to bcr-abl inhibitor)

RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L4 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:325750 CAPLUS

DOCUMENT NUMBER: 150:511500

TITLE: A panel of isogenic human cancer cells

suggests a therapeutic approach for cancers with inactivated p53

AUTHOR(S): Sur, Surojit; Pagliarini, Raymond; Bunz, Fred; Rago, Carlo; Diaz, Luis A., Jr.; Kinzler, Kenneth W.; Vogelstein, Bert; Papadopoulos, Nickolas

CORPORATE SOURCE: The Howard Hughes Medical Institute and The Ludwig Center for Cancer Genetics and Therapeutics, The Johns Hopkins Kimmel Cancer Center, Baltimore, MD, 21231, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2009), 106(10), 3964-3969
CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Through targeted homologous recombination, we developed a panel of matched colorectal cancer cell lines that differ only with respect to their endogenous TP53 status. We then used these lines to define the genes whose expression was altered after DNA damage induced by ionizing radiation. Transcriptome analyses revealed a consistent upregulation of polo-like kinase 1 (PLK1) as well as other genes controlling the G2/M transition in the cells whose TP53 genes were inactivated compared with those with WT TP53 genes. This led to the hypothesis that the viability of stressed cells without WT TP53 depended on PLK1. This hypothesis was validated by demonstrating that stressed cancer cells without WT TP53 alleles were highly sensitive to PLK1 inhibitors, both in vivo and in vitro.

IT 592542-59-1, ON 01910
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(panel of isogenic human cancer cells suggests therapeutic approach for cancers with inactivated p53)

RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:291726 CAPLUS
DOCUMENT NUMBER: 150:327889
TITLE: Novel methods and antibodies for treating cancer
INVENTOR(S): Van De Winkel, Jan; Parren, Paul; Bleeker, Willem Karel; Edvardsen, Klaus; Lammerts Van Bueren, Jeroen; Valerius, Thomas; Dechant, Michael; Weisner, Wencke; Berger, Sven
PATENT ASSIGNEE(S): Genmab A/S, Den.
SOURCE: PCT Int. Appl., 133pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2009030239	A1	20090312	WO 2008-DK50220	20080905
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: DK 2007-1278 A 20070906
DK 2008-912 A 20080630

AB The authors disclose a method for inducing complement-mediated cell killing in the treatment of a tumor. The method comprises the combined administration of a first and a second antibody wherein the first antibody binds a tumor-specific epitope of EGF receptors, the second antibody binds wild-type EGF receptor, and the first and second antibodies are non-cross-blocking.


IT 592543-24-3, ON 012380

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in anti-EGFR antibody combination therapy for cancer)

RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:237899 CAPLUS

DOCUMENT NUMBER: 150:252611

TITLE: Methods and compositions of a hedgehog signaling antagonist and a BCR-ABL inhibitor for treating cancers

INVENTOR(S): Dierks, Christine; Warmuth, Markus

PATENT ASSIGNEE(S): Irm LLC, Bermuda

SOURCE: PCT Int. Appl., 49pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009026075	A1	20090226	WO 2008-US73049	20080813
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2007-956295P P 20070816

AB This invention provides a combination of antagonists of the hedgehog signaling pathway with a BCR-ABL inhibitor. The combination of the present invention may be used for treating cancers known to be associated with protein tyrosine kinases such as, for example, Src, BCR-ABL and c-kit. Thus, the combination of ABL inhibitor (AMN-107, 50 mg/kg qd) and Smo inhibitor (cyclopamine, 25 mg/kg bid) in mice with chronic myeloid leukemia (CML)-like disease reduced the amount of colony forming units and

enhanced time to relapse, indicating that the combination of AMN-107 and cyclopamine may be beneficial in the treatment of CML.

IT 592543-24-3, ON 012380

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(combination of hedgehog signaling antagonist and BCR-ABL inhibitor for treating cancers)

RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1412920 CAPLUS

DOCUMENT NUMBER: 150:136262

TITLE: Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay

AUTHOR(S): Jimeno, A.; Chan, A.; Cusatis, G.; Zhang, X.; Wheelhouse, J.; Solomon, A.; Chan, F.; Zhao, M.; Cosenza, S. C.; Ramana Reddy, M. V.; Rudek, M. A.; Kulesza, P.; Donehower, R. C.; Reddy, E. P.; Hidalgo, M.

CORPORATE SOURCE: Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA

SOURCE: Oncogene (2009), 28(4), 610-618

CODEN: ONCNES; ISSN: 0950-9232

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The purpose of this study was to evaluate the activity of ON 01910.Na, a mitotic inhibitor, in in vitro and in vivo models of pancreatic cancer and to discover biomarkers predictive of efficacy.

Successive in vitro and in vivo models were used; these included cell line-derived and patient-derived tumors from our PancXenoBank, a live collection of freshly generated pancreatic cancer xenografts.

ON 01910.Na showed equivalent activity to gemcitabine against pancreatic cancer cell lines in vitro. The activity of the agent correlated with suppression of phospho-CDC25C and cyclin B1. These markers were optimized for a fine-needle aspirate ex vivo rapid assay. Cyclin B1 mRNA evaluation yielded the most optimal combination of accuracy and reproducibility. Next, nine patient-derived tumors from the PancXenoBank were profiled using the assay developed in cell lines and treated with ON 01910.Na for 28 days. Two cases were cataloged as potential responders and seven as resistant. There was a correlation between the ex vivo assay and sensitivity to the tested agent, as the two cases prospectively identified as sensitive met prespecified criteria for response. Of the seven tumors of predictive resistant, only one was sensitive to ON 01910.Na. In addition, there was a good correlation between cyclin B1 downregulation ex vivo and changes in cyclin B1 protein post-treatment. The novel mitotic inhibitor, ON 01910.Na, showed activity in preclin. model of pancreatic cancer. A rapid assay was rationally developed that not only identified cases sensitive to ON 01910.Na, but also anticipated the pharmacodynamic events occurring after in vivo exposure.

IT 592542-60-4


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclin. development of an ex vivo predictive assay)

RN 592542-60-4 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, sodium salt (1:1) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1368234 CAPLUS

DOCUMENT NUMBER: 149:550457

TITLE: Protein sequences of Plk1 kinase substrate Myt1 and CENPB and methods for modulation of Plk1 kinase activity


INVENTOR(S): Loganzo, Frank, Jr.; Krishnamurthy, Girija; Ding, Weidong Warren; Tan, Xingzhi Cindy; Patel, Jagruti Hasmukh
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 64pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080279874	A1	20081113	US 2008-115750	20080506
PRIORITY APPLN. INFO.:			US 2007-916433P	P 20070507
			US 2007-974618P	P 20070924

AB The invention describes compns. and methods for activating a Plk1 protein as well as phospho-specific anti-Myt1 antibodies that can be used to detect phosphorylation of Myt1. The protein sequences of human Myt1 kinase and CENPB have been presented. Activated Plk1 protein, phospho-specific anti-Myt1 antibodies, and/or Plk1 substrates can be used in screening assays to identify compds. that modulate the ability of Plk1 to phosphorylate and/or bind to a Plk1 substrate. The invention relates to a method of detecting the kinase activity of Plk1 protein. The method includes the steps of : contacting a Plk1 protein with a Plk1 substrate to permit phosphorylation of the Plk1 substrate, wherein the Plk1 substrate is a CENPB protein. The invention further provides a method for generating a compound that inhibits the interaction between a Plk1 protein and a CENPB protein. The method includes the steps of : providing a three-dimensional structure of a mol. or a mol. complex containing a Plk1 protein or a CENPB-binding fragment and designing a compound containing a region that inhibits the interaction between a Plk1 protein and CEPB.

IT 592542-59-1, On01910
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-Plk1 agent; protein sequences of Plk1 kinase substrate Myt1 and CENPB and methods for modulation of Plk1 kinase activity)
RN 592542-59-1 CAPLUS
CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1441255 CAPLUS

DOCUMENT NUMBER: 148:238835

TITLE: Design, Synthesis, and Biological Evaluation of
(E)-Styrylbenzylsulfones as Novel Anticancer Agents

AUTHOR(S): Reddy, M. V. Ramana; Mallireddigari, Muralidhar R.;
Cosenza, Stephen C.; Pallela, Venkat R.; Iqbal, Nabisa
M.; Robell, Kimberly A.; Kang, Anthony D.; Reddy, E.
Premkumar

CORPORATE SOURCE: Fels Institute for Cancer Research and Molecular
Biology, Temple University School of Medicine,
Philadelphia, PA, 19140-5101, USA

SOURCE: Journal of Medicinal Chemistry (2008), 51(1), 86-100
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 148:238835

AB Cell cycle progression is regulated by cyclins and cyclin-dependent kinases, which are formed at specific stages of the cell cycle and regulate the G1/S and G2/M phase transitions, employing a series of checkpoints governed by phosphorylation of their substrates. Tumor development is associated with the loss of these checkpoint controls and this provides an approach for the development of therapeutic agents that can specifically target tumor cells. Here, the authors describe the synthesis and SAR of a novel group of cytotoxic mols. that selectively induce growth arrest of normal cells in the G1 phase while inducing a mitotic arrest of tumor cells resulting in selective killing of tumor cell populations with little or no effect on normal cell viability. The broad spectrum of antitumor activity in vitro and xenograft models, lack of in vivo toxicity and drug resistance suggest potential for use of these agents in cancer therapy.

IT 300700-00-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)


(preparation of [(phenylmethyl)sulfonyl]ethenyl]benzene derivs. and determination

of their activity as anticancer agents)

RN 300700-00-9 CAPLUS

CN Benzene, 1-methoxy-4-[[[(1E)-2-(4-nitrophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)

Double bond geometry as shown.



IT 300699-94-9P

300699-95-0P

334969-29-8P

334969-31-2P	334969-37-8P	334969-39-0P
334969-40-3P	334969-44-7P	334969-46-9P
334969-47-0P	334969-52-7P	334969-54-9P
409357-58-0P	409357-60-4P	409357-62-6P
409357-63-7P	409357-67-1P	409357-71-7P
409357-73-9P	409357-77-3P	851799-32-1P
865783-95-5P	865784-01-6P	908343-87-3P
1005494-38-1P	1005494-39-2P	1005494-40-5P
1005494-41-6P	1005494-42-7P	1005494-43-8P
1005494-44-9P	1005494-45-0P	1005494-46-1P
1005494-47-2P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(preparation of [(phenylmethyl)sulfonyl]ethenyl]benzene derivs. and determination

of their activity as anticancer agents)

RN 300699-94-9 CAPLUS

CN Benzene, 1-fluoro-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 300699-95-0 CAPLUS

CN Benzene, 1-chloro-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-29-8 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-31-2 CAPLUS

CN Benzene, 1,2,3-trimethoxy-5-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-37-8 CAPLUS

CN Phenol, 3,5-dimethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-39-0 CAPLUS

CN Benzene, 1,2,4-trimethoxy-5-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-40-3 CAPLUS

CN Benzene, 1,2,3-trimethoxy-4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-44-7 CAPLUS

CN Benzene, 5-fluoro-1,3-dimethoxy-2-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-46-9 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-1,3,5-trimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-47-0 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-chlorophenyl]methyl]sulfonyl]ethenyl]-1,3,5-trimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-52-7 CAPLUS

CN Benzene, 1,2,3-trimethoxy-4-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 334969-54-9 CAPLUS

CN Benzene, 1,2,3-trimethoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-58-0 CAPLUS

CN Benzene, 1,3-dimethoxy-2-[(1E)-2-[[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-60-4 CAPLUS

CN Benzene, 2,4-dimethoxy-1-[(1E)-2-[[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-62-6 CAPLUS

CN Benzene, 1,3-dimethoxy-5-[(1E)-2-[[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-63-7 CAPLUS

CN Benzene, 1,4-dimethoxy-2-[(1E)-2-[[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-67-1 CAPLUS

CN Benzene, 1,2-dimethoxy-4-[(1E)-2-[[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-71-7 CAPLUS

CN Benzene, 1-[(1E)-2-[[(4-methoxyphenyl)methyl]sulfonyl]ethenyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-73-9 CAPLUS

CN Benzene, 2-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-1,3-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 409357-77-3 CAPLUS

CN Benzene, 1-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]-3,5-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 851799-32-1 CAPLUS

CN Benzoic acid, 4-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865783-95-5 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-01-6 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]-, 1-(dihydrogen phosphate), sodium salt (1:2) (CA INDEX NAME)

Double bond geometry as shown.




● 2 Na

RN 908343-87-3 CAPLUS

CN Benzene, 1-methoxy-4-[[[(1E)-2-(4-methoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-38-1 CAPLUS

CN Benzenamine, 4-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-39-2 CAPLUS

CN Benzene, 1-methoxy-2-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-40-5 CAPLUS

CN Benzene, 2-chloro-4-fluoro-1-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-41-6 CAPLUS

CN Benzene, 4-fluoro-2-methoxy-1-[(1E)-2-[[4-methoxyphenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-42-7 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[[[4-(trifluoromethoxy)phenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-43-8 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(3,4,5-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-44-9 CAPLUS

CN Phenol, 4-[(1E)-2-[[3-hydroxy-4-methoxyphenyl)methyl]sulfonyl]ethenyl]-3,5-dimethoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-45-0 CAPLUS

CN Benzene, 1,3,5-trimethoxy-2-[(1E)-2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-46-1 CAPLUS

CN Benzonitrile, 4-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1005494-47-2 CAPLUS

CN Phenol, 4-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 865783-99-9P, (E)-5-[[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl dihydrogen phosphate 865784-00-5P
865784-04-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of [(phenylmethyl)sulfonyl]ethenyl]benzene derivs. and determination

of their activity as anticancer agents)

RN 865783-99-9 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]-, 1-(dihydrogen phosphate) (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-00-5 CAPLUS

CN Phosphoric acid, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl bis(phenylmethyl) ester (CA INDEX NAME)


Double bond geometry as shown.



RN 865784-04-9 CAPLUS

CN Phenol, 2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]-, 1-(4-methylbenzenesulfonate)
(CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:996362 CAPLUS

DOCUMENT NUMBER: 147:442786

TITLE: Validation and implementation of a liquid
chromatography/tandem mass spectrometry assay to
quantitate ON 01910.Na, a mitotic progression
modulator, in human plasma

AUTHOR(S): Li, Jing; Zhao, Ming; Jimeno, Antonio; He, Ping;
Reddy, M. V. Ramana; Hidalgo, Manuel; Donehower, Ross
C.; Rudek, Michelle A.

CORPORATE SOURCE: The Sidney Kimmel Comprehensive Cancer Center at Johns
Hopkins, Baltimore, MD, 21231, USA

SOURCE: Journal of Chromatography, B: Analytical Technologies
in the Biomedical and Life Sciences (2007), 856(1-2),
198-204

CODEN: JCBAAI; ISSN: 1570-0232

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal
LANGUAGE: English

AB A reverse-phase high performance liquid chromatog. method with tandem mass spectrometry (LC-MS/MS) was developed and validated for the quantitation of ON 01910.Na, a novel synthetic benzyl styryl sulfone, in human plasma. The assay involved a simple sample preparation with acetonitrile protein precipitation

ON 01910.Na and the internal standard temazepam were separated on a Waters X-Terra

MS C18 column with mobile phase of acetonitrile containing 0.1% formic acid /10 mM ammonium acetate (55:45, volume/volume) using isocratic flow at 0.2 mL/min for 5 min. The analytes were monitored by tandem-mass spectrometry with electrospray pos. ionization. Two calibration curves were generated over the range of 10-2000 ng/mL and 100-20,000 ng/mL. The lower limit of quantitation (LLOQ) was 10 ng/mL for ON 01910.Na in human plasma. The accuracy and within- and between-day precisions were within the acceptance criteria for bioanal. assays. ON 01910.Na was found stable in plasma at -70° for at least 1 yr. The method was successfully applied to characterize the plasma concentration-time profiles of ON 01910.Na in the cancer patients in the Phase I study.


IT 592542-59-1, ON 01910 592542-60-4

RL: ANT (Analyte); ANST (Analytical study)
(validation and implementation of liquid chromatog./tandem mass spectrometry assay to quantitate ON 01910.Na as mitotic progression modulator, in human plasma)

RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592542-60-4 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, sodium salt (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● Na

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:678223 CAPLUS

DOCUMENT NUMBER: 145:137820

TITLE: Treatment of drug-resistant proliferative disorders

INVENTOR(S): Reddy, Ramana M. V.; Reddy, Premkumar E.; Cosenza, Stephen C.; Baker, Stacey J.

PATENT ASSIGNEE(S): Temple University-of the Commonwealth System of Higher Education, USA

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006074149	A2	20060713	WO 2006-US59	20060104
WO 2006074149	A3	20071115		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2006204103	A1	20060713	AU 2006-204103	20060104
CA 2593523	A1	20060713	CA 2006-2593523	20060104
EP 1841420	A2	20071010	EP 2006-717284	20060104

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
BA, HR, MK, YU

JP 2008526852 T 20080724 JP 2007-550417 20060104

KR 2007094956 A 20070927 KR 2007-718000 20070803

PRIORITY APPLN. INFO.:

US 2005-641378P P 20050105

WO 2006-US59 W 20060104

OTHER SOURCE(S): MARPAT 145:137820

AB The invention discloses a method of treating a protein kinase-dependent proliferative disorder, particularly cancer, in an individual, which disorder is resistant to treatment with an ATP-competitive protein kinase inhibitor, said method comprising administering to the individual in need of such treatment an effective amount of at least one compound according to the formula Ar1XRSOnCH=CHAr2 where Ar1 and Ar2 are independently selected from substituted and unsubstituted aryl and substituted and unsubstituted heteroaryl; X = N or CH; n = 1 or 2; and R = H or (C1-C8)hydrocarbonyl.


IT 592542-82-0

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)

RN 592542-82-0 CAPLUS

CN Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.




IT 592542-59-1 592543-23-2 592543-24-3
851799-47-8 851799-49-0 851799-50-3
851799-51-4 852283-27-3 852283-45-5
897013-49-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (treatment of drug-resistant proliferative disorders resistant to ATP-competitive protein kinase inhibitors)

RN 592542-59-1 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 592543-23-2 CAPLUS

CN D-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 592543-24-3 CAPLUS

CN L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 851799-47-8 CAPLUS

CN Benzene, 1-[(1E)-2-[[[4-bromophenyl)methyl]sulfonyl]ethenyl]-2,4-difluoro-
(CA INDEX NAME)

Double bond geometry as shown.




RN 851799-49-0 CAPLUS

CN Benzeneacetic acid, α -[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-, (α R)- (CA INDEX NAME)Absolute stereochemistry.
Double bond geometry as shown.

RN 851799-50-3 CAPLUS


CN Benzeneacetic acid, α -[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-, (α S)- (CA INDEX NAME)Absolute stereochemistry.
Double bond geometry as shown.



RN 851799-51-4 CAPLUS

CN Benzeneacetic acid, α -[[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]amino]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-27-3 CAPLUS

CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 852283-45-5 CAPLUS

CN	L-Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfinyl]methyl]phenyl]-	(CA INDEX NAME)
----	--	-----------------


Absolute stereochemistry.
Double bond geometry as shown.



RN 897013-49-9 CAPLUS

CN Alanine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, monosodium salt (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



● Na

L4 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:288947 CAPLUS

DOCUMENT NUMBER: 145:39705


TITLE: Targeting polo-like kinase 1 for cancer therapy

AUTHOR(S) : Strebhardt, Klaus; Ullrich, Axel

CORPORATE SOURCE: Department of Obstetrics and Gynecology, School of
Medicine, J.W. Goethe-University, Frankfurt, 60590,
Germany

SOURCE: Nature Reviews Cancer (2006), 6(4), 321-330
CODEN: NRCAC4; ISSN: 1474-175X
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Human polo-like kinase 1 (PLK1) is essential during mitosis and in the maintenance of genomic stability. PLK1 is overexpressed in human tumors and has prognostic potential in cancer, indicating its involvement in carcinogenesis and its potential as a therapeutic target. The use of different PLK1 inhibitors has increased our knowledge of mitotic regulation and allowed us to assess their ability to suppress tumor growth in vivo. We address the structural features of the kinase domain and the unique polo-box domain of PLK1 that are most suited for drug development and discuss our current understanding of the therapeutic potential of PLK1.
IT 592542-59-1, ON 01910
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(targeting polo-like kinase 1 for cancer therapy)
RN 592542-59-1 CAPLUS
CN Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



OS.CITING REF COUNT: 109 THERE ARE 109 CAPLUS RECORDS THAT CITE THIS RECORD (109 CITINGS)
REFERENCE COUNT: 129 THERE ARE 129 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:981450 CAPLUS
DOCUMENT NUMBER: 140:217590
TITLE: Synthesis and biological evaluation of [4-(2-phenylethenesulfonylmethyl)phenyl]-quinazolin-4-yl-amines as orally active anti-cancer agents
AUTHOR(S): Sharma, Vedula M.; Seshu, K. V. Adi; Sekhar, V. Chandra; Madan, Sachin; Vishnu, B.; Babu, P. Aravind; Krishna, C. Vamsee; Sreenu, J.; Krishna, V. Ravi; Venkateswarlu, A.; Rajagopal, Sriram; Ajaykumar, R.; Kumar, T. Sravan
CORPORATE SOURCE: Discovery Chemistry, Discovery Research, Dr. Reddy's

SOURCE: Laboratories, Hyderabad, 500 049, India
 Bioorganic & Medicinal Chemistry Letters (2004),
 14(1), 67-71
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 140:217590
 GI



I

AB A series of N-[4-(2-phenylethenesulfonylmethyl)phenyl]quinazolin-4-yl-
 amines, e.g., I (R1 = R2 = R3 = R4 = H) was prepared and tested for its in
 vitro cytotoxic activity against a panel of 12 human cancer cell
 lines. I [R1 = R3 = R4 = H; R2 = F (II); R1 = R2 = Cl; R3 = R4 = H, OMe;
 R3 = Br; R4 = H] showed good in vitro activity and were further tested for
 their in vivo efficacy in the HT-29 human colon adenocarcinoma xenograft
 model. II exhibited promising activity in this model. Dose-response
 studies for II against HT-29 human colon adeno carcinoma xenografts at
 100, 200, and 400 mg/kg doses were performed.


IT 664979-26-4P 664979-27-5P 664979-28-6P
 664979-29-7P 664979-30-0P 664979-31-1P
 664979-32-2P 664979-33-3P 664979-34-4P
 664979-35-5P 664979-36-6P 664979-37-7P
 664979-38-8P 664979-39-9P 664979-40-2P
 664979-41-3P 664979-42-4P 664979-43-5P
 664979-44-6P 664979-45-7P 664979-46-8P
 664979-47-9P 664979-48-0P 664979-49-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of (phenylethenylsulfonylmethyl)phenylamines via substitution
 of nitrobenzyl bromide with mercaptoacetic acid followed by oxidation,
 Knoevenagel condensation with arylaldehydes, and reduction in the
 preparation of
 anticancer agents)


RN 664979-26-4 CAPLUS

CN Benzene, 1-nitro-4-[[2-(phenylethenyl)sulfonyl]methyl]- (CA INDEX NAME)




RN 664979-27-5 CAPLUS

CN Benzene, 1-fluoro-4-[2-[[(4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)




RN 664979-28-6 CAPLUS

CN Benzonitrile, 4-[2-[[(4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)




RN 664979-29-7 CAPLUS

CN Benzene, 1,2-dichloro-4-[2-[[(4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)




RN 664979-30-0 CAPLUS

CN Benzene, 1-bromo-4-[2-[[(4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)




RN 664979-31-1 CAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)




RN 664979-32-2 CAPLUS

CN Benzene, 1-chloro-4-[2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)




RN 664979-33-3 CAPLUS

CN Benzene, 2,4-dichloro-1-[2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)




RN 664979-34-4 CAPLUS


CN Benzene, 2,4-difluoro-1-[2-[[4-nitrophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)



RN 664979-35-5 CAPLUS


CN Benzene, 2-chloro-4-fluoro-1-[2-[(4-nitrophenyl)methylsulfonyl]ethenyl]-
(CA INDEX NAME)

RN 664979-36-6 CAPLUS

CN Benzene, 2-fluoro-1-[2-[(4-nitrophenyl)methylsulfonyl]ethenyl]-4-(trifluoromethyl)-
(CA INDEX NAME)


RN 664979-37-7 CAPLUS

CN Phenol, 4-[2-[(4-nitrophenyl)methylsulfonyl]ethenyl]- (CA INDEX NAME)




RN 664979-38-8 CAPLUS

CN Benzenamine, 4-[[(2-phenylethenyl)sulfonyl]methyl]- (CA INDEX NAME)




RN 664979-39-9 CAPLUS

CN Benzenamine, 4-[[[2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)




RN 664979-40-2 CAPLUS

CN Benzonitrile, 4-[2-[[[4-(aminophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)




RN 664979-41-3 CAPLUS

CN Benzenamine, 4-[[[2-(3,4-dichlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)




RN 664979-42-4 CAPLUS

CN Benzenamine, 4-[[[2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)




RN 664979-43-5 CAPLUS

CN Phenol, 4-[2-[[[4-(aminophenyl)methyl]sulfonyl]ethenyl]-2,6-bis(1,1-dimethylethyl)- (CA INDEX NAME)




RN 664979-44-6 CAPLUS

CN Benzenamine, 4-[[[2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)




RN 664979-45-7 CAPLUS

CN Benzenamine, 4-[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)




RN 664979-46-8 CAPLUS

CN Benzenamine, 4-[[[2-(2-chloro-4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)




RN 664979-47-9 CAPLUS

CN Benzenamine, 4-[[[2-(2-chloro-4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)




RN 664979-48-0 CAPLUS

CN Benzenamine, 4-[[[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]sulfonyl]methyl]- (CA INDEX NAME)



RN 664979-49-1 CAPLUS

CN Phenol, 4-[2-[[[4-(aminophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)



IT 664979-76-4P 664979-77-5P 664979-78-6P

664979-79-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-[(phenylethenylsulfonylmethyl)phenyl](chloroalkoxy)quinazolinylamines via substitution of acetoxychloroquinazoline with (phenylethenylsulfonylmethyl)phenylamines followed by hydrolysis and substitution with bromochloroalkenes)


RN 664979-76-4 CAPLUS

CN 6-Quinazolinol, 4-[[4-[[[2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-7-methoxy-, 6-acetate (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-77-5 CAPLUS
CN 6-Quinazolinol, 4-[[4-[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-7-methoxy-, 6-acetate
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-78-6 CAPLUS
CN 6-Quinazolinol, 4-[[4-[[[2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-7-methoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-79-7 CAPLUS
CN 6-Quinazolinol, 4-[[4-[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]amino]-7-methoxy-2-quinazolinol] (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




IT 664979-83-3P 664979-84-4P 664979-85-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation, anticancer activity, and SAR of
 N-[(phenylethenylsulfonylmethyl)phenyl] (aminoalkoxy)quinazolinylamine
 s via substitution of N-
 [(phenylethenylsulfonylmethyl)phenyl] (chloroalkoxy)quinazolinylamines
 with morpholine)
 RN 664979-83-3 CAPLUS
 CN 4-Quinazolinamine, N-[4-[[[2-(4-
 fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]-7-methoxy-6-[2-(4-
 morpholinyl)ethoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-84-4 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]-7-methoxy-6-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-85-5 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]-7-methoxy-6-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




IT 664979-80-0P 664979-81-1P 664979-82-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation, anticancer activity, and SAR of
 N-[(phenylethenylsulfonylmethyl)phenyl] (aminoalkoxy)quinazolinylamine
 s via substitution of N-
 [(phenylethenylsulfonylmethyl)phenyl] (chloroalkoxy)quinazolinylamines
 with morpholine)
 RN 664979-80-0 CAPLUS
 CN 4-Quinazolinamine, 6-(2-chloroethoxy)-N-[4-[[[2-(4-
 fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]-7-methoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-81-1 CAPLUS
CN 4-Quinazolinamine, 6-(3-chloropropoxy)-N-[4-[[[2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]-7-methoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-82-2 CAPLUS
CN 4-Quinazolinamine, 6-(3-chloropropoxy)-N-[4-[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]-7-methoxy- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT	664979-50-4P	664979-51-5P	664979-52-6P
	664979-53-7P	664979-54-8P	664979-55-9P
	664979-56-0P	664979-57-1P	664979-58-2P
	664979-59-3P	664979-60-6P	664979-61-7P
	664979-62-8P	664979-63-9P	664979-64-0P
	664979-65-1P	664979-66-2P	664979-67-3P
	664979-68-4P	664979-69-5P	664979-70-8P
	664979-71-9P	664979-72-0P	664979-73-1P
	664979-74-2P	664979-75-3P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation, anticancer activity, and structure-activity relationship of N-[(phenylethenylsulfonylmethyl)phenyl]quinazolinylamines via substitution of chloroquinazolines with (phenylethenylsulfonylmethyl)phenylamines)

RN 664979-50-4 CAPLUS

CN 4-Quinazolinamine, N-[4-[[[(2-phenylethenyl)sulfonyl]methyl]phenyl]]- (CA


INDEX NAME)




RN 664979-51-5 CAPLUS

CN 4-Quinazolinamine, N-[4-[[[2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-52-6 CAPLUS
CN Benzonitrile, 4-[2-[[[4-(4-quinazolinylamino)phenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-53-7 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(3,4-

dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-54-8 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(4-bromophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN	664979-55-9	CAPLUS	
CN	Phenol, 2,6-bis(1,1-dimethylethyl)-4-[2-[[[4-(4-quinazolinylamino)phenyl]methyl]sulfonyl]ethenyl]-		(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-56-0 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-57-1 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-58-2 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(2,4-difluorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-59-3 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(2-chloro-4-fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-60-6 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-61-7 CAPLUS
CN Phenol, 4-[2-[[[4-(4-quinazolinylamino)phenyl]methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-62-8 CAPLUS
CN 4-Quinazolinamine, 6-bromo-N-[4-[[[2-(3,4-dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-63-9 CAPLUS
CN 4-Quinazolinamine, 6-bromo-N-[4-[[[2-(4-bromophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-64-0 CAPLUS
CN 4-Quinazolinamine, 6-bromo-N-[4-[[[2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-65-1 CAPLUS
CN Phenol, 4-[2-[[[4-[(6-bromo-4-quinazolinyl)amino]phenyl]methyl]sulfonyl]ethenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-66-2 CAPLUS
CN 4-Quinazolinamine, 6-bromo-N-[4-[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-67-3 CAPLUS
CN 4-Quinazolinamine, 6-bromo-N-[4-[[[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-68-4 CAPLUS
CN 4-Quinazolinamine, 6-bromo-N-[4-[[[2-(2,4-difluorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-69-5 CAPLUS
CN 4-Quinazolinamine, 7-chloro-N-[4-[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-70-8 CAPLUS
CN 4-Quinazolinamine, 7-chloro-N-[4-[[[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-71-9 CAPLUS
CN 4-Quinazolinamine, 7-chloro-N-[4-[[[2-(2-chloro-4-fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-72-0 CAPLUS
CN 4-Quinazolinamine, 7-chloro-N-[4-[[[2-(2,4-difluorophenyl)ethenyl]sulfonyl]methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-73-1 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(2,4-dichlorophenyl)ethenyl]sulfonyl]methyl]phenyl]-6,7-dimethoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-74-2 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]phenyl]-6,7-dimethoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 664979-75-3 CAPLUS
CN 4-Quinazolinamine, N-[4-[[[2-(4-bromophenyl)ethenyl]sulfonyl]methyl]phenyl]-6,7-dimethoxy- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:449847 CAPLUS
DOCUMENT NUMBER: 139:17566
TITLE: Z-styryl sulfone anticancer agents, and preparation thereof
INVENTOR(S): Reddy, E. Premkumar; Reddy, M. V. Ramana
PATENT ASSIGNEE(S): Temple University, USA
SOURCE: U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 282,855.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6576675	B1	20030610	US 2001-937805	20010928
US 6201154	B1	20010313	US 1999-282855	19990331
WO 2000057872	A1	20001005	WO 2000-US8350	20000330

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-282855 A2 19990331
WO 2000-US8350 W 20000330

OTHER SOURCE(S): MARPAT 139:17566
GI



AB (Z)-styryl benzyl sulfones I (R1 = H, Cl, NO2; R2 = H, lower alkyl, lower alkoxy, Cl, Br, I, F; R3, R4 = H, lower alkyl, NO2, Cl, Br, I, F; provided that at least one of R1 or R2 is H) are useful as anticancer agents. The corresponding (Z)-styryl benzyl sulfides are useful as intermediates in the preparation of the biol. active (Z)-styryl benzyl sulfones.

IT 32291-81-9P 136272-42-9P 158606-43-0P
158606-44-1P 158606-45-2P 298197-01-0P
298197-03-2P 298197-05-4P 298197-09-8P
298197-11-2P 298197-13-4P 298197-14-5P
298197-15-6P 298197-16-7P 298197-17-8P
298197-18-9P 298197-19-0P 298197-20-3P
298197-21-4P 298197-22-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Z-styryl sulfone anticancer agents, and preparation)

RN 32291-81-9 CAPLUS

CN Benzene, [[[1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 136272-42-9 CAPLUS

CN Benzene, 1-chloro-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 158606-43-0 CAPLUS

CN Benzene, 1-methyl-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 158606-44-1 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 158606-45-2 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-01-0 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-03-2 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-05-4 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-phenylethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-09-8 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 298197-11-2 CAPLUS

CN Benzene, 1-chloro-4-[(1Z)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-13-4 CAPLUS

CN Benzene, 1-fluoro-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 298197-14-5 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-15-6 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-16-7 CAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX
NAME)


Double bond geometry as shown.



RN 298197-17-8 CAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-18-9 CAPLUS

CN Benzene, 1-[[[(1Z)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]-2-chloro-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-19-0 CAPLUS

CN Benzene, 1-bromo-4-[(1Z)-2-[(4-fluorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-20-3 CAPLUS

CN Benzene, 1-chloro-4-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-21-4 CAPLUS

CN Benzene, 1-chloro-2-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 298197-22-5 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1Z)-2-(4-methylphenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)

Double bond geometry as shown.




IT 298197-23-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(Z-styryl sulfone anticancer agents, and preparation)

RN 298197-23-6 CAPLUS

CN Benzene, 1-fluoro-4-[(1Z)-2-[[[4-iodophenyl]methyl]sulfonyl]ethenyl]- (CA
INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 5

THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

REFERENCE COUNT: 43

THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:143297 CAPLUS

DOCUMENT NUMBER: 136:183608

TITLE: Preparation of styryl aryl sulfones as anticancer agents

INVENTOR(S): Reddy, E. Premkumar; Reddy, M. V. Ramana

PATENT ASSIGNEE(S): Temple University, USA

SOURCE: U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of U.S. Ser. No. 509,227.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020022666	A1	20020221	US 2001-919061	20010731
US 6548553	B2	20030415		
WO 9918068	A1	19990415	WO 1998-US20580	19981001
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6359013	B1	20020319	US 2000-509227	20000324
US 20030114538	A1	20030619	US 2002-255218	20020926
PRIORITY APPLN. INFO.:			US 1997-60933P	P 19971003
			WO 1998-US20580	W 19981001
			US 2000-509227	A2 20000324
			US 2001-919061	A3 20010731

OTHER SOURCE(S): MARPAT 136:183608

GI




AB Title compds. (I; Q = (CH₂)_n; n = 0, 1; R₁ = H, Cl, F, Br; R₂ = H, Cl, F, Br, Me, MeO; R₃ = H, Cl, F; R₂ may not = Me or MeO when R₁ and R₃ both = H and n = 0, 1; and R₁, R₂ and R₃ may not all = H when n = 1), were prepared Thus, 4-bromobenzylsulfonylacetic acid reacted with 4-fluorobenzaldehyde to give 82% (E)-4-fluorostyryl 4-bromobenzyl sulfone. The latter inhibited growth of H157 non-small cell lung cancer cells with

IC50 <1.0 μ M.


IT 93468-07-6P 118672-28-9P 118672-29-0P
136272-35-0P 222639-19-2P 222639-21-6P
222639-24-9P 222639-26-1P 222639-29-4P
222639-31-8P 222639-33-0P 300699-47-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of styryl aryl sulfones as anticancer agents)
RN 93468-07-6 CAPLUS
CN Benzene, 1-chloro-4-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX
NAME)

Double bond geometry as shown.




RN 118672-28-9 CAPLUS
CN Benzene, 1-chloro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)

Double bond geometry as shown.



RN 118672-29-0 CAPLUS
CN Benzene, 1-chloro-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 136272-35-0 CAPLUS

CN Benzene, 1-chloro-2-[(1E)-2-[(phenylmethyl)sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 222639-19-2 CAPLUS

CN Benzene, 1-fluoro-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 222639-21-6 CAPLUS

CN Benzene, 2,4-difluoro-1-[(1E)-2-[[[(4-fluorophenyl)methyl]sulfonyl]ethenyl]]- (CA INDEX NAME)


Double bond geometry as shown.



RN 222639-24-9 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-fluorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 222639-26-1 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-bromophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 222639-29-4 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[4-fluorophenyl)methyl]sulfonyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 222639-31-8 CAPLUS

CN Benzene, 1-bromo-4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 222639-33-0 CAPLUS

CN Benzene, 1-bromo-4-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 300699-47-2 CAPLUS

CN Benzene, 2-chloro-1-[(1E)-2-[[4-chlorophenyl)methyl]sulfonyl]ethenyl]-4-
fluoro- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

=>

---Logging off of STN---

=>

Executing the logoff script...

10/574,993

08/24/2009

STN: SEARCH

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

684.04

870.36

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-98.40

-98.40

STN INTERNATIONAL LOGOFF AT 08:14:07 ON 24 AUG 2009